<SEC-DOCUMENT>0001193125-22-059849.txt : 20220301
<SEC-HEADER>0001193125-22-059849.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220301074627
ACCESSION NUMBER:		0001193125-22-059849
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intra-Cellular Therapies, Inc.
		CENTRAL INDEX KEY:			0001567514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				364742850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36274
		FILM NUMBER:		22693979

	BUSINESS ADDRESS:	
		STREET 1:		430 EAST 29TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		212-923-3344

	MAIL ADDRESS:	
		STREET 1:		430 EAST 29TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oneida Resources Corp.
		DATE OF NAME CHANGE:	20130122
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d234590d10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:itci="http://www.intracellulartherapies.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2021To12_31_2021">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2021To12_31_2021">FY</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden37872734" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P1Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden37872336" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">P3M</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2021To12_31_2021">0001567514</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="itci-20211231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_10_2020To01_10_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-10</xbrli:startDate> <xbrli:endDate>2020-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2020To09_15_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-15</xbrli:startDate> <xbrli:endDate>2020-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_10_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_07_2022To01_07_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-07</xbrli:startDate> <xbrli:endDate>2022-01-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_25_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >itci:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IndefinitePeriodCarryForwardMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >itci:IndefinitePeriodCarryForwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ExpireIn2037MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >itci:ExpireIn2037Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:TimeBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:InducementAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:RealEstatesLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:VehicleFleetLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="itci:ResearchAndOtherCommitmentAxis" >itci:SiegfriedCampaignAndLonzaCampaignMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis" >us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:InducementAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:VehicleFleetLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="itci:ResearchAndOtherCommitmentAxis" >itci:SiegfriedCampaignAndLonzaCampaignMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis" >us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InventoriableCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >itci:InventoriableCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:InducementAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:TimeBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GrantMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis" >itci:VehicleFleetLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:VehicleFleetLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerThreeMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >itci:CustomerThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >itci:CustomerOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >itci:CustomerTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CaplytaMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >itci:CaplytaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InventoriableCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >itci:InventoriableCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:InducementAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RealEstateLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis" >itci:RealEstateLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ITCINationalDemocraticAllianceMemberMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis" >itci:ITCINationalDemocraticAllianceMemberMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis" >itci:ClinicalTralMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >itci:CustomerOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >itci:CustomerTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CaplytaMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >itci:CaplytaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >itci:VehicleFleetLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:InducementAwardPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GrantMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis" >itci:ClinicalTralMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CaplytaMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >itci:CaplytaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:InducementAwardPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_10_2020To01_10_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-10</xbrli:startDate> <xbrli:endDate>2020-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2020To09_15_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-15</xbrli:startDate> <xbrli:endDate>2020-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2018_NYsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" >stpr:NY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2019_MDsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" >stpr:MD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2005-05-31</xbrli:startDate> <xbrli:endDate>2005-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2013To12_31_2013_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-12-01</xbrli:startDate> <xbrli:endDate>2013-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_23_2019To12_23_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_NationalDemocraticAllianceMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis" >itci:NationalDemocraticAllianceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-23</xbrli:startDate> <xbrli:endDate>2019-12-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2019_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_07_2022To01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-07</xbrli:startDate> <xbrli:endDate>2022-01-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2014To12_31_2014_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2014-12-01</xbrli:startDate> <xbrli:endDate>2014-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_AmtTaxCreditMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >itci:AmtTaxCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_31_2020To03_31_2020_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-31</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2018_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >itci:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2020_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >itci:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_12_2019To09_12_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-12</xbrli:startDate> <xbrli:endDate>2019-09-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567514</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>itci:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div><div style="background-color:white;display: inline;"><div style="margin-top: 0pt; margin-bottom: 17pt;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2021To12_31_2021">10-K</ix:nonNumeric></div> </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(Mark One) </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2021To12_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2021To12_31_2021" format="ixt:datemonthdayyearen"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2021To12_31_2021" format="ixt:datemonthdayen">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2021To12_31_2021">2021</ix:nonNumeric></ix:nonNumeric> </div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">OR </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2021To12_31_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div> </div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission file number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2021To12_31_2021">001-36274</ix:nonNumeric></div> </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 22pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2021To12_31_2021">Intra-Cellular Therapies, Inc.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of registrant as specified in its charter) </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2021To12_31_2021">36-4742850</ix:nonNumeric></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification No.)</div></div></td></tr></table><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2021To12_31_2021">430 East 29th Street</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2021To12_31_2021">New York</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2021To12_31_2021">10016</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices) (Zip Code) </div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2021To12_31_2021">646</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2021To12_31_2021"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">440-9333</div></ix:nonNumeric> </div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Exchange Act: </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of each class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Symbol(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">on which registered</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2021To12_31_2021">Common Stock</ix:nonNumeric>, $0.0001 Par Value Per Share</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2021To12_31_2021">ITCI</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></div></div></td></tr></table><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Exchange Act: None </div></div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2021To12_31_2021">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2021To12_31_2021">No</ix:nonNumeric>&#160;&#160;&#9746; </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2021To12_31_2021">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2021To12_31_2021">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2021To12_31_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td>
<td colspan="2" style="height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging growth company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2021To12_31_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td></tr></table><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2021To12_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric> </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2021To12_31_2021" format="ixt:booleanfalse">&#160;&#160;&#9746;</ix:nonNumeric> </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The aggregate market value of the registrant&#8217;s voting and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> common stock held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">3.2</ix:nonFraction>&#160;billion. </div><div style="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">As of February&#160;25, 2022, the registrant had <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn02_25_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">93,593,748</ix:nonFraction></div></div>&#160;shares of common stock outstanding. </div><div style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Auditors Firm ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="P01_01_2021To12_31_2021">42</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Auditors Name: <ix:nonNumeric name="dei:AuditorName" contextRef="P01_01_2021To12_31_2021">Ernst &amp; Young LLP</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Auditors Location: <ix:nonNumeric name="dei:AuditorLocation" contextRef="P01_01_2021To12_31_2021">Baltimore, MD</ix:nonNumeric> </div><div style="font-size: 2pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="toc" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TABLE OF CONTENTS </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><a href="#tx234590_1">PART I</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;1.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_2">Business</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;1A.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_3">Risk Factors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;1B.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_4">Unresolved Staff Comments</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;2.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_5">Properties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;3.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_6">Legal Proceedings</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;4.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_7">Mine Safety Disclosures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><a href="#tx234590_8">PART II</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">56</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;5.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_9">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;6.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_10">[Reserved]</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;7.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_11">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;7A.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_12">Quantitative and Qualitative Disclosures About Market Risk</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;8.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_13">Financial Statements and Supplementary Data</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;9.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;9A.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_15">Controls and Procedures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;9B.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_16">Other Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;9C.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_17">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><a href="#tx234590_18">PART&#160;III</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">77</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;10.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_19">Directors, Executive Officers and Corporate Governance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;11.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_20">Executive Compensation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;12.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_21">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;13.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_22">Certain Relationships and Related Transactions, and Director Independence</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;14.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_23">Principal Accountant Fees and Services</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><a href="#tx234590_24">PART IV</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">78</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;15</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_25">Exhibits and Financial Statement Schedules</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Item&#160;16.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#tx234590_26">Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> Summary</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#tx234590_27">Signatures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top">83</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">DOCUMENTS INCORPORATED BY REFERENCE </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents (or parts thereof) are incorporated by reference into the following parts of this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K:</div> Certain information required in Part III of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> is incorporated by reference from the Registrant&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="tx234590_1" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">PART I </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">All brand names or trademarks appearing in this report are the property of their respective holders. Use or display by us of other parties&#8217; trademarks, trade dress, or products in this report is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners. Unless the context requires otherwise, references in this report to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Intra-Cellular Therapies, Inc. and its wholly-owned subsidiaries, ITI, Inc. and ITI Limited. </div></div></div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td id="tx234590_2" style="width:10%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">BUSINESS </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Overview </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019, CAPLYTA<div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">&#174;</div> (lumateperone) was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in late March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in late December 2021. As used in this report, &#8220;CAPLYTA&#8221; refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and &#8220;lumateperone&#8221; refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Our Product </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, CAPLYTA was approved by the FDA for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in late March 2020. In support of our commercialization efforts, we employ a national salesforce. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). CAPLYTA is the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in late December 2021. In support of the commercial launch of lumateperone for the treatment of bipolar depression, we have expanded our sales force from approximately 240 sales representatives to approximately 320 sales representatives. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The efficacy of CAPLYTA 42 mg in schizophrenia was demonstrated in two placebo-controlled trials, showing a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score. The most common adverse reactions (&gt;5% and twice the rate of placebo) for the recommended dose of CAPLYTA versus placebo were somnolence/sedation (24% vs. 10%) and dry mouth (6% vs. 2%). In pooled data from short term studies, mean changes from baseline in weight gain, fasting glucose, triglycerides and total cholesterol were similar between CAPLYTA and placebo. The incidence of extrapyramidal symptoms was 6.7% for CAPLYTA and 6.3% for placebo. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase 3 placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402). In these studies, the efficacy of CAPLYTA 42 mg was established by demonstrating statistically significant improvements over placebo for the change from baseline in the Montgomery-Asberg Depression Rating scale, or MADRS, total score at week 6. CAPLYTA 42 mg also showed a statistically significant improvement in the key secondary endpoint relating to clinical global impression of bipolar disorder in each study. In addition, CAPLYTA demonstrated a favorable tolerability and safety profile consistent with </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">findings in prior clinical studies in schizophrenia. The most common reported adverse reactions (occurring at a rate of 5% or more and at least twice the rate of placebo) were somnolence/sedation, dizziness, nausea, and dry mouth. Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and LDL cholesterol were similar between CAPLYTA and placebo. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Our Development Programs </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline includes several product candidates in clinical development and additional product candidates in preclinical testing. We believe that our product candidates offer innovative therapeutic approaches and may provide advantages relative to current therapies. The following table summarizes our product candidates and programs: </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">OUR THERAPEUTIC PIPELINE </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g234590g00d00.jpg"/> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lumateperone Development Program </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The efficacy of lumateperone could be mediated through a combination of antagonist activity at central serotonin <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-HT2A</div> receptors and postsynaptic antagonist activity at central dopamine D2 receptors. In terms of pharmacodynamics, lumateperone has high binding affinity for serotonin <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-HT2A</div> receptors and moderate binding affinity for dopamine D2 receptors, serotonin transporters, dopamine D1 receptors, dopamine D4 receptors and adrenergic alpha 1A and alpha 1B receptors. It lacks biologically relevant interactions with other receptors including muscarinic and histaminergic receptors. As a result, we believe lumateperone may represent a potential treatment across multiple therapeutic indications. </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lumateperone for the treatment of major depressive disorder and other mood disorders </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a potent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-HT2A</div> receptor antagonist and serotonin reuptake inhibitor we believe that lumateperone could improve symptoms of depression with fewer side effects than currently marketed antipsychotics and antidepressants. Dopamine modulation by lumateperone may also reduce irritability and aggression that can accompany many mood disorders. Lumateperone, as a standalone agent, indirectly enhances glutamatergic </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">neurotransmission through both AMPA and NMDA channels in the prefrontal cortex via lumateperone&#8217;s dopamine D1 receptor activation. By enhancing AMPA neurotransmission, lumateperone also activates key proteins in the mTOR pathway which has shown antidepressant effects. As such, lumateperone may represent a potential treatment for mood disorders including major depressive disorder (MDD) and post-traumatic stress disorder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lumateperone is in Phase 3 clinical development as a novel treatment for MDD. Patient enrollment in Study 501 and Study 502, our global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD has commenced. We expect to file a supplemental New Drug Application, or sNDA, with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in 2024. In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with Bipolar I or Bipolar II disorder and mixed features in patients with MDD. We expect to complete Study 403 in the second half of 2022 and following completion we intend to discuss the results with the FDA to determine whether Study 403, as amended, will provide supportive data for a potential future regulatory filing for this indication. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have also initiated a Phase 3 study evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;6-week,&#160;open-label&#160;run-in&#160;phase</div></div> during which all patients will receive 42 mg of lumateperone per day, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week,&#160;open-label</div> stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase 26 weeks in duration during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;2-week&#160;safety&#160;follow-up</div></div> phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Indications for Lumateperone </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Within the lumateperone portfolio, we are also developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have completed the preclinical development of an LAI formulation and in December 2020 we initiated a Phase 1 single ascending dose study of lumateperone LAI, a formulation of lumateperone designed to be administered subcutaneously and to maintain therapeutic levels of lumateperone for at least one month. This study is evaluating the pharmacokinetics, safety and tolerability of lumateperone LAI in patients with stable symptoms of schizophrenia. We are now exploring alternate sites of injection with this formulation as well as progressing other formulations. This will assist us in evaluating dosing strategies and formulation for our efficacy studies. The goal of our program is to develop LAI formulations that are effective, safe and well tolerated with treatment durations of one month and longer. Given the encouraging tolerability data to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We hold exclusive, worldwide commercialization rights to lumateperone and a family of compounds from Bristol-Myers Squibb Company pursuant to an exclusive license. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Product Candidates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> for the treatment of behavioral disturbances in patients with dementia, the treatment of dementia-related psychosis and for the treatment of certain depressive disorders, in the elderly. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> is formulated as an oral solid dosage form </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (&gt;&#160;than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL.</div></div></div> In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated our program evaluating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> for the treatment of agitation in patients with probable Alzheimer&#8217;s disease. We are in discussions with the FDA regarding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> toxicological profile of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL.</div></div></div> The FDA has informed us that they do not believe the deuterated and undeuterated forms of lumateperone are identical. As a result, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> data from lumateperone may not be broadly applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> and we may be required to conduct additional toxicology studies in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-rodent</div> species and this could delay the commencement of our clinical program. We expect to commence clinical conduct in this program in 2022. Additional studies in dementia-related psychosis, and certain depressive disorders in the elderly are also planned for 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have another major program&#160;that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several CNS <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-CNS&#160;conditions</div> with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include heart failure, immune system regulation, neurodegenerative diseases, cancers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#160;non-CNS&#160;disorders.&#160;Lenrispodun&#160;(ITI-214)</div></div> is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for&#160;lenrispodun&#160;for Parkinson&#8217;s disease and commenced patient enrollment in the third quarter of 2017 in a Phase 1/2 clinical trial of&#160;lenrispodun&#160;in patients with Parkinson&#8217;s disease to evaluate safety and tolerability in this patient population, as well as motor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-motor&#160;exploratory</div> endpoints. In the fourth quarter of 2018, we announced that the Phase 1/2 clinical trial of&#160;lenrispodun&#160;has been completed and topline results demonstrated&#160;lenrispodun&#160;was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. We have initiated our Phase&#160;2 clinical program with&#160;lenrispodun&#160;for Parkinson&#8217;s disease and expect to commence patient enrollment in the first half of 2022. In addition, in the second quarter of 2020, we announced topline results from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Study&#160;ITI-214-104,&#160;a</div></div> Phase 1/2 translational study of single ascending doses of&#160;lenrispodun&#160;in patients with chronic systolic heart failure with reduced ejection fraction. In this study,&#160;lenrispodun&#160;improved cardiac output by increasing heart contractility and decreasing vascular resistance. Agents that both increase heart contractility (inotropism) and decrease vascular resistance (vasodilation) are called inodilators. Inodilators in current clinical use are associated with the development of arrhythmias, which are abnormal heart rhythms that when serious can impair heart function and lead to mortality.&#160;Lenrispodun,&#160;which acts through a novel mechanism of action, was not associated with arrhythmias in this study and was generally well-tolerated in all patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also have a development program with our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-addictive</div> treatments to manage pain. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> is a novel compound that uniquely combines activity as an antagonist at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">serotonin&#160;5-HT2A&#160;receptors</div> and a partial agonist at &#181;-opioid receptors. These combined actions support the potential utility <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;ITI-333&#160;in</div> the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. In December 2020, we initiated a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> in healthy volunteers. This study was recently completed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> achieved plasma exposures at or above those required for efficacy and was generally safe and well-tolerated. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we expect will fund a significant portion of the early stage clinical development costs associated with this program. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Drug Discovery Platform and Capabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Based on the pioneering efforts of our late <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> and Nobel laureate, Dr.&#160;Paul Greengard, we have developed a detailed understanding of intracellular signaling pathways and intracellular targets. We have used that knowledge to develop several state of the art technology platforms, including one called CNSProfile<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM</div>. This technology monitors the phosphoprotein changes elicited by major psychotropic drug classes and subclasses, and generates a unique molecular signature for drug compounds. By monitoring how the levels of these phosphoproteins change <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div>, we identify intracellular signaling pathways through which several major drug classes operate. Along with what we believe to be state of the art drug discovery efforts, we have used, and may continue to use, this information as a tool to validate our selection of preclinical candidate molecules. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the nature of our research and development and business activities, we do not expect that&#160;compliance with federal, state and local environmental laws will result in material costs or have a significant negative effect on our operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disease and Market Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our programs for small molecule therapeutics are designed to address various CNS and other diseases that we believe are underserved or unmet by currently available therapies and that represent large potential commercial market opportunities for us. Background information on the diseases and related commercial markets that may be addressed by our programs is set forth below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Schizophrenia </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Schizophrenia is a disabling and chronic mental illness that is characterized by multiple symptoms during an acute phase of the disorder that can include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> &#8220;positive&#8221; symptoms, such as hallucinations, hearing voices, grandiose beliefs and suspiciousness or paranoia. These symptoms can be accompanied by additional, harder to treat symptoms, such as social withdrawal, blunted emotional response and speech deficits, collectively referred to as &#8220;negative&#8221; symptoms, difficulty concentrating and disorganized thoughts, or cognitive impairment, depression and insomnia. Such residual symptoms often persist even after the acute positive symptoms subside, and contribute substantially to the social and employment disability associated with schizophrenia. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the American Psychiatric Association and the National Institute of Mental Health, about 1% of the population (2.4&#160;million adults in the United States) suffer from schizophrenia in any given year. A landmark study funded by the National Institute of Mental Health, the Clinical Antipsychotic Trials of Intervention Effectiveness, also referred to as CATIE, which was published in The New England Journal of Medicine in September 2005, found that 74% of patients taking typical or atypical antipsychotics discontinued treatment within 18 months because of side effects or lack of efficacy. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bipolar Disorder </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bipolar disorder, sometimes referred to as manic-depressive illness, is characterized by extreme shifts in mood. Individuals with bipolar disorder may experience intense feelings of over-excitement, irritability, impulsivity with grandiose beliefs and racing thoughts, referred to as a manic episode. Symptoms of depression may include feeling tired, hopeless and sad, with difficulty concentrating and thoughts of suicide. Some people experience both types of symptoms in the same &#8220;mixed&#8221; episode. Severe symptoms of bipolar disorder can be associated with hallucinations or delusions, otherwise referred to as psychosis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the National Institute of Mental Health, an estimated 4.4% of adults in the United States (approximately 11&#160;million adults in the United States) experience bipolar disorder at some time in their lives. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Bipolar disorder is often treated with antipsychotic medications alone or in combination with mood stabilizers. The side effects and safety risks associated with antipsychotic drugs in patients with bipolar disorder are similar to those experienced by patients with schizophrenia. Moreover, a large national research program conducted from 1998 to 2005 called the Systematic Treatment Enhancement Program for Bipolar Disorder, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">STEP-BD,</div> followed 4,360 patients with bipolar disorder long term and showed that about half of patients who were treated for bipolar disorder, still experienced lingering and recurrent symptoms, indicating a clear need for improved treatments. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major Depressive Disorder </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Major depressive disorder, or MDD, is a brain disorder that can be associated with symptoms of sadness, hopelessness, helplessness, feelings of guilt, irritability, loss of interest in formerly pleasurable activities, cognitive impairment, disturbed sleep patterns, and suicide ideation or behavior. Different people may experience different symptoms, but everyone with major depression experiences symptoms that are severe enough to interfere with everyday functioning, such as the ability to concentrate at work or school, social interactions, eating and sleeping. Sometimes the depressive episode can be so severe it is accompanied by psychosis (hallucinations and delusions). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">According to the National Institute of Mental Health, approximately 7.8% of adults experience MDD each year. The antidepressant market is primarily composed of selective serotonin reuptake inhibitors such as escitalopram and selective norepinephrine reuptake inhibitors, or SNRIs, such as duloxetine. Antipsychotics such as quetiapine, aripriprazole and Rexulti<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> are also used as adjunctive treatments with antidepressant treatment. The National Institute of Mental Health-funded Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, study showed that only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of treated patients experience complete remission of depressive symptoms. Nearly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of patients with depression do not fully recover on an anti-depressant medication. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Behavioral Disturbances in Dementia </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The World Health Organization estimates that approximately 55&#160;million people worldwide have dementia, and there are nearly 10&#160;million new cases every year. The Alzheimer&#8217;s Association estimated more than 6&#160;million Americans were living with Alzheimer&#8217;s dementia (AD) in 2021. While the diagnostic criteria for AD and other dementias mostly focus on the related cognitive deficits, it is often the behavioral and psychiatric symptoms that are most troublesome for caregivers and lead to poor quality of life for patients. Several behavioral symptoms are quite prevalent in patients with dementia, including patients with AD. In view of the potential multiple effects of lumateperone on aggression, agitation, sleep disorders and depression, and its safety profile to date, we believe that lumateperone may provide a novel therapy for treating the behavioral disturbances accompanying dementia, including AD. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA has not approved any drug to treat the behavioral symptoms of dementia, including AD. We believe there is a large unmet medical need for a safe and effective therapy to treat the behavioral symptoms in patients with dementia, including AD. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parkinson&#8217;s Disease </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Parkinson&#8217;s disease is a chronic and progressive neurodegenerative disorder that involves malfunction and death of neurons in a region of the brain that controls movement. This neurodegeneration creates a shortage of an important brain signaling chemical, or neurotransmitter, known as dopamine, thereby rendering patients unable to direct or control their movements in a normal manner. Parkinson&#8217;s disease is characterized by well-known motor symptoms, including tremors, limb stiffness, slowness of movements, and difficulties with posture and balance, as well as by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-motor</div> symptoms, which include sleep disturbances, mood disorders, cognitive impairment and psychosis. Parkinson&#8217;s disease progresses slowly in most people and the severity of symptoms tends to worsen over time. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">According to the National Parkinson Foundation, about 1&#160;million people in the United States and more than 10&#160;million people worldwide suffer from this disease. Parkinson&#8217;s disease is more common in people over 60 years of age, and the prevalence of this disease is expected to increase significantly as the average age of the population increases. Parkinson&#8217;s disease patients are commonly treated with dopamine replacement therapies, such as levodopa, commonly referred to as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">L-DOPA,</div> which is metabolized to dopamine, and dopamine agonists, which are molecules that mimic the action of dopamine. Global Data estimated global sales of therapeutics such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">L-DOPA,</div> and dopamine agonists used to treat the disease to be nearly $4&#160;billion in 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-motor</div> symptoms can be particularly distressing and even more troublesome to patients with Parkinson&#8217;s disease than the primary motor disturbances. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-motor</div> symptoms substantially contribute to the burden of Parkinson&#8217;s disease and deeply affect the quality of life of patients and their caregivers. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-motor</div> symptoms of Parkinson&#8217;s disease are associated with increased caregiver stress and burden, nursing home placement, and increased morbidity and mortality. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-motor</div> symptoms associated with Parkinson&#8217;s disease poses a challenge to physicians. Current dopamine replacement drugs used to treat the motor symptoms of Parkinson&#8217;s disease do not help, and sometimes worsen, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-motor</div> symptoms. We believe there is a large unmet medical need for the treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-motor</div> symptoms associated with Parkinson&#8217;s disease. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Heart Failure </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body&#8217;s needs for blood and oxygen. In some types of heart failure, the left ventricle loses its ability to contract normally. The heart is unable to pump with enough force to push enough blood into circulation (heart failure with reduced ejection fraction). Eventually the heart and body cannot compensate, and the person experiences fatigue, breathing problems or other symptoms. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approximately 6.2&#160;million adults in the United States have heart failure. About half of people who develop heart failure die within 5 years of diagnosis. Heart failure cost the nation an estimated $30.7&#160;billion in 2021. This total includes the cost of health care services, medications to treat heart failure, and missed days of work. Current treatments prolong life and improve the heart&#8217;s function, but there is no cure. There is a pressing need for improved treatments to improve and reverse these changes in cardiac function. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opioid Use Disorder </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the 2019 CDC annual surveillance report of drug-related risks and outcomes, opioid misuse is widespread with over 10&#160;million Americans reporting opioid misuse and nearly 50,000 opioid overdose deaths reported in the United States. The opioid crisis was declared a public health emergency in 2017. Opioids are a class of drugs that include the illegal drug&#160;heroin, synthetic opioids such as fentanyl, and&#160;pain relievers&#160;available legally by prescription, including oxycodone, hydrocodone, codeine and morphine. Opioids produce high levels of positive reinforcement, increasing the odds that people will continue using them despite negative consequences. Opioid use disorder is a chronic lifelong disorder, with serious potential consequences including disability, relapses, and death.&#160;While medications including methadone, buprenorphine and naltrexone are approved to treat opioid use disorder, these medications do not effectively treat psychiatric comorbidities (e.g., mood and anxiety disorders) that may drive opioid use/abuse or dysphoria or the dysphoria and mood disturbances (e.g., depression and anxiety) that often accompany opioid withdrawal and abstinence. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our goal is to discover, develop and commercialize novel small molecule therapeutics for the treatment of CNS diseases and other diseases in order to improve the lives of people suffering from such illnesses. Using our </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">key understanding of intracellular signaling, we seek to accomplish our goal, using our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> expert drug discovery and clinical development teams, in two ways: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we seek to have the capability to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> medications with novel mechanisms that have the potential to treat CNS diseases and other diseases for which there are no previously marketed drugs; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we seek to develop drugs that either can differentiate themselves in competitive markets by addressing aspects of CNS diseases and other diseases which are not adequately treated by currently marketed drugs or can be effective with fewer side effects. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key elements of our strategy are to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continue to commercialize CAPLYTA, which has been approved by the FDA for the treatment of schizophrenia in adults, in the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercialize CAPLYTA, which has been approved by the FDA for the treatment of bipolar depression in adults, in the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">complete the development of lumateperone for additional neuropsychiatric indications, such as MDD; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expand the commercial potential of lumateperone by investigating its usefulness in additional neurological areas, such as autism spectrum disorder, and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">continue to advance our other product candidates in clinical development such as lenrispodun, for the treatment of CNS and other disorders; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284,</div> for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333,</div> for substance use disorders, pain and psychiatric comorbidities including depression and anxiety; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advance the earlier stage product candidates in our pipeline. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our Patent Portfolio </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;1, 2022, we owned or controlled approximately 125 patent families filed in the United States and other major markets worldwide, including approximately 115 issued or allowed U.S. patents, 54 pending U.S. patent applications, 420 issued foreign patents and 359 pending foreign patent applications, directed to novel compounds, formulations, methods of treatment, synthetic methods, and platform technologies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lumateperone tosylate is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> as CAPLYTA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> for the treatment of schizophrenia and for the treatment of bipolar depression. We have extensively characterized this compound and related compounds and filed additional patent applications on salt forms, polymorphs, pharmaceutical formulations, new indications, improved methods of manufacture, metabolites, derivatives, and structurally related novel compounds. As of February&#160;1, 2022, our lumateperone program consisted of approximately 33 patent families that we own or control, filed in the United States and other major markets, including 43 issued U.S. patents, 22 pending U.S. patent applications, 167 issued foreign patents and 158&#160;pending foreign patent applications. Thirteen patents are currently Orange Book listed in the United States. In addition to patent protection, lumateperone has five years of new chemical entity data exclusivity with the FDA, until December 2024. Patent protection for lumateperone includes: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary&#160;Description&#160;of&#160;Patent</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;Patent&#160;Application</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">United&#160;States&#160;or&#160;Foreign</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration&#160;Date</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007</div> Product Patent (approved drug product&#8212;lumateperone tosylate&#8212;in any pharmaceutical form)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted:</div></div> US (10,464,938*), AU</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;12, 2028 (US: does not include expected <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> extension in US for pediatric studies)</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary&#160;Description&#160;of&#160;Patent</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;Patent&#160;Application</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">United&#160;States&#160;or&#160;Foreign</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration&#160;Date</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007</div> Crystal Form Patent (approved drug product&#8212;lumateperone tosylate&#8212;in solid crystalline form)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted:</div></div> US (8,648,077*; 9,199,995*; 9,586,960*; RE48,825*), EP (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IT, LT, LU, LV, NL, NO, PL, PT, RO, SE, SI, SK, TR), AU, CA, CN, KR, HK, JP and MX</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">December&#160;1, 2029 (US; does not include expected <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> extension for pediatric studies; additional patent term extension possible through 2033**);</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">March&#160;12, 2029 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ex-US)</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Pending in IL, IN</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007</div> Dosage and Method of Treatment Patents (including schizophrenia, bipolar depression, sleep disorder indications)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted:</div></div> US (8,598,119*; 9,186,258, 9,616,061*; 10,117,867*; 10,702,522; RE48,839*), AU, CN, JP, KR, MX</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending: US (continuation), EP, IN, KR (divisional), MX (divisional)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">December&#160;28, 2029 (US; does not include expected <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> extension for pediatric studies; additional patent term extension possible through 2033**);</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">May&#160;27, 2029 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ex-US)</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007</div> Residual Symptoms Patent (treatment of negative/residual symptoms of schizophrenia)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted:</div></div> US (9,956,227*; 10,960,009*; 11,026,951*), AU, EP, JP, KR, MX, RU</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending: US (continuation), AU (divisional), JP (divisional), EP (divisional), IN, KR (divisional), MX (divisional), CA, BR IL, CN</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">December&#160;3, 2034 (US and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-US;</div> does not include expected US <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> extension for pediatric studies;)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents for Additional Dosage Forms</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted:</div></div> US (10,695,345*; 11,052,084)</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending: US (continuation), AU, CA, CN, EP, IN, IL, JP, KR, MX, RU</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">2037-2039</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents for Additional Indications (including post-traumatic stress disorder, impulse control disorder, symptoms associated with dementia, acute depression, and acute anxiety)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Granted: </div></div>US (11,053,245; 11,124,514)</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">Granted<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>or pending in US, EP, JP, and other countries</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">2033-2034</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orange-Book listed U.S. patents (NB: U.S. 8,598,119 and U.S. 9,586,960 have been requested for delisting as they have been superseded by RE48,839 and RE48,825, respectively) </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have filed patent term extension applications on two U.S. patents. The U.S. Patent and Trademark Office, or USPTO, has not completed its review of these applications. In the United States, we are permitted to extend the term of one U.S. patent for lumateperone or the use thereof. Accordingly, on completion of the USPTO&#8217;s review of our patent term extension applications, we must select one of the two patents to which any patent term extension granted will attach. Patent terms may be subject to change not only due to potential patent term extensions but also to any terminal disclaimer that reduces patent term, as well as other factors. Because the U.S. patent laws and related judicial interpretations change, modifications or new interpretations of the laws may impact our patent terms. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284</div> program relates to novel lumateperone derivatives for the treatment of behavioral disturbances associated with dementia, and other central nervous system disorders. Six families of patent applications have </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">been filed, which have already resulted in seven U.S. patents and fifteen foreign patents. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284</div> molecule has composition of matter protection to 2037, with possible extensions and additional Orange Book-listable protection to 2042. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our program on PDE1 inhibitors for cognition, dopamine-mediated and other disorders, cardiovascular disorders, as well as several others, includes patent protection across 52 families, including 31 families for the lead molecule, lenrispodun, as well as a wide range of filings on other proprietary compounds and indications. The lenrispodun lead molecule has composition of matter protection to 2029, with possible extensions and additional Orange Book-listable protection to 2034. Additionally, we expect to have data exclusivity in the European Union for up to 11 years from commercial launch. We have obtained patent coverage for lenrispodun in the treatment of cardiovascular disorders, including heart failure, that extends to 2034. We are also evaluating potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> compounds for lenrispodun which would have patent protection beyond 2030. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> program relates to novel compounds for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-addictive</div> treatment of pain and for the treatment of opiate use disorder. 16 families of patent applications have been filed, including four families which have already resulted in four U.S. patents and one EP grant, as well as four other foreign grants. These patent families will protect the lead compound, as well as many other analogs under development, beyond 2037 (exclusive of any patent term extensions and regulatory exclusivities). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also filed patent applications on novel proprietary targets and lead compounds for AD, which would provide compound protection beyond 2028 or beyond 2034, depending on which compound is ultimately selected for development. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Bristol-Myers Squibb License Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;31, 2005, we entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company, or BMS, pursuant to which we hold a license to certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of BMS relating to lumateperone and other specified compounds. The agreement was amended on November&#160;3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. We have the right to grant sublicenses of the rights conveyed by BMS. We are obliged under the license to use commercially reasonable efforts to develop and commercialize the licensed technology. We are also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the agreement, we made an upfront payment of $1.0&#160;million to BMS, a milestone payment of $1.25&#160;million in December&#160;2013, and a milestone payment of $1.5&#160;million in December&#160;2014 following the initiation of our first Phase 3 clinical trial for lumateperone for patients with schizophrenia. Upon FDA acceptance of a New Drug Application, or NDA, filing for lumateperone, we were obligated to pay BMS a $2.0&#160;million milestone payment. The FDA accepted our NDA filing for lumateperone for the treatment of schizophrenia in the third quarter of 2018 and, as a result, we paid the milestone payment in the first quarter of 2019. The FDA approved our NDA filing on December&#160;23, 2019 and as a result, we accrued $5.0&#160;million related to that milestone in the fourth quarter of 2019 which was paid in the first quarter of 2020. Remaining potential milestone payments under the agreement with respect to lumateperone total $5.0&#160;million if approvals to market the product are received in certain countries outside the U.S. Under the agreement, we may be obliged to make other milestone payments to BMS, for licensed products other than lumateperone, of up to an aggregate of approximately $14.75&#160;million. We are also obliged to make tiered single digit percentage royalty payments ranging between 5 &#8211; 9% on sales of licensed products. We are obliged to pay to BMS a percentage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> payments made in consideration of any sublicense. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The agreement extends, and royalties are payable, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis, through the later of ten&#160;years after first commercial sale of a licensed product in such country, expiration of the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, we may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not own or operate manufacturing facilities for the production of CAPLYTA or any of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials, active pharmaceutical ingredient, or API, and finished product for commercial sales of CAPLYTA and for our preclinical research and clinical trials, including our ongoing and anticipated trials. We believe that we would be able to contract with other third-party contract manufacturers to obtain API if our existing sources of API were no longer available, but there is no assurance that API would be available from other third-party manufacturers on acceptable terms, on the timeframe that our business would require, or at all. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Siegfried Supply Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;4, 2017, we entered into a supply agreement, or the Siegfried Agreement, with Siegfried Evionnaz SA, or Siegfried. Under the Siegfried Agreement, Siegfried has agreed to manufacture and supply the API for lumateperone in commercial quantities. We agreed to provide Siegfried with a rolling forecast of our anticipated requirements for supply of the API. Under the agreement, our purchase prices for supply of the API from Siegfried are specified prices based on the volume of API produced. The initial term of the Siegfried Agreement was five years, and in December 2021, the term was extended to January&#160;4, 2023. Either party may terminate the agreement prior to its expiration upon an uncured material breach by the other party, the liquidation or dissolution of the other party, the commencement of insolvency procedures or other bankruptcy-related proceedings that are not dismissed within a certain period of time, the appointment of any receiver, trustee or assignee to take possession of the properties of the other party, the cessation of all or substantially all of the other party&#8217;s business operations, a continuing force majeure event affecting the other party, or the debarment or certain other events involving the other party&#8217;s employees, affiliates or agents. Under the Siegfried Agreement, we have the right to and may purchase the API for lumateperone from other suppliers. As of December&#160;31, 2021, the Company has committed to purchasing production campaigns of API from Siegfried that are expected to be delivered in the first half of 2022 through 2023. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Lonza Manufacturing Services Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2017, we entered into a manufacturing services agreement, or the Lonza Agreement, with Lonza Ltd., or Lonza. Under the Lonza Agreement, Lonza has agreed to manufacture lumateperone, with purchase prices determined in each project plan. We agreed to provide Lonza with a written forecast of our estimated quarterly requirements. The term of the Lonza Agreement ends on the later of the seventh anniversary of the effective date of the agreement or five years after the first marketing approval by the FDA or European Medicines Agency, or EMA, of lumateperone from the Lonza facility for commercial supply. Either party may terminate the agreement prior to its expiration upon a prior written notice, an uncured material breach by the other party, the insolvency, liquidation, dissolution or bankruptcy of the other party, or a continuing force majeure event affecting the other party, and may be extended by mutual consent. As of December&#160;31, 2021, the Company has committed to purchasing a production campaign of API from Lonza that is expected to be delivered in the second half of 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development and commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to manage our manufacturing contractors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We initiated the commercial launch of CAPLYTA in the United States in late March 2020. In support of our commercialization efforts, we hired a national sales force initially consisting of approximately 240 sales representatives, and in support of the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021, we expanded our sales force to approximately 320 sales representatives. In the future, we may choose to commercialize CAPLYTA or any other products, in markets outside of the United States, if approved for sale in such markets, by establishing one or more strategic alliances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are currently approved to sell CAPLYTA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults in the U.S. market. CAPLYTA is priced in line with other currently marketed branded antipsychotics indicated for the treatment of schizophrenia and for the treatment of bipolar depression. We distribute CAPLYTA principally through three third-party wholesale drug distributors whose concentration are between 28% and 40% of total sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. We compete, or will compete, with existing and new products being developed by our competitors. Some of these competitors are pursuing the development of pharmaceuticals that target the same diseases and conditions that our research and development programs target. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we are successful in commercializing CAPLYTA and developing and obtaining approval of our product candidates, we would compete with a variety of established drugs in the areas of our targeted CNS therapeutic indications. CAPLYTA for the treatment of schizophrenia and for the treatment of bipolar depression competes with, among other branded products, Latuda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Sunovion, Rexulti<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Otsuka Pharmaceutical, VRAYLAR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Allergan, LYBALVI<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Alkermes, and Fanapt<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Vanda Pharmaceuticals. In addition, CAPLYTA competes and our product candidates, if approved, would compete with, among other generic antipsychotic products, aripiprazole, haloperidol, paliperidone, risperidone, quetiapine/XR, olanzapine and clozapine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the companies described above and other competitors may have a variety of drugs in development or be awaiting FDA approval that could reach the market and become established before our approved product is established in the market or before we are able to sell our product candidates, if approved. Our competitors may also develop alternative therapies that could further limit the market for any drugs that we may develop. Many of our competitors are using technologies or methods different or similar to ours to identify and validate drug targets and to discover novel small molecule drugs. Many of our competitors and their collaborators have significantly greater experience than we do in the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identifying and validating targets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">screening compounds against targets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">preclinical studies and clinical trials of potential pharmaceutical products; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining FDA and other regulatory clearances. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, many of our competitors and their collaborators have substantially greater advantages in the following areas: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">capital resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">research and development resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacturing capabilities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales and marketing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Smaller companies also may prove to be significant competitors, particularly through proprietary research discoveries and collaborative arrangements with large pharmaceutical and established biotechnology companies. Many of our competitors have products that have been approved by the FDA or are in advanced development. We face competition from other companies, academic institutions, governmental agencies and other public and private research organizations for collaborative arrangements with pharmaceutical and biotechnology companies, in recruiting and retaining highly qualified scientific and management personnel and for licenses to additional technologies. Our competitors, either alone or with their collaborators, may succeed in developing technologies or drugs that are more effective, safer, and more affordable or more easily administered than ours and may achieve patent protection or commercialize drugs sooner than us. Developments by others may render our product candidates or our technologies obsolete. Our failure to compete effectively could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">United States&#8212;FDA Process </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The research, development, testing, manufacture, labeling, promotion, advertising, import and export, distribution and marketing, among other things, of drug products are extensively regulated by governmental authorities in the United States and other countries. In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning letters, fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Drug Approval Process.</div></div> None of our drug product candidates may be marketed in the United States until the drug has received FDA approval. Such approval can take many years to obtain and may be rejected by the FDA at a number of steps. The steps required before a drug may be marketed in the United States generally include the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completion of extensive preclinical laboratory tests, animal studies, and formulation studies in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an Investigational New Drug application, or IND, for human clinical testing, which must become effective before human clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an NDA after completion of all clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">satisfactory completion of an FDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility or facilities at which the API and finished drug product are produced and tested to assess compliance with current Good Manufacturing Practices, or cGMPs; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of FDA inspections of clinical trial sites to assure that data supporting the safety and effectiveness of product candidates has been generated in compliance with Good Clinical Practices; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical tests include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND, which must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the conduct of the trial, such as whether human research subjects will be exposed to an unreasonable health risk. In such a case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. The FDA, sponsor or an Institutional Review Board, or IRB, may place a study on hold at any time during development. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Clinical trials involve administration of the investigational drug to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol must be provided to the FDA as part of a separate submission to the IND. Further, an IRB, for each medical center proposing to conduct the clinical trial, must review and approve the study protocol and informed consent information for study subjects for any clinical trial before it commences at that center, and the IRB must monitor the study until it is completed. There are also requirements governing reporting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> clinical trials and clinical trial results to public registries. Study subjects must sign an informed consent form before participating in a clinical trial. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials necessary for product approval typically are conducted in three sequential phases, but the phases may overlap. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1 usually involves the initial introduction of the investigational drug into a limited population, typically healthy humans, to evaluate its short-term safety, dosage tolerance, metabolism, pharmacokinetics and pharmacologic actions, and, if possible, to gain an early indication of its effectiveness. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2 usually involves trials in a limited patient population to (i)&#160;evaluate dosage tolerance and appropriate dosage; (ii)&#160;identify possible adverse effects and safety risks; and (iii)&#160;evaluate preliminarily the efficacy of the drug for specific targeted indications. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3 trials, commonly referred to as pivotal studies, are undertaken in an expanded patient population at multiple, geographically dispersed clinical trial centers to further evaluate clinical efficacy and test further for safety by using the drug in its final form. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or an IRB may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. The FDA may approve an NDA for a product candidate, but require that the sponsor conduct additional clinical trials to further assess the drug after NDA approval under a post-approval commitment. Post-approval trials are typically referred to as Phase 4 clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the development of a new drug, sponsors are given an opportunity to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach an agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial that they believe will support approval of the new drug. A sponsor may request a Special Protocol Assessment, or SPA, to reach an agreement with the FDA that the protocol design, clinical endpoints, and statistical analyses are acceptable to support regulatory approval of the product candidate with respect to effectiveness in the indication studied. If such an agreement is reached, it will be documented and made part of the administrative record, and it will be binding on the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> issue essential to determining the safety or effectiveness of the product after clinical studies begin, or if the sponsor fails to follow the protocol that was agreed upon with the FDA. There is no guarantee that a study will ultimately be adequate to support an approval even if the study is subject to an SPA. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal safety studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and the manufacturer must develop methods for testing the quality, purity and potency of the final drugs. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of preclinical studies and of clinical studies, together with other detailed information, including information on the manufacture and composition of the drug, are submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. An NDA must be accompanied by a significant user fee, which is waived for the first NDA submitted by a qualifying small business. The NDA is subject to a <div style="white-space:nowrap;display:inline;">sixty-day</div> acceptance period, and if sufficiently complete to permit substantive review, will be filed by the FDA at the end of that period. For NDAs that are assigned a standard review designation, the FDA&#8217;s goal is to complete its review ten months from the date the FDA files the NDA and, for priority review of those NDAs, six months from the date the FDA files the NDA. These goals can be extended by the FDA through requests for additional information from the sponsor. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources. The FDA will review the NDA and may deem it to be inadequate to support approval, and we cannot be sure that any approval will be granted on a timely basis, if at all. The FDA may also refer the application to the appropriate advisory committee, typically a panel of clinicians, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendations of the advisory committee, but it typically follows such recommendations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA inspects the facility or the facilities at which the drug and/or its active pharmaceutical ingredient is manufactured and will not approve the product unless the manufacturing is in compliance with cGMPs. If the FDA evaluates the NDA and the manufacturing facilities are deemed acceptable, the FDA may issue an approval letter, or in some cases a Complete Response Letter. The approval letter authorizes commercial marketing of the drug for specific indications. As a condition of NDA approval, the FDA may require post-marketing testing and surveillance to monitor the drug&#8217;s safety or efficacy, or impose other conditions. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or additional clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials is not always conclusive and the FDA may interpret data differently than we or our collaborators interpret data. Alternatively, the FDA could also approve the NDA with a Risk Evaluation and Mitigation Strategy to mitigate risks of the drug, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. Once the FDA approves a drug, the FDA may withdraw product approval if <div style="white-space:nowrap;display:inline;">on-going</div> regulatory requirements are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase 4 clinical trials, and surveillance programs to monitor the safety effects of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs or other information. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Post-Approval Requirements.</div> After a drug has been approved by the FDA for sale, the FDA may require that certain post-approval requirements be satisfied, including the conduct of additional clinical trials. In </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> addition, certain changes to an approved product, such as adding new indications, making certain manufacturing changes, or making certain additional labeling claims, are subject to further FDA review and approval. Before a company can market products for additional indications, it must obtain additional approvals from the FDA, typically through the submission and approval of a supplemental NDA. Obtaining approval for a new indication generally requires that additional clinical trials be conducted. A company cannot be sure that any additional approval for new indications for any product candidate will be approved on a timely basis, or at all. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If post-approval conditions are not satisfied, the FDA may withdraw its approval of the drug. In addition, holders of an approved NDA are required to (i)&#160;report certain adverse reactions to the FDA and maintain pharmacovigilance programs to proactively look for these adverse events; (ii)&#160;comply with certain requirements concerning advertising and promotional labeling for their products; and (iii)&#160;continue to have quality control and manufacturing procedures conform to cGMPs after approval. The FDA periodically inspects the sponsor&#8217;s records related to safety reporting and/or manufacturing facilities, which includes assessment of <div style="white-space:nowrap;display:inline;">on-going</div> compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. We intend to continue to use third-party manufacturers to produce our products in clinical and commercial quantities, and future FDA inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including recall of the product from the market or withdrawal of approval of the NDA for that drug. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Patent Term Restoration and Marketing Exclusivity.</div> Depending upon the timing, duration and specifics of FDA approval of the use of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally <div style="white-space:nowrap;display:inline;">one-half</div> the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the extension must be requested prior to expiration of the patent. Also, the approval must be the first permitted commercial marketing or use of the active ingredient under the relevant provision of law. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We have applied for, and in the future we intend to apply for, restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data and market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of <div style="white-space:nowrap;display:inline;">non-patent</div> data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <div style="white-space:nowrap;display:inline;">non-infringement.</div> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> applicant submitting a full NDA would be required to conduct, or obtain a right of reference to all of the preclinical studies, adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. The FDCA also provides seven years of market exclusivity for a drug designated for a rare disease or condition (e.g., a disease or condition that affects less than 200,000 people in the United States). The exclusivity prohibits the approval of the same drug for the same disease or condition, unless there is a showing of clinical superiority. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Foreign Regulation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials and approval of foreign countries or economic areas, such as the European Union, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Pricing and Reimbursement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and internationally, sales of any approved products, and our ability to generate revenues on such sales, are dependent, in significant part, on the availability of adequate coverage and reimbursement from third-party payors, such as state and federal governments, managed care providers and private insurance plans. Private insurers, such as health maintenance organizations and managed care providers, have implemented cost-cutting and reimbursement initiatives and likely will continue to do so in the future. These include establishing formularies that govern the drugs and biologics that will be offered and the <div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> obligations of member patients for such products. We may need to conduct pharmacoeconomic studies to demonstrate the cost-effectiveness of our products for formulary coverage and reimbursement. Even with such studies, our products may be considered less safe, less effective or less cost-effective than existing products, and third-party payors may not provide coverage and reimbursement for our product candidates, in whole or in part. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, particularly in the United States and increasingly in other countries, we are required to provide discounts and pay rebates to state and federal governments and agencies in connection with purchases of our products that are reimbursed by such entities. It is possible that future legislation in the United States and other jurisdictions could be enacted to potentially impact reimbursement rates for the products we are developing and may develop in the future and could further impact the levels of discounts and rebates paid to federal and state government entities. Any legislation that impacts these areas could impact, in a significant way,&#160;our ability to generate revenues from sales of any approved product that we bring to market. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Political, economic and regulatory influences are subjecting the health care industry in the United States to fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the health care system in ways that could significantly affect our future business. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, or collectively, the ACA, enacted in March 2010, substantially changed the way health care is financed by both governmental and private insurers. Certain legislative changes to and regulatory changes under the ACA have occurred over the past few years. For instance, the Bipartisan Budget Act of 2018 increased the ACA required manufacturer <div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">point-of-sale</div></div> discount from 50% to 70% off the negotiated price for Medicare Part D beneficiaries during their coverage gap period beginning in 2019. Further legislative changes to and regulatory changes under the ACA remain possible. We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that may be charged for any of our product candidates, if approved. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Sales and Marketing </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, in conjunction with the U.S. Federal Trade Commission, or FTC, regulates all advertising and promotion activities for products under FDA&#8217;s jurisdiction prior to and after approval, including standards and regulations for <div style="white-space:nowrap;display:inline;"><div style="white-space:nowrap;display:inline;">direct-to-consumer</div></div> advertising, dissemination of <div style="white-space:nowrap;display:inline;">off-label</div> information, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to the drug, including changes in indications, labeling, or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new or supplemental NDA, which may require us to collect additional data or conduct additional nonclinical studies and clinical trials. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising, consent decrees and the full range of civil and criminal penalties available to the FDA. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians may prescribe legally available drugs for uses that are not described in the drug&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such <div style="white-space:nowrap;display:inline;">off-label</div> uses are common across medical specialties, and often reflect a physician&#8217;s belief that the <div style="white-space:nowrap;display:inline;">off-label</div> use is the best treatment for the patient. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers&#8217; communications regarding <div style="white-space:nowrap;display:inline;">off-label</div> uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising, consent decrees and the full range of civil and criminal penalties available to the FDA. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, our ability to market a product is contingent upon obtaining marketing authorization from the appropriate regulatory authorities. The requirements governing marketing authorization, pricing and reimbursement vary widely from country to country. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At such time as we market, sell and distribute any products for which we obtain marketing approval, it is possible that our business activities could be subject to scrutiny and enforcement under one or more federal or state health care fraud and abuse laws and regulations. These fraud and abuse laws include: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Anti-Kickback Law, which prohibits, among other things, knowingly or willingly offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any health care items or service for which payment may be made, in whole or in part, by federal health care programs such as Medicare and Medicaid; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense, or knowingly and willfully making false statements relating to healthcare matters; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, requires certain pharmaceutical manufacturers to engage in extensive tracking of payments and other transfers of value to physicians and teaching hospitals, and to submit such data to the Centers for Medicare and Medicaid Studies, or CMS, which will then make all of this data publicly available on the CMS website; and </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Analogous state laws and regulations, including state anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states, </div></td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"> apply regardless of the payer, as well as other state laws that require pharmaceutical companies to report expenses related to the marketing and promotion of pharmaceutical products, prohibit certain gifts or payments to health care providers in the state, and/or require pharmaceutical companies to implement compliance programs or marketing codes of conduct. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Violations of fraud and abuse laws may be punishable by significant criminal and/or civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal health care programs (including Medicare and Medicaid) and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties also may be imposed upon executive officers and employees, including criminal sanctions against executive officers under the <div style="white-space:nowrap;display:inline;">so-called</div> &#8220;responsible corporate officer&#8221; doctrine, even in situations where the executive officer did not intend to violate the law and was unaware of any wrongdoing. Given the penalties that may be imposed on companies and individuals if convicted, allegations of such violations often result in settlements even if the company or individual being investigated admits no wrongdoing. Settlements often include significant civil sanctions, including fines and civil monetary penalties, and corporate integrity agreements. If the government was to allege or convict us or our executive officers, employees or consultants of violating these laws, our business could be harmed. In addition, private individuals have the ability to bring similar actions under some of the fraud and abuse laws described above. Our activities could be subject to challenge for the reasons discussed above and due to the broad scope of these laws and extensive enforcement of them by law enforcement authorities. Further, federal and state laws that require manufacturers to make reports on pricing and marketing information could subject us to penalty provisions. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Human Capital </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&#160;1, 2022, we employed 512&#160;employees all of whom were full-time. We consider our relations with our employees to be good. To successfully commercialize CAPLYTA and develop our drug candidates, we must be able to attract and retain highly skilled personnel. We anticipate hiring a number of additional employees during 2022. We continually evaluate the business need and opportunity and balance <div style="white-space:nowrap;display:inline;">in-house</div> expertise and capacity with outsourced expertise and capacity. Currently, we outsource substantial clinical trial work to clinical research organizations and drug manufacturing to contract manufacturers. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. Pharmaceutical companies both large and small compete for a limited number qualified applicants to fill specialized positions. To attract qualified applicants, we offer a total rewards package consisting of base salary and cash target bonus, a comprehensive benefit package and equity compensation for every employee. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Actual bonus payout is based on performance. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were originally incorporated in the State of Delaware in August 2012 under the name &#8220;Oneida Resources Corp.&#8221; Oneida Resources Corp. was a &#8220;shell&#8221; company registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act, with no specific business plan or purpose until it began operating the business of Intra-Cellular Therapies, Inc. (now <div style="white-space:nowrap;display:inline;">re-named</div> ITI, Inc., or ITI) through a reverse merger transaction on August&#160;29, 2013, or the Merger. ITI was incorporated in Delaware in May 2001 to focus primarily on the development of novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Effective upon the Merger, a wholly owned subsidiary of the Company merged with </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and into ITI. ITI and ITI Limited continue as the operating subsidiaries of the Company. As used herein, the words the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Intra-Cellular Therapies, Inc. and its wholly owned subsidiaries, ITI, Inc. and ITI Limited. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters and laboratory are located at 430 East 29th Street, New York, New York 10016, and our telephone number is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(646)&#160;440-9333.</div> We also have an office in Towson, Maryland. We maintain a website at www.intracellulartherapies.com, to which we regularly post copies of our press releases as well as additional information about us. We make available free of charge through the Investors section of our web site our Annual Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> Quarterly Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> Current Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission.&#160;The Securities and Exchange Commission&#160;maintains an internet site (<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">http://www.sec.gov</div>)&#160;that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the&#160;Securities and Exchange Commission.&#160;We include our web site address in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> only as an inactive textual reference. Information contained in our website does not constitute a part of this report or our other filings with the SEC. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td id="tx234590_3" style="width:10%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1A.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">RISK FACTORS </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Except for the historical information contained herein, this report contains forward-looking statements that involve risks and uncertainties. These statements include projections about our finances, plans and objectives for the future, future operating and economic performance and other statements regarding future performance. These statements are not guarantees of future performance or events. Our actual results could differ materially from those discussed in this report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in the following section, as well as those discussed in Part II, Item&#160;7 entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere throughout this report. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You should consider carefully the following risk factors, together with all of the other information included or incorporated by reference in this report. If any of the following risks, either alone or taken together, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment. </div></div></div> <div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Summary of Risk Factors </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks and uncertainties, including those highlighted in this section below, that represent challenges that we face in connection with the successful implementation of our strategy. The occurrence of one or more of the events or circumstances described in more detail in the risk factors below, alone or in combination with other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations. Such risks include, but are not limited to: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">In order to execute our business plan and achieve profitability, we need to effectively commercialize CAPLYTA, which received FDA approval in December 2019 for the treatment of schizophrenia in adults and in December 2021 for the treatment of bipolar depression in adults. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">If we do not obtain regulatory approval of lumateperone for other indications in the United States, or for any indication in foreign jurisdictions, we will not be able to market lumateperone for other indications or in other jurisdictions, which will limit our commercial revenues. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">If our newly established sales and marketing capabilities or our third-party relationships for the commercialization of lumateperone are not effective, lumateperone may not be successfully commercialized. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We have generated limited revenue from product sales and there is no guarantee that our revenue from the sale of CAPLYTA or other product candidates, if approved, will be substantial. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">There is no guarantee that our planned clinical trials for lumateperone will be successful. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We expect our net losses to continue for at least a few years and are unable to predict the extent of future losses or when we will become profitable, if ever. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We may require additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Even though the FDA has granted approval of CAPLYTA for the treatment of schizophrenia and bipolar depression, the terms of the approval may limit its commercial potential. Additionally, CAPLYTA is still subject to ongoing regulatory requirements. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Delays, suspensions and terminations in our clinical trials could result in increased costs to us, delay our ability to generate product revenues and therefore may have a material adverse effect on our business, results of operations and future growth prospects. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Safety issues with our product candidates or approved product, or with product candidates or approved products of third parties that are similar to our product candidates, could give rise to delays in the regulatory approval process, restrictions on labeling or product withdrawal after approval. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Preliminary and interim data from our clinical studies that we may announce or publish from time to time may change as more patient data become available. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing our product candidates. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Even if we successfully complete the clinical trials of one or more of our product candidates, the product candidates may fail for other reasons. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We are subject to ongoing regulatory obligations and restrictions with regard to lumateperone and, following regulatory approval of any of our product candidates, we will be subject to ongoing regulatory obligations and restrictions with regard to such product candidates, which may result in significant expense and limit our ability to commercialize lumateperone and our other potential products. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">CAPLYTA and our product candidates, if approved, may not gain acceptance among physicians, patients, or the medical community, thereby limiting our potential to generate revenues, which will undermine our future growth prospects. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">CAPLYTA has only recently been, and our other product candidates have never been, manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop larger scale manufacturing processes that are more efficient and cost-effective to commercialize our product candidates which may not be successful. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We rely on third-party manufacturers to manufacture and supply lumateperone and our other product candidates for us. If one of our suppliers or manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers or manufacturers. We may also face significant delays in our clinical trials, regulatory approvals and product introductions and commercialization. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">We will need to continue to manage our organization and we may encounter difficulties with our staffing and any future transitions, which could adversely affect our results of operations. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Our ability to compete may be undermined if we do not adequately protect our proprietary rights. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Our ability to generate product revenues will be diminished if lumateperone or any of our other potential products does not receive coverage from payors or sell for inadequate prices, or if patients are unable to obtain adequate levels of reimbursement. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Many of our competitors have greater resources and capital than us, putting us at a competitive disadvantage. If our competitors develop and market products that are more effective than lumateperone or our other product candidates, they may reduce or eliminate our commercial opportunity. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could continue to have a material impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and preclinical studies. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Numerous factors could result in substantial volatility in the trading price of our stock. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The price of our common stock could be subject to volatility related or unrelated to our operations. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Our management has broad discretion over the use of our cash and we may not use our cash effectively, which could adversely affect our results of operations. </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Risks Related to Our Business </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">In order to execute our business plan and achieve profitability, we need to effectively commercialize CAPLYTA, which received FDA approval in December 2019 for the treatment of schizophrenia in adults and in December 2021 for the treatment of bipolar depression in adults. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CAPLYTA is our only drug that has been approved for sale and it has been approved only for the treatment of schizophrenia in adults and bipolar depression in adults in the United States. We are focusing a significant portion of our activities and resources on CAPLYTA, and we believe our prospects are highly dependent on, and a significant portion of the value of our company relates to, our ability to successfully commercialize CAPLYTA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults in the United States. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful commercialization of CAPLYTA is subject to many risks. We have never, as an organization, launched or commercialized any other product, and there is no guarantee that we will be able to successfully commercialize CAPLYTA for its approved indications. There are numerous examples of failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than us. We expect that continued commercial success of CAPLYTA for the treatment of schizophrenia and bipolar depression will depend on many factors, including the following: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the efficacy, cost, approved use, and side-effect profile of CAPLYTA regimens relative to competitive treatment regimens for the treatment of schizophrenia and bipolar depression; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the effectiveness of our commercial strategy for the marketing of CAPLYTA, including our pricing strategy and the effectiveness of our efforts to obtain adequate third-party reimbursements; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">maintaining and successfully monitoring commercial manufacturing arrangements for CAPLYTA with third-party manufacturers to ensure they meet our standards and those of regulatory authorities, including the FDA, which extensively regulate and monitor pharmaceutical manufacturing facilities; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">our ability to meet the demand for commercial supplies of CAPLYTA; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the acceptance of CAPLYTA by patients, the medical community and third-party payors; and </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the effect of recent or potential health care legislation in the United States. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe that CAPLYTA for the treatment of schizophrenia and bipolar depression has a commercially competitive profile, we cannot accurately predict the amount of revenue that will be generated from the sale of CAPLYTA. If we do not effectively commercialize CAPLYTA, we will not be able to execute our business plan and may not be able to achieve profitability. If our revenues, market share and/or other indicators of market acceptance of CAPLYTA do not meet the expectations of investors or public market analysts, the market price of our common stock would likely decline. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">If we do not obtain regulatory approval of lumateperone for other indications in the United States, or for any indication in foreign jurisdictions, we will not be able to market lumateperone for other indications or in other jurisdictions, which will limit our commercial revenues. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While CAPLYTA has been approved by the FDA for the treatment of schizophrenia and bipolar depression in adults, lumateperone has not been approved by the FDA for any other indications, and it has not been approved in any other jurisdiction for these indications or for any other indication. In order to market lumateperone for other indications or in other jurisdictions, we must obtain regulatory approval for each of those indications and in each of the applicable jurisdictions, and we may never be able to obtain such approval. Approval of CAPLYTA by the FDA for the treatment of schizophrenia and bipolar depression does not ensure that foreign jurisdictions will also approve CAPLYTA for those indications, nor does it ensure that lumateperone will be approved by the FDA for additional indications. Lumateperone is in Phase 3 clinical development as an </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adjunctive therapy for the treatment of MDD. There is no guarantee that any ongoing or future studies of lumateperone in other indications will be successful, or that the FDA or any regulatory authority in foreign jurisdictions will approve lumateperone for any of those indications. The research, testing, manufacturing, labeling, approval, sale, import, export, marketing, and distribution of pharmaceutical product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, whose regulations differ from country to country. We will be required to comply with different regulations and policies of the jurisdictions where we seek approval for our product candidates, and we have not yet identified all of the requirements that we will need to satisfy to submit lumateperone for approval for other indications or in other jurisdictions. This will require additional time, expertise and expense, including the potential need to conduct additional studies or development work for other jurisdictions beyond the work that we have conducted to support our NDA submission in schizophrenia or our sNDA submissions in bipolar depression. In addition, strategic considerations need to be taken into account when determining whether and when to submit lumateperone for approval in other jurisdictions. If we do not receive marketing approval for lumateperone for any other indication or from any regulatory agency outside of the United States, we will never be able to commercialize lumateperone for any other indication in the United States or for any indication in any other jurisdiction. Even if we do receive additional regulatory approvals, we may not be successful in commercializing those opportunities. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the results or timing of regulatory filings, the regulatory process, regulatory developments, clinical trials or preclinical studies, or other activities, actions or decisions related to lumateperone do not meet our or others&#8217; expectations, the market price of our common stock could decline significantly. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">If the sales and marketing capabilities we have established or our third-party relationships for the commercialization of lumateperone are not effective, lumateperone may not be successfully commercialized. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the commercial launch of CAPLYTA in late March 2020, we had no experience as a company in marketing drugs or with respect to pricing and obtaining adequate third-party reimbursement for drugs. We continue to build our commercial organization and capabilities in the United States in order to market CAPLYTA for the treatment of schizophrenia and bipolar depression. We will need to successfully complete the expansion of our capabilities and/or enter into arrangements with third parties to sell and market CAPLYTA for the treatment of schizophrenia and bipolar depression and, if approved, our other product candidates. If our sales and marketing capabilities or our third-party relationships for the commercialization of our products are not effective, our business could be materially harmed. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">We have generated limited revenue from product sales and there is no guarantee that our revenue from the sale of CAPLYTA will be substantial. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from product sales and achieve profitability depends on our ability to successfully commercialize CAPLYTA for the treatment of schizophrenia and bipolar depression in adults in the United States and to complete the development of and obtain regulatory approvals necessary to commercialize lumateperone in other indications and our other product candidates. We have a limited operating history on which to evaluate our business and prospects. To date, we have generated limited product revenues from CAPLYTA and we cannot guarantee that CAPLYTA will be successfully commercialized or that any of our product candidates currently in development will ever become marketable products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must demonstrate that our product candidates satisfy rigorous standards of safety and efficacy for their intended uses before the FDA and other regulatory authorities in the European Union and elsewhere will approve them for commercialization. Significant additional research, preclinical testing and clinical testing is required before we can file applications with the FDA or other regulatory authorities for approval of our drug candidates. In addition, to compete effectively, our drugs must be easy to administer, cost-effective and economical to manufacture on a commercial scale. We may not achieve any of these objectives. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lumateperone is in Phase 3 clinical development as a novel treatment for MDD. In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with Bipolar I or Bipolar II disorder and mixed features in patients with MDD. We expect to complete Study 403 in the second half of 2022 and following completion we intend to discuss the results with the FDA to determine whether Study 403, as amended, will provide supportive data for a potential future regulatory filing for this indication. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we intend to pursue the development of our PDE program, including lenrispodun for the treatment of several CNS and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-CNS</div> conditions, including cardiovascular disease. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for lenrispodun for Parkinson&#8217;s disease. In the fourth quarter of 2018, we announced that the Phase 1/2 clinical trial of lenrispodun has been completed and topline results demonstrated lenrispodun was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. We have initiated our Phase&#160;2 clinical program with&#160;lenrispodun&#160;for Parkinson&#8217;s disease and expect to commence patient enrollment in the first half of 2022. In addition, in the second quarter of 2020, we announced topline results from Study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-214-104,</div></div> a Phase 1/2 translational study of single ascending doses of lenrispodun in patients with chronic systolic heart failure with reduced ejection fraction. In this study, lenrispodun improved cardiac output by increasing heart contractility and decreasing vascular resistance. Agents that both increase heart contractility (inotropism) and decrease vascular resistance (vasodilation) are called inodilators. Inodilators in current clinical use are associated with the development of arrhythmias, which are abnormal heart rhythms that when serious can impair heart function and lead to mortality. Lenrispodun, which acts through a novel mechanism of action, was not associated with arrhythmias in this study and was generally well-tolerated in all patients. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that the clinical development of these or any other drug candidates in preclinical testing or clinical development will be successful, that we will receive the regulatory approvals required to commercialize them or that any of our other research and drug discovery programs will yield a drug candidate suitable for investigation through clinical trials. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">There is no guarantee that our planned clinical trials for lumateperone will be successful. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical rate of failures for product candidates in clinical development and late-stage clinical trials is high. We are conducting and plan to conduct further clinical trials in lumateperone in indications beyond schizophrenia and bipolar depression, and there is no guarantee that we will have the same level of success in these trials as we have had in certain of our previous clinical trials, or be successful at all. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, although we believe that lumateperone and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> compounds may also have clinical utility in indications other than schizophrenia and bipolar depression, such as behavioral disturbances in dementia, intermittent explosive disorder, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-motor</div> disorders associated with Parkinson&#8217;s disease, obsessive compulsive disorder and anxiety disorders and post-traumatic stress disorder, we have never tested lumateperone in Phase 3 clinical trials in the patient populations for these other indications, except for our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007-201</div></div> Phase 3 trial in patients with a clinical diagnosis of probable AD and clinically significant symptoms of agitation, which we determined to discontinue following our independent data monitoring committee&#8217;s recommendation that the study should be stopped for futility. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not successfully complete clinical development and obtain approval of lumateperone in indications beyond schizophrenia and bipolar depression, we will be unable to market, sell and generate revenue from lumateperone in any of these other indications. Even though we have successfully completed certain clinical trials for CAPLYTA in patients with schizophrenia and bipolar depression, those results are not necessarily predictive of results of future trials that may be needed before we may submit an NDA to the FDA for any </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">indication beyond schizophrenia and bipolar depression. Of the vast number of drugs in development, only a small percentage result in the submission of an NDA to the FDA, and even less result in the NDA ultimately being approved by the FDA for commercialization. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">We expect our net losses to continue for at least a few years and are unable to predict the extent of future losses or when we will become profitable, if ever. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced significant net losses since inception. As of December&#160;31, 2021, we had an accumulated deficit of approximately $1.2&#160;billion. We expect to incur net losses over the next few years as we advance our programs and incur significant clinical development costs. To date, we have received limited revenues from the commercialization of CAPLYTA. Prior to our commercial launch of CAPLYTA in late March 2020, substantially all of our revenues were from our license and collaboration agreement with Takeda and our agreements with various U.S. governmental agencies and other parties, including our research and development grants. To obtain revenues from lumateperone, we must successfully commercialize lumateperone in its approved indications. To obtain revenues from our product candidates, we must succeed, either alone or with others, in developing, obtaining regulatory approval for, and manufacturing and marketing drugs with significant market potential. We may never succeed in these activities, and may never generate revenues that are significant enough to achieve profitability. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">We may require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have consumed substantial amounts of capital since our inception. Our cash, cash equivalents, investment securities and restricted cash totaled $413.7&#160;million at December&#160;31, 2021. In January 2022, we completed an underwritten public offering of shares of our common stock resulting in net proceeds to us of approximately $433.7&#160;million, after deducting underwriting discounts and commissions and offering expenses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">With our cash, cash equivalents and investment securities, including the net proceeds from our public offering in January 2022, we intend to fund the following:&#160;commercialization activities in connection with the commercialization of CAPLYTA for the treatment of schizophrenia and bipolar depression; the development of lumateperone in our late stage clinical programs; the development of our other product candidates, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284,</div> lenrispodun and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333;</div> working capital needs in connection with the commercialization of CAPLYTA; and the remaining proceeds, if any, to fund new and ongoing research and development activities, manufacturing activities in connection with new products, general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of our intellectual property. Accordingly, we will continue to require substantial additional capital beyond the net proceeds from our January 2022 offering to continue our clinical development and commercialization activities. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our products under development. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount of product sales from lumateperone; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of maintaining and expanding our sales and marketing capabilities for lumateperone; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of preparing applications for regulatory approvals for lumateperone in additional indications other than in schizophrenia and bipolar depression, and potentially in jurisdictions other than the United States, and for other product candidates, as well as the costs required to support review of such applications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of manufacturing and distributing lumateperone for commercial use in the United States; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">our ability to obtain regulatory approval for, and subsequently generate product sales from, lumateperone in additional indications other than in schizophrenia and bipolar depression or in jurisdictions other than the United States; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the progress in, and the costs of, our preclinical studies and clinical trials and other research and development programs; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the scope, prioritization and number of our research and development programs; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the ability of any future collaborators and us to reach the milestones, and other events or developments, triggering payments under any future collaboration agreements or to otherwise make payments under such agreements; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">our ability to enter into new, and to maintain any existing, collaboration and license agreements; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the extent to which any future collaborators are obligated to reimburse us for clinical trial costs under any future collaboration agreements; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the costs of maintaining or securing manufacturing and supply arrangements for clinical or commercial production of lumateperone or our other product candidates; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the costs of preparing applications for regulatory approvals for our product candidates; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the costs of preparing for and establishing, or contracting for, sales and marketing capabilities if we obtain regulatory approvals for our product candidates; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the costs involved in expanding the accounting and data management systems to support commercial operations; and </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the costs associated with litigation, including the costs incurred in defending against any product liability claims that may be brought against us related to lumateperone or our other product candidates. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through our existing cash, cash equivalents and investment securities, strategic collaborations, private or public sales of our securities, debt financings, grant funding, or by licensing all or a portion of our products, product candidates or technology. Turmoil and volatility in the financial markets have adversely affected the market capitalizations of many biotechnology companies, and generally made equity and debt financing more difficult to obtain. This, coupled with other factors, may limit our access to additional financing. This could have a material adverse effect on our ability to access sufficient funding. We cannot be certain that additional funding will be available to us on acceptable terms, or at all. If we do obtain additional funding through equity offerings, the ownership of our existing stockholders and purchasers of shares of our common stock in any such offering will be diluted, and the terms of any financing may adversely affect the rights of our stockholders. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline. If funds are not available, we will be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts. We also could be required to seek funds through arrangements with collaboration partners or otherwise that may require us to relinquish rights to some of our technologies, products or product candidates or otherwise agree to terms unfavorable to us. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Our management has broad discretion over the use of our cash and we may not use our cash effectively, which could adversely affect our results of operations. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has significant flexibility in applying our cash resources and could use these resources for corporate purposes that do not increase our market value, or in ways with which our stockholders may not agree. We may use our cash resources for corporate purposes that do not yield a significant return or any return at all for our stockholders, which could adversely affect our future growth prospects. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Delays, suspensions and terminations in our clinical trials or the need to conduct additional clinical or nonclinical trials could result in increased costs to us, delay our ability to generate product revenues and therefore may have a material adverse effect on our business, results of operations and future growth prospects. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commencement of clinical trials can be delayed for a variety of reasons, including delays in: demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial; reaching agreement on acceptable terms with prospective contract research organizations and clinical trial sites; manufacturing sufficient quantities of a product candidate; obtaining clearance from the FDA to commence clinical trials pursuant to an IND; obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site; and patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective treatments for the relevant disease and the eligibility criteria for the clinical trial. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a clinical trial has begun, it may be delayed, suspended or terminated due to a number of factors, including: ongoing discussions with regulatory authorities regarding the scope or design of our clinical trials or requests by them for supplemental information with respect to our clinical trial results; failure to conduct clinical trials in accordance with regulatory requirements; lower than anticipated screening or retention rates of patients in clinical trials; serious adverse events or side effects experienced by participants; and insufficient supply or deficient quality of product candidates or other materials necessary for the conduct of our clinical trials. In the fourth quarter of 2018, a DMC completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> interim analysis of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007-201</div></div> Phase 3 trial in patients with a clinical diagnosis of probable AD and clinically significant symptoms of agitation, concluded that the trial is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility. As a result, we determined to discontinue the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007-201</div></div> trial. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of these factors may also ultimately lead to denial of regulatory approval of a current or potential product candidate. If we experience delays, suspensions or terminations in a clinical trial or are required to conduct additional clinical or nonclinical trials, our costs will increase, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Even though the FDA has granted approval of CAPLYTA for the treatment of schizophrenia and bipolar depression, the terms of the approval may limit its commercial potential. Additionally, CAPLYTA is still subject to ongoing regulatory requirements. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though the FDA has granted approval of CAPLYTA, the scope and terms of the approval may limit our ability to commercialize CAPLYTA and, therefore, our ability to generate substantial sales revenues. The FDA has approved CAPLYTA only for the treatment of schizophrenia and bipolar depression in adults. The label for CAPLYTA also contains a &#8220;boxed&#8221; warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death and that CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for CAPLYTA will also continue to be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing processes, good clinical practices, international council for harmonization guidelines and good laboratory practices, which are regulations and guidelines enforced by the FDA for all of our nonclinical and clinical development and for any clinical trials that we conduct post-approval. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discovery of any issues post-approval, including any safety concerns, such as unexpected side effects or drug-drug interaction problems, adverse events of unanticipated severity or frequency, or concerns over misuse or abuse of the product, problems with the facilities where the product is manufactured, packaged or distributed, </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or failure to comply with regulatory requirements, may result in, among other things, restrictions on CAPLYTA or on us, including: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">withdrawal of approval, addition of warnings or narrowing of the approved indication in the product label; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">requirement of a Risk Evaluation and Mitigation Strategy to mitigate the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use in populations where the FDA may believe that the potential risks of use may outweigh its benefits; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">voluntary or mandatory recalls; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">warning letters; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">suspension of any ongoing clinical studies; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals; </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">restrictions on operations, including restrictions on the marketing or manufacturing of the product or the imposition of costly new manufacturing requirements; or </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">seizure or detention, or refusal to permit the import or export of products. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these actions were to occur, we may have to delay or discontinue the commercialization of CAPLYTA, limit our sales and marketing efforts, conduct further post-approval studies, and/or delay, discontinue or change any other ongoing or planned clinical studies, which in turn could result in significant expense and delay or limit our ability to generate sales revenues. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Safety issues with our product candidates or approved product, or with product candidates or approved products of third parties that are similar to our product candidates, could give rise to delays in the regulatory approval process, restrictions on labeling or product withdrawal after approval. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Problems with product candidates or approved products marketed by third parties that utilize the same therapeutic target or that belong to the same therapeutic class as our product candidates or approved product could adversely affect the development, regulatory approval and commercialization of our product candidates or approved product. In 2012, the FDA released draft guidance recommending that prospective suicidality assessments be performed in clinical trials of any drug being developed for a psychiatric indication. Our development programs are focused on psychiatric indications. Our PDE program is a novel target and may have unexpected safety effects that do not appear until late in clinical development or after commercial approval. As we continue the development and clinical trials of our product candidates and continue to commercialize our approved product, there can be no assurance that our product candidates or approved product will not experience significant safety issues. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discovery of previously unknown class effect problems may prevent or delay clinical development and commercial approval of product candidates or result in restrictions on permissible uses after their approval, including withdrawal of the medicine from the market. Many drugs acting on the CNS include boxed warnings and precautions related to suicidal behavior or ideation, driving impairment, somnolence/sedation and dizziness, discontinuation, weight gain, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-insulin</div> dependent (type II) diabetes, cardiovascular side effects, sleep disturbances, and motor disturbances. The label for CAPLYTA contains a &#8220;boxed&#8221; warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death and that CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. If we or others later identify undesirable side effects caused by the mechanisms of action or classes of our products or product candidates or any specific products or product candidates: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">we may be required to conduct additional clinical trials or implement a Risk Evaluation and Mitigation Strategies program prior to or following approval; </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may not approve our product candidates or, as a condition of approval, may require specific warnings and contraindications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may withdraw their approval of the product and require us to take our drug off the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may have limitations on how we promote our drugs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales of products may decrease significantly; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be subject to litigation or product liability claims; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our reputation may suffer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase our commercialization costs and expenses, which, in turn, could delay or prevent us from generating significant revenues from its sale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finally, if the FDA determines that a drug may present a risk of substance abuse, it can recommend to the Drug Enforcement Administration that the drug be scheduled under the Controlled Substances Act. Any failure or delay in commencing or completing clinical trials or obtaining regulatory approvals for our product candidates would delay commercialization of our product candidates, and severely harm our business, results of operations, financial condition and cash flows. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we seek to enter into strategic alliances for our drug candidates, but fail to enter into and maintain successful strategic alliances, we may have to reduce or delay our drug candidate development or increase our expenditures. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An important element of a biotechnology company&#8217;s strategy for developing, manufacturing and commercializing its drug candidates may be to enter into strategic alliances with pharmaceutical companies or other industry participants to advance its programs and enable it to maintain its financial and operational capacity. We may face significant competition in seeking appropriate alliances. If we seek such alliances, we may not be able to negotiate alliances on acceptable terms, if at all. In addition, these alliances may be unsuccessful. On October&#160;31, 2014, we entered into the Termination Agreement with Takeda, which terminated the Takeda License Agreement, pursuant to which all rights granted under the Takeda License Agreement were returned to us. If we seek such alliances and then fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our drug development or research programs. If we elect to fund drug development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">To the extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biotechnology companies at our stage of development sometimes become dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of drug candidates, particularly after the Phase 2 stage of clinical testing. If we elect to enter into collaborative arrangements or strategic alliances, these arrangements may place the development of our drug candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dependence on collaborative arrangements or strategic alliances would subject us to a number of risks, including the risk that: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not be able to control the amount and timing of resources that our collaborators may devote to the drug candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our collaborators may experience financial difficulties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to relinquish important rights, such as marketing and distribution rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business combinations or significant changes in a collaborator&#8217;s business strategy may also adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as more patient data become available. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim data of a clinical trial are not necessarily predictive of final data. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could affect our planned clinical path for our product candidates, including increasing costs of and/or causing delays in such development, and could significantly harm our business prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we design and manage our current preclinical studies and clinical trials, we do not now have the ability to conduct clinical trials for our product candidates on our own. In addition to our collaborators, we rely on contract research organizations, medical institutions, clinical investigators, and contract laboratories to perform data collection and analysis and other aspects of our clinical trials. In addition, we also rely on third parties to assist with our preclinical studies, including studies regarding biological activity, safety, absorption, metabolism, and excretion of product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our preclinical activities or clinical trials may be delayed, suspended, or terminated if: the quality or accuracy of the data obtained by the third parties on whom we rely is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or if for other reasons, these third parties do not successfully carry out their contractual duties or fail to meet regulatory obligations or expected deadlines, or these third parties need to be replaced. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the third parties on whom we rely fail to perform, our development costs may increase, our ability to obtain regulatory approval, and consequently, to commercialize our product candidates may be delayed or prevented altogether. We currently use several contract research organizations to perform services for our preclinical studies and clinical trials. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without delays or incurring additional expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, we are currently conducting clinical trials for our product candidates in many countries, including the United States, Europe, Russia and Ukraine and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by political instability or conflict. For example, in connection with Studies 501, 502 and 503 for MDD and Study 403 for major depressive episodes with mixed features in bipolar disorder, we have third-party clinical sites located in Ukraine and Russia, which are experiencing significant conflict. Political instability and conflict in Ukraine and Russia, and any other areas in the world where we have clinical operations, may delay our trials and negatively affect our business and operations in those regions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we successfully complete the clinical trials of one or more of our product candidates, the product candidates may fail for other reasons. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we successfully complete the clinical trials for one or more of our product candidates, the product candidates may fail for other reasons, including the possibility that the product candidates will: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fail to receive the regulatory approvals required to market them as drugs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to proprietary rights held by others requiring the negotiation of a license agreement prior to marketing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be difficult or expensive to manufacture on a commercial scale; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have adverse side effects that make their use less desirable; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fail to compete with product candidates or other treatments commercialized by our competitors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to receive the required regulatory approvals, secure our intellectual property rights, minimize the incidence of any adverse side effects or fail to compete with our competitors&#8217; products, our business, financial condition, cash flows and results of operations could be materially and adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to ongoing regulatory obligations and restrictions with regard to CAPLYTA and, following regulatory approval of any of our product candidates, we will be subject to ongoing regulatory obligations and restrictions with regard to such product candidates, which may result in significant expense and limit our ability to commercialize lumateperone and our other potential products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">With regard to CAPLYTA and our product candidates, if any, approved by the FDA, or by another regulatory authority, we are held to extensive regulatory requirements over product manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements or additional regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. If we are not able to maintain regulatory compliance, we might not be permitted to market our drugs and our business could suffer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CAPLYTA and our product candidates, if approved, may not gain acceptance among physicians, patients, or the medical community, thereby limiting our potential to generate revenues, which will undermine our future growth prospects. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of market acceptance by physicians, health care professionals and third-party payors of CAPLYTA, and any product candidate for which we obtain regulatory approval, and our profitability and growth will depend on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to provide acceptable evidence of safety and efficacy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of the approved indication(s) for the product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inclusion of any warnings or contraindications in the product label; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing and cost effectiveness, which may be subject to regulatory control; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain sufficient third-party insurance coverage or reimbursement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effectiveness of our or our collaborators&#8217; sales and marketing strategy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">relative convenience and ease of administration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patient adherence to treatment; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prevalence and severity of any adverse side effects; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability of alternative treatments. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any product that we develop does not provide a treatment regimen that is at least as beneficial as the current standard of care or otherwise does not provide some additional patient benefit over the current standard of care, that product will not achieve market acceptance and we will not generate sufficient revenues to achieve profitability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The failure to attract and retain skilled personnel and key relationships could impair our drug development and commercialization efforts. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are highly dependent on our senior management and key clinical development, sales and marketing, scientific and technical personnel. Competition for these types of personnel is intense. The loss of the services of any member of our senior management, clinical development, sales and marketing, scientific or technical staff may significantly delay or prevent the achievement of drug development, commercialization and other business objectives and could have a material adverse effect on our business, operating results and financial condition. We also rely on consultants and advisors to assist us in formulating our strategy. All of our consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, that may affect their ability to contribute to us. We intend to expand and develop new drug candidates, and will need additional funding to grow our business. We will need to hire additional employees in order to continue our research and clinical trials and to market our drugs when approved. This strategy will require us to recruit additional executive management and clinical development, regulatory, scientific, technical and sales and marketing personnel. There is currently intense competition for skilled executives and employees with relevant clinical development, scientific, technical and sales and marketing expertise, and this competition is likely to continue. The inability to attract and retain sufficient clinical development, scientific, technical, sales and marketing, and managerial personnel, due to intense competition and our limited resources, would limit or delay our product development and commercialization efforts, which would adversely affect the development of our drug candidates and commercialization of CAPLYTA and growth of our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to continue or fully exploit our partnerships with outside scientific and clinical advisors, which could impair the progress of our clinical trials and our research and development efforts. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We work with scientific and clinical advisors at academic and other institutions who are experts in the field of CNS disorders. They advise us with respect to our clinical trials. These advisors are not our employees and may have other commitments that would limit their future availability to us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services, which may impair our reputation in the industry and delay the development or commercialization of our approved product or product candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CAPLYTA has only recently been, and our other product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which may not be successful. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">scale-up,</div> process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our manufacturers will be successful in establishing a larger-scale commercial manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition, there is no assurance that our manufacturers will be able to manufacture our product candidates to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of such products or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities of lumateperone for commercialization, our commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third-party manufacturers to manufacture and supply lumateperone and our other product candidates for us. If one of our suppliers or manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers or manufacturers. We may also face significant delays in our clinical trials, regulatory approvals and product introductions and commercialization. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have no manufacturing facilities and have limited experience in the manufacturing of drugs or in designing drug-manufacturing processes. We have contracted with third-party manufacturers to produce, in collaboration with us, our product candidates, including lumateperone, for clinical trials and to produce lumateperone for commercial sales. For example, in January 2017, we entered into a supply agreement with Siegfried under which Siegfried has agreed to manufacture and supply the API for lumateperone in commercial quantities. Each month, we will provide Siegfried with a rolling forecast of our anticipated requirements for supply of the API. Under the Siegfried Agreement, we have the right to and may purchase the API for lumateperone from other suppliers. In addition, in January 2017, we entered into a manufacturing services agreement with Lonza under which Lonza has agreed to manufacture and supply the API for lumateperone commercial quantities, with purchase prices determined in each project plan. We agreed to provide Lonza with a written forecast of our estimated quarterly requirements. While we believe that there are alternative sources available to manufacture our product candidates, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without delays or additional expenditures. We cannot estimate these delays or costs with certainty but, if they were to occur, they could cause a delay in our development and commercialization efforts. If our existing or planned third-party manufacturing arrangements are terminated or if the sources of supply from such arrangements are inadequate and we must seek supply agreements from alternative sources, we may be unable to enter into such agreements or do so on commercially reasonable terms, which could delay a product launch or subject our commercialization efforts to significant supply risk. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Manufacturers of our product candidates are obliged to operate in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-mandated</div> current good manufacturing practices, or cGMPs. The manufacture of pharmaceutical products in compliance with the cGMPs requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product or product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide product for commercial sale or product candidates in our clinical trials would be jeopardized. Any delay or interruption in the supply of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercial quantities of approved product could have a material adverse impact on our revenue from product sales and any delay or interruption in the supply of clinical trial materials could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at significant additional expense or terminate the clinical trials completely. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the facilities used by our contract manufacturers or other third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections conducted following our request for regulatory approval for our product candidates from the FDA. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have little control over our manufacturers&#8217; compliance with these regulations and standards. A failure of any of our current or future contract manufacturers to establish and follow cGMPs and to document their adherence to such practices may lead to significant delays in clinical trials or in obtaining regulatory approval of product candidates or the ultimate launch of products, if approved, into the market. Failure by our current or future third-party manufacturers or us to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of the government to grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of products, operating restrictions, and criminal prosecutions. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical studies, regulatory submissions, approvals or commercialization of our product candidates or approved product, entail higher costs or impair our reputation. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will need to continue to manage our organization and we may encounter difficulties with our staffing and any future transitions, which could adversely affect our results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We will need to manage our operations and facilities effectively in order to advance our drug development programs (including lumateperone, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284,</div> lenrispodun and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333),</div> facilitate any future collaborations, and pursue other development activities. It is possible that our infrastructure may be inadequate to support our future efforts and growth. In particular, we will need to further develop information technology systems and internal sales, marketing, and distribution capabilities for any drug that we may successfully develop, including additional indications for CAPLYTA. We may not successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ability to generate product revenues will be diminished if lumateperone or any of our other potential products does not receive coverage from payors or sell for inadequate prices, or if patients are unable to obtain adequate levels of reimbursement. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Adequate coverage and reimbursement from governmental health care programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Even if we obtain coverage for lumateperone or other potential products, the resulting reimbursement payment rates might not be adequate or may require <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> that patients find unacceptably high. Patients are unlikely to use lumateperone or other product candidates, if approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of those products. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the market for lumateperone or any product candidate for which we may receive regulatory approval will depend significantly on access to third-party payors&#8217; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available, even if not approved for the indication for which lumateperone is approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party payors, whether foreign or domestic, governmental or commercial, are developing increasingly sophisticated methods of controlling health care costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The current environment is putting pressure on companies to price products below what they may feel is appropriate. Selling lumateperone at less than an optimized price could impact our revenues and overall success as a company. We do not know if the price we have selected, or may select in the future, for lumateperone is or will be the optimized price. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products such as lumateperone may differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our drug products such as lumateperone to each payor separately, with no assurance that coverage will be obtained. If we are unable to obtain coverage of, and adequate payment levels for, our products from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize any approved products and thereby adversely impact our profitability, results of operations, financial condition, and future success. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Health care legislation may make it more difficult to receive revenues from CAPLYTA or future products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals in recent years to change the health care system in ways that could impact our ability to sell our products profitably. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, or collectively, ACA, became law in the United States. The ACA substantially changed the way health care is financed by both governmental and private insurers and significantly affects the health care industry. Among the provisions of ACA of importance to lumateperone and our other potential products are the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">imposition of an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government health care programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January&#160;1, 2010, to 23% and 13% of the average manufacturer price for most branded and generic drugs, respectively; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expansion of health care fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a Medicare Part D coverage gap discount program, in which manufacturers agreed to offer 50% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expansion of eligibility criteria for Medicaid programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting any &#8220;payments or transfers of value&#8221; made or distributed to prescribers, teaching hospitals and other health care providers and reporting any ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations during the preceding calendar year; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Some of the details regarding the implementation of the ACA are yet to be determined and, at this time, it remains unclear what the full effect that the ACA will have on our business. Moreover, certain legislative changes to and regulatory changes under the ACA have occurred over the past few years. For instance, the Bipartisan Budget Act of 2018 increased the ACA required manufacturer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discount from 50% to 70% off the negotiated price for Medicare Part D beneficiaries during their coverage gap period beginning in 2019. Further legislative changes to and regulatory changes under the ACA remain possible. We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that may be charged for lumateperone or any of our other product candidates, if approved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. In some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with any products we may market, which could negatively impact our profitability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that the ACA, in its current form or as it may be amended, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other health care reforms may prevent us from being able to generate revenue, attain profitability, or commercialize CAPLYTA or any other products for which we receive regulatory approval. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We currently have very limited experience as a company in marketing and distributing pharmaceutical products and rely on third-party distributors to distribute CAPLYTA. If we are unable to effectively commercialize CAPLYTA, we may not be able to generate adequate product revenues. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAPLYTA, which was approved by the FDA in December 2019 for the treatment of schizophrenia in adults in the United States and in December 2021 for the treatment of bipolar depression in adults in the United States, is our only drug that has been approved for sale by any regulatory body. We initiated the commercial launch of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAPLYTA in late March 2020. As such, as an organization, this was the first time we have launched or commercialized any pharmaceutical product. In order to continue to successfully market CAPLYTA, we must continue to develop our sales, marketing, managerial, compliance, and related capabilities or make arrangements with third parties to perform these services. If we are unable to maintain and develop adequate sales, marketing, and distribution capabilities, whether independently or with third parties, we may not be able to continue to appropriately commercialize and generate revenue from sales of CAPLYTA and may not become profitable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are employing our own internal sales force to commercialize CAPLYTA for the treatment of schizophrenia and bipolar depression as part of our commercialization strategy in the United States. We are competing with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. These efforts will continue to be expensive and time-consuming, and we cannot be certain that we will be able to successfully complete the hiring of our U.S. sales force and refine and further develop our sales force. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, our strategy in the United States includes distributing CAPLYTA through third-party distributors. While we have entered into, or will attempt to enter into, agreements with these distributors to distribute CAPLYTA in the United States, they may not perform as agreed or they may terminate their agreements with us. Also, we may need to enter into agreements with additional distributors, and there is no guarantee that we will be able to do so on commercially reasonable terms or at all. If we are unable to maintain and, if needed, expand, our network of distributors, we would be exposed to substantial distribution risk. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event we are unable to effectively develop and maintain our commercial team, including our U.S. sales force, or maintain and, if needed, expand, our network of distributors, our ability to effectively commercialize CAPLYTA and generate product revenues would be limited. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There are possible limitations on our use of net operating losses. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we had net operating loss carryforwards, or NOLs, of approximately $543.4&#160;million, which are available to reduce any future federal and state taxable income, of which $131.1&#160;million will begin to expire at various dates through 2037 and $412.3&#160;million do not expire. The use of our NOLs may be restricted due to changes in our ownership, including as a result of our public offerings. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, changes in our ownership (as defined by the foregoing sections of the Code) may limit the amount of NOLs and tax credit carryforwards that could be utilized annually in the future to offset taxable income. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2021, 2020 and 2019, we performed a Section&#160;382 ownership analysis and determined that no ownership change occurred (within the meaning of Section&#160;382 of the Code) as a result of our public offerings in 2020. Our previous ownership analysis, through December&#160;31, 2015, reflected an ownership change occurred as a result of our 2015 public offerings. Although an ownership analysis with respect to the January 2022 public offering has not been performed, we do not believe that the Section&#160;382 annual limitation will impact our ability to utilize the tax attributes that existed as of the date of the ownership change in a material manner. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, we licensed certain intellectual property rights to our wholly-owned subsidiary, ITI Limited, which was formed in the third quarter of 2016. The costs to develop, test, manufacture and perform other activities related to the lumateperone program will be the responsibility of ITI Limited and will be incurred outside of the United States. Historically, the majority of our losses incurred did not result in additional NOLs in the United States as the majority of our expenditures related to the lumateperone program. However, as our commercialization efforts continue, we will see more NOLs in the United States to be carried forward and used against future net income of the U.S. operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The comprehensive tax reform bill could adversely affect our business and financial condition. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2017, the &#8220;Tax Cuts and Jobs Act,&#8221; or TCJA, was signed into law and significantly reforms the Internal Revenue Code of 1986, as amended. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating loss carryforwards, allows for the expensing of capital expenditures, and puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system. In addition, the TCJA repealed the alternative minimum tax, or AMT, and provides for a refund of AMT paid or a reduction of future taxes payable over a prescribed period of years between 2018 and 2021. With the passing of the TCJA, the Company would receive a refund in future periods for AMT paid in prior years. As of December&#160;31, 2020, the Company received all of these refunds. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (CARES) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate AMT credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the years ended December&#160;31, 2021 and 2020.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $0.3&#160;million to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December&#160;31, 2019 and received the refund in July 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We continue to examine the impact this tax reform legislation may have on our business and depending on possible foreign operations, among other things, the impact of this tax reform is uncertain and could be adverse. This report does not discuss any such tax legislation or the manner in which it might affect holders of our common stock. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the ordinary course of our business, we, our clinical research organizations and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain a portion of our applications and data utilizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> systems. These applications and data encompass a wide variety of business critical information, including research and development information and business and financial information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, viruses, breaches, interruptions due to employee error, malfeasance or other disruptions, lapses in compliance with privacy and security mandates, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act, or HIPAA, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial information, manage various general and administrative aspects of our business and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the commercialization of our approved product and the further development of our product candidates could be delayed or otherwise adversely impacted. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could continue to have a material impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and preclinical studies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, a novel strain of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">coronavirus,&#160;SARS-CoV-2,</div></div> which causes coronavirus disease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019&#160;(COVID-19),&#160;surfaced</div> in Wuhan, China. Since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">then,&#160;SARS-CoV-2&#160;and&#160;COVID-19&#160;have</div></div></div> spread to countries worldwide, including the United States. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;COVID-19&#160;pandemic</div> continues to evolve, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. In response to the spread <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;SARS-CoV-2&#160;and&#160;COVID-19,&#160;we</div></div></div> have instructed the majority of our office-based employees to work from home. In connection with our commercial launch of CAPLYTA, which is approved by FDA for the treatment of schizophrenia and bipolar depression in adults, our commercial organization and sales force and medical organization continue to have significantly reduced personal interactions with physicians and customers and continue to conduct many promotional activities virtually, and elected to cease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> interactions with physicians and customers entirely for some period of time in the interest of employee and community safety. Even though certain of our sales force and medical organization are able to have personal interactions with physicians and customers, we may have to cease such personal interactions depending on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;situation.</div> In addition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;situation</div> has resulted in a decrease in the number of patient visits to healthcare providers. As a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic,</div> or similar pandemics, we may experience disruptions that could severely impact our business, including our ability to successfully commercialize our only commercial product, CAPLYTA, in the United States, and these disruptions could negatively impact our sales of CAPLYTA. Business interruptions from the current or future pandemics may also adversely impact the third parties we rely on to sufficiently manufacture CAPLYTA and to produce our product candidates in quantities we require, which may impair the commercialization and our research and development activities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are currently conducting clinical trials for our product candidates in many countries, including the United States, Europe and Russia and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> or other pandemics. Some factors from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic that have or may adversely affect the timing and conduct of our clinical trials and adversely impact our business generally, include but are not limited to delays or difficulties in clinical site initiation, diversion of healthcare resources away from clinical trials to pandemic concerns, limitations on travel, regulatory delays and supply chain disruptions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic,</div> in March 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and products, as well as routine surveillance inspections of domestic manufacturing facilities, and it also provided guidance regarding the conduct of clinical trials, which has been further updated several times since that time. In <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020,</div> the FDA noted it was continuing to ensure timely reviews of applications for medical products during <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> in line with its user fee performance goals and conducting mission-critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. The FDA subsequently publicized its development and use of an internal rating system called the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Advisory Rating system, to assist in determining when and where it is safest to conduct such inspections based on data about the virus&#8217;s trajectory in a given country, state and locality and the rules and guidelines that are put in place by foreign, state and local </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">governments. As of October 2021, FDA is either continuing to, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;case-by-case&#160;basis,</div></div> conduct only &#8220;mission-critical&#8221; inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">include&#160;pre-approval&#160;inspections,</div> or PAIs. Foreign&#160;PAIs that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;case-by-case&#160;basis.</div></div> FDA will use similar data to inform resumption of other prioritized operations abroad as it becomes feasible and advisable to do so. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the global response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, moreover, there have been strategic redeployments of government resources to priority projects, including FDA and EMA resources and staff, which could have an impact on the timeline for review and approval of new marketing applications. Over the course of the pandemic, FDA&#8217;s new drug review programs continued to meet key performance goals related to working with applicants and approving NDAs and NDA supplements, although the agency has also stated that the uncertainty of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation may make it difficult to sustain that level of performance indefinitely. The FDA may not be able to maintain its normal pace with respect to new drug applications and delays or setbacks are possible in the future. The FDA has told industry that it intends to be as transparent as possible about its workload and performance metrics as the situation evolves, and also that it intends to communicate proactively with applicants during the review cycle regarding the need for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection and whether such PAI is considered &#8220;mission-critical.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Should FDA determine that a PAI is necessary for approval of an NDA or NDA supplement and such an inspection cannot be completed during the review cycle due to restrictions on travel or other safety protocols, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Such decisions will be based on the totality of the information available to the FDA, including considerations of whether it can obtain existing inspection reports from trusted foreign regulatory partners through mutual recognition and confidentiality agreements and/or secure additional records from the applicant, the manufacturing facility, or other inspected entities. Accordingly, FDA has encouraged applicants to effectively communicate with all their facilities and sites to ensure timely responses to any inquiries from FDA for information needed to support its assessment of pending drug applications. FDA has also stated that it is using all available tools and sources of information to support regulatory decisions on NDAs such as the historical compliance status of a manufacturing facility and other risk-benefit considerations pertaining to the proposed new drug product and its manufacturing process and facilities. In addition, whether or not FDA considers a facility inspection to be &#8220;mission-critical&#8221; involves several factors related to the public health benefits of the proposed new drug product, including but not limited to whether the candidate has been granted breakthrough therapy designation and whether the candidate is intended to treat or prevent a serious disease or medical condition for which there is no other appropriate substitute. Regulatory authorities outside the United States, including but not limited to the EMA, may adopt similar restrictions or other policy measures in response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19</div> pandemic. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;COVID-19&#160;pandemic</div> continues to rapidly evolve, and the severity and duration of the pandemic remain uncertain. The extent to which the pandemic impacts our business, including our commercial results, clinical trials, and preclinical studies will depend on future developments, which are highly uncertain. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ability to compete may be undermined if we do not adequately protect our proprietary rights. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success depends on obtaining and maintaining proprietary rights to our products and product candidates and technologies and their uses, as well as successfully defending these rights against third-party challenges. We will only be able to protect our products and product candidates, proprietary technologies, and their uses from unauthorized use by third parties to the extent that valid and enforceable patents, or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">effectively protected trade secrets, cover them. We have patent rights under issued patents in many cases covering our lumateperone, lenrispodun and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> development programs. Nonetheless, the issued patents and patent applications covering our primary technology programs remain subject to uncertainty and continuous monitoring and action by us due to a number of factors, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not have been the first to make the inventions covered by our pending patent applications or issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not have been the first to file patent applications for our products, product candidates or the technologies we rely upon; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any or all of our pending patent applications may not result in issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not seek or obtain patent protection in all countries that will eventually provide a significant business opportunity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any patents issued to us or our collaborators may not provide a basis for commercially viable products, may not provide us with any competitive advantages or may be challenged by third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our proprietary technologies may not be patentable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may design around our patent claims to produce competitive products which fall outside of the scope of our patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may identify prior art which could invalidate our patents; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes to patent laws may limit the exclusivity rights of patent holders. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we have or obtain patents covering our products, product candidates or technologies, we may still be barred from making, using and selling our products, product candidates or technologies because of the patent rights of others. Others have or may have filed, and in the future are likely to file, patent applications covering compounds, assays, genes, gene products and therapeutic products that are similar or identical to ours. There are many issued U.S. and foreign patents relating to genes, nucleic acids, polypeptides, chemical compounds or therapeutic products, and some of these may encompass reagents utilized in the identification of candidate drug compounds or compounds that we desire to commercialize. Numerous U.S. and foreign issued patents and pending patent applications owned by others exist in the area of CNS disorders and the other fields in which we are developing product candidates. These could materially affect our ability to develop our product candidates or sell our products. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, that may later result in issued patents that our products, product candidates or technologies may infringe. These patent applications may have priority over patent applications filed by us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We regularly conduct searches to identify patents or patent applications that may prevent us from obtaining patent protection for our proprietary compounds or that could limit the rights we have claimed in our patents and patent applications. Disputes may arise regarding the ownership or inventorship of our inventions. It is difficult to determine how such disputes would be resolved. Others may challenge the validity, enforceability, scope and term of our patents. Additionally, any patent term extensions that we seek may not be granted on a timely basis, if at all. If our patents are found to be invalid, we will lose the ability to exclude others from making, using or selling the inventions claimed in our patents. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of our academic institutional licensors, research collaborators and scientific advisors have rights to publish data and information to which we have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations, then our ability to receive patent </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">protection or protect our proprietary information will be impaired. Additionally, any employee whose employment with us terminates, whether voluntarily by the employee or by us in connection with restructurings or otherwise, may seek future employment with our competitors. Although each of our employees is required to sign a confidentiality agreement with us at the time of hire, we cannot guarantee that the confidential nature of our proprietary information will be maintained in the course of such future employment. In addition, technology that we may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">license-in</div> may become important to some aspects of our business. We generally will not control the patent prosecution, maintenance or enforcement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> technology. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we operate in the highly technical field of drug discovery and development of small molecule drugs, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We enter into confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties any confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. The failure to obtain or maintain trade secret protection could adversely affect our competitive position. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is significant litigation in our industry regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products, product candidates, technologies or activities infringe the intellectual property rights of others. If our drug development or commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. We may need to resort to litigation to enforce a patent issued to us, protect our trade secrets or determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of their prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We also may not be able to afford the costs of litigation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. The standards of the U.S. Patent and Trademark Office, or USPTO, are uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to reexamination proceedings in the USPTO (and foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office), which proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">application. Similarly, opposition or invalidity proceedings could result in loss of rights or reduction in the scope of one or more claims of a patent in foreign jurisdictions. In addition, such interference, reexamination and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, changes in or different interpretations of patent laws in the United States and foreign countries may permit others to use our discoveries or to develop and commercialize our technology, products and product candidates without providing any compensation to us or may limit the number of patents or claims we can obtain. In particular, there have been proposals to shorten the exclusivity periods available under U.S. patent law that, if adopted, could substantially harm our business. Our approved product and the product candidates that we are developing are protected by intellectual property rights, including patents and patent applications. For our approved product and any of our product candidates that become a marketable product, if any, we will rely on our exclusivity under patents to sell the compound and recoup our investments in the research and development of the compound. If the exclusivity period for patents is shortened, then our ability to generate revenues without competition will be reduced and our business could be materially adversely impacted. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. For example, some countries, including many in Europe, do not grant patent claims directed to methods of treating humans and, in these countries, patent protection may not be available at all to protect our products or product candidates. In addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect our products, product candidates and/or technologies or limit the exclusivity periods that are available to patent holders. For example, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was recently signed into law and includes a number of significant changes to U.S. patent law. These include changes to transition from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first-to-invent&#8221;</div></div> system to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first-to-file&#8221;</div></div> system and to the way issued patents are challenged. These changes may favor larger and more established companies that have more resources to devote to patent application filing and prosecution. The USPTO has been in the process of implementing regulations and procedures to administer the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act may affect our ability to obtain, enforce or defend our patents. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend our issued patents. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to obtain and maintain patent protection and trade secret protection of our products, product candidates, proprietary technologies and their uses, we could lose our competitive advantage and competition we face would increase, reducing our potential revenues and adversely affecting our ability to attain or maintain profitability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect our intellectual property and proprietary rights throughout the world, which could negatively impact our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing, prosecuting and defending patents relating to our products, product candidates and technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as U.S. laws. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies have encountered significant difficulties in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult, costly or impossible for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us or any of our future licensors. We may not prevail in any lawsuits or other adversarial proceedings that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Transfer of Certain Intellectual Property Rights to our Foreign Subsidiary </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may need to utilize all of our available net operating losses, and we may be subject to additional income taxes in connection with our transfer of certain intellectual property rights to our foreign subsidiary. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, we licensed certain intellectual property rights to our wholly-owned Bermuda subsidiary, ITI Limited for $125&#160;million and other consideration. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this license represented a prior year gain for U.S. tax purposes which was offset partially by prior year losses. However, the Internal Revenue Service, or IRS, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require us to utilize a portion, or all, of our available NOLs at such time. If an IRS valuation exceeds our available NOLs, we could incur additional income taxes in the future. Our ability to use our NOLs is generally subject to the limitations of Code Section&#160;382, as well as expiration of federal and state net operating loss carryforwards. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Industry </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to stringent regulation in connection with the marketing of CAPLYTA and any other products derived from our product candidates, which could delay the development and commercialization of our products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pharmaceutical industry is subject to stringent regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Neither we nor our collaborators can market a pharmaceutical product in the United States until it has completed rigorous preclinical testing and clinical trials and an extensive regulatory clearance process implemented by the FDA. Satisfaction of regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product, and requires substantial resources. Even if regulatory approval is obtained, it may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, and/or marketing of such products, and requirements for post-approval studies, including additional research and development and clinical trials. For example, the label for CAPLYTA contains a &#8220;boxed&#8221; warning that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death and that CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. These limitations may limit the size of the market for the product or result in the incurrence of additional costs. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues and continue our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside the United States, the ability to market a product is contingent upon receiving approval from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing, and reimbursement vary widely from country to country. Only after the appropriate regulatory authority is satisfied that adequate evidence of safety, quality, and efficacy has been presented will it grant a marketing authorization. Approval by the FDA does not automatically lead to the approval by regulatory authorities outside the United States and, similarly, approval by regulatory authorities outside the United States will not automatically lead to FDA approval. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Many of our competitors have greater resources and capital than us, putting us at a competitive disadvantage. If our competitors develop and market products that are more effective than lumateperone or our other product candidates, they may reduce or eliminate our commercial opportunity. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition in the pharmaceutical and biotechnology industries is intense and increasing. We face competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. Some of these competitors have products or are pursuing the development of drugs that target the same diseases and conditions that are the focus of our drug development programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, CAPLYTA for the treatment of schizophrenia and the treatment of bipolar depression compete with, among other branded products, Latuda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Sunovion, Rexulti<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Otsuka Pharmaceutical, VRAYLAR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Allergan, LYBALVI<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Alkermes, and Fanapt<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, marketed by Vanda Pharmaceuticals. In addition, lumateperone and our other product candidates, if approved, will compete with, among other generic antipsychotic products, aripiprazole, haloperidol, paliperidone, risperidone, quetiapine/XR, olanzapine and clozapine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors and their collaborators have significantly greater experience than we do in the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identifying and validating targets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">screening compounds against targets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">preclinical studies and clinical trials of potential pharmaceutical products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining FDA and other regulatory approvals; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercializing pharmaceutical products. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, many of our competitors and their collaborators have substantially greater capital and research and development resources, manufacturing, sales and marketing capabilities, and production facilities. Smaller companies also may prove to be significant competitors, particularly through proprietary research discoveries and collaboration arrangements with large pharmaceutical and established biotechnology companies. Many of our competitors have products that have been approved or are in advanced development and may develop superior technologies or methods to identify and validate drug targets and to discover novel small molecule drugs. Our competitors, either alone or with their collaborators, may succeed in developing drugs that are more effective, safer, more affordable, or more easily administered than ours, have fewer side effects than ours, and may achieve patent protection or commercialize drugs sooner than us. Our competitors may also develop alternative therapies that could further limit the market for any drugs that we may develop. Our failure to compete effectively could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any claims relating to improper handling, storage, or disposal of biological, hazardous, and radioactive materials used in our business could be costly and delay our research and development efforts. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research and development activities involve the controlled use of potentially harmful hazardous materials, including volatile solvents, biological materials such as blood from patients that have the potential to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transmit disease, chemicals that cause cancer, and various radioactive compounds. Our operations also produce hazardous waste products. We face the risk of contamination or injury from the use, storage, handling or disposal of these materials. We are subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations could be significant, and current or future environmental regulations may impair our research, development, or production efforts. If one of our employees were accidentally injured from the use, storage, handling, or disposal of these materials, the medical costs related to his or her treatment would be covered by our workers&#8217; compensation insurance policy. However, we do not carry specific biological or hazardous waste insurance coverage and our general liability insurance policy specifically excludes coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be subject to criminal sanctions or fines or be held liable for damages, our operating licenses could be revoked, and we could be required to suspend or modify our operations and our research and development efforts. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of lumateperone or any other product for which we obtain regulatory approval, or development or commercialization of our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face an inherent risk of product liability as a result of commercial sales of lumateperone in the United States and the clinical testing of our product candidates, and will face an even greater risk following commercial launch of lumateperone in additional jurisdictions, if approved, or if we engage in the clinical testing of new product candidates or commercialize any additional products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, we may be sued if lumateperone or any other product we develop allegedly causes injury or is found to be otherwise unsuitable for administration in humans. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection laws. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for our products or product candidates that we may develop; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injury to our reputation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of clinical trial participants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">initiation of investigations by regulators; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs to defend the related litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a diversion of management&#8217;s time and our resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to trial participants or patients; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of revenue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exhaustion of any available insurance and our capital resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to commercialize our products or product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a decline in our stock price. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we currently have product liability insurance that covers our clinical trials and the commercialization of CAPLYTA for the treatment of schizophrenia and bipolar depression, we may need to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increase and expand this coverage, including if lumateperone is approved for the treatment of indications beyond schizophrenia and bipolar depression or if other product candidates are approved for commercial sale. This insurance may be prohibitively expensive or may not fully cover our potential liabilities. Inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of products that we or our collaborators develop. If we determine that it is prudent to increase our product liability coverage, we may be unable to obtain such increased coverage on acceptable terms or at all. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Our liability could exceed our total assets if we do not prevail in a lawsuit from any injury caused by our drug products. Product liability claims could have a material adverse effect on our business and results of operations. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business is affected by macroeconomic conditions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our product by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including high-grade corporate bonds and commercial paper. If any of the issuers or counter parties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows. Interest rates and the ability to access credit markets could also adversely affect the ability of our customers and distributors to purchase, pay for and effectively distribute our products. Similarly, these macroeconomic factors could affect the ability of our suppliers and manufacturers to supply or manufacture our product. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Owning Our Common Stock </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerous factors could result in substantial volatility in the trading price of our stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the price per share of our common stock on the Nasdaq Global Select Market has ranged from a high of $55.20 to a low of $28.40. We have several stockholders who hold substantial blocks of our stock. Sales of large numbers of shares by any of our large stockholders could adversely affect our trading price. If stockholders holding shares of our common stock sell, indicate an intention to sell, or if it is perceived that they will sell, substantial amounts of their common stock in the public market, the trading price of our common stock could decline. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the success of our commercialization of CAPLYTA in the United States for the treatment of schizophrenia and bipolar depression; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">timing and announcement of regulatory developments, submissions and approvals or preliminary, interim or final results of clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual or anticipated quarterly variation in our results of operations or the results of our competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements of medical innovations or new products or product candidates by our competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issuance of new or changed securities analysts&#8217; reports or recommendations for our stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developments or disputes concerning our intellectual property or other proprietary rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commencement of, or our involvement in, litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market conditions in the biopharmaceutical industry; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any future sales of our common stock or other securities in connection with raising additional capital or otherwise; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any major change to the composition of our board of directors or management; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">general economic conditions and slow or negative growth of our markets. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock market in general, and market prices for the securities of biotechnology companies like ours in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies. These broad market and industry fluctuations may adversely affect the market price of our common stock, regardless of our operating performance. In several recent situations where the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, such as the purported class action lawsuits brought against us and certain of our executive officers in May 2017, consolidated in July 2017 and voluntarily dismissed in November 2017, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our products, product candidates and technology and, to a lesser extent, grant funding, although there can be no assurances such financing can be obtained. We filed a universal shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which was declared effective on September&#160;12, 2019, on which we registered for sale up to $350&#160;million of any combination of our common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that we may determine, including up to $75&#160;million of common stock which we could offer and sell, from time to time at our sole discretion, under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-the-market</div></div> program sales agreement that we entered into with SVB Leerink LLC in August 2019. In the quarter ended June&#160;30, 2020, we sold 230,000 shares of common stock under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program which resulted in our receiving net proceeds of $5.6&#160;million in July 2020. In the quarter ended September 30, 2020, we issued an additional 512,791 shares of common stock under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program and received approximately $12.3&#160;million of net proceeds. On September&#160;10, 2020, we terminated the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program agreement with SVB Leerink LLC. In addition, on January&#160;6, 2020, we filed an automatic shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which became effective upon filing, on which we registered for sale an unlimited amount of any combination of our common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that we may determine, so long as we continue to satisfy the requirements of a &#8220;well-known seasoned issuer&#8221; under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. In January 2022, we completed an underwritten public offering of 10,952,381 shares of our common stock resulting in net proceeds to us of approximately $433.7 million, after deducting underwriting discounts and commissions and offering expenses. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses on terms that are not favorable to us. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The price of our common stock could be subject to volatility related or unrelated to our operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market price of our common stock could fluctuate substantially due to a variety of factors, including market perception of our ability to meet our growth projections and expectations, quarterly operating results of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our business and the business of others in our industry. In addition, the stock market itself is subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market price of securities issued by many companies for reasons related and unrelated to their operating performance and could have the same effect on our common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our operating results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we have incurred and will incur significant legal, accounting and other expenses, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with current corporate governance requirements, including requirements under Section&#160;404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented by the SEC or the Nasdaq Global Select Market or any other stock exchange or inter-dealer quotations system on which our common stock may be listed in the future. The expenses incurred by public companies for reporting and corporate governance purposes have increased dramatically in recent years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#8217; views of us. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to comply with Section&#160;404 of the Sarbanes-Oxley Act. Section&#160;404 of the Sarbanes-Oxley Act requires public companies to maintain effective internal control over financial reporting. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting. In addition, we are required to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting. Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be evaluated frequently. Additional financial controls have been assessed and implemented to address the increased complexity of revenue recognition associated with commercial sales of a pharmaceutical product. We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. If we fail to maintain the effectiveness of our internal controls or fail to comply in a timely manner with the requirements of the Sarbanes-Oxley Act, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, this could have a material adverse effect on our business. We could lose investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on the price of our common stock and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources. In addition, if our efforts to comply with new or changed laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to successfully implement our business plan and comply with Section&#160;404 requires us to be able to prepare timely and accurate financial statements. We expect that we will need to continue to improve existing, and implement new operational and financial systems, procedures and controls to manage our business effectively. Any delay in the implementation of, or disruption in the transition to, new or enhanced systems, procedures or controls, may cause our operations to suffer and we may be unable to conclude that our internal control over financial reporting is effective and to obtain an unqualified report on internal controls from our independent registered public accounting firm as required under Section&#160;404 of the Sarbanes-Oxley Act. This, in turn, could have an adverse impact on trading prices for our common stock, and could adversely affect our ability to access the capital markets. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If securities or industry analysts do not publish, or cease publishing, research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our common stock is and will be influenced by whether industry or securities analysts publish or continue to publish research and reports about us, our business, our market or our competitors and, to the extent analysts do publish such reports, what they publish in those reports. We may not continue to have or to obtain analyst coverage in the future. Any analysts that do cover us may make adverse recommendations regarding our stock, adversely change their recommendations from time to time, and/or provide more favorable relative recommendations about our competitors. If any analyst who covers us or may cover us in the future were to cease coverage of us or fail to regularly publish reports on us, or if analysts fail to cover us or publish reports about us at all, we could lose, or never gain, visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">As a result of the death of Richard Lerner, M.D., who was an independent director and served on the Audit Committee, we are not in compliance with certain Nasdaq listing requirements, and if we do not regain compliance, we could face delisting from the Nasdaq. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Richard Lerner, M.D., who was a member of our Board of Directors, passed away in December 2021. Dr.&#160;Lerner was a member of the Company&#8217;s Audit Committee and Nominating and Governance Committee. As a result of Dr.&#160;Lerner&#8217;s death, we are no longer in compliance with Nasdaq Marketplace Rule 5605(c)(2)(A) because our Audit Committee no longer has at least three members. We have received notice that we must regain full compliance before the earlier of our next annual stockholders&#8217; meeting or December&#160;2, 2022 or, if the next annual stockholders&#8217; meeting is held before May&#160;31, 2022, no later than May&#160;31, 2022. If we fail to regain compliance within such time period, our common stock may be subject <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;de-listing&#160;from</div> Nasdaq. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provisions of the Delaware law, our restated certificate of incorporation and our restated bylaws may delay or prevent a takeover which may not be in the best interests of our stockholders. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provisions of Delaware law and our restated certificate of incorporation and restated bylaws could discourage or make it more difficult to accomplish a proxy contest or other change in our management or the acquisition of control by a holder of a substantial amount of our voting stock. It is possible that these provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or in our best interests. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions also may have the effect of preventing changes in our management. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not anticipate paying cash dividends in the foreseeable future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We currently intend to retain any future earnings for funding growth. We do not anticipate paying any cash dividends in the foreseeable future. As a result, you should not rely on an investment in our securities if you require dividend income. Capital appreciation, if any, of our shares may be your sole source of gain for the foreseeable future. Moreover, you may not be able to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-sell</div> your shares at or above the price you paid for them. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This report includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;targets,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on our projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. The description of our Business set forth in Item 1, the Risk Factors set forth in this Item 1A and our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations set forth in Item 7 as well as other sections in this report, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the accuracy of our estimates regarding expenses, revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our expectations regarding our commercialization of CAPLYTA, including the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the commercialization of CAPLYTA and our ability to adapt our approach as appropriate; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the duration and severity of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and its impact on our business; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the supply and availability of and demand for our product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the initiation, cost, timing, progress and results of our development activities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies and clinical trials; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our plans to research, develop and commercialize lumateperone and our other current and future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the election by any collaborator to pursue research, development and commercialization activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain future reimbursement and/or milestone payments from our collaborators; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to attract collaborators with development, regulatory and commercialization expertise; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain intellectual property protection for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to successfully commercialize lumateperone and our other product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the size and growth of the markets for lumateperone and our other product candidates and our ability to serve those markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the rate and degree of market acceptance of any current or future products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the success of competing drugs that are or become available; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory developments in the United States and other countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain additional financing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our use of the proceeds from our securities offerings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any restrictions on our ability to use our net operating loss carryforwards; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our exposure to investment risk, interest rate risk and capital market risk; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to attract and retain key scientific, management or sales and marketing personnel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this report, particularly in the Risk Factors set forth in Item&#160;1A of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this report are made as of the date of this report, and we do not assume, and specifically disclaim, any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_4" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNRESOLVED STAFF COMMENTS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_5" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PROPERTIES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our headquarters are located at 430 East 29th Street, New York, New York 10016, where we occupy approximately 32,287 square feet of useable office and laboratory space. The term of the lease, as amended, expires in March 2029. We also lease a small amount of office space in Towson, Maryland. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_6" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL PROCEEDINGS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are not currently a party to any material legal proceedings. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_7" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MINE SAFETY DISCLOSURES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx234590_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_9" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;ITCI.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;25, 2022, we had 93,593,748 outstanding shares of common stock and no outstanding shares of preferred stock. As of February&#160;25, 2022, there were approximately 82 holders of record of our outstanding shares of common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unregistered Sales of Securities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuer Purchases of Equity Securities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_10" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">[RESERVED] </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_11" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;7.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion of the financial condition and results of our operations should be read in conjunction with the financial statements and the notes to those statements appearing elsewhere in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> This section of this Annual Report on Form 10-K generally discusses the fiscal years ended December&#160;31, 2021 and 2020 items and year to year comparisons between the fiscal years ended December&#160;31, 2021 and 2020. The discussion around results of operations for the fiscal year ended December&#160;31, 2019 and a comparison of our results for the fiscal years ended December&#160;31, 2020 and 2019 is included in Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for fiscal year ended December&#160;31, 2020, filed with the SEC on February 25, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should read the Risk Factors set forth in Item&#160;1A of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019, CAPLYTA (lumateperone) was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in late March 2020. In support of our commercialization efforts, we employ a national sales force. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). CAPLYTA is the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in late December 2021. In support of the commercial launch of lumateperone for the treatment of bipolar depression, we have expanded our sales force from approximately 240 sales representatives to approximately 320 sales representatives. As used in this report, &#8220;CAPLYTA&#8221; refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and &#8220;lumateperone&#8221; refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder, or MDD. Patient enrollment in Study 501 and Study 502, our global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD has commenced. We expect to file an sNDA with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in 2024. In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with Bipolar I or Bipolar II disorder and mixed features in patients with MDD. We expect to complete Study 403 in the second half of 2022 and following completion we intend to discuss the results with the FDA to determine whether Study 403, as amended, will provide supportive data for a potential future regulatory filing for this indication. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have also initiated a Phase 3 study evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;6-week,&#160;open-</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">label&#160;run-in&#160;phase</div> during which all patients will receive 42 mg of lumateperone per day, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week,&#160;open-label</div> stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase 26 weeks in duration during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;2-week&#160;safety&#160;follow-up</div></div> phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Within the lumateperone portfolio, we are also developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have completed the preclinical development of an LAI formulation and in December 2020 we initiated a Phase 1 single ascending dose study of lumateperone LAI, a formulation of lumateperone designed to be administered subcutaneously and to maintain therapeutic levels of lumateperone for at least one month. This study is evaluating the pharmacokinetics, safety and tolerability of lumateperone LAI in patients with stable symptoms of schizophrenia. We are now exploring alternate sites of injection with this formulation as well as progressing other formulations. This will assist us in evaluating dosing strategies and formulation for our efficacy studies. The goal of our program is to develop LAI formulations that are effective, safe and well tolerated with treatment durations of one month and longer. Given the encouraging tolerability data to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> for the treatment of behavioral disturbances in patients with dementia, the treatment of dementia-related psychosis and for the treatment of certain depressive disorders, in the elderly. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> is formulated as an oral solid dosage form that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (&gt;&#160;than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL.</div></div></div> In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated our program evaluating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> for the treatment of agitation in patients with probable Alzheimer&#8217;s disease. We are in discussions with the FDA regarding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> toxicological profile of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL.</div></div></div> The FDA has informed us that they do not believe the deuterated and undeuterated forms of lumateperone are identical. As a result, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> data from lumateperone may not be broadly applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284-ODT-SL</div></div></div> and we may be required to conduct additional toxicology studies in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-rodent</div> species and this could delay the commencement of our clinical program. We expect to commence clinical conduct in this program in 2022. Additional studies in dementia-related psychosis, and certain depressive disorders in the elderly are also planned for 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have another major program&#160;that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several CNS <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-CNS&#160;conditions</div> with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include heart failure, immune system regulation, neurodegenerative diseases, cancers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#160;non-CNS&#160;disorders.&#160;Lenrispodun&#160;(ITI-214)</div></div> is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for&#160;lenrispodun&#160;for Parkinson&#8217;s disease and commenced patient enrollment in the third quarter of 2017 in a Phase 1/2 clinical trial of&#160;lenrispodun&#160;in patients with Parkinson&#8217;s disease to evaluate safety and tolerability in this patient population, as well as motor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-motor&#160;exploratory</div> endpoints. In the fourth quarter of 2018, we announced that the Phase 1/2 clinical trial of&#160;lenrispodun&#160;has been completed </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">and topline results demonstrated&#160;lenrispodun&#160;was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. We have initiated our Phase&#160;2 clinical program with&#160;lenrispodun&#160;for Parkinson&#8217;s disease and expect to commence patient enrollment in the first half of 2022. In addition, in the second quarter of 2020, we announced topline results from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Study&#160;ITI-214-104,&#160;a</div></div> Phase 1/2 translational study of single ascending doses of&#160;lenrispodun&#160;in patients with chronic systolic heart failure with reduced ejection fraction. In this study,&#160;lenrispodun&#160;improved cardiac output by increasing heart contractility and decreasing vascular resistance. Agents that both increase heart contractility (inotropism) and decrease vascular resistance (vasodilation) are called inodilators. Inodilators in current clinical use are associated with the development of arrhythmias, which are abnormal heart rhythms that when serious can impair heart function and lead to mortality.&#160;Lenrispodun,&#160;which acts through a novel mechanism of action, was not associated with arrhythmias in this study and was generally well-tolerated in all patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also have a development program with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">our&#160;ITI-333&#160;compound</div> as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-addictive</div> treatments to manage pain. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> is a novel compound that uniquely combines activity as an antagonist at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">serotonin&#160;5-HT2A&#160;receptors</div> and a partial agonist at &#181;-opioid receptors. These combined actions support the potential utility <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;ITI-333&#160;in</div> the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. In December 2020, we initiated a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> in healthy volunteers. This study was recently completed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> achieved plasma exposures at or above those required for efficacy and was generally safe and well-tolerated. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that we expect will fund a significant portion of the early stage clinical development costs associated with this program. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have assembled a management team with significant industry experience to lead the commercialization of our product and the discovery, development and potential commercialization of our product candidates. We complement our management team with a group of scientific and clinical advisors that includes recognized experts in the fields of schizophrenia, bipolar depression and other CNS disorders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, a novel strain of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">coronavirus,&#160;SARS-CoV-2,</div></div> which causes coronavirus disease 2019 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19),</div> surfaced in Wuhan, China. Since then, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> have spread to countries worldwide, including the United States. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to evolve, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. In response to the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> we have instructed the majority of our office-based employees to work from home.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>In connection with our commercial launch of CAPLYTA, which is approved by FDA for the treatment of schizophrenia and bipolar depression in adults, our commercial organization and sales force and medical organization are having significantly reduced personal interactions with physicians and customers and continue to conduct many promotional activities virtually, and elected to cease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> interactions with physicians and customers entirely for some period of time in the interest of employee and community safety. Even though certain of our sales force and medical organization are having personal interactions with physicians and customers, we may have to cease such personal interactions depending on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation has resulted in a decrease in the number of patient visits to healthcare providers. As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, or similar pandemics, we may experience disruptions that could severely impact our business, including our ability to successfully commercialize our only commercial product, CAPLYTA, in the United States, and these disruptions could negatively impact our sales of CAPLYTA. Business interruptions from the current or future pandemics may also adversely impact the third parties we rely on to sufficiently manufacture CAPLYTA and to produce our product candidates in quantities we require, which may impair the commercialization and our research and development activities. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We conduct clinical trials for our product candidates in many countries, including the United States, Europe and Russia and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> or other pandemics. Some factors from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic that have or may adversely affect the timing and conduct of our clinical trials and adversely impact our business generally, include but are not limited to delays or difficulties in clinical site initiation, patient enrollment, diversion of healthcare resources away from clinical trials to pandemic concerns, limitations on travel, regulatory delays and supply chain disruptions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic,</div> in March 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and products, as well as routine surveillance inspections of domestic manufacturing facilities, and it also provided guidance regarding the conduct of clinical trials, which has been further updated several times since that time. In <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020,</div> the FDA noted it was continuing to ensure timely reviews of applications for medical products during <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> in line with its user fee performance goals and conducting mission-critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. The FDA subsequently publicized its development and use of an internal rating system called the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Advisory Rating system, to assist in determining when and where it is safest to conduct such inspections based on data about the virus&#8217;s trajectory in a given country, state and locality and the rules and guidelines that are put in place by foreign, state and local governments. As of October 2021, FDA is either continuing to, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;case-by-case&#160;basis,</div></div> conduct only &#8220;mission-critical&#8221; inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">include&#160;pre-approval&#160;inspections,</div> or PAIs. Foreign&#160;PAIs that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;case-by-case&#160;basis.</div></div> FDA will use similar data to inform resumption of other prioritized operations abroad as it becomes feasible and advisable to do so. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the global response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, moreover, there have been strategic redeployments of government resources to priority projects, including FDA and EMA resources and staff, which could have an impact on the timeline for review and approval of new marketing applications. Over the course of the pandemic, FDA&#8217;s new drug review programs continued to meet key performance goals related to working with applicants and approving NDAs and NDA supplements, although the agency has also stated that the uncertainty of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation may make it difficult to sustain that level of performance indefinitely. The FDA may not be able to maintain its normal pace with respect to new drug applications and delays or setbacks are possible in the future. The FDA has told industry that it intends to be as transparent as possible about its workload and performance metrics as the situation evolves, and also that it intends to communicate proactively with applicants during the review cycle regarding the need for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection and whether such PAI is considered &#8220;mission-critical.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should FDA determine that a PAI is necessary for approval of an NDA or NDA supplement and such an inspection cannot be completed during the review cycle due to restrictions on travel or other safety protocols, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Such decisions will be based on the totality of the information available to the FDA, including considerations of whether it can obtain existing inspection reports from trusted foreign regulatory partners through mutual recognition and confidentiality agreements and/or secure additional records from the applicant, the manufacturing facility, or other inspected entities. Accordingly, FDA has encouraged applicants to effectively communicate with all their facilities and sites to ensure timely responses to any inquiries from FDA for information needed to support its assessment of pending drug applications. FDA has also stated that it is using all available tools and sources of information to support regulatory decisions on NDAs such as the historical compliance status of a manufacturing facility and other risk-benefit considerations pertaining to the proposed new drug product and its manufacturing process and facilities. In addition, whether or not FDA considers a facility inspection to be &#8220;mission-critical&#8221; involves several factors related to the public health </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">benefits of the proposed new drug product, including but not limited to whether the candidate has been granted breakthrough therapy designation and whether the candidate is intended to treat or prevent a serious disease or medical condition for which there is no other appropriate substitute. Regulatory authorities outside the United States, including but not limited to the EMA, may adopt similar restrictions or other policy measures in response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19</div> pandemic. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;COVID-19&#160;pandemic</div> continues to rapidly evolve, and the severity and duration of the pandemic remain uncertain. The extent to which the pandemic impacts our business, including our commercial results, clinical trials, and preclinical studies will depend on future developments, which are highly uncertain. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA for the treatment of schizophrenia in adults in December 2019 and for the treatment of bipolar depression in adults in December 2021. We initiated the commercial launch of CAPLYTA in late March 2020. During the years ended December&#160;31, 2021 and 2020, net sales increased from approximately $22.5&#160;million for the year ended December&#160;31, 2020 to approximately $81.7&#160;million for the year ended December&#160;31, 2021. In addition, we had approximately $2.1&#160;million of grant revenues for the year ended December&#160;31, 2021, compared to approximately $0.3&#160;million of grant revenues for the year ended December&#160;31, 2020. We have received and may continue to receive grants from U.S. government agencies and foundations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not expect any revenues that we may generate in the next few years to be significant enough to completely fund our operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. We are unable with certainty to estimate either the costs or the timelines in which those costs will be incurred. The costs associated with the commercialization of CAPLYTA will be substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical development of lumateperone for the treatment of MDD consumes and, together with our anticipated clinical development programs for lenrispodun, will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our PDE program has a compound,&#160;lenrispodun <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ITI-214),</div> in Phase 1/2 development. We intend to pursue the development of our PDE program, including&#160;lenrispodun for the treatment of several CNS <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-CNS</div> conditions. We have ongoing development programs for&#160;lenrispodun for Parkinson&#8217;s disease. Our other projects are still in the preclinical stages, and will require extensive funding not only to complete preclinical testing, but to commence and complete clinical trials. Expenditures that we incur on these projects will be subject to availability of funding in addition to the funding required for the advancement of lumateperone. Any failure or delay in the advancement of lumateperone could require us to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-allocate</div> resources from our other projects to the advancement of lumateperone, which could have a material adverse impact on the advancement of these other projects and on our results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operating expenses are comprised of (i)&#160;costs of product sales; (ii)&#160;research and development expenses; (iii)&#160;general and administrative expenses and (iv)&#160;selling expenses. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs of product sales are comprised of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">direct costs of formulating, manufacturing and packaging drug product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">overhead costs consisting of labor, share-based compensation, shipping, outside inventory management and other miscellaneous operating costs; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">royalty payments on product sales. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research and development costs are comprised of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">internal recurring costs, such as costs relating to labor and fringe benefits, materials, supplies, facilities and maintenance; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">fees paid to external parties who provide us with contract services, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing, manufacturing and related testing, clinical trial activities and license milestone payments. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling expenses are incurred in three major categories: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">salaries and related benefit costs of a dedicated sales force; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales operation costs; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing and promotion expenses. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses are incurred in three major categories: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">salaries and related benefit costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patent, legal, and professional costs; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">office and facilities overhead. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Product sold through December&#160;31, 2021 consisted of drug product that was previously charged to research and development expense prior to FDA approval of CAPLYTA and other direct, indirect, and overhead costs required to make final product for sale. Because the Company&#8217;s prior policy did not allow for the capitalization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> product, the cost of drug product sold is lower than it would have been and has a positive impact on our cost of product sales for the years ended December&#160;31, 2021 and 2020. The Company&#8217;s reported cost of product sales as a percentage of product sales, net was 9.8% or approximately $8.0&#160;million for the year ended December&#160;31, 2021, as compared to 8.4% or approximately $1.9&#160;million for the year ended December&#160;31, 2020, of which more than half related to royalty payments accrued to BMS.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will expect to continue to have this favorable impact on cost of product sales and related product gross margins until our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We are currently unable to estimate how long it will be until we begin selling product entirely manufactured post FDA approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect that research and development expenses will increase as we proceed with our clinical trials, increased manufacturing of drug product for clinical trials <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;pre-clinical</div> development activities. We also expect that our selling, general and administrative costs will increase from prior periods primarily due to costs associated with promotional activities to support the commercial sales of CAPLYTA as well as cost associated with building and maintaining infrastructure, which will include hiring additional personnel and increasing technological capabilities. We granted significant shared-based awards in 2020 and 2021. We expect to continue to grant share-based awards in the future due to our growing employee base, which will increase our share-based compensation expense in future periods. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our revenues, operating expenses, interest income, net and income tax expense for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2020</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2019</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">83,803</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">22,813</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of product sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,035</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">88,845</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65,782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">89,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">272,611</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">186,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,948</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total costs&#160;&amp; expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">369,491</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">254,041</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">154,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(285,688</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(231,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(154,012</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,568</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(284,126</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(227,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(147,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comparison of Years Ended December&#160;31, 2021 and December&#160;31, 2020 </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total Revenues, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenues, net for the year ended December&#160;31, 2021 were approximately $83.8&#160;million compared to $22.8&#160;million for the year ended December&#160;31, 2020. Net product sales were approximately $81.7&#160;million for the year ended December&#160;31, 2021 and $22.5&#160;million for the year ended December&#160;31, 2020. Net product sales were comprised of sales of CAPLYTA, which was approved by the FDA for the treatment of schizophrenia on December&#160;20, 2019 and became available to wholesalers in March 2020. In addition, revenue from a government grant was approximately $2.1&#160;million and $0.3&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of Product Sales </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of product sales was approximately $8.0&#160;million and $1.9&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. Cost of product sales consisted primarily of product royalty fees, overhead and direct costs. Product sold through December&#160;31, 2021 consisted of drug product that was previously charged to research and development expense prior to FDA approval of CAPLYTA and other direct, indirect, overhead costs required to make final product for sale. This minimal cost drug product had a positive impact on our cost of product sales and related product gross margins for the years ended December&#160;31, 2021 and 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to have a lower cost of product sales that excludes the cost of the drug product that was incurred prior to FDA approval until our sales of CAPLYTA include drug product that is entirely manufactured after the FDA approval. We expect that this will be the case for the near-term and as a result, our cost of product sales will be less than we anticipate it will be in future periods. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2020</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">External costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,791</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,679</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Research and development expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lumateperone costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,884</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing costs of drug candidates</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share- based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other projects and overhead</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,796</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Research and development expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development expenses increased to $88.8&#160;million for the year ended December&#160;31, 2021 as compared to $65.8&#160;million for the year ended December&#160;31, 2020, representing an increase of approximately $23.0&#160;million, or 35%. This increase is due primarily to an increase of $15.7&#160;million for lumateperone clinical trial and other costs, approximately $4.9&#160;million for other projects and overhead, including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-214,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-333</div> programs, among others, and approximately $3.0&#160;million for share-based compensation expense. Internal costs increased by approximately $8.7&#160;million for the period due primarily to labor related costs and share-based compensation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As the development of lumateperone progresses, we anticipate research and development costs for lumateperone programs to increase moderately due primarily to conducting ongoing and planned Phase 3 and other clinical trials relating to our lumateperone programs in the next several years. We are also required to complete <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> testing to obtain FDA approval and manufacture material needed for clinical trial use, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> testing of the drug product and drug product in anticipation of possible additional FDA approvals of lumateperone for indications beyond schizophrenia and bipolar depression. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we employed 67 full time personnel in our research and development group as compared to 43 full time personnel in our research and development group at December&#160;31, 2020. The increase is due primarily to additional personnel for our clinical operations team as we continue our research for our lumateperone and other programs. We expect to hire additional staff as we increase our development efforts and grow our business in the upcoming years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We currently have several projects, in addition to lumateperone, that are in the research and development stages. We have used internal resources and incurred expenses not only in relation to the development of lumateperone, but also in connection with these additional projects as well, including our PDE program. We have not, however, reported these costs on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">project-by-project</div></div> basis, as these costs are broadly spread among these projects. The external costs for these projects have been modest and are reflected in the table above in this section &#8220;&#8212;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses</div></div>.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The research and development process necessary to develop a pharmaceutical product for commercialization is subject to extensive regulation by numerous governmental authorities in the United States and other countries. This process typically takes years to complete and requires the expenditure of substantial resources. The steps required before a drug may be marketed in the United States generally include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">completion of extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> laboratory tests, animal studies, and formulation studies in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an Investigational New Drug application, or IND, for human clinical testing, which must become effective before human clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of a New Drug Application, or NDA, after completion of all clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">satisfactory completion of an FDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility or facilities at which the active pharmaceutical ingredient, or API, and finished drug product are produced and tested to assess compliance with current Good Manufacturing Practices, or cGMPs; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of FDA inspections of clinical trial sites to assure that data supporting the safety and effectiveness of product candidates has been generated in compliance with Good Clinical Practices; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The successful development of our product candidates and the approval process requires substantial time, effort and financial resources, and is uncertain and subject to a number of risks. We cannot be certain that any of our product candidates will prove to be safe and effective, will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval, or will be granted marketing approval on a timely basis, if at all. Data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory approval or could result in label warnings related to or recalls of approved products. We, the FDA, or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or other problems with our product candidates. Other risks associated with our product candidates are described in the section entitled &#8220;Risk Factors&#8221; in this Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selling, General and Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative costs for the year ended December&#160;31, 2021 were $272.6&#160;million as compared to $186.4&#160;million in the year ended December&#160;31, 2020, which represents an increase of 46%. which was due to an increase in selling costs and an increase in general and administrative expenses as discussed below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling costs were $203.5&#160;million for the year ended December&#160;31, 2021 as compared to $132.5&#160;million in the year ended December&#160;31, 2020, or an increase of 54%. This increase is primarily due to an increase in sales related labor costs of $10.6&#160;million and commercialization costs of $56.6&#160;million. Salaries, bonuses and related benefit costs for our sales and marketing functions for the year ended December&#160;31, 2021 and 2020 constituted approximately 35% and 46%, respectively, of our selling costs. We expect selling costs to increase moderately as we expanded our sales force at the end of 2021 in anticipation of the launch of CAPLYTA for bipolar depression and anticipate increased marketing costs related to that launch. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses for the year ended December&#160;31, 2021 were $69.1&#160;million in 2021 as compared to $53.9&#160;million for the same period in 2020, an increase of 28%. This increase is due to increases in share based compensation expense of $7.1&#160;million, labor and related expenses of $3.7&#160;million, information technology services of $1.3&#160;million, and the remainder consisting of insurance, professional fees, lease expense, and other administrative expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the years ended December&#160;31, 2021 and 2020 constituted approximately 57% and 53%, respectively, of our general and administrative costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect selling, general and administrative costs to increase in 2022 as compared to the year ended December&#160;31, 2021. We are expanding post approval marketing, including increased efforts to educate physicians due to the limitations related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19</div> virus pandemic and market access efforts as well as our administrative infrastructure. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Income </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income has decreased to approximately $1.6&#160;million from $4.2&#160;million for the year ended December&#160;31, 2021 as compared to the year ended December&#160;31, 2020. This decrease is primarily a result of lower interest rates during 2020 and decreases in cash balances from 2020 to 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, the Company licensed certain intellectual property rights to its wholly-owned subsidiary, ITI Limited, which was formed in the third quarter of 2016. Although the license of intellectual property rights did not result in any gain or loss in the consolidated statements of operations, the transaction generated taxable net income in the United States in 2016. We utilized a portion of our available federal and state net operating loss carryforwards to offset the majority of this net income but incurred approximately $1.1&#160;million of AMT related to intercompany transactions that were treated as tax expense in our consolidated statement of operations in 2016. On December&#160;22, 2017, the &#8220;Tax Cuts and Jobs Act,&#8221; or TCJA, granted a refund of the AMT or a reduction of taxes in future periods. The Company has therefore recognized a benefit of approximately $1.1&#160;million for these taxes in 2017. The Company received approximately $0.6&#160;million in 2019 and the remainder in 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through December&#160;31, 2021, we provided funds for our operations by obtaining a total of approximately $1.6&#160;billion of cash primarily through public and private offerings of our common stock and other securities, grants from government agencies and foundations and payments received under a terminated license and collaboration agreement. In the year ended December&#160;31, 2021, we have collected approximately $87.3&#160;million from product sales, which we believe will increase going forward. We do not believe that grant revenue will be a significant source of funding in the near future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, we had a total of approximately $413.7&#160;million in cash and cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities, including $1.4&#160;million in restricted cash, and approximately $53.4&#160;million of short-term liabilities consisting entirely of liabilities from operations, including approximately $6.7&#160;million of short-term lease obligations. In the year ended December&#160;31, 2021, we spent approximately $348.8&#160;million in cash for operations and equipment. We have sources of cash which included $87.3&#160;million of collected product sales and $1.6&#160;million of interest income, resulting in net cash used in operations of $259.9&#160;million. The use of cash was primarily for selling and marketing costs in connection with our commercial launch of CAPLYTA, conducting clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> testing, product manufacturing, and funding recurring operating expenses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2022, we completed an underwritten public offering of shares of our common stock resulting in net proceeds to us of approximately $433.7&#160;million, after deducting underwriting discounts and commissions and offering expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on our current operating plans, we expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this Annual Report. During that time, we expect that our expenses will increase substantially due primarily to our commercialization activities and related infrastructure expansion in connection with the commercialization of CAPLYTA for the treatment of schizophrenia and for the treatment of bipolar depression; the development of lumateperone in our late stage clinical programs; the development of our other product candidates, including lenrispodun; the continuation of manufacturing activities for anticipated future sales of product and in connection with the development of lumateperone; and general operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For 2022, we expect to spend up to $500&#160;million primarily related to the marketing and commercialization of CAPLYTA, lumateperone clinical development including clinical trial conduct, regulatory activities, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">manufacturing and inventory production, expansion of our administrative infrastructure and other development activities. Our other development activities will include efforts related to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284,</div> lenrispodun <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;ITI-333</div> programs, among others. However, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19</div> pandemic may negatively impact our commercialization of CAPLYTA, our ability to complete our ongoing or planned nonclinical and clinical trials, our ability to obtain approval of any product candidates from the FDA or other regulatory authorities, and our workforce and therefore our research, development and commercialization activities. This may ultimately have a material adverse effect on our liquidity, although we are unable to make any prediction with certainty given the rapidly changing nature of the pandemic and governmental and other responses to it. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may require significant additional financing in the future to continue to fund our operations. We believe that we have the funding in place to commercialize CAPLYTA in patients with schizophrenia and bipolar depression. We also plan to fund additional clinical trials of lumateperone for the treatment of depressive disorders and other CNS disorders; preclinical and clinical development of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-007</div> long acting injectable development program; additional clinical trials of lumateperone; clinical development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ITI-1284,</div> continued clinical development of our PDE product candidates, including lenrispodun; research and preclinical development of our other product candidates; and the continuation of manufacturing activities in connection with the development of lumateperone. We may require additional funds for further development of lumateperone in patients with depressive disorders and other indications, and for development of our other product candidates. We have incurred losses in every year since inception with the exception of 2011, when we received an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fee and a milestone payment related to a license agreement that has been terminated. These losses have resulted in significant cash used in operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the year ended December&#160;31, 2021, we spent approximately $348.8&#160;million in cash for operations and equipment. We have sources of cash which included $87.3&#160;million of collected product sales and $1.6&#160;million of interest income, resulting in net cash used in operations of $259.9&#160;million. While we have several research and development programs underway, the lumateperone program has advanced the furthest and will continue to consume increasing amounts of cash for conducting clinical trials and the testing and manufacturing of product material. As we continue to conduct the activities necessary to pursue FDA approval of lumateperone beyond schizophrenia and bipolar depression and our other product candidates, as well as commercialization efforts, we expect the amount of cash to be used to fund operations to increase over the next several years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We seek to balance the level of cash, cash equivalents and investments on hand with our projected needs and to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. Until we can generate significant revenues from operations, we will need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our product candidates and technology and, to a lesser extent, grant funding. On August&#160;30, 2019, we filed a universal shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was declared effective by the SEC on September&#160;12, 2019, on which we registered for sale up to $350&#160;million of any combination of our common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, which included up to $75&#160;million of common stock that we could issue and sell from time to time, through SVB Leerink LLC acting as our sales agent, pursuant to the sale agreement that we entered into with SVB Leerink on August&#160;29, 2019 for our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program. In the quarter ended June&#160;30, 2020, we sold 230,000 shares of common stock under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program which resulted in our receiving net proceeds of $5.6&#160;million in July 2020. In the quarter ended September&#160;30, 2020, we issued an additional 512,791 shares of common stock under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program and received approximately $12.3&#160;million of net proceeds. On September&#160;10, 2020, we terminated the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program agreement with SVB Leerink LLC. On January&#160;6, 2020, we filed an automatic shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which became effective upon filing, on which we registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that we may determine, so long as we continue to satisfy the requirements of a &#8220;well-known seasoned issuer&#8221; under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We cannot be sure that future funding will be available to us when we need it on terms that are acceptable to us, or at all. We sell securities and incur debt when the terms of such transactions are deemed favorable to us and as necessary to fund our current and projected cash needs. The amount of funding we raise through sales of our common stock or other securities depends on many factors, including, but not limited to, the magnitude of sales of CAPLYTA, the status and progress of our product development programs, projected cash needs, availability of funding from other sources, our stock price and the status of the capital markets. Due to the volatile nature of the financial markets, equity and debt financing may be difficult to obtain. Additionally, the continued spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and uncertain market conditions may limit our ability to access any financing. In addition, any unfavorable results in the commercialization of CAPLYTA and unfavorable development or delay in the progress of our lumateperone program could have a material adverse impact on our ability to raise additional capital. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If adequate funds are not available to us on a timely basis, we may be required to: (1)&#160;delay, limit, reduce or terminate nonclinical studies, clinical trials or other clinical development activities for one or more of our product candidates, including our lead product candidate lumateperone, lenrispodun, and our other product candidates; (2)&#160;delay, limit, reduce or terminate our discovery research or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development activities; (3)&#160;enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our product candidates, technologies or intellectual property at an earlier stage of development and on less favorable terms than we would otherwise agree; or (4)&#160;limit or reduce commercialization efforts related to CAPLYTA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cash is maintained in checking accounts, money market accounts, money market mutual funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Due to the current low interest rates available for these instruments, we are earning limited interest income. We do not expect interest income to be a significant source of funding over the next several quarters. In addition, our investment portfolio historically has not been adversely impacted by problems in the credit markets, but there can be no assurance that our investment portfolio will not be adversely affected in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2014, we entered into a long-term lease with a related party which, as amended, provided for a lease of 16,753 square feet of useable laboratory and office space located at 430 East 29th Street, New York, New York 10016. Concurrent with this lease, we entered into a license agreement to occupy certain vivarium related space in the same facility for the same term, rent and escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> for accounting purposes. In September 2018, we further amended the lease to obtain an additional 15,534 square feet of office space beginning October&#160;1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, we entered into a long-term lease for 3,164 square feet of office space in Towson, Maryland beginning March&#160;1, 2019. The lease has a term of 3.2&#160;years ending in April 2022. On May&#160;17, 2019, we entered into a vehicle fleet lease with a company to acquire motor vehicles for certain employees. The vehicle fleet lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. We began leasing vehicles under the vehicle fleet lease in March 2020. Restricted cash of $1.4&#160;million on our consolidated balance sheet relates to a letter of credit issued as part of the vehicle fleet lease. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented.&#160;Judgments must also be made about the disclosure of contingent liabilities.&#160;We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management makes estimates and exercises judgment in research and development, including clinical trial accruals. Actual results may differ from those estimates and under different assumptions or conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that the following critical accounting policy affects management&#8217;s more significant judgments and estimates used in the preparation of our financial statements: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for payments made in advance of services, we expense our research and development costs as incurred. For payments made in advance, we recognize research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product, outside services, providers, materials and consulting fees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing our financial statements, we are required to estimate expenses resulting from the obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our financial statements by matching those expenses with the period in which services are performed and efforts are expended. We account for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. We determine accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and outside service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us at that time. Our clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period. For the year ended December&#160;31, 2021 we had no material change in estimate which related to the prior year estimates of accrued expenses for clinical trials. For the years ended December&#160;31, 2020 and 2019, we recorded a change in estimate of approximately $2.3&#160;million and $5.3&#160;million, respectively, both related to the prior year estimates of accrued expenses for clinical trials that resulted in a reduction of research and development expenses. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We review new accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-to-maturity</div></div> debt securities, entities will be required to estimate lifetime expected credit losses. We adopted this standard on January&#160;1, 2020 and evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January&#160;1, 2020 and for the year ended December&#160;31, 2020. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_12" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;7A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Rate Sensitivity.</div></div>&#160;As of December&#160;31, 2021, we had cash, cash equivalents, marketable securities and restricted cash of approximately $413.7&#160;million consisting of cash deposited in a highly rated financial institution in the United&#160;States and in a short-term U.S. Treasury money market fund, as well as high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations and we do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of changes in interest rates, although the recent decline in interest rates has resulted in our unrealized loss on investments, net, as of December&#160;31, 2021 of approximately $0.9&#160;million and an unrealized gain on investments, net, in 2020 totaling approximately $0.5&#160;million. We plan on holding those investments to maturity, and should interest rates rise, there would be no recognition of impairment required. Declines in interest rates, however, would reduce future investment income. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inflation Risk</div></div>. Inflation generally may affect us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases of our product. Our inability or failure to do so could adversely affect our business, financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capital Market Risk.</div></div>&#160;Although we receive product revenues from commercial sales of CAPLYTA, we continue to depend on funds raised through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_13" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INTRA-CELLULAR THERAPIES, INC. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 90%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Index to Financial Statements and Financial Statement Schedules</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_28">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_29">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_30">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_31">Consolidated Statements of Comprehensive Loss for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_32">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_33">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx234590_34">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_14" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_15" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;9A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONTROLS AND PROCEDURES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e))</div> as of the end of the period covered by this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> have concluded that, based on such evaluation, our disclosure controls and procedures were effective at the reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management&#8217;s Report on Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> under the Exchange Act, as a process designed by, or under the supervision of, the Company&#8217;s principal executive and principal financial officers and effected by the Company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company&#8217;s internal control over financial reporting includes those policies and procedures that: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on our assessment, management believes that, as of December&#160;31, 2021, the Company&#8217;s internal control over financial reporting is effective based on those criteria<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our independent registered public accounting firm has issued an audit report on the effectiveness of our internal control over financial reporting. This report appears further below in this Item&#160;9A. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Controls </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes in our internal control over financial reporting during the fourth quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders and the Board of Directors of Intra-Cellular Therapies, Inc. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on Internal Control Over Financial Reporting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited Intra-Cellular Therapies, Inc. and subsidiaries&#8217; internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Intra-Cellular Therapies, Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2021, based on the COSO criteria. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes and our report dated March&#160;1, 2022 expressed an unqualified opinion thereon. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definition and Limitations of Internal Control Over Financial Reporting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Baltimore, MD </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;1, 2022 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_16" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;9B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OTHER INFORMATION </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_17" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;9C.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx234590_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_19" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Management and Corporate Governance&#8221; and &#8220;Code of Ethics and Business Conduct&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_20" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXECUTIVE COMPENSATION </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Executive Officer and Director Compensation,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Management and Corporate Governance&#8212;Compensation Committee Interlocks and Insider Participation,&#8221; &#8220;Compensation Committee Report&#8221; and &#8220;Risks Related to Compensation Practices and Policies&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_21" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;12.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_22" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Management and Corporate Governance&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_23" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRINCIPAL ACCOUNTANT FEES AND SERVICES </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx234590_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART IV </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 12%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 86%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td id="tx234590_25" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;15.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;15(a).</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The following documents are filed as&#160;part of this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K:</div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;15(a)(1)</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and (2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">See &#8220;Index to Financial Statements and Financial Statement Schedules&#8221; at Item&#160;8 to this Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K.</div> Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;15(a)(3)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 18%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following is a list of exhibits filed as part of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: top; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">by&#160;Reference</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">herein&#160;from</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;or</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedule</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SEC&#160;File/<br/>Reg.&#160;Number</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">2.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513352243/d590056dex21.htm">Agreement and Plan of Merger, dated as of August&#160;23, 2013, by and among the Registrant, ITI, Inc. and Intra-Cellular Therapies, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;2.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/29/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">2.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex22.htm">Agreement and Plan of Merger, dated as of August&#160;29, 2013, by and between the Registrant and Intra-Cellular Therapies, Inc., relating to the name change of the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;2.2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">3.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513455074/d592775dex31.htm">Restated Certificate of Incorporation of the Registrant, as amended. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;3.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">3.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex33.htm">Certificate of Merger relating to the Merger of ITI, Inc. with and into Intra-Cellular Therapies, Inc., filed with the Secretary of State of the State of Delaware on August&#160;29, 2013. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;3.3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">3.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex34.htm">Certificate of Ownership and Merger relating to the Merger of Intra-Cellular Therapies, Inc. with and into the Registrant, filed with the Secretary of State of the State of Delaware on August&#160;29, 2013, relating to the name change of the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;3.4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">3.4</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex35.htm">Restated Bylaws of the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;3.5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">4.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex41.htm">Form of common stock certificate. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;4.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">4.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex42.htm">Description of securities. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">.1</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513420767/d610873dex1011.htm">License Agreement dated as of May&#160;31, 2005 by and between Bristol-Meyers Squibb Company and Intra-Cellular Therapies, Inc.** </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K/A</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">10/31/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: top; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">by&#160;Reference</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">herein&#160;from</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;or</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedule</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SEC&#160;File/<br/>Reg.&#160;Number</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">.2</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1012.htm">Amendment No.&#160;1 to License Agreement dated as of November&#160;3, 2010 by and between Bristol-Meyers Squibb Company and Intra-Cellular Therapies, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1.2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">.1</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312517065749/d285960dex103.htm">Supply Agreement dated as of January&#160;4, 2017 by and between Siegfried Evionnaz SA and ITI Limited.*** </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">1/5/2022</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">.2</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312521369138/d279163dex101.htm">Amendment to Supply Agreement dated as of December&#160;24, 2021 by and between Siegfried Evionnaz SA and ITI Limited. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">12/29/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520288507/d18633dex101.htm">Master Services Agreement, effective as of January&#160;10, 2017, by and between ITI Limited and Lonza Ltd.*** </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">11/9/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.4</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex103.htm">Employment Agreement effective as of February&#160;26, 2008 by and between Sharon Mates, Ph.D. and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.5</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">.1</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312515368374/d24660dex101.htm">Employment Agreement effective as of August&#160;3, 2015 by and between Michael I. Halstead and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">11/5/2015</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">.2</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312516764370/d247783dex101.htm">Amendment No.&#160;1 to Employment Agreement dated as of November&#160;9, 2016 by and between Michael I. Halstead and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">11/9/2016</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.6</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex104.htm">Employment Agreement effective as of February&#160;26, 2008 by and between Lawrence J. Hineline and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.7</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/d678830dex109.htm">Employment Agreement effective as of October&#160;15, 2018 by and between Mark Neumann and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.9)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">2/27/2019</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.8</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex108.htm">Employment Agreement effective as of September&#160;12, 2018 by and between Suresh Durgam, M.D. and Intra-Cellular Therapies, Inc.<span style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="font-weight:bold;display:inline;">* </span></span></a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.9</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex108.htm">Employee Proprietary Information, Inventions, and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</span> Agreement effective as of September&#160;1, 2003 by and between Sharon Mates, Ph.D. and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.8)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 49%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">by&#160;Reference</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">herein&#160;from</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;or</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedule</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SEC&#160;File/<br/>Reg.&#160;Number</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.10</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312515089426/d857051dex1011.htm">Employee Proprietary Information, Inventions, and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</span> Agreement effective as of July&#160;29, 2014 by and between Michael Halstead and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">3/12/2015</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.11</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex109.htm">Employee Proprietary Information, Inventions, and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</span> Agreement effective as of December&#160;1, 2003 by and between Lawrence J. Hineline and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.9)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.12</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/d678830dex1016.htm">Employee Proprietary Information, Inventions, Inventions, and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</span> Agreement effective as of December&#160;10, 2018 by and between Mark Neumann and Intra-Cellular Therapies, Inc.*</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.16)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">2/27/2019</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.13</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex1013.htm">Employee Proprietary Information, Inventions, Inventions, and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</span> Agreement effective as of September&#160;12, 2018 by and between Suresh Durgam, M.D. and Intra-Cellular Therapies, Inc.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.14</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1013.htm">Form of Indemnification Agreement by and between the Company and its directors and executive officers.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.13)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.15</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1014.htm">2003 Equity Incentive Plan, as amended.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.14)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.16</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1015.htm">Form of Stock Option Agreement under the 2003 Equity Incentive Plan, as amended.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.15)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.17</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312515227369/d943615dex101.htm">Amended and Restated 2013 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">6/18/2015</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.18</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312514114613/d675342dex1019.htm">Form of Stock Option Agreement under the 2013 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.19)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">3/25/2014</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.19</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520154280/d935875dex101.htm">Amended and Restated 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">5/28/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.20</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312518199545/d608225dex102.htm">Form of Stock Option Agreement under the 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">6/21/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.21</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312518199545/d608225dex103.htm">Form of Director Stock Option Agreement under the 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">6/21/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.22</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312518199545/d608225dex104.htm">Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">6/21/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 49%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">by&#160;Reference</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">herein&#160;from</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;or</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedule</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SEC&#160;File/<br/>Reg.&#160;Number</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">10.23</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312518199545/d608225dex105.htm">Form of Director Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">6/21/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.24</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520214163/d911713dex102.htm">Form of Stock Option Agreement under the Amended and Restated 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/10/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.25</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520214163/d911713dex103.htm">Form of Director Stock Option Agreement under the Amended and Restated 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/10/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.26</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520214163/d911713dex104.htm">Form of Restricted Stock Unit Agreement under the Amended and Restated 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/10/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.27</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520214163/d911713dex105.htm">Form of Director Restricted Stock Unit Agreement under the Amended and Restated 2018 Equity Incentive Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/10/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.28</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312521239867/d177205dex101.htm"><span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</span> Director Compensation Policy, as amended.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">8/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.29</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1017.htm">Redemption Agreement dated as of August&#160;29, 2013 by and between the Registrant and NLBDIT 2010 Services, LLC. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.17)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.30</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1018.htm">Indemnity Agreement dated as of August&#160;29, 2013 by and among the Registrant, Intra-Cellular Therapies, Inc. and Samir N. Masri. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.18)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.31</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312513358382/d590040dex1019.htm">Registration Rights Agreement dated as of August&#160;29, 2013 by and among Intra-Cellular Therapies,&#160;Inc., the stockholders named therein and the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.19)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">9/5/2013</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">000-54896</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.32</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619dex1032.htm">Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.32)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">3/2/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.33</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619dex1033.htm">Form of Restricted Stock Unit Agreement under the 2019 Inducement Award Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.33)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">3/2/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.34</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619dex1034.htm">Form of Stock Option Agreement under the 2019 Inducement Award Plan.* </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.34)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">3/2/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">21.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1567514/000119312517065749/d285960dex211.htm">Subsidiaries. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;21.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">3/1/2017</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-36274</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">23.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex231.htm">Consent of Ernst&#160;&amp; Young LLP. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">31.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex311.htm">Certification of the Chief Executive Officer. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">31.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex312.htm">Certification of the Chief Financial Officer. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 55%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">by&#160;Reference</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">herein&#160;from</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;or</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedule</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SEC&#160;File/<br/>Reg.&#160;Number</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">32.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><a href="d234590dex321.htm">Certification pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">101</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">.INS</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document&#8212;the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">.SCH</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">.CAL</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">.DEF</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">.LAB</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Label Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">.PRE</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Presentation Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">104</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101).</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management contract or compensatory plan or arrangement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Confidential treatment has been granted for portions of this Exhibit. Redacted portions filed separately with the Securities and Exchange Commission. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">***</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i)&#160;are not material and (ii)&#160;would be competitively harmful if publicly disclosed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx234590_26" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FORM&#160;10-K</div> SUMMARY </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Not Applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx234590_27" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 5%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 44%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">INTRA-CELLULAR&#160;THERAPIES,&#160;INC.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;">Date: March&#160;1, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt; font-size: 0px;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Sharon Mates, Ph.D.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Sharon Mates, Ph.D.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">Chairman, President and Chief Executive Officer</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 3%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 42%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signatures</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;&#160;&#160;&#160;Sharon Mates, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Chairman, President and Chief Executive</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;1,&#160;2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Sharon Mates, Ph.D.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Officer (principal executive officer)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;&#160;&#160;&#160;Lawrence J. Hineline</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Senior Vice President of Finance and</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;1, 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Lawrence J. Hineline</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Chief Financial Officer (principal financial officer and principal accounting officer)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;&#160;&#160;&#160;Sir Michael Rawlins, M.D., FRCP,<br/>FMedSci</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;1, 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Sir Michael Rawlins, M.D., FRCP, FMedSci</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;&#160;&#160;&#160;Joel S. Marcus</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;1, 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Joel S. Marcus</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;&#160;&#160;&#160;Rory B. Riggs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;1, 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Rory B. Riggs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/&#160;&#160;&#160;&#160;Robert L. Van Nostrand</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">March&#160;1, 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">Robert L. Van Nostrand</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx234590_28" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders and the Board of Directors of Intra-Cellular Therapies, Inc. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Intra-Cellular Therapies, Inc. and subsidiaries (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March&#160;1, 2022 expressed an unqualified opinion thereon. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Audit Matter </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 72%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical&#160;trial&#160;expenses</div></div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Description&#160;of&#160;the&#160;Matter</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">As described in Note 2 to the consolidated financial statements, at each consolidated balance sheet date, the Company is required to estimate its</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The Company recorded accrued expenses for the clinical trial accruals, which are included in accrued and other current liabilities on the December&#160;31, 2021 consolidated balance sheet and also recorded prepaid clinical trial expenses, which are included in prepaid expenses and other current assets on the December&#160;31, 2021 consolidated balance sheet. The amounts recorded for clinical trial accruals and for prepaid clinical trial expenses, within the aforementioned balance sheet captions represent the Company&#8217;s estimate of the unpaid and prepaid clinical trial expenses based on the<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>progress of the research and development services for clinical trials compared to the amounts paid for clinical trials through December&#160;31, 2021.</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Auditing the Company&#8217;s clinical trial accruals and prepaid clinical trial expenses, specifically as it relates to active studies with greater than 15% expected enrollment, involved a high degree of subjectivity due to the significant estimation required in determining the progress to completion of specific tasks conducted under its clinical trials and the costs of those tasks that will be invoiced by the vendors, clinical research organizations and consultants, and under clinical site agreements subsequent to the date that the consolidated financial statements are issued.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">How We Addressed the Matter in Our Audit</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s estimation of the clinical trial expenses, including the process of estimating the expenses incurred to date based on the progress of the clinical trials which have achieved greater than 15% of expected enrollment. For example, we tested controls over management&#8217;s review of the clinical trial expense calculation, the significant assumptions about the status of research and development services incurred, and the completeness and accuracy of the data used to calculate the estimates.</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To test the clinical trial accruals and prepaid clinical trial expenses, we performed procedures that included, among others, reading each agreement and change order with the vendors, clinical research organizations and consultants, and under clinical site agreements, and evaluating the significant assumptions described above and the methods used in developing the clinical trial estimates and calculating the amounts that were unpaid and prepaid at the balance sheet date. We made direct inquiries of financial and clinical personnel, and observed management hold discussions with the Clinical Research Organization on the status of the clinical trials, progress to completion of clinical trials, method of allocating contractual charges to specific tasks performed during the clinical trials, and the status of change orders. We compared the current estimate of expenses incurred to estimates previously made by management. We also assessed the historical accuracy of management&#8217;s estimates and examined payments made to service providers after the consolidated balance sheet date.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp;&#160;Young&#160;LLP </div></div> <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2002. </div></div> <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Baltimore, Maryland </div></div> <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;1, 2022 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Intra-Cellular Therapies, Inc. and Subsidiaries </div> <div id="tx234590_29" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Balance Sheets </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">December&#160;31,<br/> 2020</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">92,364,990</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">60,045,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investment securities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">319,968,348</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">597,402,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,400,000</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,400,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,155,994</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">10,764,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,948,126</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,056,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">25,443,372</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">14,235,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">467,280,830</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">690,904,482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,790,724</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,998,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,764,458</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">24,324,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">86,084</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">86,084</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">489,922,096</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">717,313,674</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,691,220</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,501,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other current liabilities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,072,996</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,896,942</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued customer programs</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="itci:AccruedCustomerProgramsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,963,610</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:AccruedCustomerProgramsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,005,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">6,731,792</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,541,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,896,860</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">14,907,479</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">53,356,478</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">36,853,223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">18,674,943</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">23,600,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">72,031,421</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">60,453,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">175,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">100,000,000</ix:nonFraction> shares authorized at December&#160;31, 2021 and December&#160;31, 2020, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">81,886,965</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">80,463,089</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,189</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,639,475,837</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,593,475,506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated defici<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,221,229,698</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">937,104,032</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated comprehensive (loss) income</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">363,653</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">480,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">417,890,675</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">656,860,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">489,922,096</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">717,313,674</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">F-3</div></div></div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Intra-Cellular Therapies, Inc. and Subsidiaries </div> <div id="tx234590_30" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Statements of Operations </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product sales, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">81,707,874</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">22,530,753</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Grant revenue</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,095,143</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">282,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">60,613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenues, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">83,803,017</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">22,812,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">60,613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of product sales</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="itci:Costofproductsales" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,034,589</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:Costofproductsales" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,895,029</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:Costofproductsales" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">88,845,513</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">65,782,137</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">89,124,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">272,611,040</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">186,363,444</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">64,947,625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">369,491,142</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">254,040,610</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">154,072,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">285,688,125</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">231,227,631</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">154,011,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,568,090</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,235,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">6,291,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before provision for income taxes</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,120,035</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">226,992,150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,720,578</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,631</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">13,513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,125,666</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">227,005,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,722,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic&#160;&amp; Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.50</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of common shares:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic&#160;&amp; Diluted</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">81,253,394</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">70,364,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">55,186,206</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4 </div></div></div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Intra-Cellular Therapies, Inc. and Subsidiaries </div> <div id="tx234590_31" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Statements of Comprehensive Loss </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,125,666</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">227,005,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,722,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized (loss) gain on investment securities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">844,237</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">352,267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">796,074</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,969,903</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">) </td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">226,653,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">146,926,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Intra-Cellular Therapies, Inc. and Subsidiaries </div> <div id="tx234590_32" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Statements of Stockholders&#8217; Equity </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Comprehensive<br/> Income&#160;(Loss)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December&#160;31, 2018</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">54,895,295</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,490</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">880,753,339</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">562,376,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">667,757</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">317,714,881</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options and issuances of restricted stock</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">596,558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,235,542</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,235,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock issued for services</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">194,203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">194,205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,788,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,788,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,722,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,722,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">796,074</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">796,074</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 33%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December&#160;31, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">55,507,497</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">904,971,772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">710,098,369</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">128,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">195,007,271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common shares issued</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">23,409,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,341</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">652,709,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">652,712,011</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options and issuances of restricted stock</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,536,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">153</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,464,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,464,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock issued for services</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">214,102</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">214,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">24,115,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">24,115,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">227,005,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">227,005,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">352,267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">352,267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 33%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December&#160;31, 2020</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">80,463,089</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,046</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,593,475,506</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">937,104,032</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">480,584</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">656,860,104</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options and issuances of restricted stock</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,419,331</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">143</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,518,768</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,518,911</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock issued for services</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,545</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">178,534</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">178,534</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">34,303,029</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">34,303,029</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,125,666</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,125,666</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">844,237</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">844,237</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 33%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; width: 33%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at December&#160;31, 2021</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">81,886,965</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,189</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,639,475,837</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,221,229,698</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">363,653</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">417,890,675</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 33%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6 </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Intra-Cellular Therapies, Inc. and Subsidiaries </div> <div id="tx234590_33" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Consolidated Statements of Cash Flows </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2020</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">2019</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash&#160;flows&#160;used&#160;in&#160;operating&#160;activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,125,666</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">227,005,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,722,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">533,360</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">528,118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">477,121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">34,303,029</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">24,115,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,788,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock issued for services</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">178,534</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">214,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">194,205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of premiums and discounts on investment securities, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,079,828</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">648,248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,131,597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">9,391,411</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">10,764,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">891,741</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,056,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other assets</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,207,917</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,921,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,465,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long term deferred tax asset, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">264,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">264,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,189,395</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">1,923,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">6,536,036</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities and other</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">12,123,870</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">198,036</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,327,095</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">175,110</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">73,160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">889,468</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">259,543,485</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">230,072,845</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">127,983,241</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows (used in) provided by investing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of investments</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">224,574,687</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">755,629,547</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">80,720,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Maturities of investments</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">505,244,056</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">275,601,271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">258,857,683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">325,738</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">266,724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">700,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash (used in) provided by investing activities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">280,343,631</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">480,295,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">177,436,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows provided by financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from exercise of stock options</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,518,911</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,464,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,235,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds of public offerings, net</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">652,712,011</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,518,911</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">664,176,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,235,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase (decrease) in cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">32,319,057</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">46,190,916</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">52,689,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at beginning of period</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">61,445,933</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">107,636,849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">54,947,502</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at end of period</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">93,764,990</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">61,445,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">107,636,849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for taxes</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,631</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets under operating vehicle fleet leases</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">107,809</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,917,935</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets under operating real estate leases</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2020To12_31_2020_RealEstateLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">219,703</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size:1pt">
<td colspan="13" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="12" style="vertical-align:top">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:</td>
<td style="vertical-align:top"> <div style="margin-top: 0px; margin-bottom: 0px; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash&#160;and&#160;cash&#160;equivalents</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">92,364,990</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">60,045,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">107,636,849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,400,000</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,400,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 58%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">93,764,990</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">61,445,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">107,636,849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 58%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">F-7</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"></div></div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Intra-Cellular Therapies, Inc. and Subsidiaries </div> <div id="tx234590_34" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Notes to Consolidated Financial Statements </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">December&#160;31, 2021 </div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872156"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intra-Cellular Therapies, Inc. (the &#8220;Company&#8221;), through its wholly-owned operating subsidiaries, ITI, Inc. (&#8220;ITI&#8221;) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (&#8220;CNS&#8221;). In December 2019, the Company announced that CAPLYTA<div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">TM</div> (lumateperone) had been approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of schizophrenia in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA in late March 2020. Additionally, in December 2021, the Company announced that CAPLYTA had been approved by the FDA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate (42mg/day). As used in these Notes to Consolidated Financial Statements, &#8220;CAPLYTA&#8221; refers to lumateperone approved by the FDA for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder in adults, and &#8220;lumateperone&#8221; refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and depressive episodes associated with bipolar I or II disorder. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;10, 2020, the Company completed a public offering of common stock in which the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_10_2020To01_10_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn01_10_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">29.50</ix:nonFraction> per share for aggregate gross proceeds of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_10_2020To01_10_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">295.0</ix:nonFraction>&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_10_2020To01_10_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">277.0</ix:nonFraction>&#160;million. On September&#160;15, 2020, the Company completed <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div> public offering of common stock in which the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_15_2020To09_15_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,666,667</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_15_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">30.00</ix:nonFraction> per share for aggregate gross proceeds of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P09_15_2020To09_15_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">380.0</ix:nonFraction>&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P09_15_2020To09_15_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">357.8</ix:nonFraction>&#160;million. On January&#160;7, 2022, the Company completed a public offering of common stock in which the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_07_2022To01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,952,381</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">42.00</ix:nonFraction> per share for aggregate gross proceeds of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_07_2022To01_07_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">460.0</ix:nonFraction>&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_07_2022To01_07_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">433.7</ix:nonFraction>&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Possible sources of funds include public or private sales of the Company&#8217;s equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company&#8217;s product candidates and technology and, to a lesser extent, grant funding. On August&#160;30, 2019, the Company filed a universal shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was declared effective by the SEC on September&#160;12, 2019, on which the Company registered for sale up to $<ix:nonFraction name="itci:SecuritiesAuthorizedAmountForIssuance" contextRef="PAsOn09_12_2019_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction>&#160;million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which included up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_12_2019To09_12_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction>&#160;million of common stock that the Company could issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August&#160;29, 2019 for the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program. On September&#160;10, 2020, the Company terminated the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program sales agreement with SVB Leerink LLC. During the year ended December&#160;31, 2020, the Company issued an aggregate <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">742,791</ix:nonFraction> shares of common stock under the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program which resulted in the Company receiving net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">17.9</ix:nonFraction>&#160;million. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872156"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on January&#160;6, 2020, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company</div> filed an automatic shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a &#8220;well-known seasoned issuer&#8221; under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872164"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> segment, which is discovering, developing, and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of <ix:nonNumeric name="itci:CashAndCashEquivalentMaximumMaturityPeriod" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durwordsen">three months</ix:nonNumeric> or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of <ix:nonNumeric name="itci:AvailableForSaleSecuritiesMaturityPeriod" contextRef="P01_01_2021To12_31_2021">more than three months</ix:nonNumeric> are classified separately on the consolidated balance sheets. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872168"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Investment Securities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment securities may consist of investments in U.S. Treasuries, various U.S. governmental agency debt securities, corporate bonds, certificates of deposit, and other fixed income securities with an average maturity of twelve months or less. Management classifies the Company&#8217;s investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> Such securities are carried at estimated fair value, with any unrealized holding gains or losses reported, net of any tax effects reported, as accumulated other comprehensive (loss) income, which is a separate component of stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other-than-temporary, if any, are included in consolidated results of operations. A decline in the market value of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security below cost that is deemed to be other-than-temporary results in a reduction in fair value, which is charged to earnings in that period, and a new cost basis for the security is established. Dividend and interest income are recognized as interest income on the consolidated statements of operations when earned. The cost of securities sold is calculated using the specific identification method. </div></ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872164" continuedAt="TextSelectionAppend_37872164_1"> <ix:continuation id="TextSelection_37872168"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors its investment portfolio for overall risk, specifically credit loss, <div style="letter-spacing: 0px; top: 0px;;display:inline;">quarterly</div> or more frequently if circumstances warrant. The Company has estimated the expected credit loss over the lifetime of the asset and has determined an allowance for credit losses is not material with respect to the investment portfolio. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872173"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2&#8212;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#8212;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"> no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets or liabilities that were measured for significant unobservable inputs (Level 3 assets and liabilities) as of December&#160;31, 2021 and December&#160;31, 2020. The carrying value of cash held in money market funds of approximately $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">56.5</ix:nonFraction>&#160;million as of December&#160;31, 2021 and $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.9</ix:nonFraction>&#160;million as of December&#160;31, 2020 is included in cash and cash equivalents and approximates market value based on quoted market price or Level&#160;1 inputs. </div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872230"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value measurements of the Company&#8217;s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">376,507</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,539</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">319,968</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10 </div></div></div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_1" continuedAt="TextSelectionAppend_37872164_2"><ix:continuation id="TextSelection_37872173"><ix:continuation id="TextSelection_37872230">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">259,276</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">259,276</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">124,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">124,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">203,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">203,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">625,319</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,917</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">597,402</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Financial Instruments </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits, and lease liabilities, short term, to approximate their fair value because of their relatively short maturities at December&#160;31, 2021 and December&#160;31, 2020. Management believes that the risks associated with the Company&#8217;s financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Restricted Cash </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash is collateral used under the letter of credit arrangement for the Company&#8217;s vehicle lease agreement (see Note <div style="display:inline;">6</div>). The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-18,</div> &#8220;Restricted Cash&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18&#8221;)</div> and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Accounts Receivable, net </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers&#8217; credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a Customer&#8217;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of December&#160;31, 2021 and 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable. As of December&#160;31, 2021 and 2020, our credit loss reserve on receivables was not significant. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872184"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-11 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_2" continuedAt="TextSelectionAppend_37872164_3"><ix:continuation id="TextSelection_37872184"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">years ended December&#160;31, 2021 and 2020, approximately $<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction>&#160;million, respectively, of the Company&#8217;s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 60 days. For the years ended December&#160;31, 2021 and 2020, the Company had a grant receivable of approximately $<ix:nonFraction name="itci:GrantReceivable" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="itci:GrantReceivable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. For the years ended December&#160;31, 2021 and 2020, <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">96</ix:nonFraction></ix:nonFraction>% of sales were generated from three major industry wholesalers. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">Three individual customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%, <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">28</ix:nonFraction>%, and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerThreeMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">28</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction>%, <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">29</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div>&#160;<ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerThreeMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">28</ix:nonFraction>% of product sales for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company believes that such customers are of high credit quality. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Inventory </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (&#8220;FIFO&#8221;) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes inventory costs associated with the Company&#8217;s products after regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Property and Equipment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:hidden37872336">three</span> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC&#160;Topic No.&#160;360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> such impairment losses have been recognized to date. </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-12 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_3" continuedAt="TextSelectionAppend_37872164_4"> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2019, the Company adopted FASB ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC Topic 842&#8221;). The Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. Payments for identified leases are recognized in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872195"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2018, the Company adopted FASB ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Revenue from Contracts with Customers </div></div>(&#8220;ASC Topic 606&#8221;). The Company did not generate any product related revenue prior to January&#160;1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company&#8217;s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service.&#160;The reported results for the years ended December&#160;31, 2021 and December&#160;31, 2020 reflect the application of ASC Topic 606. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div>(below). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company&#8217;s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company&#8217;s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products. The Company recognizes revenue on product sales when the customer obtains control of the Company&#8217;s product, which occurs at a point in time (upon delivery). Product revenues are </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-13 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_4" continuedAt="TextSelectionAppend_37872164_5"><ix:continuation id="TextSelection_37872195" continuedAt="TextSelectionAppend_37872195_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company&#8217;s sales of its product. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company&#8217;s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company&#8217;s estimates utilizing payer mix are based on CAPLYTA&#8217;s actual channel mix in 2021. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of December&#160;31, 2021 and 2020, therefore, the transaction price was not reduced further during the years ended December&#160;31, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>&#8212; The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the consolidated statements of operations for the years ended December&#160;31, 2021 and December&#160;31, 2020, as well as a reduction to accounts receivable, net on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>&#8212; Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product&#8217;s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>&#8212; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is </div> </ix:continuation></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-14 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_5" continuedAt="TextSelectionAppend_37872164_6"><ix:continuation id="TextSelectionAppend_37872195_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the years ended December&#160;31, 2021 and December&#160;31, 2020, these amounts were not significant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>&#8212; The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>&#8212; The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>&#8212; Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872204"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost of Product Sales </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (&#8220;BMS&#8221;), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="itci:RoyaltyPaymentPercentage" contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>-<ix:nonFraction name="itci:RoyaltyPaymentPercentage" contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>%</div> on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-15 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_6" continuedAt="TextSelectionAppend_37872164_7"><ix:continuation id="TextSelection_37872204"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the FDA approval of CAPLYTA, the Company ex<div style="letter-spacing: 0px; top: 0px;;display:inline;">pen</div>sed all costs associated with the manufacturing of lumateperone as part of research and development expenses. The cost of product sales in the years ended December&#160;31, 2021 and 2020 are lower than incurred because of previously expensed inventory. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors, among other factors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the year ended December&#160;31, 2021 the Company had no material change in estimate which related to the prior year estimates of accrued expenses for clinical trials. For the years ended December&#160;31, 2020 and 2019, we recorded a change in estimate of approximately $<ix:nonFraction name="itci:ChangeInAccountingEstimateAmount" contextRef="P01_01_2020To12_31_2020_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="itci:ChangeInAccountingEstimateAmount" contextRef="P01_01_2019To12_31_2019_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction>&#160;million, respectively, both related to the prior year estimates of accrued expenses for clinical trials that resulted in a reduction of research and development expenses. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Advertising Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the FDA approval of CAPLYTA, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. The Company incurred $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2021To12_31_2021_CaplytaMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">82.5</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2020To12_31_2020_CaplytaMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">36.3</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2019To12_31_2019_CaplytaMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> in advertising costs during the years ended December&#160;31, 2021, 2020, and 2019, respectively, related to its marketed product, CAPLYTA. </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-16 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_7" continuedAt="TextSelectionAppend_37872164_8"> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s effective tax rate for the years ended December&#160;31, 2021, 2020, and 2019 was approximately <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction>%. This effective tax rate is substantially lower than the U.S. statutory rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (&#8220;AMT&#8221;) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December&#160;31, 2021.&#160;The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn03_27_2020_AmtTaxCreditMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction>&#160;million to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December&#160;31, 2019 and received the refund in July 2020. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or losses on its investment securities in a separate statement of comprehensive loss for each period. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872217"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Share-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payments are accounted for in accordance with the provisions of ASC Topic&#160;718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>. The fair value of share-based payments related to stock options is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the &#8220;Black-Scholes Model&#8221;). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 accounts for forfeitures as they occur. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes Model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes Model, require the input of subjective assumptions, and changes </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-17 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872217" continuedAt="TextSelectionAppend_37872217_1"><ix:continuation id="TextSelectionAppend_37872164_8" continuedAt="TextSelectionAppend_37872164_9"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected volatility rates for quarterly periods prior to December&#160;31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company&#8217;s common stock. In the fourth quarter of 2019 and for all periods thereafter, expected volatility rates are based entirely on the historical volatility of the Company&#8217;s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the &#8220;simplified method,&#8221; which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen">zero</ix:nonFraction>. For stock options granted, the exercise price was determined by using the closing market price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A restricted stock unit (&#8220;RSU&#8221;) is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company&#8217;s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2020, the Company granted performance-based RSUs for approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P03_31_2020To03_31_2020_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">86,000</ix:nonFraction> shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;the approval of a planned supplemental new drug application (&#8220;sNDA&#8221;) by the FDA (the &#8220;2020 Milestone RSUs&#8221;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#8217;s peers (the &#8220;2020 TSR RSUs&#8221;). In the fourth quarter of 2021, the Company received approval from the FDA for the sNDA for the use of CAPLYTA for the treatment of bipolar depression. In the first quarter of 2021, the Company granted performance-based RSUs for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">64,518</ix:nonFraction> shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;certain operational milestones (the &#8220;2021 Milestone RSUs&#8221;, and collectively with the 2020 Milestone RSUs, the &#8220;Milestone RSUs&#8221;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#8217;s peers (the &#8220;2021 TSR RSUs,&#8221; and collectively with the 2020 TSR RSUs, the &#8220;TSR RSUs&#8221;). The Milestone RSUs are recognized when it is probable that the performance metrics will be obtained. The TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the respective agreements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic&#160;718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date&#160;or the date the required services are completed and are marked to market during the service&#160;period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2018, the Company&#8217;s stockholders approved the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) pursuant to which <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2018_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,750,000</ix:nonFraction> additional shares of common stock were reserved for future equity grants. In May 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2018 Amended and Restated Equity Incentive Plan (the &#8220;Amended 2018 Plan&#8221;) pursuant to which <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn05_31_2020_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,500,000</ix:nonFraction> additional shares of common stock were reserved for future equity grants. </div> </ix:continuation></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-18 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872164_9"> <ix:continuation id="TextSelectionAppend_37872217_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement <div style="letter-spacing: 0px; top: 0px;;display:inline;">Award</div> Plan (the &#8220;2019 Inducement Plan&#8221;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&#160;Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> shares of common stock to new employees of the Company. As of December&#160;31, 2021, stock options and RSUs for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">314,138</ix:nonFraction> shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Loss Per Share </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock option grants and RSUs. </div> <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,451,398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,517,622</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,039,945</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,598,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,600,083</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,268,679</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TSR RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">68,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">36,339</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">67,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Issued Accounting Standards </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-to-maturity</div></div> debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January&#160;1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January&#160;1, 2020 and for the years ended December&#160;31, 2021 and 2020. </div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:InvestmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872212"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Investment Securities </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872348"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment securities consisted of the following (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,752</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,955</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,919</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,394</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">) </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,164</ix:nonFraction> </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">320,333</ix:nonFraction> </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">386</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">319,968</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-19 </div></div></div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872212"><ix:continuation id="TextSelection_37872348">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">259,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">259,276</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">124,368</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">124,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">203,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">596,921</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">650</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">169</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">597,402</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has classified all of its investment securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale,</div></div> including those with maturities beyond one year, as current assets on the consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of December&#160;31, 2021 and 2020, the Company held $<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">67.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2020_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">188.5</ix:nonFraction>&#160;million, respectively, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities with contractual maturity dates more than one year and less than two&#160;years, with the remainder of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities having contractual maturity dates less than one year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate related fair value of investments with unrealized losses as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">263.5</ix:nonFraction>&#160;million, which consisted of $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">71.7</ix:nonFraction>&#160;million from U.S. government agency securities, $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">49.9</ix:nonFraction>&#160;million of commercial paper, and $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction>&#160;million of corporate notes/bonds. $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction>&#160;million of the aggregate fair value of investments with unrealized losses as of December&#160;31, 2021 has been held in a continuous unrealized loss position for over than 12 months, with the remaining $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">254.1</ix:nonFraction>&#160;million held in a continuous unrealized loss position for less than 12 months. As of December&#160;31, 2020, the aggregate related fair value of investments with unrealized losses was $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">372.3</ix:nonFraction>&#160;million and had been held in a continuous unrealized loss position for less than 12 months. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Inventory </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory consists of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,483,801</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,483,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in process</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,407,165</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,781,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,057,160</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,791,483</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,948,126</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,056,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and Equipment </div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:64%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">408,751</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">243,532</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">423,097</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">423,097</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Scientific equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,287,228</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,127,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,240,315</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,240,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">6,359,391</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">6,034,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less accumulated depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,568,667</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,036,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,790,724</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,998,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million, respecti<div style="letter-spacing: 0px; top: 0px;;display:inline;">v</div>ely. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872169"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Right of Use Assets and Lease Liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Real Estate Leases </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2014, the Company entered into a long-term lease with a related party which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company&#8217;s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October&#160;1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn09_30_2018_NYsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" format="ixt-sec:duryear">14.3</ix:nonNumeric> years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March&#160;1, 2019. The lease has a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn02_28_2019_MDsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" format="ixt-sec:duryear">3.2</ix:nonNumeric> years ending in April 2022 and includes limited rent abatement and escalation provisions. The Company has no other significant leases. In addition, no identified leases require allocations between lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div> <ix:nonNumeric name="itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" contextRef="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the real estate lease balances within the consolidated balance sheet, weighted average remaining real estate lease term, the weighted average discount rates, and operating cash outflows related to real estate leases as of December&#160;31, 2021 and 2020: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:43%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets and Liabilities &#8211;Real Estate</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">15,680,666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">17,029,248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">15,680,666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">17,029,248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,325,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,284,540</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current&#160;operating&#160;lease&#160;liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">16,997,469</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">18,562,094</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total&#160;lease&#160;liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,322,944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">21,846,634</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" format="ixt-sec:duryear">7.3</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" format="ixt-sec:duryear">8.3</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">9.10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">9.09</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,448,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,346,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,553,338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2020To12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,192,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-21 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872169" continuedAt="TextSelectionAppend_37872169_1"> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maturity analysis under the lease agreements are as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:79%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,491,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,566,466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,675,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,787,248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,902,726</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">9,937,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">28,359,867</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Present value discount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,036,924</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,322,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,325,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">16,997,468</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense for the year ended December&#160;31, 2021, 2020 and 2019 was approximately $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million for each year, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vehicle Fleet Lease </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;17, 2019, the Company entered into an agreement (the &#8220;Vehicle Lease&#8221;) with a company (the &#8220;Lessor&#8221;) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contractual period of each lease is <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" format="ixt-sec:durmonth">12</ix:nonNumeric> months, followed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $<ix:nonFraction name="us-gaap:GuaranteeObligationsCurrentCarryingValue" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million is recorded as restricted cash on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nature of the lease is one commonly referred to as &#8220;TRAC&#8221; lease, as it contains a terminal rental adjustment clause, or &#8220;TRAC&#8221; clause.&#8221; The TRAC clause limits lessee<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>exposure, or likelihood of having a variable lease payment<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than <ix:nonFraction name="itci:PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>% of the vehicle capitalized cost in the first 12 months, and <ix:nonFraction name="itci:PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>% of the vehicle capitalized cost at the beginning of subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period increments. The vehicle leases entered into since March 2020 represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872169_1"> <ix:nonNumeric name="itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Vehicle Lease balances within the consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of December&#160;31, 2021 and December&#160;31, 2020: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:36%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities &#8211; Fleet</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,083,792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,295,515</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,083,792</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,295,515</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,406,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,257,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current&#160;operating&#160;lease&#160;liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,677,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,038,253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total&#160;lease&#160;liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,083,792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,295,515</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" format="ixt-sec:duryear">1.0</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" format="ixt-sec:duryear">2.0</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">2,325,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,183,072</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,122,896</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2020To12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">511,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the maturity of the Company&#8217;s fleet lease liability as of December&#160;31, 2021: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,471,479</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,681,294</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,152,773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Present value discount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">68,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,083,792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">3,406,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,677,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Right of use assets and lease liabilities for all operating leases were approximately $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction>&#160;million, respectively, as of December&#160;31, 2021, and approximately $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">24.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction>&#160;million, respectively, as of December&#160;31, 2020. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872151"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Share-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the total number of shares reserved under all equity plans was <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,787,390</ix:nonFraction> and the Company had <ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" contextRef="PAsOn12_31_2021_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,855,106</ix:nonFraction>&#160;shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (&#8220;ISOs&#8221;) as defined by the Internal Revenue Code of 1986, as amended, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally <span style="-sec-ix-hidden:hidden37872734">one</span> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric>) and the exercise prices of such options. Options have a maximum term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years. The exercise price of stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of&#160;grant. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-23 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872151" continuedAt="TextSelectionAppend_37872151_1"> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense related to all of the Company&#8217;s share-based awards, including stock options and RSUs granted to employees, directors and consultants recognized during the years ended December&#160;31, 2021, 2020, and 2019, was comprised of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:52%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventoriable costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_InventoriableCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,624,098</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_InventoriableCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,342,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">9,832,088</ix:nonFraction> </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,072,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">9,411,056</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">22,846,843</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">15,700,390</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">11,377,632</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">34,303,029</ix:nonFraction> </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">24,115,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,788,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table describes the assumptions used for calculating the value of options granted during the years ended December&#160;31, 2021, 2020, and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:56%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">89.4</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">94.9</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">91.6</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">95.5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">85.7</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">96.5</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.87</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">5.9</ix:nonNumeric></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of December&#160;31, 2021, and changes during the period then ended, are summarized as&#160;follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:62%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">39,728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">17.18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">9.2</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">19.98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">8.2</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">35,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">8.2</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">35,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">19.70</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">8.2</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value for awards granted during the years ended December&#160;31, 2021, 2020, and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">12.84</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> per share, respectively. The total intrinsic value of the options exercised during the years ended December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction>, respectively, for the years ended December&#160;31, 2020 and 2019. The total intrinsic value of the options outstanding as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction>&#160;million. The total intrinsic value of the options exercisable as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million. The total fair value of shares vested during the years ended December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction> for the years ended December&#160;31, 2020 and 2019, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized share-based compensation expense related to stock option awards at December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million and will be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.2</ix:nonNumeric>&#160;years. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div></div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872151_1" continuedAt="TextSelectionAppend_37872151_2"> <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding RSU awards under the 2019 Inducement Plan during the period then ended are summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">251,867</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.2</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">82,355</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.2</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs cancelled in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">15.81</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.2</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">151,967</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">16.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.2</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">151,967</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">The total intrinsic value of the time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. The total intrinsic value of the time based RSU&#8217;s outstanding as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction>&#160;million. The total fair&#160;value of time based RSUs vested during the years ended December&#160;31, 2021, 2010 and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. The fair value of time based RSUs is based on the closing price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">As of December&#160;31, 2021, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million of unrecognized compensation costs related to unvested time based RSUs which will be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.2</ix:nonNumeric> years. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">During the year ended December&#160;31, 2020, the Company issued options and time based RSUs totaling <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">314,138</ix:nonFraction> shares in the 2019 Inducement Plan. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. </div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of December&#160;31, 2021, and changes during the year then ended, are summarized as&#160;follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,477,894</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">18.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">6.6</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">683,597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">30.82</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">9.2</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">696,325</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">4.7</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options canceled or expired 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">49,149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">28.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">8.4</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,416,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">21.11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">6.1</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,416,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">21.11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,838,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">18.99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">5.2</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">The weighted-average grant date fair value for awards granted during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">29.01</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">17.98</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.17</ix:nonFraction> per share, respectively. The total intrinsic value of the options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction>&#160;million, respectively. The total intrinsic value of the options outstanding as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">172.4</ix:nonFraction>&#160;million. The total intrinsic value of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">options exercisable as of December 31, 2021 was</div>&#160;$<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">127.9</ix:nonFraction>&#160;million. The total fair value of shares vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">13.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>&#160;million, respectively. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">5</div></div></div></div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872151_2" continuedAt="TextSelectionAppend_37872151_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized share-based compensation expense related to stock option awards at December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction>&#160;million, and will be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.7</ix:nonNumeric>&#160;years. </div> <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding time based RSU activity, including with respect to grants to employees as of December&#160;31, 2021, and changes during the year then ended, is summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:52%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,311,877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">18.77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.7</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">725,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">36.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.2</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">629,540</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">0.8</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs cancelled in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,631</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">30.11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.8</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,377,685</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">28.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.5</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total intrinsic value of the time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction>&#160;million,&#160;$<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">14.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction>&#160;million, respectively. The total intrinsic value of the time based RSU&#8217;s outstanding as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">72.1</ix:nonFraction>&#160;million. The total fair value of time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction>&#160;million, respectively. The fair value of time based RSUs is based on the closing price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">24.4</ix:nonFraction>&#160;million of unrecognized compensation costs related to unvested time based RSUs which will be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.0</ix:nonNumeric> years. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> share-based compensation expense related to Milestone RSU&#8217;s for the years ended December&#160;31, 2021, 2020 and 2019 of approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction>&#160;million, respectively. The total fair value of shares vested with respect to Milestone RSUs during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2020To12_31_2020_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2019To12_31_2019_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction>&#160;million, respectively. </div> <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to the Company&#8217;s Milestone RSUs and the TSR RSUs during the year ended December&#160;31,&#160;2021 are summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">72,678</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">28.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.1</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Milestone RSUs and TSR RSUs granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">64,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">44.04</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.1</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Milestone RSUs and TSR RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="itci:HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">0.0</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">137,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">35.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.6</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total intrinsic value of the Company&#8217;s Milestone RSUs and the TSR RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="P01_01_2019To12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction>&#160;million, respectively. The total intrinsic value of the Company&#8217;s Milestone RSU&#8217;s and the TSR RSUs outstanding as of December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.2</ix:nonFraction>&#160;million. The total fair value of the Company&#8217;s Milestone RSUs and the TSR RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2019To12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction>&#160;million, respectively. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="display:inline;">6</div></div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872151_3"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction>&#160;million of unrecognized compensation costs related to unvested Milestone RSU grants and TSR RSU grants which will be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.6</ix:nonNumeric> years. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average estimated fair value per share of the 2020 TSR RSUs granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">32.56</ix:nonFraction>, and the 2021 TSR RSUs granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">51.18</ix:nonFraction>, which were derived from Monte Carlo simulations. Significant assumptions utilized in estimating the value of the 2020 awards granted include an expected dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%, a risk-free rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction>%, and expected volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">91.3</ix:nonFraction>%. Significant assumptions utilized in estimating the value of the 2021 awards granted include an expected dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%, a risk-free rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction>%, and expected volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">95.8</ix:nonFraction>%. <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2020To12_31_2020">The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#8217;s common stock determined over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> performance period ending and vesting after <ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric> but before <ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayyearen">February 18, 2023</ix:nonNumeric>, provided the grantee remained in the service of the Company on the settlement date.</ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2021To12_31_2021">Similarly, the 2021 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#8217;s common stock determined over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> performance period ending and vesting after <ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" contextRef="P01_01_2021To12_31_2021" format="ixt:datemonthdayyearen">December 31, 2023</ix:nonNumeric> but before <ix:nonNumeric name="itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" contextRef="P01_01_2021To12_31_2021" format="ixt:datemonthdayyearen">February 23, 2024</ix:nonNumeric>, provided the grantee remained in the service of the Company on the settlement date.</ix:nonNumeric> The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company&#8217;s total shareholder returns, expressed as a percentile ranking of the Company&#8217;s total shareholder return as compared to the Company&#8217;s peer group. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">Total shareholder return will be determined by dividing the average share value of the Company&#8217;s common stock over the 30 trading days preceding the settlement date by the average share value of the Company&#8217;s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period.</ix:nonNumeric> The Company&#8217;s peer group included companies that compromised the Nasdaq Biotechnology Index at December&#160;31, 2019 and 2020, respectively. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872152"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2017, former President Donald Trump signed into law the &#8220;Tax Cuts and Jobs Act&#8221; (&#8220;TCJA&#8221;) that significantly reforms the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). The TCJA, among other things, includes changes to U.S.&#160;federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating loss carryforwards, allows for the expensing of capital expenditures, and puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system. While the TCJA provide for a territorial tax system, beginning in 2018, it includes two new U.S. tax base erosion provisions, the global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income (&#8220;GILTI&#8221;) provisions and the base-erosion and anti-abuse tax (&#8220;BEAT&#8221;) provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. As of the year ended December&#160;31, 2021, the Company&#8217;s foreign operations do not generate positive income and the Company is not currently subject to the GILTI provisions. The Company has not made an accounting policy election for GILTI and will analyze and formulate its GILTI accounting policy in the period which the Company becomes subject to the GILTI provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BEAT provisions eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The Company has not made any qualifying payments and the BEAT tax is not applicable in 2021. Therefore, the Company has not included any tax impacts of BEAT in its consolidated financial statements for the year ended December&#160;31, 2021. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872152" continuedAt="TextSelectionAppend_37872152_1"> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss before income taxes is as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:49%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S.</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">221,215,855</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">155,615,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">56,121,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">62,904,180</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">71,376,536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">91,599,320</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total loss before taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">284,120,035</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">226,992,150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">147,720,578</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total income tax expense for the years ended December&#160;31, 2021, 2020 and 2019 is allocated as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,631</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">13,513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">53,070,458</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">40,049,094</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">8,484,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">53,070,458</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">40,049,094</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">8,484,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxe<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,631</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">13,513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the difference between the statutory federal income tax rate and the effective income tax rate for the years ended December&#160;31, 2021, 2020 and 2019 is as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:70%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax at statutory federal rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other permanent differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.60</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.01</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign rate differential</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">4.63</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">6.60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">13.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in effective state tax rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.31</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.04</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowanc<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">18.70</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">17.65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">5.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effect of temporary differences that exist between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. As of December&#160;31, 2021, the Company had $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">543.4</ix:nonFraction>&#160;million of federal net operating loss carryforwards, of which $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_ExpireIn2037MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">131.1</ix:nonFraction>&#160;million expire at various dates through <ix:nonNumeric name="itci:FederalNetOperatingLossCarryForwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021">2037</ix:nonNumeric> and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_IndefinitePeriodCarryForwardMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">412.3</ix:nonFraction>&#160;million do not expire. The gross amount of the state net operating loss carryforwards is equal to or less than the federal net operating loss carryforwards and expires over various periods based on individual state tax law. In general, businesses with U.S. net operating losses (&#8220;NOLs&#8221;) are considered loss corporations for U.S. federal income tax purposes. Pursuant to Section&#160;382 of the Code, loss corporations that undergo an ownership change, as defined under the Code, may be subject to an annual limitation on the amount of NOLs (and certain other tax attributes) available to offset taxable income earned after such ownership change. For the years ended December&#160;31, 2015 through 2021, the Company performed a Section&#160;382 ownership analysis and determined that an ownership change occurred (within the meaning of Section&#160;382 of the Code) in 2015 but not in subsequent periods. Based on the analysis performed through December&#160;31, 2021, however, the Company does not believe that the Section&#160;382 annual limitation will impact the Company&#8217;s ability to utilize the tax attributes that existed as of the date of the ownership change in a material manner. If the Company experiences an ownership change in the future, the tax benefits related to the NOLs and tax credit carryforwards may be further limited or lost. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_37872152_1"> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020, respectively: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:59%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred&#160;tax&#160;assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">137,561,289</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">85,751,154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,154,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,363,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">9,321,214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">9,321,214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">15,947,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">15,137,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,660,441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">850,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">6,177,924</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,461,587</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred tax liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset&#8212;capital lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="itci:Deferredtaxliabilitiesrightofuseassetcapitallease" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">5,049,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="itci:Deferredtaxliabilitiesrightofuseassetcapitallease" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">6,228,138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:Deferredtaxliabilitiesunrealizedgainsoninvestment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="itci:Deferredtaxliabilitiesunrealizedgainsoninvestment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">123,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="itci:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">201,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="itci:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">244,058</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset before valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:DeferredTaxAssetsLiabilitiesGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">166,572,615</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="itci:DeferredTaxAssetsLiabilitiesGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">113,290,682</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">166,572,615</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">113,290,682</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the Company&#8217;s historical operating performance and the reported cumulative net losses to date, the Company presently does not have sufficient objective evidence to support the recovery of its net deferred tax assets. Accordingly, the Company has established a full valuation allowance against its net deferred tax assets in 2021 and 2020, for financial reporting purposes because it is not more likely than not that these deferred tax assets will be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The open years subject to tax audits vary depending on the tax jurisdictions. In the U.S federal jurisdiction, we are no longer subject to income tax audits by taxing authorities for years before 2017. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amount of unrecognized tax benefits was $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million as of December&#160;31, 2021 and December&#160;31, 2020. If recognized, none of these tax benefits would affect the effective tax rate due to valuation allowances. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_37872205"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Commitments and Contingencies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Royalty Commitments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company, pursuant to which the Company holds a license to certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of BMS relating to lumateperone and other specified compounds. The agreement was amended on November&#160;3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop, or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement, the Company made an upfront payment of $<ix:nonFraction name="itci:CollaborativeAgreementUpfrontPayments" contextRef="P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;million to BMS in 2005, a milestone payment of $<ix:nonFraction name="itci:CollaborativeArrangementMilestonePayments" contextRef="P12_01_2013To12_31_2013_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">1.25</ix:nonFraction>&#160;million in December&#160;2013, and a milestone payment of $<ix:nonFraction name="itci:CollaborativeArrangementMilestonePayments" contextRef="P12_01_2014To12_31_2014_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>&#160;million in December&#160;2014 following the initiation of the Company&#8217;s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_37872205"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">obligated to pay BMS a $<ix:nonFraction name="itci:CollaborativeArrangementAmountPayable" contextRef="PAsOn01_31_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December&#160;20, 2019 and as a result the Company accrued an additional milestone liability of $<ix:nonFraction name="itci:CollaborativeArrangementRemainingPotentialMilestonePayments" contextRef="P12_23_2019To12_23_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_NationalDemocraticAllianceMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $<ix:nonFraction name="itci:PaymentOfMilestoneAmount" contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ITCINationalDemocraticAllianceMemberMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $<ix:nonFraction name="itci:CollaborativeArrangementAmountPayable" contextRef="PAsOn12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">14.75</ix:nonFraction>&#160;million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between <ix:nonFraction name="itci:RoyaltyPaymentPercentage" contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction> &#8211; <ix:nonFraction name="itci:RoyaltyPaymentPercentage" contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>% on sales of licensed products. The Company is obliged to pay to BMS a percentage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> payments made in consideration of any sublicense. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement extends, and royalties are payable, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis, <ix:nonNumeric name="itci:CollaborativeArrangementLicenseExpirationDescription" contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product</ix:nonNumeric>, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited.&#160;In connection with the transfer, the Company guaranteed ITI Limited&#8217;s performance of its obligations under the BMS agreement. The Company expensed approximately $<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million in cost of product sales to satisfy its obligation under the BMS agreement for the years ended December&#160;31, 2021 and 2020, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Other Commitments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the Company has committed to purchasing production campaigns for active pharmaceutical ingredients (API) from each of our supply vendors &#8211; Siegfried Evionnaz SA (&#8220;Siegfried&#8221;) and Lonza Ltd. (&#8220;Lonza&#8221;). As of December&#160;31, 2021 and 2020, the Company had paid deposits totaling $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2020_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million, respectively, for the Siegfried and Lonza campaigns which are recorded within prepaids and other current assets on the consolidated balance sheets. Over the course of the vendors&#8217; manufacturing period, the Company will remit payment to the vendor based on the executed agreements. Upon title transfer of the product, the Company will recognize the material as inventory. The API campaigns are expected to be received into inventory during 2022 or the first half of 2023. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Retirement savings plan 401(k) contributions </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined contribution 401(k) plan covering all full-time employees. Participants may elect to contribute their annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> earnings up to the federally allowed maximum limits. The Company made a matching contribution of <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% on the first&#160;<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of contributions made by participants in the year ended December&#160;31, 2021, 2020 and 2019. Participant and company contributions vest immediately. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded matching contribution expense of $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the normal course of our business, we are occasionally involved with various claims and litigation. Reserves are established in connection with such matters when a loss is probable and the amount of such loss can be reasonably estimated. At December&#160;31, 2021 and 2020, no material reserves were recorded. The determination of probability and the estimation of the actual amount of any such loss are inherently unpredictable, and it is therefore possible that the eventual outcome of such claims and litigation could exceed the estimated reserves, if any. However, we believe that the likelihood that any such excess might have a material adverse effect on our financial statements is remote. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">30</div></div></div></div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><div style="font-weight:bold;display:inline;">10. Related Parties </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">The Company has no other related party transactions other than the real estate lease for the Company&#8217;s headquarters in New York, New York disclosed <div style="letter-spacing: 0px; top: 0px;;display:inline;">in Note 6.&#160;</div> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No other subsequent events have occurred since the balance sheet date other than the public offering of common stock completed by the Company on January&#160;7, 2022, as disclosed in Note 1. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:QuarterlyFinancialInformationTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Unaudited Quarterly Financial Information </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables herein set forth the Company&#8217;s unaudited condensed consolidated 2021 and 2020 quarterly statements of operations. </div> <ix:nonNumeric name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following table sets forth the Company&#8217;s unaudited condensed consolidated statements of operations for the 2021 quarters ended: </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:40%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2021&#160;Quarter&#160;Ended</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">25,670,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">22,207,201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">20,046,561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">15,878,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">111,675,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">99,531,025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">89,187,615</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">69,097,022</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">270,617</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">392,695</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">421,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">483,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">23,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">23,756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">5,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">85,733,937</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">76,908,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">68,743,782</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">52,739,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per share</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P10_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following table sets forth the Company&#8217;s unaudited condensed consolidated statements of operations for the 2020 quarters ended: </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:39%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2020&#160;Quarter&#160;Ended</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">12,454,270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">7,368,594</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,906,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,083,479</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">73,787,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">63,305,048</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">66,778,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">50,169,003</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">644,390</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">752,829</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,160,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,678,203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">10,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">3,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">60,699,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">55,183,625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">63,712,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">47,410,602</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per share</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="display:inline;">31</div></div></div></div> </div> </div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>d234590dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF THE REGISTRANT&#146;S SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTERED PURSUANT TO SECTION 12 OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intra-Cellular Therapies, Inc. (the &#147;Company&#148; or &#147;we&#148;) has one class of securities registered under Section&nbsp;12 of the Securities
Exchange Act of 1934, as amended: our common stock, par value $0.0001 per share. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue 175,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of certain provisions of our common stock does not purport to be complete. You should refer to our restated certificate of
incorporation, as amended, and our restated bylaws, both of which are incorporated by reference as exhibits to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of which this Exhibit is a part. The summary below
is also qualified by provisions of applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting
rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be
declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution
to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. There are no
redemption or sinking fund provisions applicable to the common stock. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may
be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent
and registrar for our common stock is Computershare Trust Company, N.A., with offices at 250 Royall Street, Canton, Massachusetts 02021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock
Exchange Listing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed for quotation on The Nasdaq Global Select Market under the symbol &#147;ITCI.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN PROVISIONS OF DELAWARE LAW AND OF THE COMPANY&#146;S </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION AND BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Takeover Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of
Delaware law and our restated certificate of incorporation, as amended, and restated bylaws could discourage or make it more difficult to accomplish a proxy contest or other change in our management or the acquisition of control by a holder of a
substantial amount of our voting stock. It is possible that these provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or in our best interests.
These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may
involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions also may have
the effect of preventing changes in our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Statutory Business Combinations Provision </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law. Section&nbsp;203 prohibits a publicly-held Delaware
corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business
combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. For purposes of Section&nbsp;203, a &#147;business combination&#148; is defined
broadly to include a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and, subject to certain exceptions, an &#147;interested stockholder&#148; is a person who, together with his or her
affiliates and associates, owns, or within three years prior, did own, 15% or more of the corporation&#146;s voting stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classified Board of
Directors; Removal of Directors for Cause </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our restated certificate of incorporation, as amended, and restated bylaws, our board of
directors is divided into three classes, with the term of office of the first class to expire at the first annual meeting of stockholders following the initial classification of directors, the term of office of the second class to expire at the
second annual meeting of stockholders following the initial classification of directors, and the term of office of the third class to expire at the third annual meeting of stockholders following the initial classification of directors. At each
annual meeting of stockholders, directors elected to succeed those directors whose terms expire, other than directors elected by the holders of any series of preferred stock under specified circumstances, will be elected for a three-year term of
office. All directors elected to our classified board of directors will serve until the election and qualification of their respective successors or their earlier resignation or removal. Members of the board of directors may only be removed for
cause and only by the affirmative vote of at least 80% of our outstanding voting stock. These provisions are likely to increase the time required for stockholders to change the composition of the board of directors. For example, at least two annual
meetings will be necessary for stockholders to effect a change in a majority of the members of the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advance Notice Provisions for
Stockholder Proposals and Stockholder Nominations of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated bylaws provide that, for nominations to the board of directors or for
other business to be properly brought by a stockholder before a meeting of stockholders, the stockholder must first have given timely notice of the proposal in writing to our Secretary. For an annual meeting, a stockholder&#146;s notice generally
must be delivered not less than 90 days nor more than 120 days prior to the first anniversary of the previous year&#146;s annual meeting date. For a special meeting, the notice must generally be delivered not earlier than the 90th day prior to the
meeting and not later than the later of (1)&nbsp;the 60th day prior to the meeting or (2)&nbsp;the 10th day following the day on which public announcement of the meeting is first made. Detailed requirements as to the form of the notice and
information required in the notice are specified in the restated bylaws. If it is determined that business was not properly brought before a meeting in accordance with our bylaw provisions, such business will not be conducted at the meeting. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Meetings of Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special meetings of the stockholders may be called only by our board of directors pursuant to a resolution adopted by a majority of the total number of
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Stockholder Action by Written Consent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any action to be effected by our stockholders must be effected at a duly called annual or special meeting of the stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Super Majority Stockholder Vote Required for Certain Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to
amend a corporation&#146;s certificate of incorporation or bylaws, unless the corporation&#146;s certificate of incorporation or bylaws, as the case may be, require a greater percentage. Our restated certificate of incorporation, as amended,
requires the affirmative vote of the holders of at least 80% of our outstanding voting stock to amend or repeal any of the provisions discussed in this section of this Exhibit. This 80% stockholder vote would be in addition to any separate class
vote that might in the future be required pursuant to the terms of any preferred stock that might then be outstanding. An 80% vote is also required for any amendment to, or repeal of, our restated bylaws by the stockholders. Our restated bylaws may
be amended or repealed by a simple majority vote of the board of directors. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>d234590dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EMPLOYMENT AGREEMENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS EMPLOYMENT AGREEMENT (the &#147;Agreement&#148;), is effective this 12th day of September, 2018 (the &#147;Effective Date&#148;) between
Dr.&nbsp;Suresh Durgam (&#147;Executive&#148;) and Intra-Cellular Therapies, Inc. (the &#147;Company&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Title; Capacity</U>.
Subject to terms set forth herein, the Company agrees to employ Executive in the position of Senior Vice President, Medical Affairs and Late Stage Clinical Development. Executive shall serve in an executive capacity and shall perform such duties as
are assigned to Executive from time to time, consistent with the Bylaws of the Company and as required by the Company&#146;s Board of Directors (the &#147;Board&#148;). During the term of his employment with the Company, Executive will devote his
best efforts and substantially all of his business time and attention to the business of the Company. Notwithstanding the foregoing, or any other provision of this Agreement, it shall not be a breach or violation of this Agreement for the Executive
to (i)&nbsp;serve on civic or charitable boards or committees, (ii)&nbsp;with the express written permission of the Company serve on corporate boards of companies that do not present a conflict of interest or compete directly or indirectly with the
Company, (iii)&nbsp;deliver lectures, fulfill speaking engagements or teach at educational institutions, or (iv)&nbsp;manage personal investments, so long as such activities do not significantly interfere with or significantly detract from the
performance of the Executive&#146;s responsibilities to the Company in accordance with this Agreement. The Board has approved the Executive&#146;s participation in the activities listed on <B><I>Schedule A</I></B> to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Term</U>. The term of this Agreement shall commence on the Effective Date, and shall continue for three (3)&nbsp;years from that date,
unless terminated prior thereto by either the Company or the Executive as provided in Section&nbsp;4. If either the Company or the Executive does not wish to renew this Agreement when it expires at the end of the initial or any renewal term hereof,
as hereinafter provided, or if either the Company or the Executive wishes to renew this Agreement on different terms than those contained herein, it or he shall give written notice in accordance with Section&nbsp;13 below of such intent to the other
party at least sixty (60)&nbsp;days prior to the expiration date. In the absence of such notice, this Agreement shall be renewed on the same terms and conditions contained herein for a term of one year from the date of expiration. The parties
expressly agree that designation of a term and renewal provisions in this Agreement does not in any way limit the right of the parties to terminate this Agreement at any time as hereinafter provided. Reference herein to the term of this Agreement
shall refer both to the initial term and any successive term as the context requires. Should the Company elect not to renew this Agreement for reasons other than death or Disability (as defined in Section&nbsp;4.3 below), or Cause (as defined in
Section&nbsp;4.1 below), the Executive shall be eligible for the same severance payments and benefits as Executive would receive under Section&nbsp;5.2 and on the same conditions as if Executive had been terminated by the Company without Cause,
<I>provided</I> that Executive executes a Release of claims in favor of the Company as defined in Section&nbsp;5.2(a). <I>Provided however</I>, Executive shall not receive any such severance payments and benefits unless he executes the Release
within the consideration period specified therein and until the Release becomes effective and can no longer be revoked by Executive under its terms. Executive&#146;s ability to receive such payment and benefits is further conditioned upon his:
returning all Company property; complying with his post termination obligations under this Agreement and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Proprietary Information, Inventions, and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement between the Executive and the Company; and complying with the Release including
without limitation any <FONT STYLE="white-space:nowrap">non-disparagement</FONT> and confidentiality provisions contained therein. Executive shall not be eligible for any severance payments and benefits if either the Executive or the Company wishes
to renew this Agreement on different terms than those contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Salary</U>. Executive will receive for Executive&#146;s services to be rendered under this Agreement an initial annualized base salary
at the rate of $420,000 per year, subject to annual review and adjustment by the Company in the discretion of the Board, payable subject to standard federal and state payroll withholding requirements in accordance with the Company&#146;s standard
payroll practices (&#147;<B><I>Base Salary</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Incentive Compensation</U>. In addition to Executive&#146;s Base
Salary, the Executive shall be eligible during the term of this Agreement for such bonus payments and/or equity grants as awarded to the Executive by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Policies and Fringe Benefits</U>. The employment relationship between the parties shall also be subject to the Company&#146;s personnel
policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company&#146;s sole discretion. The Executive will be eligible to participate on the same basis as other executive level employees in the
Company&#146;s benefit plans in effect from time to time during his employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan. The Company reserves the
right to change, alter, or terminate any benefit plan in its sole discretion. While this Agreement is in effect, the Company will provide the Executive with life insurance, for which the Executive may designate the beneficiary or beneficiaries in an
amount of $150,000, and long-term disability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <U>Reimbursement of Certain Expenses</U>. The Company will reimburse
Executive for reasonable business expenses in accordance with the Company&#146;s expense reimbursement policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Termination of
Employment</U>. Either Executive or the Company may terminate the employment relationship at any time, for any reason, in accordance with this Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Termination for Cause</U>. At the election of the Company, the employment relationship may be terminated for Cause upon written notice
by the Company to Executive specifying the provision or provisions of this Section&nbsp;4.1 upon which the decision to terminate is based. For the purposes of this Section&nbsp;4.1, &#147;Cause&#148; for termination shall be deemed to exist upon the
occurrence of any of the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) a good faith finding by the Company that Executive has engaged in gross negligence or gross
misconduct that is materially injurious to the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Executive&#146;s conviction of a felony or crime involving fraud or
embezzlement of Company property; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Executive&#146;s material breach of this Agreement which, if curable, has not been cured
by Executive within 60 days after he shall have received written notice from the Company stating with reasonable specificity the nature of such breach; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) material breach of fiduciary duty; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) refusal to follow or implement a clear and reasonable directive of the Board as a whole, or an officer of the Company, provided that such
directive is ethical and legal and which, if curable, has not been cured by Executive within 60 days after he shall have received written notice from the Company stating with reasonable specificity the nature of such refusal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Termination by the Company Without Cause or by the Executive for Good Reason</U>. At the election of the Company it may terminate
Executive&#146;s employment for reasons other than Cause, death or Disability, at any time upon written notice by the Company to Executive. The Executive may resign from Executive&#146;s employment for &#147;Good Reason&#148; within sixty
(60)&nbsp;days after the occurrence of one of the events specified below, by giving prior written notice, <I>provided that</I> Executive has not consented in writing to one of the specified events or been notified previously of the Company&#146;s
intention to terminate Executive&#146;s employment. As used in this Agreement Good Reason shall mean: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The assignment to Executive of
any duties or responsibilities which result in the material diminution of Executive&#146;s position; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) a 5% or greater reduction by the
Company in Executive&#146;s annual Base Salary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) a material change in the geographic location at which the Executive is required to
perform services; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) material breach by the Company of any material provision of this Agreement<I>; provided however</I>, that any
actions taken by the Company to accommodate a disability of the Executive or pursuant to the Family and Medical Leave Act shall not be a Good Reason for purposes of this Agreement. Notwithstanding the occurrence of any of the events enumerated in
Section&nbsp;4.2 (a) through (d), such occurrence shall not be deemed to constitute Good Reason if, within 30 days after the giving by Executive of notice of the occurrence or existence of an event or circumstance specified above, such event or
circumstance has been fully corrected (provided that such right of correction by the Company shall only apply to the first such notice given by Executive). In the absence of such correction, Executive&#146;s resignation shall be effective thirty
(30)&nbsp;days following the Executive&#146;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>Death or Disability</U>. The Executive&#146;s employment will terminate upon
the death or determination of disability of Executive. As used in this Agreement, the determination of &#147;disability&#148; shall occur when the Executive is unable due to a physical or mental condition to perform the essential functions of his
position with or without reasonable accommodation for 90 consecutive days, or 180 days in the aggregate whether or not consecutive, during any <FONT STYLE="white-space:nowrap">360-day</FONT> period, or based on the written certification by a
licensed physician of the likely continuation of such condition for such period. A determination of disability shall be made by a physician satisfactory to both Executive and the Company, <I>provided that</I> if Executive and the Company do not
agree on a physician, Executive and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding on all parties. This definition shall be interpreted and
applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Termination by Executive without Good Reason</U>. At the election of Executive, he
may terminate employment upon not less than 30 days prior written notice by Executive to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Effect of Termination</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>General; Termination for Cause or by the Executive Without Good Reason</U>. In the event that Executive&#146;s employment is
terminated for any reason, the Company shall pay to Executive the compensation and benefits, including payment for accrued but untaken vacation days, payable to Executive through the last day of Executive&#146;s actual employment by the Company. If
the termination is by the Company for Cause pursuant to Section&nbsp;4.1 or at the election of Executive pursuant to Section&nbsp;4.4, the Company shall have no further obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <U>Termination by the Company Without Cause or by the Executive for Good Reason</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Employee shall not receive any of the benefits pursuant to this Section&nbsp;5.2 unless he executes a general release in favor of the
Company, in a form acceptable to the Company and substantially similar to the form attached hereto as <B><I>Schedule B (</I></B>the &#147;Release&#148;) within the consideration period specified therein (the &#147;Release Review Period&#148;) and
until the Release becomes effective and can no longer be revoked by Employee under its terms. Employee&#146;s ability to receive benefits pursuant to this Section&nbsp;5.2 is further conditioned upon his: returning all Company property; complying
with his post termination obligations under this Agreement and the Proprietary Information, Inventions and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement; and complying with the Release including without limitation any <FONT
STYLE="white-space:nowrap">non-disparagement</FONT> and confidentiality provisions contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that
Executive&#146;s employment is terminated pursuant to Section&nbsp;4.2 by the Company without Cause or by the Executive for Good Reason, the Company shall pay to Executive as severance twelve months of his annual Base Salary then in effect, together
with an additional amount calculated by dividing by 365 the number of days employed in the year of termination and multiplying that number by the amount of the Executive&#146;s previous year&#146;s bonus (if any), such amount to be paid in one lump
sum on the date the Release becomes effective, subject to standard payroll deductions and withholdings, provided, however, that if the Release Review Period begins in one tax year and ends in a later tax year, the payments under this
Section&nbsp;5.2(b) will be made following the date that the Release is effective that occurs in the later tax year . Additionally, if Executive timely elects and remains eligible for continued coverage under COBRA, the Company, as part of this
Agreement, will pay that portion of Executive&#146;s COBRA premiums it was paying prior to the Separation Date for twelve (12)&nbsp;months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event Executive&#146;s employment is terminated pursuant to Section&nbsp;4.2, and
not for Cause, death or Disability, all unvested equity awards shall become fully vested, all unvested stock options shall become fully vested and exercisable and any ISO&#146;s issued to Executive will automatically convert to a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> options on the 91<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day following termination, provided it has not been exercised, subject to the terms of the applicable stock plan and option
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination for Death or Disability</U>. In the event that Executive&#146;s employment is terminated by death or
because of Disability pursuant to Section&nbsp;4.3, in addition to the payment of accrued salary and unused vacation provided in Section&nbsp;5.1, the Company shall pay to Executive&#146;s estate or to Executive, as the case may be, compensation
which would otherwise be payable to Executive through the end of the month in which such termination occurs, and payment for any accrued but untaken vacation days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Code Sections 409A and 280G</U>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that the payments or benefits set forth in Section&nbsp;5.2 of this Agreement constitute
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; subject to Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), then the following conditions apply to such payments or
benefits: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any termination of Executive&#146;s employment triggering payment of benefits under Section&nbsp;5 must
constitute a &#147;separation from service&#148; under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h)</FONT> before distribution of such benefits can commence. To the extent that the
termination of Executive&#146;s employment does not constitute a separation of service under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h)</FONT> (as the result of further services that
are reasonably anticipated to be provided by Executive to Company at the time Executive&#146;s employment terminates), any such payments under Section&nbsp;5 that constitute deferred compensation under Section&nbsp;409A of the Code shall be delayed
until after the date of a subsequent event constituting a separation of service under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h).</FONT> For purposes of clarification, this
Section&nbsp;5.3(a) shall not cause any forfeiture of benefits on Executive&#146;s part, but shall only act as a delay until such time as a &#147;separation from service&#148; occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding any other provision with respect to the timing of payments under Section&nbsp;5.2 if, at the time of
Executive&#146;s termination, Executive is deemed to be a &#147;specified employee&#148; of Company (within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code), then limited only to the extent necessary to comply with the requirements of
Section&nbsp;409A of the Code, any payments to which Executive may become entitled under Section&nbsp;5 which are subject to Section&nbsp;409A of the Code (and not otherwise exempt from its application) shall be withheld until the first (1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>) business day of the seventh (7<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) month following the termination of Executive&#146;s employment, at which time Executive shall be paid an
aggregate amount equal to the accumulated, but unpaid, payments otherwise due to Executive under the terms of Section&nbsp;5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) It is intended that each installment of the payments and benefits provided under
Section&nbsp;5 of this Agreement shall be treated as a separate &#147;payment&#148; for purposes of Section&nbsp;409A of the Code. Neither Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or
benefits except to the extent specifically permitted or required by Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other
provision of this Agreement to the contrary, this Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section&nbsp;409A of the Code, or the payment of increased taxes,
excise taxes or other penalties under Section&nbsp;409A of the Code. The parties intend this Agreement to be in compliance with Section&nbsp;409A of the Code. Executive acknowledges and agrees that Company does not guarantee the tax treatment or tax
consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If any payment or benefit Executive would receive under Section&nbsp;5.4 of this Agreement, when combined with any other payment or
benefit Executive receives pursuant to a Change of Control (for purposes of this section, a &#147;Payment&#148;) would: (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G the Code; and (ii)&nbsp;but for this
sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;Excise Tax&#148;), then such Payment shall be either: (A)&nbsp;the full amount of such Payment; or (B)&nbsp;such lesser amount (with cash payments being
reduced before equity compensation) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes, and
the Excise Tax, results in Executive&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Effect of a Change in Control</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event either (i)&nbsp;Executive&#146;s employment with the Company is terminated by the Company for reasons other than death or
Disability (as defined above) within three months before or 12 months following a Change in Control (as defined below) or (ii)&nbsp;Executive terminates his employment for Good Reason (as defined above) within three months before or 12 months
following a Change in Control (as defined below), then provided that Executive executes the Release (as defined in Section&nbsp;5.2) within the consideration period specified therein and it becomes effective and can no longer be revoked by Executive
under its terms, and provided further that Executive returns all Company property&#146; complies with his post termination obligations under this Agreement and the Proprietary Information, Inventions and
<FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement, and complies with the Release including without limitation any <FONT STYLE="white-space:nowrap">non-disparagement</FONT> and confidentiality provisions contained therein, Executive
shall be entitled to the payments, equity acceleration and benefits described in this Section&nbsp;5.4 in lieu of, and not in addition to, the benefits provided for in Section&nbsp;5.2. The Company shall pay to the Executive, in lieu of the
severance described in Section&nbsp;5.2(a), severance equivalent to 18 months of his annual Base Salary then in effect, together with an additional amount calculated by dividing by 365 the number of days employed in the year of termination and
multiplying that number by the amount of the Executive&#146;s previous year&#146;s bonus (if any), paid in a lump sum on the eighth day following the date the Release becomes effective, subject to standard payroll deductions and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholdings, provided, however, that if the Release Review Period begins in one tax year and ends in a later tax year, the payments under this Section&nbsp;5.4(a) will be made following the date
that the Release is effective that occurs in the later tax year. On the date of termination of Executive&#146;s employment, any unvested equity awards granted to the Executive shall immediately vest and, in the case of stock options, become
exercisable. Additionally, if Executive timely elects and remains eligible for continued coverage under COBRA, the Company, as part of this Agreement, will pay that portion of Executive&#146;s COBRA premiums it was paying prior to the Separation
Date for eighteen (18)&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Definition of Change in Control</U>. For purposes of this Agreement, a &#147;Change in
Control&#148; means the occurrence of any of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a sale, lease or other disposition of all or
substantially all of the assets of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a consolidation or merger of the Company with or into any other
corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the Company immediately prior to such consolidation, merger or reorganization, own less than fifty percent (50%) of the outstanding voting
power of the surviving entity (and its parent) following the consolidation, merger or reorganization; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any
transaction (or series of related transactions involving a person or entity, or a group of affiliated persons or entities) in which in excess of fifty percent (50%) of the Company&#146;s outstanding voting power is transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, a Change in Control shall not be deemed to occur on account of the sale or acquisition of the Company&#146;s capital stock by
institutional investors or venture capital firms for the primary purpose of obtaining financing for the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Mitigation</U>.
Executive shall have no obligation to mitigate any amount of any payment or benefit contemplated by this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<U>Cooperation</U>. For one month following termination of the Executive&#146;s employment for any reason, and, additionally, for the number of months for which the Executive is receiving severance following termination, he will reasonably cooperate
with the Company in all matters relating to the winding up of his pending work including, but not limited to, any litigation in which the Company is involved, and the orderly transfer of any such pending work to such other employees as may be
designated by the Company. The Company will reimburse the Executive for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses associated with such cooperation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Insurance and Indemnification</U>. The Company shall purchase a directors and officers insurance policy for which Executive shall
receive usual and customary coverage for all acts undertaken as an officer of the Company. In addition, the Company shall indemnify Executive to the fullest extent permitted by its charter, bylaws and by law for all costs, charges, damages, fees
including without limitation, attorneys fees or other expenses that Executive incurs or potentially may incur in connection with Executives&#146; duties herewith and also enter into an indemnification agreement with Executive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Pronouns</U>. Whenever the context may require, any pronouns used in this Agreement
shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Complete Agreement</U>. This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject
matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements. This Agreement is entered into
without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties have entered into a
separate Proprietary Information, Inventions, and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement and have or may enter into separate equity grant agreements. These separate agreements govern other aspects of the relationship
between the parties, have or may have provisions that survive termination of the Executive&#146;s employment under this Agreement, may be amended or superseded by the parties without regard to this agreement and are enforceable according to their
terms without regard to the enforcement provision of this Agreement. In the event of a conflict between this Agreement and any other agreement between the Executive and the Company, this Agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Amendment</U>. This Agreement may be amended or modified only by a written instrument executed by both the Company and Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Governing Law</U>. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the State of New York and
any action arising from or relating to this Agreement shall be commenced in the Federal or State courts located in New York County. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.
<U>Notices</U>. Any notices required hereunder to be in writing shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified; (b)&nbsp;when sent by electronic mail, telex or confirmed facsimile if sent during normal
business hours on the day sent, and, if not, then on the next business day; (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Employee at Employee&#146;s address as listed on the
Company payroll, or at such other address as the Company or the Employee may designate by ten (10)&nbsp;days advance written notice to the other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Successors and Assigns</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.1 <U>Assumption by Successors</U>. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise and whether or not after a Change in Control) to all or substantially all of the business or assets of the Company to assume in writing prior to such succession and to agree to perform its obligations under this Agreement in the same
manner and to the same extent that the Company would be required to perform it if no such succession had taken place. Successions by virtue of the sale of stock shall be governed by operation of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.2 <U>Successor Benefits</U>. This Agreement shall be binding upon and inure to the
benefit of both parties and their respective successors and assigns, including any corporation into which the Company may be merged or which may succeed to its assets or business, <I>provided, however</I>, that the obligations of Executive are
personal and shall not be assigned by Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1 <U>No Waiver</U>. No delay or omission by either party in exercising any right under this Agreement shall operate as a waiver of that or
any other right. A waiver or consent given by either party on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.2 <U>Captions</U>. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or
affect the scope or substance of any section of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.3 <U>Severability</U>. In case any provision of this Agreement shall
be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.4 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NTRA</SMALL>-<SMALL>CELLULAR</SMALL> T<SMALL>HERAPIES</SMALL>, I<SMALL>NC</SMALL>.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>E<SMALL>XECUTIVE</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lawrence Hineline</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Suresh Durgam</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>L<SMALL>AWRENCE</SMALL> H<SMALL>INELINE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>D<SMALL>R</SMALL>.&nbsp;S<SMALL>URESH</SMALL> D<SMALL>URGAM</SMALL></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>C<SMALL>HIEF</SMALL> F<SMALL>INANCIAL</SMALL> <SMALL>OFFICER</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>CHEDULE</SMALL> A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ERMITTED</SMALL> A<SMALL>CTIVITIES</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ELEASE</SMALL> <SMALL>OF</SMALL> C<SMALL>LAIMS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release of Claims (<B><I>Release</I></B>&#148;) is made as of _______________ by and between ________________ (&#147;<B><I>the
Executive</I></B>&#148;) and Intra-Cellular Therapies, Inc. (the &#147;<B><I>Company</I></B>&#148;) f(together, the &#147;<B><I>Parties</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. In consideration for Executive&#146;s execution of this Release, the Company will make a severance payment to Executive in the amount set
forth in the Employment Agreement between the Executive and the Company. This amount will be paid following the Effective Date (as defined below) in accordance with the Employment Agreement, provided the Company has received the executed Agreement
from Executive on or before that date. This payment will be subject to standard payroll deductions and withholdings. If Executive timely elects and remains eligible for continued coverage under COBRA, the Company will pay that portion of
Executive&#146;s COBRA premiums it was paying prior to the Separation Date for the time period set forth in the Employment Agreement between the Executive and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Executive hereby releases, acquits and forever discharges the Company, its parents and subsidiaries, and their officers, directors, agents,
servants, employees, stockholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of every kind and nature, in law,
equity, or otherwise, which were known or through reasonable diligence should have been known, arising out of or in any way related to Releases, events, acts or conduct at any time prior to the date Executive executes this Settlement Release,
including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with Executive&#146;s employment with the Company, including but not limited to, claims of intentional and negligent infliction
of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense
reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, any and all claims and causes of action that the Company, its parents and
subsidiaries, and its and their respective officers, directors, agents, servants, employees, attorneys, shareholders, successors, assigns or affiliates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has violated its personnel policies, handbooks, contracts of employment, or covenants of good faith and fair
dealing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has discriminated against him on the basis of age, race, color, sex (including sexual harassment), national
origin, ancestry, disability, religion, sexual orientation, marital status, parental status, source of income, entitlement to benefits, any union activities or other protected category in violation of any local, state or federal law, constitution,
ordinance, or regulation, including but not limited to: Title VII of the Civil Rights Act of 1964, as amended; 42 U.S.C. &#167; 1981, as amended; the Equal Pay Act; the Americans With Disabilities Act; the Family and Medical Leave Act; the New York
State Law Human Rights Law; the New York City Human Rights Law; the Employee Retirement Income Security Act; Section&nbsp;510; and the National Labor Relations Act; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has violated any statute, public policy or common law (including but not limited to claims for retaliatory
discharge; negligent hiring, retention or supervision; defamation; intentional or negligent infliction of emotional distress and/or mental anguish; intentional interference with contract; negligence; detrimental reliance; loss of consortium to him
or any member of his family and/or promissory estoppel). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Excluded from this Release are any claims which cannot be waived by law.
Executive is waiving, however, his right to any monetary recovery should any governmental agency or entity, such as the EEOC or the DOL, pursue any claims on his behalf. Executive acknowledges that he is knowingly and voluntarily waiving and
releasing any rights he may have under the ADEA, as amended. Executive also acknowledges that (i)&nbsp;the consideration given to his in exchange for the waiver and release in this Release is in addition to anything of value to which he was already
entitled, and (ii)&nbsp;that he has been paid for all time worked, have received all the leave, leaves of absence and leave benefits and protections for which he is eligible, and have not suffered any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">on-the-job</FONT></FONT> injury for which he has not already filed a claim. Executive further acknowledges that he has been advised by this writing that: (a)&nbsp;his waiver and release do not apply to any rights or claims
that may arise after the execution date of this Release; (b)&nbsp;he has been advised hereby that he has the right to consult with an attorney prior to executing this Release; (c)&nbsp;he has <FONT STYLE="white-space:nowrap">twenty-one</FONT>
(21)&nbsp;days to consider this Release (although Executive may choose to voluntarily execute this Release earlier and if he does he will sign the Consideration Period waiver below); (d) he has seven (7)&nbsp;days following his execution of this
Release to revoke the Release; and (e)&nbsp;this Release shall not be effective until the date upon which the revocation period has expired unexercised (the &#147;Effective Date&#148;), which shall be the eighth day after Executive executes this
Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. On or before the last day of Executive&#146;s employment, Executive agrees to return to the Company all Company documents
(and all copies thereof) and other Company property that Executive has had in his possession at any time, including, but not limited to, Company files, notes, drawings, records, business plans and forecasts, financial information, specifications,
computer-recorded information, tangible property (including, but not limited to, computers), credit cards, entry cards, identification badges and keys; and, any materials of any kind that contain or embody any proprietary or confidential information
of the Company (and all reproductions thereof). Executive shall coordinate the return of Company property with Allen Fienberg, Vice President of Business Development or an appropriated officer designated by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Executive further agrees that both during and after Executive&#146;s employment Executive acknowledges his continuing obligations under his
Proprietary Information, Inventions and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement not to use or disclose any confidential or proprietary information of the Company and to refrain from certain solicitation and competitive
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. It is understood that Executive shall hold the provisions of this Release in strictest confidence and shall not publicize
or disclose it in any manner whatsoever; <I>provided, however</I>, that: (a)&nbsp;Executive may disclose this Release to his immediate family; (b)&nbsp;Executive may disclose this Release in confidence to his attorney, accountant, auditor, tax
preparer, and financial advisor; and (c)&nbsp;Executive may disclose this Release insofar as such disclosure may be required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Executive agrees not to disparage the Company, and the Company&#146;s attorneys,
directors, managers, partners, employees, agents and affiliates, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that Executive may respond accurately and fully to any question,
inquiry or request for information when required by legal process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This Release does not constitute an admission by the Company of any
wrongful action or violation of any federal, state, or local statute, or common law rights, including those relating to the provisions of any law or statute concerning employment actions, or of any other possible or claimed violation of law or
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Executive agrees that upon any breach of this Release Executive will forfeit all amounts paid or owing to Executive under this
Release. Executive further acknowledges that it may be impossible to assess the damages caused by violation of the terms of paragraphs 3, 4, 5 and 6 of this Release and further agree that any threatened or actual violation or breach of those
paragraphs of this Release will constitute immediate and irreparable injury to the Company. Executive therefore agrees that any such breach of this Release is a material breach of this Release, and, in addition to any and all other damages and
remedies available to the Company upon Executive&#146;s breach of this Release, the Company shall be entitled to an injunction to prevent Executive from violating or breaching this Release. Executive agrees that if the Company is successful in whole
or part in any legal or equitable action against Executive under this Release, Executive agree to pay all of the costs, including reasonable attorney&#146;s fees, incurred by the Company in enforcing the terms of this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. This Release constitutes the complete, final and exclusive embodiment of the entire Release between the Parties with regard to this subject
matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Release may not be modified or
amended except in a writing signed by both Executive and a duly authorized officer of the Company. This Release will bind the heirs, personal representatives, successors and assigns of the Parties, and inure to the benefit of the Parties, their
heirs, successors and assigns. If any provision of this Release is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Release and the provision in question will be modified
by the court so as to be rendered enforceable. This Release will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of New York as applied to contracts made and to be performed entirely
within New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the Parties have duly authorized
and caused this Agreement to be executed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I<SMALL>NTRA</SMALL>-C<SMALL>ELLULAR</SMALL> T<SMALL>HERAPIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[NAME]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>[Name]</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>d234590dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTRA-CELLULAR THERAPIES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYEE PROPRIETARY INFORMATION, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVENTIONS, AND <FONT STYLE="white-space:nowrap">NON-COMPETITION</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of my employment or continued employment by <B>I<SMALL>NTRA</SMALL>-<SMALL>CELLULAR</SMALL> T<SMALL>HERAPIES</SMALL>,
I<SMALL>NC</SMALL>.</B> (the &#147;<B>Company</B>&#148;), and the compensation now and hereafter paid to me, I hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>N<SMALL>ONDISCLOSURE</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Recognition of Company&#146;s Rights; Nondisclosure.</B> At all times during my employment and thereafter, I
will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company&#146;s Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection with my work for the
Company, or unless an officer of the Company expressly authorizes such in writing. I will obtain Company&#146;s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at
Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its
assigns. I have been informed and acknowledge that the unauthorized taking of the Company&#146;s trade secrets may subject me to civil and/or criminal penalties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Proprietary Information.</B> The term &#147;<B>Proprietary Information</B>&#148; shall mean any and all
confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, &#147;<B>Proprietary Information</B>&#148; includes (a)&nbsp;tangible and intangible information relating to antibodies and
other biological materials, cell lines, samples of assay components, media and/or cell lines and procedures and formulations for producing any such assay components, media and/or cell lines, formulations, products, processes, <FONT
STYLE="white-space:nowrap">know-how,</FONT> designs, formulas, methods, developmental or experimental work, clinical data, improvements, discoveries, plans for research, new products (<B><I>&#147;Inventions&#148;</I></B>); (b) marketing and selling,
business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (c)&nbsp;information regarding the skills and compensation of other employees of the Company. Notwithstanding the foregoing, it is
understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this Agreement, and my own, skill, knowledge,
<FONT STYLE="white-space:nowrap">know-how</FONT> and experience to whatever extent and in whichever way I wish. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B>Third Party Information.</B> I understand, in addition, that the Company has received and in the future will
receive from third parties confidential or proprietary information (&#147;<B>Third Party Information</B>&#148;) subject to a duty on the Company&#146;s part to maintain the confidentiality of such information and to use it only for certain limited
purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work
for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> <B>No Improper Use of Information of Prior Employers and
Others.</B> During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not
bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person. I
will use in the performance of my duties only information which is generally known and used by persons with training and experience comparable to my own, which is common knowledge in the industry or otherwise legally in the public domain, or which
is otherwise provided or developed by the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>SSIGNMENT</SMALL> <SMALL>OF</SMALL> I<SMALL>NVENTIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Proprietary Rights.</B> The term &#147;<B>Proprietary Rights</B>&#148; shall mean all trade secret, patent,
copyright, mask work and other intellectual property rights or &#147;moral rights&#148; throughout the world. &#147;Moral rights&#148; refers to any rights to claim authorship of an Invention or to object to or prevent the modification of any
Invention, or to withdraw from circulation or control the publication or distribution of any Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not
such right is denominated or generally referred to as a &#147;moral right.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Prior Inventions.</B>
Inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on
<I>Exhibit</I><I></I><I>&nbsp;A </I>(Previous Inventions) attached hereto a complete list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to
practice prior to the commencement of my employment with the Company, that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as &#147;<B>Prior
Inventions</B>&#148;). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in <I>Exhibit</I><I></I><I>&nbsp;A</I> but am only to disclose a
cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on <I>Exhibit A</I> for such purpose. If no such
disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a
nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I
will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company&#146;s prior written consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Assignment of Inventions.</B> Subject to Sections 2.4, and 2.6, I hereby assign and agree to assign in the
future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and to any and all Inventions (and all Proprietary Rights
with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with the Company.
Inventions assigned to the Company, or to a third party as directed by the Company pursuant to this Section&nbsp;2, are hereinafter referred to as &#147;<B>Company Inventions</B>.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Unassigned Inventions.</B> I recognize that this Agreement
will not be deemed to require assignment of any Invention that was developed entirely on my own time without using the Company&#146;s equipment, supplies, facilities, or trade secrets and neither related to the Company&#146;s actual or anticipated
business, research or development, nor resulted from work performed by me for the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Obligation to
Keep Company Informed.</B> During the period of my employment and for six (6)&nbsp;months after termination of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced
to practice by me, either alone or jointly with others. In addition, I will promptly disclose to the Company all patent applications filed by me or on my behalf within a year after termination of employment. The Company will keep in confidence and
will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B>Government or Third Party.</B> I also agree to assign all my right, title and interest in and to any particular
Company Invention to a third party, including without limitation the United States, as directed by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B>Works for Hire.</B> I acknowledge that all original works of authorship which are made by me (solely or jointly
with others) within the scope of my employment and which are protectable by copyright are &#147;works made for hire,&#148; pursuant to United States Copyright Act (17 U.S.C., Section&nbsp;101). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8</B> <B>Enforcement of Proprietary Rights.</B> I will assist the Company in every proper way to obtain, and from time to
time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as the
Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Proprietary
Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my employment, but the Company shall
compensate me at a reasonable rate after my termination for the time actually spent by me at the Company&#146;s request on such assistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event
the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly
authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the
purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any
Proprietary Rights assigned hereunder to the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>R<SMALL>ECORDS</SMALL>.</B><B> </B>I agree to keep and maintain adequate and current records (in the
form of notes, sketches, drawings and in any other form that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the Company, which records shall be
available to and remain the sole property of the Company at all times. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>D<SMALL>UTY</SMALL> <SMALL>OF</SMALL> L<SMALL>OYALTY</SMALL> D<SMALL>URING</SMALL>
E<SMALL>MPLOYMENT</SMALL>.</B> I understand that my employment with the Company requires my full attention and effort. I agree that during the period of my employment by the Company I will not, without the Company&#146;s express written consent,
engage in any employment or business activity other than for the Company, including but not limited to employment or business activity which is competitive with, or would otherwise conflict with, my employment by the Company. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>N<SMALL>O</SMALL> S<SMALL>OLICITATION</SMALL> <SMALL>OF</SMALL> E<SMALL>MPLOYEES</SMALL>,
C<SMALL>ONSULTANTS</SMALL>, C<SMALL>ONTRACTORS</SMALL> <SMALL>OR</SMALL> C<SMALL>USTOMERS</SMALL>.</B> I agree that for the period of my employment by the Company and for one (1)&nbsp;year after the date my employment by the Company ends for any
reason, including but not limited to voluntary termination by me or involuntary termination by the Company, I will not, either directly or through others, (i)&nbsp;solicit or attempt to solicit any employee of the Company to end his or her
relationship with the Company; and (ii)&nbsp;solicit any consultant, contractor, or customer of the Company, with whom I had contact or whose identity I learned as a result of my employment with the Company to diminish or materially alter its
relationship with the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agree that for purposes of this Agreement, a customer is any person or
entity to which the Company has provided goods or services at any time during the period commencing six (6)&nbsp;months prior to my employment with the Company and ending on the date my employment with the Company ends. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-C</FONT><SMALL>OMPETE</SMALL>
P<SMALL>ROVISION</SMALL>.</B> I agree that for the period of my employment with the Company, and for the period of one (1)&nbsp;year after the later of (1)&nbsp;the date my employment ends for any reason, including but not limited to voluntary
termination by me or involuntary termination by the Company; or (2)&nbsp;the date a court of competent jurisdiction enters an order enforcing this provision, I will not provide services, similar to those I provided to the Company, to any person or
entity in competition (as defined below) with the Company. I acknowledge that this <FONT STYLE="white-space:nowrap">non-compete</FONT> provision is limited to the types of activities and services I provided in my employment with the Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the present time, the Company engages in the research and discovery of genes and their function,<B> </B>and
therefore entities and individuals which provide similar products or services are defined as in competition with the Company. The parties understand that the scope and nature of my activities and services, and the Company&#146;s business, products
or services, may change as the Company develops. The parties agree that the scope of this provision will change to cover any changes in my activities or services, as well as any changes in the Company&#146;s business, products or services, during my
employment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>N<SMALL>O</SMALL> C<SMALL>ONFLICTING</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>OR</SMALL>
O<SMALL>BLIGATION</SMALL>.</B> I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement or obligation of any kind made prior to my employment by the Company,
including agreements or obligations I may have with prior employers or entities for which I have provided services. I have not entered into, and I agree I will not enter into, any agreement or obligation either written or oral in conflict herewith.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>R<SMALL>ETURN</SMALL> <SMALL>OF</SMALL> C<SMALL>OMPANY</SMALL> D<SMALL>OCUMENTS</SMALL>.</B> When I
leave the employ of the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Company
Inventions, Third Party Information or Proprietary Information of the Company. I further agree that any property situated on the Company&#146;s premises and owned by the Company, including disks and other storage media, filing cabinets or other work
areas, is subject to inspection by Company personnel at any time with or without notice. Prior to leaving, I will cooperate with the Company in completing and signing the Company&#146;s termination statement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>L<SMALL>EGAL</SMALL> <SMALL>AND</SMALL> E<SMALL>QUITABLE</SMALL> R<SMALL>EMEDIES</SMALL>.</B> I
recognize that in the course of employment with the Company, I will have access to Proprietary Information, to Third Party Information, and to employees, consultants, contractors, clients, and customers of the Company. I also recognize that the
services I will be employed to provide are personal and unique. I understand that because of this the Company may sustain irreparable injury if I violate this Agreement. In order to limit or prevent such irreparable injury, the Company shall have
the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach of this
Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>N<SMALL>OTICES</SMALL>.</B> Any notices required or permitted hereunder shall be given to the
appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery to the appropriate address or if sent by certified or registered mail, three
(3)&nbsp;days after the date of mailing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>N<SMALL>OTIFICATION</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL> E<SMALL>MPLOYER</SMALL>.</B> In the
event that I leave the employ of the Company, I authorize the Company to provide notice of my rights and obligations under this Agreement to my subsequent employer and to any other entity or person to whom I provide services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1</B> <B>Governing Law; Consent to Personal Jurisdiction.</B> This Agreement will be governed by and construed according
to the laws of the State of New York, as such laws are applied to agreements entered into and to be performed entirely within New York between New York residents. I hereby expressly consent to the personal jurisdiction of the state and federal
courts for New York County, New York in any lawsuit filed there against me by Company arising from or related to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2</B> <B>Severability.</B> In case any one or more of the provisions, subsections, or sentences contained in this
Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been contained herein. Moreover, if any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope,
activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3</B> <B>Successors and Assigns.</B> This Agreement will be binding upon my heirs, executors, administrators and other
legal representatives and will be for the benefit of the Company, its successors, and its assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4</B>
<B>Survival.</B> The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.5</B> <B>Employment <FONT STYLE="white-space:nowrap">At-Will.</FONT></B> I agree and understand that I am employed <FONT
STYLE="white-space:nowrap">at-will,</FONT> and that nothing in this Agreement shall change this <FONT STYLE="white-space:nowrap">at-will</FONT> status or confer any right with respect to continuation of employment by the Company, nor shall it
interfere in any way with my right or the Company&#146;s right to terminate my employment at any time, with or without cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.6</B> <B>Waiver.</B> No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or
succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.7</B> <B>Entire Agreement.</B> The obligations pursuant to Sections 1 and 2 of this Agreement shall apply to any time
during which I was previously employed, or am in the future employed, by the Company as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive
agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective
unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall be effective as of the first day of my employment with the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I <SMALL>HAVE</SMALL> <SMALL>READ</SMALL> <SMALL>THIS</SMALL> <SMALL>AGREEMENT</SMALL> <SMALL>CAREFULLY</SMALL> <SMALL>AND</SMALL>
<SMALL>UNDERSTAND</SMALL> <SMALL>ITS</SMALL> <SMALL>TERMS</SMALL>. I <SMALL>HAVE</SMALL> <SMALL>COMPLETELY</SMALL> <SMALL>FILLED</SMALL> <SMALL>OUT</SMALL> E<SMALL>XHIBIT</SMALL>&nbsp;A <SMALL>TO</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL>.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September&nbsp;12, 2018 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Suresh Durgam</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>(Signature)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Suresh Durgam</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>(Printed Name)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>CCEPTED</SMALL> <SMALL>AND</SMALL> A<SMALL>GREED</SMALL> T<SMALL>O</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>I<SMALL>NTRA</SMALL>-<SMALL>CELLULAR</SMALL> T<SMALL>HERAPIES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s Lawrence Hineline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">430 E. 29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> St.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Address)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">New York, NY</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September&nbsp;18, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d234590dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the following Registration Statements: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Registration Statement (Form <FONT STYLE="white-space:nowrap">S-3</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-235817)</FONT> of Intra-Cellular
Therapies, Inc., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Registration Statement (Form <FONT STYLE="white-space:nowrap">S-3</FONT>
<FONT STYLE="white-space:nowrap">No.&nbsp;333-233537)</FONT> of Intra-Cellular Therapies, Inc., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Registration Statement (Form <FONT
STYLE="white-space:nowrap">S-8</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-243716)</FONT> pertaining to the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan of Intra-Cellular Therapies, Inc., </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-236828)</FONT> pertaining to the
Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan of Intra-Cellular Therapies, Inc., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Registration Statement (Form <FONT
STYLE="white-space:nowrap">S-8</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-225799)</FONT> pertaining to the Intra-Cellular Therapies, Inc. 2018 Equity Incentive Plan of Intra-Cellular Therapies, Inc., </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-205070)</FONT> pertaining to the
Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(7) Registration Statement
(Post-Effective Amendment No.&nbsp;3 to Form <FONT STYLE="white-space:nowrap">S-1</FONT> on Form <FONT STYLE="white-space:nowrap">S-3</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-191238)</FONT> of Intra-Cellular Therapies, Inc., and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(8) Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-193310)</FONT> pertaining to the
ITI, Inc. 2003 Equity Incentive Plan, as amended, and the Intra-Cellular Therapies, Inc. 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of
our reports dated March&nbsp;1, 2022, with respect to the consolidated financial statements of Intra-Cellular Therapies, Inc. and the effectiveness of internal control over financial reporting of Intra-Cellular Therapies, Inc. included in this
Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> of Intra-Cellular Therapies, Inc. for the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baltimore, Maryland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;1, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>d234590dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Sharon
Mates, Ph.D., certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Intra-Cellular Therapies, Inc.;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The
registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant
and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d) Disclosed in
this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The
registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of
directors (or persons performing the equivalent functions): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;1, 2022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sharon Mates, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sharon Mates, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman, President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal executive officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>d234590dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Lawrence J.
Hineline, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Intra-Cellular Therapies, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The
registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant
and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d) Disclosed in
this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The
registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of
directors (or persons performing the equivalent functions): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;1, 2022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Lawrence J. Hineline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lawrence J. Hineline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior&nbsp;Vice&nbsp;President&nbsp;of&nbsp;Finance&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal&nbsp;financial&nbsp;officer&nbsp;and&nbsp;principal&nbsp;accounting&nbsp;officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>d234590dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 906 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b)&nbsp;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the
&#147;Company&#148;), does hereby certify, to such officer&#146;s knowledge, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Annual Report for the year ended December&nbsp;31, 2021 (the <FONT
STYLE="white-space:nowrap">&#147;Form&nbsp;10-K&#148;)</FONT> of the Company fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> fairly presents, in all material respects, the financial condition and results of operations of the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated:&nbsp;March 1, 2022</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sharon Mates, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sharon Mates, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman, President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal executive officer)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: March&nbsp;1, 2022</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Lawrence J. Hineline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lawrence J. Hineline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President of Finance and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal financial officer and principal accounting officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>itci-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-March-2022 [08:21:39] {AM}-->
<schema targetNamespace="http://www.intracellulartherapies.com/20211231" elementFormDefault="qualified" xmlns:itci="http://www.intracellulartherapies.com/20211231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
<link:definition>1008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/Organization" id="Organization">
<link:definition>1009 - Disclosure - Organization</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/InvestmentSecurities" id="InvestmentSecurities">
<link:definition>1011 - Disclosure - Investment Securities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/Inventory" id="Inventory">
<link:definition>1012 - Disclosure - Inventory</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1013 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities" id="RightOfUseAssetsAndLeaseLiabilities">
<link:definition>1014 - Disclosure - Right Of Use Assets and Lease Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1015 - Disclosure - Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1016 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RelatedParties" id="RelatedParties">
<link:definition>1018 - Disclosure - Related Parties</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1019 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation" id="UnauditedQuarterlyFinancialInformation">
<link:definition>1020 - Disclosure - Unaudited Quarterly Financial Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" id="InvestmentSecuritiesTables">
<link:definition>1023 - Disclosure - Investment Securities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/InventoryTables" id="InventoryTables">
<link:definition>1024 - Disclosure - Inventory (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1025 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" id="RightOfUseAssetsAndLeaseLiabilitiesTables">
<link:definition>1026 - Disclosure - Right Of Use Assets and Lease Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1027 - Disclosure - Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1028 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables" id="UnauditedQuarterlyFinancialInformationTables">
<link:definition>1029 - Disclosure - Unaudited Quarterly Financial Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" id="OrganizationAdditionalInformationDetail">
<link:definition>1030 - Disclosure - Organization - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1031 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail">
<link:definition>1032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" id="SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail">
<link:definition>1033 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" id="InvestmentSecuritiesAdditionalInformationDetail">
<link:definition>1034 - Disclosure - Investment Securities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail" id="InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail">
<link:definition>1035 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" id="InventoryScheduleOfInventoryCurrentDetail">
<link:definition>1036 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" id="PropertyAndEquipmentPropertyAndEquipmentDetail">
<link:definition>1037 - Disclosure - Property and Equipment - Property and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail" id="PropertyAndEquipmentAdditionalInformationDetail">
<link:definition>1038 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" id="RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Right Of Use Assets and Lease Liabilities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" id="RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail">
<link:definition>1040 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" id="RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail">
<link:definition>1041 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail" id="RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail">
<link:definition>1042 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" id="ShareBasedCompensationAdditionalInformationDetail">
<link:definition>1043 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" id="ShareBasedCompensationTotalStockBasedCompensationExpenseDetail">
<link:definition>1044 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" id="ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail">
<link:definition>1045 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" id="ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail">
<link:definition>1046 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" id="ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail">
<link:definition>1047 - Disclosure - Share-Based Compensation- Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" id="ShareBasedCompensationStockOptionsActivityDetail">
<link:definition>1048 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" id="ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail">
<link:definition>1049 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" id="ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail">
<link:definition>1050 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1051 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail" id="IncomeTaxesLossBeforeIncomeTaxesDetail">
<link:definition>1052 - Disclosure - Income Taxes - Loss before Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail" id="IncomeTaxesTotalIncomeTaxExpenseDetail">
<link:definition>1053 - Disclosure - Income Taxes - Total Income Tax Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" id="IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail">
<link:definition>1054 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail">
<link:definition>1055 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail" id="UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail">
<link:definition>1057 - Disclosure - Unaudited Quarterly Financial Information - Schedule of Quarterly Financial Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="itci-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="AccruedCustomerProgramsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_AccruedCustomerProgramsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Costofproductsales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_Costofproductsales" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="VehicleFleetLeaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_VehicleFleetLeaseMember" substitutionGroup="xbrli:item" />
<element name="RealEstateLeaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_RealEstateLeaseMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ItciRealEstatesLeaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ItciRealEstatesLeaseMember" substitutionGroup="xbrli:item" />
<element name="InducementAwardPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_InducementAwardPlanMember" substitutionGroup="xbrli:item" />
<element name="MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="TimeBasedRestrictedStockUnitsRSUMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_TimeBasedRestrictedStockUnitsRSUMember" substitutionGroup="xbrli:item" />
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="SecuritiesAuthorizedAmountForIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_SecuritiesAuthorizedAmountForIssuance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_PerformanceBasedRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="Investment1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_Investment1Axis" substitutionGroup="xbrldt:dimensionItem" />
<element name="Investment1Domain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_Investment1Domain" substitutionGroup="xbrli:item" />
<element name="TwoThousandEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_TwoThousandEighteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="AvailableForSaleSecuritiesMaturityPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_AvailableForSaleSecuritiesMaturityPeriod" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentMaximumMaturityPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_CashAndCashEquivalentMaximumMaturityPeriod" substitutionGroup="xbrli:item" />
<element name="ChangeInAccountingEstimateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ChangeInAccountingEstimateAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RoyaltyPaymentPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_RoyaltyPaymentPercentage" substitutionGroup="xbrli:item" />
<element name="GrantReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_GrantReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CustomerOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_CustomerOneMember" substitutionGroup="xbrli:item" />
<element name="CustomerTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_CustomerTwoMember" substitutionGroup="xbrli:item" />
<element name="CustomerThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_CustomerThreeMember" substitutionGroup="xbrli:item" />
<element name="AmtTaxCreditMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_AmtTaxCreditMember" substitutionGroup="xbrli:item" />
<element name="ClinicalTralMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ClinicalTralMember" substitutionGroup="xbrli:item" />
<element name="CaplytaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_CaplytaMember" substitutionGroup="xbrli:item" />
<element name="BristolMyersSquibbCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_BristolMyersSquibbCompanyMember" substitutionGroup="xbrli:item" />
<element name="FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" substitutionGroup="xbrli:item" />
<element name="TotalShareholderReturnRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_TotalShareholderReturnRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" substitutionGroup="xbrli:item" />
<element name="PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" substitutionGroup="xbrli:item" />
<element name="RealEstatesLeaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_RealEstatesLeaseMember" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestoneRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_MilestoneRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" substitutionGroup="xbrli:item" />
<element name="InventoriableCostsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_InventoriableCostsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" substitutionGroup="xbrli:item" />
<element name="HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" substitutionGroup="xbrli:item" />
<element name="IndefinitePeriodCarryForwardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_IndefinitePeriodCarryForwardMember" substitutionGroup="xbrli:item" />
<element name="ExpireIn2037Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ExpireIn2037Member" substitutionGroup="xbrli:item" />
<element name="FederalNetOperatingLossCarryForwardExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_FederalNetOperatingLossCarryForwardExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" substitutionGroup="xbrli:item" />
<element name="Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLiabilitiesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_DeferredTaxAssetsLiabilitiesGross" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_DeferredTaxLiabilitiesDepreciation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Deferredtaxliabilitiesrightofuseassetcapitallease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_Deferredtaxliabilitiesrightofuseassetcapitallease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Deferredtaxliabilitiesunrealizedgainsoninvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NationalDemocraticAllianceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_NationalDemocraticAllianceMember" substitutionGroup="xbrli:item" />
<element name="ITCINationalDemocraticAllianceMemberMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ITCINationalDemocraticAllianceMemberMember" substitutionGroup="xbrli:item" />
<element name="PaymentOfMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_PaymentOfMilestoneAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CollaborativeAgreementUpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_CollaborativeAgreementUpfrontPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CollaborativeArrangementAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="itci_CollaborativeArrangementAmountPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CollaborativeArrangementLicenseExpirationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_CollaborativeArrangementLicenseExpirationDescription" substitutionGroup="xbrli:item" />
<element name="CollaborativeArrangementMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_CollaborativeArrangementMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CollaborativeArrangementRemainingPotentialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="itci_CollaborativeArrangementRemainingPotentialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ResearchAndOtherCommitmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ResearchAndOtherCommitmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ResearchAndOtherCommitmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_ResearchAndOtherCommitmentDomain" substitutionGroup="xbrli:item" />
<element name="SiegfriedCampaignAndLonzaCampaignMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="itci_SiegfriedCampaignAndLonzaCampaignMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>itci-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-March-2022 [08:21:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InventoryScheduleOfInventoryCurrentDetail" roleURI="http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentPropertyAndEquipmentDetail" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesTotalIncomeTaxExpenseDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AccruedCustomerProgramsCurrent" xlink:label="loc_ITCI_AccruedCustomerProgramsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ITCI_AccruedCustomerProgramsCurrent" use="optional" order="23" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Costofproductsales" xlink:label="loc_ITCI_Costofproductsales" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_ITCI_Costofproductsales" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="9" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xlink:label="loc_ITCI_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ITCI_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" order="3" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_DeferredTaxAssetsLiabilitiesGross" xlink:label="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xlink:label="loc_ITCI_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_ITCI_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_ITCI_DeferredTaxLiabilitiesDepreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_ITCI_DeferredTaxLiabilitiesDepreciation" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xlink:label="loc_ITCI_Deferredtaxliabilitiesrightofuseassetcapitallease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_ITCI_Deferredtaxliabilitiesrightofuseassetcapitallease" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xlink:label="loc_ITCI_Deferredtaxliabilitiesunrealizedgainsoninvestment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ITCI_DeferredTaxAssetsLiabilitiesGross" xlink:to="loc_ITCI_Deferredtaxliabilitiesunrealizedgainsoninvestment" use="optional" order="11" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_ITCI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_ITCI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_ITCI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_ITCI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>itci-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-March-2022 [08:21:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesTables" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationTables" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#OrganizationAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecuritiesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentPropertyAndEquipmentDetail" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#CoverPage" roleURI="http://www.intracellulartherapies.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipment" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentTables" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensation" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxes" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesTables" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#CommitmentsAndContingencies" roleURI="http://www.intracellulartherapies.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RelatedParties" roleURI="http://www.intracellulartherapies.com/role/RelatedParties" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#UnauditedQuarterlyFinancialInformation" roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#UnauditedQuarterlyFinancialInformationTables" roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationStockOptionsActivityDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesTotalIncomeTaxExpenseDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail" roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#Organization" roleURI="http://www.intracellulartherapies.com/role/Organization" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilities" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#Inventory" roleURI="http://www.intracellulartherapies.com/role/Inventory" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InventoryTables" roleURI="http://www.intracellulartherapies.com/role/InventoryTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InventoryScheduleOfInventoryCurrentDetail" roleURI="http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecurities" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecurities" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecuritiesTables" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SubsequentEvents" roleURI="http://www.intracellulartherapies.com/role/SubsequentEvents" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827749" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_InvestmentIncomeInterest_65" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_OperatingIncomeLoss_64" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_56" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_59" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Costofproductsales" xlink:label="loc_itci_Costofproductsales_826553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_itci_Costofproductsales_826553" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_60" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_us-gaap_OperatingExpenses_61" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_EarningsPerShareAbstract_57" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_62" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_827746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_StatementTable_827746" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_827747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_827746" xlink:to="loc_us-gaap_StatementClassOfStockAxis_827747" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_827748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_827747" xlink:to="loc_us-gaap_ClassOfStockDomain_827748" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_827748_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_827747" xlink:to="loc_us-gaap_ClassOfStockDomain_827748_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_827750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_827746" xlink:to="loc_srt_ProductOrServiceAxis_827750" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_827751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_827750" xlink:to="loc_srt_ProductsAndServicesDomain_827751" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_827751_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_827750" xlink:to="loc_srt_ProductsAndServicesDomain_827751_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_827752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_827751" xlink:to="loc_us-gaap_ProductMember_827752" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_827753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_827751" xlink:to="loc_us-gaap_GrantMember_827753" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_NetIncomeLoss_69" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_58" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_58" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_70" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StatementTable_83" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81" xlink:to="loc_us-gaap_EquityComponentDomain_79" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_79_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81" xlink:to="loc_us-gaap_EquityComponentDomain_79_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_86" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_CommonStockMember_85" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_87" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_RetainedEarningsMember_87" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_102" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_NetIncomeLoss_105" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_SharesOutstanding_92" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockholdersEquity_90" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_101" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_106" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_99" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_100" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_91" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827762" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_131" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_129" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_128" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_119" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_118" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_Depreciation_116" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_ShareBasedCompensation_117" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_137" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_121" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_123" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_120" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_122" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_124" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xlink:label="loc_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent_613747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent_613747" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_827754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_827754" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_ProfitLoss_136" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_135" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_132" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_134" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_133" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_139" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_138" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_IncomeTaxesPaid_142" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_828893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_828893" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_420844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_828893" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_420844" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_827759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_StatementTable_827759" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_827759" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_827768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" xlink:to="loc_itci_VehicleFleetLeaseMember_827768" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RealEstateLeaseMember" xlink:label="loc_itci_RealEstateLeaseMember_827771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" xlink:to="loc_itci_RealEstateLeaseMember_827771" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_827760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_827759" xlink:to="loc_us-gaap_StatementClassOfStockAxis_827760" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_827761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_827760" xlink:to="loc_us-gaap_ClassOfStockDomain_827761" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_827761_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_827760" xlink:to="loc_us-gaap_ClassOfStockDomain_827761_default" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_826739" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xlink:label="loc_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock_826775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826739" xlink:to="loc_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock_826775" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_826657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_826739" xlink:to="loc_us-gaap_StatementTable_826657" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_826658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_826657" xlink:to="loc_us-gaap_LeaseContractualTermAxis_826658" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826658" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826659" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826659_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826658" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826659_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_826665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826659" xlink:to="loc_itci_VehicleFleetLeaseMember_826665" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ItciRealEstatesLeaseMember" xlink:label="loc_itci_ItciRealEstatesLeaseMember_1309259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826659" xlink:to="loc_itci_ItciRealEstatesLeaseMember_1309259" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_419338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826739" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_419338" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_581" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_585" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_587" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_586" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_StatementTable_582" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_582" xlink:to="loc_us-gaap_AwardTypeAxis_579" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_827265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" xlink:to="loc_itci_InducementAwardPlanMember_827265" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" xlink:to="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_584" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TimeBasedRestrictedStockUnitsRSUMember" xlink:label="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" xlink:to="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_583" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_588" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_163" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SecuritiesAuthorizedAmountForIssuance" xlink:label="loc_itci_SecuritiesAuthorizedAmountForIssuance_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_itci_SecuritiesAuthorizedAmountForIssuance_165" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_SharePrice_162" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_826621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_826621" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_srt_ConsolidatedEntitiesAxis_145" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_145" xlink:to="loc_srt_ConsolidatedEntitiesDomain_146" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_146_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_145" xlink:to="loc_srt_ConsolidatedEntitiesDomain_146_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_150" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_150_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_150_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_srt_RangeAxis_153" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_153" xlink:to="loc_srt_RangeMember_154" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_153" xlink:to="loc_srt_RangeMember_154_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_154" xlink:to="loc_srt_MaximumMember_169" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_513653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_513653" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_513654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_513653" xlink:to="loc_us-gaap_EquityComponentDomain_513654" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_513654_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_513653" xlink:to="loc_us-gaap_EquityComponentDomain_513654_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_513655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_513654" xlink:to="loc_us-gaap_CommonStockMember_513655" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_156" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_156" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_156" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155" xlink:to="loc_us-gaap_IPOMember_171" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_472647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_srt_StatementScenarioAxis_472647" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_472648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_472647" xlink:to="loc_srt_ScenarioUnspecifiedDomain_472648" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_472648_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_472647" xlink:to="loc_srt_ScenarioUnspecifiedDomain_472648_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_586483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_586483" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_586484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_586483" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_586484" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_586484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_586483" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_586484_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_586485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_586484" xlink:to="loc_us-gaap_SubsequentEventMember_586485" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_826622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_CommonStockSharesIssued_826622" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_161" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SignificantAccountingPoliciesLineItems" xlink:label="loc_itci_SignificantAccountingPoliciesLineItems_188" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AvailableForSaleSecuritiesMaturityPeriod" xlink:label="loc_itci_AvailableForSaleSecuritiesMaturityPeriod_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_AvailableForSaleSecuritiesMaturityPeriod_202" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_210" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CashAndCashEquivalentMaximumMaturityPeriod" xlink:label="loc_itci_CashAndCashEquivalentMaximumMaturityPeriod_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_CashAndCashEquivalentMaximumMaturityPeriod_201" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_225" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_211" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_209" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_218" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_220" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_215" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SignificantAccountingPoliciesTable" xlink:label="loc_itci_SignificantAccountingPoliciesTable_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_SignificantAccountingPoliciesTable_189" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" xlink:to="loc_us-gaap_TypeOfAdoptionMember_192" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_192_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" xlink:to="loc_us-gaap_TypeOfAdoptionMember_192_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_AwardTypeAxis_176" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_613526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" xlink:to="loc_itci_InducementAwardPlanMember_613526" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PerformanceBasedRestrictedStockUnitsMember" xlink:label="loc_itci_PerformanceBasedRestrictedStockUnitsMember_827739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" xlink:to="loc_itci_PerformanceBasedRestrictedStockUnitsMember_827739" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_177" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_177" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_178" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_178_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_177" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_178_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Axis" xlink:label="loc_itci_Investment1Axis_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_itci_Investment1Axis_181" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Domain" xlink:label="loc_itci_Investment1Domain_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_itci_Investment1Axis_181" xlink:to="loc_itci_Investment1Domain_182" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Domain" xlink:label="loc_itci_Investment1Domain_182_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_itci_Investment1Axis_181" xlink:to="loc_itci_Investment1Domain_182_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_194" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_190" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_190" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_191" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_191_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_190" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_191_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_RangeAxis_185" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_185" xlink:to="loc_srt_RangeMember_186" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_186_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_185" xlink:to="loc_srt_RangeMember_186_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_186" xlink:to="loc_srt_MaximumMember_198" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_186" xlink:to="loc_srt_MinimumMember_197" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_PlanNameAxis_183" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_183" xlink:to="loc_us-gaap_PlanNameDomain_184" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_184_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_183" xlink:to="loc_us-gaap_PlanNameDomain_184_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_184" xlink:to="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_196" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_827669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_MajorCustomersAxis_827669" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_827670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_827669" xlink:to="loc_srt_NameOfMajorCustomerDomain_827670" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_827670_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_827669" xlink:to="loc_srt_NameOfMajorCustomerDomain_827670_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerOneMember" xlink:label="loc_itci_CustomerOneMember_827671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_827670" xlink:to="loc_itci_CustomerOneMember_827671" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerTwoMember" xlink:label="loc_itci_CustomerTwoMember_827672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_827670" xlink:to="loc_itci_CustomerTwoMember_827672" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerThreeMember" xlink:label="loc_itci_CustomerThreeMember_827673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_827670" xlink:to="loc_itci_CustomerThreeMember_827673" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_827676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675" xlink:to="loc_us-gaap_AccountsReceivableMember_827676" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_827683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_827683" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_827683_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_827683_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_827684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_827683" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_827684" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_827714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_827714" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_827714" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_827714" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AmtTaxCreditMember" xlink:label="loc_itci_AmtTaxCreditMember_827717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716" xlink:to="loc_itci_AmtTaxCreditMember_827717" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893_default" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ClinicalTralMember" xlink:label="loc_itci_ClinicalTralMember_613895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893" xlink:to="loc_itci_ClinicalTralMember_613895" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_827692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_ProductOrServiceAxis_827692" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_827693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_827692" xlink:to="loc_srt_ProductsAndServicesDomain_827693" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_827693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_827692" xlink:to="loc_srt_ProductsAndServicesDomain_827693_default" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CaplytaMember" xlink:label="loc_itci_CaplytaMember_837571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_827693" xlink:to="loc_itci_CaplytaMember_837571" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_827695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_827693" xlink:to="loc_us-gaap_ProductMember_827695" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_827697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_CounterpartyNameAxis_827697" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_827697" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_827697" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698_default" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_BristolMyersSquibbCompanyMember" xlink:label="loc_itci_BristolMyersSquibbCompanyMember_827699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698" xlink:to="loc_itci_BristolMyersSquibbCompanyMember_827699" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_214" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_NumberOfOperatingSegments_200" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_221" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ChangeInAccountingEstimateAmount" xlink:label="loc_itci_ChangeInAccountingEstimateAmount_613888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_ChangeInAccountingEstimateAmount_613888" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_827667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_827667" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_837566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_AdvertisingExpense_837566" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_613515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_613515" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_827711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_827711" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_827737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_827737" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RoyaltyPaymentPercentage" xlink:label="loc_itci_RoyaltyPaymentPercentage_827691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_RoyaltyPaymentPercentage_827691" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_1309240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_AccountsReceivableNet_1309240" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_GrantReceivable" xlink:label="loc_itci_GrantReceivable_1309242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_GrantReceivable_1309242" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1310006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1310006" use="optional" order="84" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail">
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xlink:label="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems_264" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems_264" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_270" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems_264" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_262" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_262_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_262_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_262" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_267" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_us-gaap_InvestmentTypeAxis_265" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_265" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_266" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_266_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_265" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_266_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_MoneyMarketFundsMember_271" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_272" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_CertificatesOfDepositMember_274" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_CommercialPaperMember_275" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_276" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_268" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_269" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_280" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_280" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_280" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" xlink:to="loc_us-gaap_EmployeeStockOptionMember_284" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_285" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" xlink:to="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_286" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1309229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" xlink:to="loc_us-gaap_InvestmentTypeAxis_1309229" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1309229" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1309232_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1309229" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1309232_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" xlink:label="loc_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember_1309231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember_1309231" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_1309237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_us-gaap_CommercialPaperMember_1309237" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1309238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1309238" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309233" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309250" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1309251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1309251" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1309254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1309254" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1309332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1309332" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_1310015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_1310015" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1309281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1309281" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1309282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1309282" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1309284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1309284" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309287" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1309271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" xlink:to="loc_us-gaap_InvestmentTypeAxis_1309271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1309271" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1309272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1309271" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1309272_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1309278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1309278" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309273" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1309276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1309276" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_1309277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_CommercialPaperMember_1309277" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_293" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_295" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_294" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_ComputerEquipmentMember_296" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_EquipmentMember_298" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_297" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_299" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_419459" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_419481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_419481" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_419475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_419475" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_419477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_OperatingLeaseLiability_419477" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_419456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_StatementTable_419456" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NY" xlink:label="loc_stpr_NY_419462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" xlink:to="loc_stpr_NY_419462" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD_419463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" xlink:to="loc_stpr_MD_419463" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_419472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" xlink:to="loc_us-gaap_TypeOfAdoptionMember_419472" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_419472_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" xlink:to="loc_us-gaap_TypeOfAdoptionMember_419472_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_419457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_StatementClassOfStockAxis_419457" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_419458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_419457" xlink:to="loc_us-gaap_ClassOfStockDomain_419458" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_419458_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_419457" xlink:to="loc_us-gaap_ClassOfStockDomain_419458_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_513065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_srt_StatementScenarioAxis_513065" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_513066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_513065" xlink:to="loc_srt_ScenarioUnspecifiedDomain_513066" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_513066_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_513065" xlink:to="loc_srt_ScenarioUnspecifiedDomain_513066_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_829049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_829049" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_829049_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_829049_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_513069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_513069" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_513069_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_513069_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_827152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_LeaseContractualTermAxis_827152" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_827154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_827152" xlink:to="loc_us-gaap_LeaseContractualTermDomain_827154" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_827154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_827152" xlink:to="loc_us-gaap_LeaseContractualTermDomain_827154_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_827155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_827154" xlink:to="loc_itci_VehicleFleetLeaseMember_827155" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_419715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_OperatingLeaseExpense_419715" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_829046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_829046" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_829051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_RestrictedCash_829051" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xlink:label="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths_829054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths_829054" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xlink:label="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths_829056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths_829056" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_826866" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_419423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_419423" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_419424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_419424" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_419421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_419421" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_420850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_420850" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_420851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_420851" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_826857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_StatementTable_826857" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_826863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_826857" xlink:to="loc_us-gaap_LeaseContractualTermAxis_826863" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826863" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826864" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826864_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826863" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826864_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RealEstatesLeaseMember" xlink:label="loc_itci_RealEstatesLeaseMember_826865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826864" xlink:to="loc_itci_RealEstatesLeaseMember_826865" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_419434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_419434" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_419437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_OperatingLeaseLiability_419437" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_419431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_419431" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_419428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_419428" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_419430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_419430" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_1309305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_1309305" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_826972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_StatementTable_826972" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_826973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_826972" xlink:to="loc_us-gaap_LeaseContractualTermAxis_826973" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826973" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826974" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826974_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826973" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826974_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_826975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826974" xlink:to="loc_itci_VehicleFleetLeaseMember_826975" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ItciRealEstatesLeaseMember" xlink:label="loc_itci_ItciRealEstatesLeaseMember_1309248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826974" xlink:to="loc_itci_ItciRealEstatesLeaseMember_1309248" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_826987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_826987" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_826989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_826989" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_826993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_826993" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_826995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseLiability_826995" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_826998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_826998" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_827000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_827000" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1309243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseCost_1309243" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_1309244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_VariableLeaseCost_1309244" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_827062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_StatementTable_827062" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_827063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_827062" xlink:to="loc_us-gaap_LeaseContractualTermAxis_827063" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_827065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_827063" xlink:to="loc_us-gaap_LeaseContractualTermDomain_827065" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_827065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_827063" xlink:to="loc_us-gaap_LeaseContractualTermDomain_827065_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_827069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_827065" xlink:to="loc_itci_VehicleFleetLeaseMember_827069" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_827097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_827097" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_827098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_827098" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_827099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_OperatingLeaseLiability_827099" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_827090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_827090" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_827093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_827093" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_827101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_827101" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_827103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_827103" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_827089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_827089" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_1309274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_1309274" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_1309275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_1309275" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_329" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_318" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_327" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_326" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_328" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_us-gaap_AwardTypeAxis_305" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_337" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_us-gaap_EmployeeStockOptionMember_339" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneRestrictedStockUnitsMember_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_MilestoneRestrictedStockUnitsMember_338" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TimeBasedRestrictedStockUnitsRSUMember" xlink:label="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_336" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_585659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_InducementAwardPlanMember_585659" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_613691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_613691" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_613693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_613693" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_srt_RangeAxis_308" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_308" xlink:to="loc_srt_RangeMember_309" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_309_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_308" xlink:to="loc_srt_RangeMember_309_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_309" xlink:to="loc_srt_MaximumMember_317" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_309" xlink:to="loc_srt_MinimumMember_316" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_us-gaap_PlanNameAxis_306" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_306" xlink:to="loc_us-gaap_PlanNameDomain_307" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_306" xlink:to="loc_us-gaap_PlanNameDomain_307_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_307" xlink:to="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_315" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_srt_TitleOfIndividualAxis_313" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_313" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_314" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_314_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_313" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_314_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_319" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_330" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_585658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_585658" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_613670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_613670" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_613621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_613621" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_613646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_613646" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_613673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_613673" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_322" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_321" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_323" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_334" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_623223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_623223" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate_1310128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate_1310128" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate_1310130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate_1310130" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1309375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1309375" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_343" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_343" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_344" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_344" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_344" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_348" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InventoriableCostsMember" xlink:label="loc_itci_InventoriableCostsMember_828780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345" xlink:to="loc_itci_InventoriableCostsMember_828780" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_343" xlink:to="loc_us-gaap_ShareBasedCompensation_347" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" xlink:to="loc_us-gaap_AwardTypeAxis_830024" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_830024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_830024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_830026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025" xlink:to="loc_itci_InducementAwardPlanMember_830026" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830033" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830031" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_830038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_830038" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830041" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830043" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_830032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_830032" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830053" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_830054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_830054" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2_830055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2_830055" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830045" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830046" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_830056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_830056" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_1309292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_1309292" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1309298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1309298" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830071" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" xlink:to="loc_us-gaap_AwardTypeAxis_830066" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_830066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_830066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_830069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067" xlink:to="loc_itci_InducementAwardPlanMember_830069" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830072" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830089" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830092" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_830104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_830104" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xlink:label="loc_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited_830108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited_830108" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830075" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_830085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_830085" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_830087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_830087" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830103" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830100" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_830101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_830101" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830095" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613700" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_392" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_386" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xlink:to="loc_us-gaap_AwardTypeAxis_382" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_382" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_382" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_396" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_389" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_394" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_613701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_613701" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_613715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_613715" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms_613716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms_613716" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_391" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_388" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_393" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_AwardTypeAxis_399" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_413" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_585647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_585647" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_403" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613830" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_408" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_410" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_405" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:label="loc_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_1309340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_1309340" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms_1309341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms_1309341" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_613753" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_613750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_us-gaap_StatementTable_613750" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_613751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_613750" xlink:to="loc_us-gaap_TaxPeriodAxis_613751" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_613752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_613751" xlink:to="loc_us-gaap_TaxPeriodDomain_613752" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_613752_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_613751" xlink:to="loc_us-gaap_TaxPeriodDomain_613752_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IndefinitePeriodCarryForwardMember" xlink:label="loc_itci_IndefinitePeriodCarryForwardMember_613782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_613752" xlink:to="loc_itci_IndefinitePeriodCarryForwardMember_613782" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ExpireIn2037Member" xlink:label="loc_itci_ExpireIn2037Member_613886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_613752" xlink:to="loc_itci_ExpireIn2037Member_613886" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xlink:label="loc_itci_FederalNetOperatingLossCarryForwardExpirationPeriod_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_itci_FederalNetOperatingLossCarryForwardExpirationPeriod_436" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_us-gaap_OperatingLossCarryforwards_435" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_439" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PaymentOfMilestoneAmount" xlink:label="loc_itci_PaymentOfMilestoneAmount_613655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_PaymentOfMilestoneAmount_613655" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeAgreementUpfrontPayments" xlink:label="loc_itci_CollaborativeAgreementUpfrontPayments_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeAgreementUpfrontPayments_502" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementAmountPayable" xlink:label="loc_itci_CollaborativeArrangementAmountPayable_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementAmountPayable_504" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementLicenseExpirationDescription" xlink:label="loc_itci_CollaborativeArrangementLicenseExpirationDescription_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementLicenseExpirationDescription_507" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementMilestonePayments" xlink:label="loc_itci_CollaborativeArrangementMilestonePayments_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementMilestonePayments_503" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xlink:label="loc_itci_CollaborativeArrangementRemainingPotentialMilestonePayments_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementRemainingPotentialMilestonePayments_505" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_613657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_613657" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_613658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_613657" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_613658" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_613658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_613657" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_613658_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_srt_RangeAxis_489" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_489" xlink:to="loc_srt_RangeMember_490" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_490_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_489" xlink:to="loc_srt_RangeMember_490_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_490" xlink:to="loc_srt_MaximumMember_499" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_490" xlink:to="loc_srt_MinimumMember_498" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_srt_CounterpartyNameAxis_488" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_488" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_488" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_BristolMyersSquibbCompanyMember" xlink:label="loc_itci_BristolMyersSquibbCompanyMember_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493" xlink:to="loc_itci_BristolMyersSquibbCompanyMember_501" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="loc_us-gaap_RegulatoryAgencyAxis_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_RegulatoryAgencyAxis_491" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaap_RegulatoryAgencyDomain_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RegulatoryAgencyAxis_491" xlink:to="loc_us-gaap_RegulatoryAgencyDomain_492" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaap_RegulatoryAgencyDomain_492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RegulatoryAgencyAxis_491" xlink:to="loc_us-gaap_RegulatoryAgencyDomain_492_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_NationalDemocraticAllianceMember" xlink:label="loc_itci_NationalDemocraticAllianceMember_501066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RegulatoryAgencyDomain_492" xlink:to="loc_itci_NationalDemocraticAllianceMember_501066" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ITCINationalDemocraticAllianceMemberMember" xlink:label="loc_itci_ITCINationalDemocraticAllianceMemberMember_614045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RegulatoryAgencyDomain_492" xlink:to="loc_itci_ITCINationalDemocraticAllianceMemberMember_614045" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="loc_us-gaap_PurchaseCommitmentMember_828946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945" xlink:to="loc_us-gaap_PurchaseCommitmentMember_828946" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_srt_ProductOrServiceAxis_496" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_501126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_496" xlink:to="loc_srt_ProductsAndServicesDomain_501126" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_501126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_496" xlink:to="loc_srt_ProductsAndServicesDomain_501126_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_613683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_501126" xlink:to="loc_us-gaap_ProductMember_613683" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentAxis" xlink:label="loc_itci_ResearchAndOtherCommitmentAxis_1309234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_itci_ResearchAndOtherCommitmentAxis_1309234" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentDomain" xlink:label="loc_itci_ResearchAndOtherCommitmentDomain_1309235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_itci_ResearchAndOtherCommitmentAxis_1309234" xlink:to="loc_itci_ResearchAndOtherCommitmentDomain_1309235" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentDomain" xlink:label="loc_itci_ResearchAndOtherCommitmentDomain_1309235_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_itci_ResearchAndOtherCommitmentAxis_1309234" xlink:to="loc_itci_ResearchAndOtherCommitmentDomain_1309235_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SiegfriedCampaignAndLonzaCampaignMember" xlink:label="loc_itci_SiegfriedCampaignAndLonzaCampaignMember_1309236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_itci_ResearchAndOtherCommitmentDomain_1309235" xlink:to="loc_itci_SiegfriedCampaignAndLonzaCampaignMember_1309236" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_828929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_828929" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_828930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_828930" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_828931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_828931" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_828943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_Cash_828943" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RoyaltyPaymentPercentage" xlink:label="loc_itci_RoyaltyPaymentPercentage_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_RoyaltyPaymentPercentage_506" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_828927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_CostOfRevenue_828927" use="optional" order="42" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>itci-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-March-2022 [08:21:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Investment securities, available-for-sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Estimated Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property Plant and Equipment Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right of use assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value: 175,000,000 and 100,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; 81,886,965 and 80,463,089 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated comprehensive (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xml:lang="en-US">Accrued Employee Benefits, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, short-term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AccruedCustomerProgramsCurrent" xlink:label="loc_itci_AccruedCustomerProgramsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_AccruedCustomerProgramsCurrent" xml:lang="en-US">Accrued Customer Programs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_AccruedCustomerProgramsCurrent" xml:lang="en-US">Accrued Customer Programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_AccruedCustomerProgramsCurrent" xlink:to="lab_itci_AccruedCustomerProgramsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_AccruedCustomerProgramsCurrent" xml:lang="en-US">Accrued customer programs current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Costs and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Costofproductsales" xlink:label="loc_itci_Costofproductsales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_Costofproductsales" xml:lang="en-US">CostOfProductSales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_Costofproductsales" xml:lang="en-US">Cost of product sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_Costofproductsales" xlink:to="lab_itci_Costofproductsales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_Costofproductsales" xml:lang="en-US">Cost Of Product Sales.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per common share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic &amp; Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Weighted average number of common shares:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic &amp; Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product sales, net [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantMember" xml:lang="en-US">Grant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GrantMember" xml:lang="en-US">Grant revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Unrealized (loss) gain on investment securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common shares issued, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Initial public offering, Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock issued for services, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Exercise of stock options and issuances of restricted stock (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Common shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Exercise of stock options and issuances of restricted stock (Value)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Comprehensive Gain (Loss) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds of public offerings, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Amortization of premiums and discounts on investment securities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Total share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xml:lang="en-US">Long term deferred tax asset, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued liabilities and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xlink:label="loc_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xml:lang="en-US">Increase Decrease In Operating Lease Liabilitites Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xml:lang="en-US">Lease liabilities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xlink:to="lab_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xml:lang="en-US">Increase decrease in operating lease liabilitites, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows (used in) provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Maturities of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right of use assets under operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_VehicleFleetLeaseMember" xml:lang="en-US">Vehicle Fleet Lease [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_VehicleFleetLeaseMember" xml:lang="en-US">Vehicle Fleet Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_VehicleFleetLeaseMember" xlink:to="lab_itci_VehicleFleetLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_VehicleFleetLeaseMember" xml:lang="en-US">Vehicle fleet lease.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RealEstateLeaseMember" xlink:label="loc_itci_RealEstateLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_RealEstateLeaseMember" xml:lang="en-US">Real Estate Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_RealEstateLeaseMember" xlink:to="lab_itci_RealEstateLeaseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTextBlock" xml:lang="en-US">Investment [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Right Of Use Assets and Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xml:lang="en-US">Unaudited Quarterly Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of product sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Receivables, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Accounts Receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development, including Clinical trial expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xlink:label="loc_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule Of Quantitative Information About Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule Of Quantitative Information About Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xlink:to="lab_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of quantitative information about operating leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule Of Maturity Analysis Under Lease Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ItciRealEstatesLeaseMember" xlink:label="loc_itci_ItciRealEstatesLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ItciRealEstatesLeaseMember" xml:lang="en-US">ITCI Real Estates Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ItciRealEstatesLeaseMember" xlink:to="lab_itci_ItciRealEstatesLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ItciRealEstatesLeaseMember" xml:lang="en-US">ITCI real estates lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_InducementAwardPlanMember" xml:lang="en-US">Inducement Award Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_InducementAwardPlanMember" xml:lang="en-US">Inducement Award Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_InducementAwardPlanMember" xlink:to="lab_itci_InducementAwardPlanMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Milestone And Total Shareholder Return Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Milestone and Total Shareholder Return Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Milestone And Total Shareholder Return Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:to="lab_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Milestone and total shareholder return restricted stock units.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TimeBasedRestrictedStockUnitsRSUMember" xlink:label="loc_itci_TimeBasedRestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_TimeBasedRestrictedStockUnitsRSUMember" xml:lang="en-US">Time Based Restricted Stock Units R S U [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_TimeBasedRestrictedStockUnitsRSUMember" xml:lang="en-US">Time Based Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_TimeBasedRestrictedStockUnitsRSUMember" xlink:to="lab_itci_TimeBasedRestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_TimeBasedRestrictedStockUnitsRSUMember" xml:lang="en-US">Time based restricted stock units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Total Stock-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Assumptions Used for Calculating Value of Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Information Regarding RSU Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Total Income Tax Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Summary of Loss Before Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xml:lang="en-US">Schedule of Quarterly Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Initial public offering, Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SecuritiesAuthorizedAmountForIssuance" xlink:label="loc_itci_SecuritiesAuthorizedAmountForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SecuritiesAuthorizedAmountForIssuance" xml:lang="en-US">Securities Authorized Amount For Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_SecuritiesAuthorizedAmountForIssuance" xml:lang="en-US">Universal shelf registration statement, effective date value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SecuritiesAuthorizedAmountForIssuance" xlink:to="lab_itci_SecuritiesAuthorizedAmountForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SecuritiesAuthorizedAmountForIssuance" xml:lang="en-US">Securities Authorized Amount For Issuance</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Initial public offering, Price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Initial public offering, Net proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SignificantAccountingPoliciesTable" xlink:label="loc_itci_SignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SignificantAccountingPoliciesTable" xlink:to="lab_itci_SignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PerformanceBasedRestrictedStockUnitsMember" xlink:label="loc_itci_PerformanceBasedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_PerformanceBasedRestrictedStockUnitsMember" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_itci_PerformanceBasedRestrictedStockUnitsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Axis" xlink:label="loc_itci_Investment1Axis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_Investment1Axis" xml:lang="en-US">Investment1 [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_Investment1Axis" xml:lang="en-US">Investment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_Investment1Axis" xlink:to="lab_itci_Investment1Axis" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Domain" xlink:label="loc_itci_Investment1Domain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_Investment1Domain" xml:lang="en-US">Investment1 [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_Investment1Domain" xml:lang="en-US">Investment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_Investment1Domain" xlink:to="lab_itci_Investment1Domain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Significant Unobservable Inputs (Level 3) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_itci_TwoThousandEighteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_TwoThousandEighteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_TwoThousandEighteenEquityIncentivePlanMember" xml:lang="en-US">2018 Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_itci_TwoThousandEighteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_TwoThousandEighteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SignificantAccountingPoliciesLineItems" xlink:label="loc_itci_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems" xlink:to="lab_itci_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AvailableForSaleSecuritiesMaturityPeriod" xlink:label="loc_itci_AvailableForSaleSecuritiesMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_AvailableForSaleSecuritiesMaturityPeriod" xml:lang="en-US">Available For Sale Securities Maturity Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_AvailableForSaleSecuritiesMaturityPeriod" xml:lang="en-US">Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_AvailableForSaleSecuritiesMaturityPeriod" xlink:to="lab_itci_AvailableForSaleSecuritiesMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_AvailableForSaleSecuritiesMaturityPeriod" xml:lang="en-US">Available For Sale Securities Maturity Period</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets measured using quoted prices</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Available-for-sale investment securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CashAndCashEquivalentMaximumMaturityPeriod" xlink:label="loc_itci_CashAndCashEquivalentMaximumMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CashAndCashEquivalentMaximumMaturityPeriod" xml:lang="en-US">Cash And Cash Equivalent Maximum Maturity Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CashAndCashEquivalentMaximumMaturityPeriod" xml:lang="en-US">Maturity of highly liquid investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CashAndCashEquivalentMaximumMaturityPeriod" xlink:to="lab_itci_CashAndCashEquivalentMaximumMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_CashAndCashEquivalentMaximumMaturityPeriod" xml:lang="en-US">Cash And Cash Equivalent Maximum Maturity Period</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Additional shares of common stock reserved for future equity grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities measured using quoted prices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Carrying value of cash held in money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">US statutory rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax at statutory federal rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment losses recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property and equipment, estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Assumed expected dividend rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ChangeInAccountingEstimateAmount" xlink:label="loc_itci_ChangeInAccountingEstimateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ChangeInAccountingEstimateAmount" xml:lang="en-US">Change In Accounting Estimate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ChangeInAccountingEstimateAmount" xml:lang="en-US">Reveral of accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ChangeInAccountingEstimateAmount" xlink:to="lab_itci_ChangeInAccountingEstimateAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ChangeInAccountingEstimateAmount" xml:lang="en-US">Change in accounting estimate amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Issuance of shares, Inducement Award Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Time based RSU's granted, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Time based RSU's granted, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Milestone RSUs and TSR RSUs granted, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RoyaltyPaymentPercentage" xlink:label="loc_itci_RoyaltyPaymentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_RoyaltyPaymentPercentage" xml:lang="en-US">Royalty Payment Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_RoyaltyPaymentPercentage" xml:lang="en-US">Royalty payment, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_RoyaltyPaymentPercentage" xlink:to="lab_itci_RoyaltyPaymentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_RoyaltyPaymentPercentage" xml:lang="en-US">Royalty Payment Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_GrantReceivable" xlink:label="loc_itci_GrantReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_GrantReceivable" xml:lang="en-US">Grant Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_GrantReceivable" xlink:to="lab_itci_GrantReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_GrantReceivable" xml:lang="en-US">Grant receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Awards granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerOneMember" xlink:label="loc_itci_CustomerOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CustomerOneMember" xml:lang="en-US">Customer One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CustomerOneMember" xml:lang="en-US">Customer one [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CustomerOneMember" xlink:to="lab_itci_CustomerOneMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerTwoMember" xlink:label="loc_itci_CustomerTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CustomerTwoMember" xml:lang="en-US">Customer Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CustomerTwoMember" xml:lang="en-US">Customer two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CustomerTwoMember" xlink:to="lab_itci_CustomerTwoMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerThreeMember" xlink:label="loc_itci_CustomerThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CustomerThreeMember" xml:lang="en-US">Customer Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CustomerThreeMember" xml:lang="en-US">Customer three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CustomerThreeMember" xlink:to="lab_itci_CustomerThreeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AmtTaxCreditMember" xlink:label="loc_itci_AmtTaxCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_AmtTaxCreditMember" xml:lang="en-US">Amt Tax Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_AmtTaxCreditMember" xlink:to="lab_itci_AmtTaxCreditMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ClinicalTralMember" xlink:label="loc_itci_ClinicalTralMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ClinicalTralMember" xml:lang="en-US">Clinical Tral [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ClinicalTralMember" xlink:to="lab_itci_ClinicalTralMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ClinicalTralMember" xml:lang="en-US">Clinical tral [member].</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CaplytaMember" xlink:label="loc_itci_CaplytaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CaplytaMember" xml:lang="en-US">CAPLYTA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CaplytaMember" xlink:to="lab_itci_CaplytaMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_BristolMyersSquibbCompanyMember" xlink:label="loc_itci_BristolMyersSquibbCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_BristolMyersSquibbCompanyMember" xml:lang="en-US">Bristol Myers Squibb Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_BristolMyersSquibbCompanyMember" xml:lang="en-US">Bristol-Myers Squibb Company [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_BristolMyersSquibbCompanyMember" xlink:to="lab_itci_BristolMyersSquibbCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_BristolMyersSquibbCompanyMember" xml:lang="en-US">Bristol Myers Squibb company.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xlink:label="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xlink:to="lab_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">U.S. Government Agency Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Notes/Bonds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">RSUs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_TotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Total Shareholder Return Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_TotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Total Shareholder Return Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_itci_TotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Total Shareholder Return Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember" xlink:to="lab_itci_TotalShareholderReturnRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_TotalShareholderReturnRestrictedStockUnitsMember" xml:lang="en-US">Total shareholder return restricted stock units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Number of anti-dilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" xlink:label="loc_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" xml:lang="en-US">Contractual Maturity More Than One Year And Less Than Two Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" xlink:to="lab_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" xml:lang="en-US">Contractual Maturity More Than One Year And Less Than Two Years [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Aggregate related fair value of investments with unrealized losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Investment securities, held in continuous unrealized loss position for less than 12 months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xml:lang="en-US">Amortized Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Unrealized (Losses)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Work in process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Scientific Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property plant and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xml:lang="en-US">Name of Property [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xml:lang="en-US">Name of Property [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NY" xlink:label="loc_stpr_NY" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_NY" xml:lang="en-US">NEW YORK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_MD" xml:lang="en-US">MARYLAND</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Term of long term lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Net lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total Lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total Lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xml:lang="en-US">Guarantee Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xlink:label="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xml:lang="en-US">Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xml:lang="en-US">Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xlink:to="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xml:lang="en-US">Percentage of minimum net proceeds of capitalized costs in first twelve months.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xlink:label="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xml:lang="en-US">Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xml:lang="en-US">Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xlink:to="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xml:lang="en-US">Percentage of minimum net proceeds of capitalized costs later than twelve months.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RealEstatesLeaseMember" xlink:label="loc_itci_RealEstatesLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_RealEstatesLeaseMember" xml:lang="en-US">Real Estates Lease [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_RealEstatesLeaseMember" xml:lang="en-US">Real Estates Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_RealEstatesLeaseMember" xlink:to="lab_itci_RealEstatesLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_RealEstatesLeaseMember" xml:lang="en-US">Real estates lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Year ending December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Year ending December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Year ending December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: Present value discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Year ending December 31, 2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Year ending December 31, 2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Six</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:to="lab_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xml:lang="en-US">Lessee operating lease liability payments due after year six.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xml:lang="en-US">Year ending December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xml:lang="en-US">Year ending December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xml:lang="en-US">Year ending December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xml:lang="en-US">Year ending December 31, 2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_MilestoneRestrictedStockUnitsMember" xml:lang="en-US">Milestone Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_MilestoneRestrictedStockUnitsMember" xml:lang="en-US">Milestone Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_MilestoneRestrictedStockUnitsMember" xlink:to="lab_itci_MilestoneRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_MilestoneRestrictedStockUnitsMember" xml:lang="en-US">Milestone Restricted Stock Units [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Non-cash stock-based compensation expense recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xml:lang="en-US">Shares of common stock reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized share-based compensation expense, weighted-average recognition period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Unrecognized compensation costs related to unvested RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized share-based compensation expense related to employee stock option awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Options, vesting term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Options, maximum term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xml:lang="en-US">Total instrinsic value of stock units vested,other than options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Total instrinsic value of stock units outstanding options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Total instrinsic value of stock units exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Total instrinsic value of stock units outstanding other than options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Weighted-average risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value of the options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value of stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Total fair value of shares vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US">Terms of award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Total fair value of time based vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Vesting Start Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xml:lang="en-US">Share based compensation arrangement by share based payment award vesting start date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Vesting Start Date</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Vesting End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xml:lang="en-US">Share based compensation arrangement by share based payment award vesting end date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Vesting End Date</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US">&#160;Requisite Service Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InventoriableCostsMember" xlink:label="loc_itci_InventoriableCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_InventoriableCostsMember" xml:lang="en-US">Inventoriable Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_InventoriableCostsMember" xml:lang="en-US">Inventoriable Costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_InventoriableCostsMember" xlink:to="lab_itci_InventoriableCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_InventoriableCostsMember" xml:lang="en-US">InventoriableCostsMember.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected volatility, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected volatility, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at end of period, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at beginning of period, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Vested or expected to vest at end of period, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable at end of period, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at beginning of period, Weighted-Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at end of period, Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Options granted, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Vested or expected to vest at end of period, Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable at end of period, Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term 2</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Options granted, Weighted-Average Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options grants in period weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted, exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted, Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options exercised, Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding at end of period, Weighted-Average Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Options exercised, Weighted-Average Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share-based compensation arrangements by share-based payment award options exercises in period weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Exercisable at end of period, Weighted-Average Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Outstanding at beginning of year, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Outstanding at end of year, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Outstanding at beginning of year, Weighted-Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Outstanding at end of year, Weighted-Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Time based RSU's granted, Weighted-Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options granted average remaining contractual terms.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xlink:label="loc_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xml:lang="en-US">Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xml:lang="en-US">Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xlink:to="lab_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xml:lang="en-US">Share based compensation by share based payment arrangement other than options weighted average contractual term of instruments forfeited.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Time based RSU's cancelled, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Vested or expected to vest, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, number.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xml:lang="en-US">Exercisable, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:to="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Number.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Vested or expected to vest, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding Weighted Average Exercise Price.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable, Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Weighted Average Exercise Price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Time based RSU's cancelled, Weighted-Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options canceled or expired, Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Options canceled or expired, Weighted-Average Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Options canceled or expired, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options forfeited average remaining contractual terms.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Time based RSU's vested, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Time based RSU's vested, Weighted-Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:label="loc_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xml:lang="en-US">hare Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:to="lab_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xlink:to="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options grants in period remaining contractual terms.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IndefinitePeriodCarryForwardMember" xlink:label="loc_itci_IndefinitePeriodCarryForwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_IndefinitePeriodCarryForwardMember" xml:lang="en-US">Indefinite Period Carry Forward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_IndefinitePeriodCarryForwardMember" xml:lang="en-US">Indefinite Period Carry Forward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_IndefinitePeriodCarryForwardMember" xlink:to="lab_itci_IndefinitePeriodCarryForwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_IndefinitePeriodCarryForwardMember" xml:lang="en-US">Indefinite period carry forward.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ExpireIn2037Member" xlink:label="loc_itci_ExpireIn2037Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ExpireIn2037Member" xml:lang="en-US">Expire In 2037 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ExpireIn2037Member" xml:lang="en-US">Expire In 2037 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ExpireIn2037Member" xlink:to="lab_itci_ExpireIn2037Member" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xlink:label="loc_itci_FederalNetOperatingLossCarryForwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xml:lang="en-US">Federal Net Operating Loss Carry Forward Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xml:lang="en-US">Federal net operating loss carryforwards expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xlink:to="lab_itci_FederalNetOperatingLossCarryForwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xml:lang="en-US">Federal net operating loss carry forward expiration period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Federal net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Non-U.S.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">U.S.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in effective state tax rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xml:lang="en-US">Effective Income Tax Rate Reconciliation Other Permanent Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xml:lang="en-US">Other permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="lab_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xml:lang="en-US">Effective income tax rate reconciliation other permanent differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xlink:label="loc_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xml:lang="en-US">DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCapitalLease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xml:lang="en-US">Capital lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xlink:to="lab_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Capital Lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_DeferredTaxAssetsLiabilitiesGross" xlink:label="loc_itci_DeferredTaxAssetsLiabilitiesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_DeferredTaxAssetsLiabilitiesGross" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_itci_DeferredTaxAssetsLiabilitiesGross" xml:lang="en-US">Net deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_DeferredTaxAssetsLiabilitiesGross" xlink:to="lab_itci_DeferredTaxAssetsLiabilitiesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_DeferredTaxAssetsLiabilitiesGross" xml:lang="en-US">Deferred tax assets liabilities gross.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_itci_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_itci_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_DeferredTaxLiabilitiesDepreciation" xlink:to="lab_itci_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred tax liabilities depreciation.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xlink:label="loc_itci_Deferredtaxliabilitiesrightofuseassetcapitallease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAssetCapitalLease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xml:lang="en-US">Right of use asset&#8212;capital lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xlink:to="lab_itci_Deferredtaxliabilitiesrightofuseassetcapitallease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset Capital Lease.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xlink:label="loc_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xml:lang="en-US">DeferredTaxLiabilitiesUnrealizedGainsOnInvestment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xml:lang="en-US">Unrealized gains on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xlink:to="lab_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xml:lang="en-US">Deferred Tax Liabilities Unrealized Gains On Investment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="loc_us-gaap_RegulatoryAgencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RegulatoryAgencyAxis" xml:lang="en-US">Regulatory Agency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegulatoryAgencyAxis" xlink:to="lab_us-gaap_RegulatoryAgencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaap_RegulatoryAgencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RegulatoryAgencyDomain" xml:lang="en-US">Regulatory Agency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegulatoryAgencyDomain" xlink:to="lab_us-gaap_RegulatoryAgencyDomain" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_NationalDemocraticAllianceMember" xlink:label="loc_itci_NationalDemocraticAllianceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_NationalDemocraticAllianceMember" xml:lang="en-US">National Democratic Alliance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_NationalDemocraticAllianceMember" xml:lang="en-US">National Democratic Alliance [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_NationalDemocraticAllianceMember" xlink:to="lab_itci_NationalDemocraticAllianceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_NationalDemocraticAllianceMember" xml:lang="en-US">National Democratic Alliance.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ITCINationalDemocraticAllianceMemberMember" xlink:label="loc_itci_ITCINationalDemocraticAllianceMemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ITCINationalDemocraticAllianceMemberMember" xml:lang="en-US">ITCI National Democratic Alliance Member [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_ITCINationalDemocraticAllianceMemberMember" xml:lang="en-US">ITCI National Democratic Alliance Member [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ITCINationalDemocraticAllianceMemberMember" xlink:to="lab_itci_ITCINationalDemocraticAllianceMemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ITCINationalDemocraticAllianceMemberMember" xml:lang="en-US">ITCI national democratic alliance [member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PaymentOfMilestoneAmount" xlink:label="loc_itci_PaymentOfMilestoneAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_PaymentOfMilestoneAmount" xml:lang="en-US">Payment Of Milestone Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_PaymentOfMilestoneAmount" xml:lang="en-US">Payment of milestone amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_PaymentOfMilestoneAmount" xlink:to="lab_itci_PaymentOfMilestoneAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_PaymentOfMilestoneAmount" xml:lang="en-US">Payment of milestone amount.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeAgreementUpfrontPayments" xlink:label="loc_itci_CollaborativeAgreementUpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CollaborativeAgreementUpfrontPayments" xml:lang="en-US">Collaborative Agreement Upfront Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CollaborativeAgreementUpfrontPayments" xml:lang="en-US">Company made an upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CollaborativeAgreementUpfrontPayments" xlink:to="lab_itci_CollaborativeAgreementUpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_CollaborativeAgreementUpfrontPayments" xml:lang="en-US">Collaborative Agreement Upfront Payments</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementAmountPayable" xlink:label="loc_itci_CollaborativeArrangementAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CollaborativeArrangementAmountPayable" xml:lang="en-US">Collaborative Arrangement Amount Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CollaborativeArrangementAmountPayable" xml:lang="en-US">Obliged to make milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CollaborativeArrangementAmountPayable" xlink:to="lab_itci_CollaborativeArrangementAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_CollaborativeArrangementAmountPayable" xml:lang="en-US">Collaborative arrangement amount payable.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementLicenseExpirationDescription" xlink:label="loc_itci_CollaborativeArrangementLicenseExpirationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CollaborativeArrangementLicenseExpirationDescription" xml:lang="en-US">Collaborative Arrangement License Expiration Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CollaborativeArrangementLicenseExpirationDescription" xml:lang="en-US">License expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CollaborativeArrangementLicenseExpirationDescription" xlink:to="lab_itci_CollaborativeArrangementLicenseExpirationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_CollaborativeArrangementLicenseExpirationDescription" xml:lang="en-US">Collaborative arrangement license expiration description.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementMilestonePayments" xlink:label="loc_itci_CollaborativeArrangementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CollaborativeArrangementMilestonePayments" xml:lang="en-US">Collaborative Arrangement Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CollaborativeArrangementMilestonePayments" xml:lang="en-US">Company made milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CollaborativeArrangementMilestonePayments" xlink:to="lab_itci_CollaborativeArrangementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_CollaborativeArrangementMilestonePayments" xml:lang="en-US">Collaborative Arrangement Milestone Payments</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xlink:label="loc_itci_CollaborativeArrangementRemainingPotentialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xml:lang="en-US">Collaborative Arrangement Remaining Potential Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xml:lang="en-US">Company remaining milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xlink:to="lab_itci_CollaborativeArrangementRemainingPotentialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xml:lang="en-US">Collaborative arrangement remaining potential milestone payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Employer matching contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Contributions made by participants for which the company makes matching contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Contribution expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of product sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="loc_us-gaap_PurchaseCommitmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentMember" xml:lang="en-US">Purchase Commitment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PurchaseCommitmentMember" xml:lang="en-US">Purchase Commitment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentMember" xlink:to="lab_us-gaap_PurchaseCommitmentMember" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentAxis" xlink:label="loc_itci_ResearchAndOtherCommitmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ResearchAndOtherCommitmentAxis" xml:lang="en-US">Research and Other Commitment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ResearchAndOtherCommitmentAxis" xlink:to="lab_itci_ResearchAndOtherCommitmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ResearchAndOtherCommitmentAxis" xml:lang="en-US">Research and other commitment.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentDomain" xlink:label="loc_itci_ResearchAndOtherCommitmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_ResearchAndOtherCommitmentDomain" xml:lang="en-US">Research and Other Commitment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_ResearchAndOtherCommitmentDomain" xlink:to="lab_itci_ResearchAndOtherCommitmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_ResearchAndOtherCommitmentDomain" xml:lang="en-US">Research and other commitment.</label>
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SiegfriedCampaignAndLonzaCampaignMember" xlink:label="loc_itci_SiegfriedCampaignAndLonzaCampaignMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_itci_SiegfriedCampaignAndLonzaCampaignMember" xml:lang="en-US">Siegfried Campaign and Lonza Campaign [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_itci_SiegfriedCampaignAndLonzaCampaignMember" xlink:to="lab_itci_SiegfriedCampaignAndLonzaCampaignMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_itci_SiegfriedCampaignAndLonzaCampaignMember" xml:lang="en-US">Siegfried campaign and lonza campaign.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenue, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>itci-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-March-2022 [08:21:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#CoverPage" roleURI="http://www.intracellulartherapies.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#Organization" roleURI="http://www.intracellulartherapies.com/role/Organization" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecurities" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecurities" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#Inventory" roleURI="http://www.intracellulartherapies.com/role/Inventory" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipment" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilities" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensation" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxes" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#CommitmentsAndContingencies" roleURI="http://www.intracellulartherapies.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RelatedParties" roleURI="http://www.intracellulartherapies.com/role/RelatedParties" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SubsequentEvents" roleURI="http://www.intracellulartherapies.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#UnauditedQuarterlyFinancialInformation" roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecuritiesTables" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InventoryTables" roleURI="http://www.intracellulartherapies.com/role/InventoryTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentTables" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesTables" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationTables" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesTables" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#UnauditedQuarterlyFinancialInformationTables" roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#OrganizationAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" roleURI="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecuritiesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail" roleURI="http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#InventoryScheduleOfInventoryCurrentDetail" roleURI="http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentPropertyAndEquipmentDetail" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#PropertyAndEquipmentAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail" roleURI="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationStockOptionsActivityDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" roleURI="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesTotalIncomeTaxExpenseDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="itci-20211231.xsd#UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail" roleURI="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_500128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_500128" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_462938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_462938" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_500127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_500127" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_500126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_500126" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_462939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentAnnualReport_462939" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_500130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_500130" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_462940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentTransitionReport_462940" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_500129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_500129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_585525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_585525" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_585527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityVoluntaryFilers_585527" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_462969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_462969" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_462937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_462937" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_462932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_462932" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_462920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_462920" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_462922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_462922" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_462921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_462921" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_462963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_462963" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_462966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_462966" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_462961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_462961" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_462936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFileNumber_462936" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_462935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityTaxIdentificationNumber_462935" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_462934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityIncorporationStateCountryCode_462934" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_462924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressAddressLine1_462924" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_462925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressCityOrTown_462925" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_462926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_462926" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_462928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressPostalZipCode_462928" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_462929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CityAreaCode_462929" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_462930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_LocalPhoneNumber_462930" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_462931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_462931" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_462933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_462933" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_462962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_462962" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_586450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityPublicFloat_586450" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_828523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_IcfrAuditorAttestationFlag_828523" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1310243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AuditorName_1310243" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1310244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AuditorFirmId_1310244" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1310246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AuditorLocation_1310246" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22" xlink:to="loc_us-gaap_AssetsAbstract_23" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_33" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_826518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_RestrictedCashCurrent_826518" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_826519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_826519" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_826520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_InventoryNet_826520" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_34" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AssetsCurrent_35" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_28" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_396040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_396040" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_Assets_31" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_39" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_40" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AccruedCustomerProgramsCurrent" xlink:label="loc_itci_AccruedCustomerProgramsCurrent_1309099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_itci_AccruedCustomerProgramsCurrent_1309099" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_396041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_396041" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_41" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_42" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_396052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_396052" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_Liabilities_37" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_27" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_CommonStockValue_43" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_44" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquity_47" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_50" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_51" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49" xlink:to="loc_us-gaap_CommonStockSharesIssued_52" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_53" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_827746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_55" xlink:to="loc_us-gaap_StatementTable_827746" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_827747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827746" xlink:to="loc_us-gaap_StatementClassOfStockAxis_827747" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_827748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_827747" xlink:to="loc_us-gaap_ClassOfStockDomain_827748" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_827750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827746" xlink:to="loc_srt_ProductOrServiceAxis_827750" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_827751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_827750" xlink:to="loc_srt_ProductsAndServicesDomain_827751" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_827752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_827751" xlink:to="loc_us-gaap_ProductMember_827752" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_827753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_827751" xlink:to="loc_us-gaap_GrantMember_827753" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827746" xlink:to="loc_us-gaap_StatementLineItems_827749" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_56" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Costofproductsales" xlink:label="loc_itci_Costofproductsales_826553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_itci_Costofproductsales_826553" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_59" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_60" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_56" xlink:to="loc_us-gaap_OperatingExpenses_61" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_OperatingIncomeLoss_64" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_InvestmentIncomeInterest_65" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_NetIncomeLoss_69" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_EarningsPerShareAbstract_57" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_62" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827749" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_58" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_58" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_70" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_72" xlink:to="loc_us-gaap_NetIncomeLoss_75" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_74" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_72" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_76" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_78" xlink:to="loc_us-gaap_StatementTable_83" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81" xlink:to="loc_us-gaap_EquityComponentDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_CommonStockMember_85" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_86" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_RetainedEarningsMember_87" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_88" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_83" xlink:to="loc_us-gaap_StatementLineItems_82" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockholdersEquity_90" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_SharesOutstanding_92" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_91" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_99" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_100" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_101" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_102" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_NetIncomeLoss_105" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_106" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_StockholdersEquity_107" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82" xlink:to="loc_us-gaap_SharesOutstanding_108" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_110" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_827759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_110" xlink:to="loc_us-gaap_StatementTable_827759" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827759" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_827765" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_827768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" xlink:to="loc_itci_VehicleFleetLeaseMember_827768" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RealEstateLeaseMember" xlink:label="loc_itci_RealEstateLeaseMember_827771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_827766" xlink:to="loc_itci_RealEstateLeaseMember_827771" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_827760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827759" xlink:to="loc_us-gaap_StatementClassOfStockAxis_827760" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_827761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_827760" xlink:to="loc_us-gaap_ClassOfStockDomain_827761" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_827762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827759" xlink:to="loc_us-gaap_StatementLineItems_827762" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_ProfitLoss_136" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_Depreciation_116" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_ShareBasedCompensation_117" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_118" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_111" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_119" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_120" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_827754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_827754" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_121" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_122" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_123" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_124" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent" xlink:label="loc_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent_613747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_112" xlink:to="loc_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent_613747" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_115" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_137" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_132" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_133" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_134" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_114" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_135" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_128" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_129" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_113" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_131" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_138" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_139" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_140" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_IncomeTaxesPaid_142" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_828893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_827762" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_828893" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_420844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_828893" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_420844" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_828422" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_828438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_828422" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_828438" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_828439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_828422" xlink:to="loc_us-gaap_RestrictedCashCurrent_828439" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_828440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_828422" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_828440" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/Organization">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_542" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_544" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_544" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_545" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InvestmentSecurities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1309210" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock_1309211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1309210" xlink:to="loc_us-gaap_InvestmentTextBlock_1309211" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/Inventory">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_828727" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_828730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_828727" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_828730" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_569" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_569" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_570" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_396299" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_396300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_396299" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_396300" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_575" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_575" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_576" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_593" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_594" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_606" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_606" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_607" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RelatedParties">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_615" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_615" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_616" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1309258" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1309260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1309258" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1309260" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_618" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_618" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_619" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_547" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_548" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_UseOfEstimates_549" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_550" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_551" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_552" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_553" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_826640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_826640" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_555" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_554" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_826641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_826641" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_556" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1309174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1309174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_826642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_826642" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_826644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_826644" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_557" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_837354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_837354" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_558" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_559" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_560" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_561" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_547" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_562" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_564" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_564" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_564" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1309219" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1309220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1309219" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1309220" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InventoryTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_828736" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_828738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_828736" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_828738" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_572" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_572" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_573" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_419331" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_826657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_419331" xlink:to="loc_us-gaap_StatementTable_826657" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_826658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_826657" xlink:to="loc_us-gaap_LeaseContractualTermAxis_826658" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826658" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826659" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_826665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826659" xlink:to="loc_itci_VehicleFleetLeaseMember_826665" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ItciRealEstatesLeaseMember" xlink:label="loc_itci_ItciRealEstatesLeaseMember_1309259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826659" xlink:to="loc_itci_ItciRealEstatesLeaseMember_1309259" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_826739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_826657" xlink:to="loc_us-gaap_StatementLineItems_826739" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_419338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826739" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_419338" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock" xlink:label="loc_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock_826775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826739" xlink:to="loc_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock_826775" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_578" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_578" xlink:to="loc_us-gaap_StatementTable_582" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_582" xlink:to="loc_us-gaap_AwardTypeAxis_579" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TimeBasedRestrictedStockUnitsRSUMember" xlink:label="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" xlink:to="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" xlink:to="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_827265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_580" xlink:to="loc_itci_InducementAwardPlanMember_827265" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_582" xlink:to="loc_us-gaap_StatementLineItems_581" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_585" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_586" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_587" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_581" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_588" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_596" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_596" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_597" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_596" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_598" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_596" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_596" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_621" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_621" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_622" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_144" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_144" xlink:to="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_srt_RangeAxis_153" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_153" xlink:to="loc_srt_RangeMember_154" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_154" xlink:to="loc_srt_MaximumMember_169" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_srt_ConsolidatedEntitiesAxis_145" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_145" xlink:to="loc_srt_ConsolidatedEntitiesDomain_146" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_147" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_148" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_149" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_150" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_156" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_156" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_155" xlink:to="loc_us-gaap_IPOMember_171" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_472647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_srt_StatementScenarioAxis_472647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_472648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_472647" xlink:to="loc_srt_ScenarioUnspecifiedDomain_472648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_513653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_513653" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_513654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_513653" xlink:to="loc_us-gaap_EquityComponentDomain_513654" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_513655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_513654" xlink:to="loc_us-gaap_CommonStockMember_513655" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_586483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_586483" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_586484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_586483" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_586484" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_586485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_586484" xlink:to="loc_us-gaap_SubsequentEventMember_586485" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_152" xlink:to="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_161" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_SharePrice_162" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_163" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_164" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SecuritiesAuthorizedAmountForIssuance" xlink:label="loc_itci_SecuritiesAuthorizedAmountForIssuance_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_itci_SecuritiesAuthorizedAmountForIssuance_165" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_826621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_826621" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_826622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_151" xlink:to="loc_us-gaap_CommonStockSharesIssued_826622" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_174" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SignificantAccountingPoliciesTable" xlink:label="loc_itci_SignificantAccountingPoliciesTable_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_174" xlink:to="loc_itci_SignificantAccountingPoliciesTable_189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_RangeAxis_185" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_185" xlink:to="loc_srt_RangeMember_186" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_186" xlink:to="loc_srt_MinimumMember_197" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_186" xlink:to="loc_srt_MaximumMember_198" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_AwardTypeAxis_176" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_613526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" xlink:to="loc_itci_InducementAwardPlanMember_613526" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PerformanceBasedRestrictedStockUnitsMember" xlink:label="loc_itci_PerformanceBasedRestrictedStockUnitsMember_827739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_187" xlink:to="loc_itci_PerformanceBasedRestrictedStockUnitsMember_827739" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_PlanNameAxis_183" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_183" xlink:to="loc_us-gaap_PlanNameDomain_184" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_184" xlink:to="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_196" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Axis" xlink:label="loc_itci_Investment1Axis_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_itci_Investment1Axis_181" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Investment1Domain" xlink:label="loc_itci_Investment1Domain_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_Investment1Axis_181" xlink:to="loc_itci_Investment1Domain_182" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_175" xlink:to="loc_us-gaap_TypeOfAdoptionMember_192" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_179" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_180" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_194" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_177" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_177" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_178" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_190" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_190" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_191" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_613892" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ClinicalTralMember" xlink:label="loc_itci_ClinicalTralMember_613895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_613893" xlink:to="loc_itci_ClinicalTralMember_613895" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_827669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_MajorCustomersAxis_827669" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_827670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_827669" xlink:to="loc_srt_NameOfMajorCustomerDomain_827670" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerOneMember" xlink:label="loc_itci_CustomerOneMember_827671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_827670" xlink:to="loc_itci_CustomerOneMember_827671" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerTwoMember" xlink:label="loc_itci_CustomerTwoMember_827672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_827670" xlink:to="loc_itci_CustomerTwoMember_827672" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CustomerThreeMember" xlink:label="loc_itci_CustomerThreeMember_827673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_827670" xlink:to="loc_itci_CustomerThreeMember_827673" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_827674" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_827676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_827675" xlink:to="loc_us-gaap_AccountsReceivableMember_827676" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_827683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_827682" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_827683" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_827684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_827683" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_827684" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_827692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_ProductOrServiceAxis_827692" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_827693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_827692" xlink:to="loc_srt_ProductsAndServicesDomain_827693" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_827695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_827693" xlink:to="loc_us-gaap_ProductMember_827695" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CaplytaMember" xlink:label="loc_itci_CaplytaMember_837571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_827693" xlink:to="loc_itci_CaplytaMember_837571" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_827697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_srt_CounterpartyNameAxis_827697" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_827697" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_BristolMyersSquibbCompanyMember" xlink:label="loc_itci_BristolMyersSquibbCompanyMember_827699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_827698" xlink:to="loc_itci_BristolMyersSquibbCompanyMember_827699" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_827714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_827714" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_827714" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AmtTaxCreditMember" xlink:label="loc_itci_AmtTaxCreditMember_827717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_827716" xlink:to="loc_itci_AmtTaxCreditMember_827717" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SignificantAccountingPoliciesLineItems" xlink:label="loc_itci_SignificantAccountingPoliciesLineItems_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesTable_189" xlink:to="loc_itci_SignificantAccountingPoliciesLineItems_188" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_NumberOfOperatingSegments_200" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CashAndCashEquivalentMaximumMaturityPeriod" xlink:label="loc_itci_CashAndCashEquivalentMaximumMaturityPeriod_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_CashAndCashEquivalentMaximumMaturityPeriod_201" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_AvailableForSaleSecuritiesMaturityPeriod" xlink:label="loc_itci_AvailableForSaleSecuritiesMaturityPeriod_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_AvailableForSaleSecuritiesMaturityPeriod_202" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_209" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_210" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_211" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_214" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_215" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_218" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_220" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_221" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_225" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_613515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_613515" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ChangeInAccountingEstimateAmount" xlink:label="loc_itci_ChangeInAccountingEstimateAmount_613888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_ChangeInAccountingEstimateAmount_613888" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_827667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_827667" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RoyaltyPaymentPercentage" xlink:label="loc_itci_RoyaltyPaymentPercentage_827691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_RoyaltyPaymentPercentage_827691" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_827711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_827711" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_827737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_827737" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_837566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_AdvertisingExpense_837566" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_1309240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_AccountsReceivableNet_1309240" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_GrantReceivable" xlink:label="loc_itci_GrantReceivable_1309242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_itci_GrantReceivable_1309242" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1310006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_SignificantAccountingPoliciesLineItems_188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1310006" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_258" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_258" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_260" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_268" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_269" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_261" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_262" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_262" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_267" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_us-gaap_InvestmentTypeAxis_265" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_265" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_266" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_MoneyMarketFundsMember_271" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_272" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_CertificatesOfDepositMember_274" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_CommercialPaperMember_275" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_266" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_276" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems" xlink:label="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_259" xlink:to="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems_264" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems_264" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_270" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_278" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_278" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" xlink:to="loc_us-gaap_EmployeeStockOptionMember_284" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_285" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_281" xlink:to="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_286" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_280" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_280" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1309224" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1309224" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1309229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" xlink:to="loc_us-gaap_InvestmentTypeAxis_1309229" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1309229" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember" xlink:label="loc_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember_1309231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember_1309231" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309233" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_1309237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_us-gaap_CommercialPaperMember_1309237" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1309238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309232" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1309238" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309225" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1309251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1309251" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1309254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1309254" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1309332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1309332" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_1310015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309241" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_1310015" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1309265" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1309265" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1309271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" xlink:to="loc_us-gaap_InvestmentTypeAxis_1309271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1309271" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1309273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1309276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1309276" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_1309277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_CommercialPaperMember_1309277" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1309278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1309272" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1309278" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1309267" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1309281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_1309281" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1309282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1309282" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1309284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1309284" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1309279" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1309287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_828745" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_828746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_828745" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_828746" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_828754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_828745" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_828754" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_828749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_828745" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_828749" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_828750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_828745" xlink:to="loc_us-gaap_InventoryNet_828750" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_288" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_288" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_ComputerEquipmentMember_296" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_297" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_EquipmentMember_298" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_291" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_299" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_293" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_294" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_295" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_301" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_301" xlink:to="loc_us-gaap_Depreciation_302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_419454" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_419456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_419454" xlink:to="loc_us-gaap_StatementTable_419456" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_419460" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NY" xlink:label="loc_stpr_NY_419462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" xlink:to="loc_stpr_NY_419462" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD_419463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_419461" xlink:to="loc_stpr_MD_419463" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_419457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_StatementClassOfStockAxis_419457" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_419458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_419457" xlink:to="loc_us-gaap_ClassOfStockDomain_419458" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_513065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_srt_StatementScenarioAxis_513065" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_513066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_513065" xlink:to="loc_srt_ScenarioUnspecifiedDomain_513066" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_513069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_513068" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_513069" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_419472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_419471" xlink:to="loc_us-gaap_TypeOfAdoptionMember_419472" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_827152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_LeaseContractualTermAxis_827152" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_827154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_827152" xlink:to="loc_us-gaap_LeaseContractualTermDomain_827154" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_827155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_827154" xlink:to="loc_itci_VehicleFleetLeaseMember_827155" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_829049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_829048" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_829049" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_419459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_419456" xlink:to="loc_us-gaap_StatementLineItems_419459" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_419475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_419475" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_419477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_OperatingLeaseLiability_419477" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_419481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_419481" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_419715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_OperatingLeaseExpense_419715" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_829046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_829046" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_829051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_us-gaap_RestrictedCash_829051" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths" xlink:label="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths_829054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths_829054" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths" xlink:label="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths_829056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_419459" xlink:to="loc_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths_829056" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_419418" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_826857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_419418" xlink:to="loc_us-gaap_StatementTable_826857" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_826863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_826857" xlink:to="loc_us-gaap_LeaseContractualTermAxis_826863" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826863" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826864" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RealEstatesLeaseMember" xlink:label="loc_itci_RealEstatesLeaseMember_826865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826864" xlink:to="loc_itci_RealEstatesLeaseMember_826865" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_826866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_826857" xlink:to="loc_us-gaap_StatementLineItems_826866" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_419421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_419421" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_419423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_419423" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_419424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_419424" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_419428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_419428" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_419430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_419430" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_1309305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_1309305" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_419431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_419431" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_419434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_419434" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_419437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_OperatingLeaseLiability_419437" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_420850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_420850" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_420851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826866" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_420851" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_826971" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_826972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_826971" xlink:to="loc_us-gaap_StatementTable_826972" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_826973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_826972" xlink:to="loc_us-gaap_LeaseContractualTermAxis_826973" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_826974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_826973" xlink:to="loc_us-gaap_LeaseContractualTermDomain_826974" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_826975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826974" xlink:to="loc_itci_VehicleFleetLeaseMember_826975" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ItciRealEstatesLeaseMember" xlink:label="loc_itci_ItciRealEstatesLeaseMember_1309248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_826974" xlink:to="loc_itci_ItciRealEstatesLeaseMember_1309248" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_826972" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_826987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_826987" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_826989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_826989" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_826993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_826993" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_826995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseLiability_826995" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_826998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_826998" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_827000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_827000" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1309243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_OperatingLeaseCost_1309243" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_1309244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_826976" xlink:to="loc_us-gaap_VariableLeaseCost_1309244" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_827060" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_827062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_827060" xlink:to="loc_us-gaap_StatementTable_827062" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_827063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827062" xlink:to="loc_us-gaap_LeaseContractualTermAxis_827063" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_827065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_827063" xlink:to="loc_us-gaap_LeaseContractualTermDomain_827065" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_VehicleFleetLeaseMember" xlink:label="loc_itci_VehicleFleetLeaseMember_827069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_827065" xlink:to="loc_itci_VehicleFleetLeaseMember_827069" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_827062" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_827089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_827089" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_827090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_827090" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_827093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_827093" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_1309274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_1309274" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_1309275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_1309275" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_827097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_827097" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_827098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_827098" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_827099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_OperatingLeaseLiability_827099" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_827101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_827101" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_827103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_827072" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_827103" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_304" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_304" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_us-gaap_AwardTypeAxis_305" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TimeBasedRestrictedStockUnitsRSUMember" xlink:label="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_TimeBasedRestrictedStockUnitsRSUMember_336" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_337" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneRestrictedStockUnitsMember_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_MilestoneRestrictedStockUnitsMember_338" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_us-gaap_EmployeeStockOptionMember_339" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_585659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_InducementAwardPlanMember_585659" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_613691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_TotalShareholderReturnRestrictedStockUnitsMember_613691" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_613693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_312" xlink:to="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_613693" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_us-gaap_PlanNameAxis_306" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_306" xlink:to="loc_us-gaap_PlanNameDomain_307" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_307" xlink:to="loc_itci_TwoThousandEighteenEquityIncentivePlanMember_315" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_srt_RangeAxis_308" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_308" xlink:to="loc_srt_RangeMember_309" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_309" xlink:to="loc_srt_MinimumMember_316" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_309" xlink:to="loc_srt_MaximumMember_317" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_srt_TitleOfIndividualAxis_313" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_313" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_314" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_318" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_319" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_585658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_585658" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_321" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_322" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_323" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_326" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_327" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_328" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_329" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_330" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_334" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_613621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_613621" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_613646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_613646" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_613670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_613670" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_613673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_613673" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_623223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_623223" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate_1310128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate_1310128" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate_1310130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate_1310130" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1309375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_311" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1309375" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_342" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_342" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_344" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_344" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InventoriableCostsMember" xlink:label="loc_itci_InventoriableCostsMember_828780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345" xlink:to="loc_itci_InventoriableCostsMember_828780" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_348" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_346" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_343" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_343" xlink:to="loc_us-gaap_ShareBasedCompensation_347" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_351" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_352" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_353" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_354" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_355" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_356" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830022" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830022" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" xlink:to="loc_us-gaap_AwardTypeAxis_830024" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_830024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_830026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830025" xlink:to="loc_itci_InducementAwardPlanMember_830026" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830031" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_830032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_830032" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_830033" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830035" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_830038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_830038" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830041" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830043" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_830045" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_830046" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830049" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830053" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_830054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_830054" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2_830055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2_830055" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_830056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_830056" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_1309292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_1309292" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1309298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830030" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1309298" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830064" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_830064" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_830066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" xlink:to="loc_us-gaap_AwardTypeAxis_830066" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_830066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_InducementAwardPlanMember" xlink:label="loc_itci_InducementAwardPlanMember_830069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_830067" xlink:to="loc_itci_InducementAwardPlanMember_830069" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_830065" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830071" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_830072" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_830075" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_830078" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_830085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_830085" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_830087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_830087" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830089" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_830092" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_830095" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_830098" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_830100" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_830101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_830101" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_830103" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_830104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_830104" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited" xlink:label="loc_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited_830108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830070" xlink:to="loc_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited_830108" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_360" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_361" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_362" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_363" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_364" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_365" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_366" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_367" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_368" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_369" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_370" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_371" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_372" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2_375" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm_376" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm_377" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_378" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_358" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_379" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_381" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_381" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xlink:to="loc_us-gaap_AwardTypeAxis_382" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_382" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_396" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_386" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_387" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_388" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_389" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_390" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_391" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_392" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_393" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_394" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_395" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613700" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_613701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms_613701" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_613715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_613715" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms_613716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms_613716" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_AwardTypeAxis_399" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_399" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember" xlink:label="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember_413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_403" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_404" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_405" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_407" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_408" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_585647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_585647" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_410" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_412" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_613830" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms" xlink:label="loc_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_1309340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms_1309340" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms" xlink:label="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms_1309341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms_1309341" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_432" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_613750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_432" xlink:to="loc_us-gaap_StatementTable_613750" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_613751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_613750" xlink:to="loc_us-gaap_TaxPeriodAxis_613751" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_613752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_613751" xlink:to="loc_us-gaap_TaxPeriodDomain_613752" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_IndefinitePeriodCarryForwardMember" xlink:label="loc_itci_IndefinitePeriodCarryForwardMember_613782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_613752" xlink:to="loc_itci_IndefinitePeriodCarryForwardMember_613782" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ExpireIn2037Member" xlink:label="loc_itci_ExpireIn2037Member_613886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_613752" xlink:to="loc_itci_ExpireIn2037Member_613886" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_613753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_613750" xlink:to="loc_us-gaap_StatementLineItems_613753" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_us-gaap_OperatingLossCarryforwards_435" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_FederalNetOperatingLossCarryForwardExpirationPeriod" xlink:label="loc_itci_FederalNetOperatingLossCarryForwardExpirationPeriod_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_itci_FederalNetOperatingLossCarryForwardExpirationPeriod_436" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_613753" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_439" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_441" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_441" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_442" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_441" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_443" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_441" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_444" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_446" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_446" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_446" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_448" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_446" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_449" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_446" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_450" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_452" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_453" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_455" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_456" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_459" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_460" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_461" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_452" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_462" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_464" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_464" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_467" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_468" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_469" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_470" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1309160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1309160" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease" xlink:label="loc_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease_585576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_465" xlink:to="loc_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease_585576" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_464" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxliabilitiesrightofuseassetcapitallease" xlink:label="loc_itci_Deferredtaxliabilitiesrightofuseassetcapitallease_585580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" xlink:to="loc_itci_Deferredtaxliabilitiesrightofuseassetcapitallease_585580" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_Deferredtaxliabilitiesunrealizedgainsoninvestment" xlink:label="loc_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment_585585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" xlink:to="loc_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment_585585" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_itci_DeferredTaxLiabilitiesDepreciation_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" xlink:to="loc_itci_DeferredTaxLiabilitiesDepreciation_475" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_DeferredTaxAssetsLiabilitiesGross" xlink:label="loc_itci_DeferredTaxAssetsLiabilitiesGross_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" xlink:to="loc_itci_DeferredTaxAssetsLiabilitiesGross_476" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_477" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_466" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_478" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_486" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_486" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_srt_ProductOrServiceAxis_496" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_501126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_496" xlink:to="loc_srt_ProductsAndServicesDomain_501126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_613683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_501126" xlink:to="loc_us-gaap_ProductMember_613683" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_srt_CounterpartyNameAxis_488" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_488" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_BristolMyersSquibbCompanyMember" xlink:label="loc_itci_BristolMyersSquibbCompanyMember_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_493" xlink:to="loc_itci_BristolMyersSquibbCompanyMember_501" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="loc_us-gaap_RegulatoryAgencyAxis_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_RegulatoryAgencyAxis_491" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="loc_us-gaap_RegulatoryAgencyDomain_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegulatoryAgencyAxis_491" xlink:to="loc_us-gaap_RegulatoryAgencyDomain_492" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_NationalDemocraticAllianceMember" xlink:label="loc_itci_NationalDemocraticAllianceMember_501066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegulatoryAgencyDomain_492" xlink:to="loc_itci_NationalDemocraticAllianceMember_501066" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ITCINationalDemocraticAllianceMemberMember" xlink:label="loc_itci_ITCINationalDemocraticAllianceMemberMember_614045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegulatoryAgencyDomain_492" xlink:to="loc_itci_ITCINationalDemocraticAllianceMemberMember_614045" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_srt_RangeAxis_489" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_489" xlink:to="loc_srt_RangeMember_490" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_490" xlink:to="loc_srt_MinimumMember_498" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_490" xlink:to="loc_srt_MaximumMember_499" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_613657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_613657" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_613658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_613657" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_613658" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_828944" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentMember" xlink:label="loc_us-gaap_PurchaseCommitmentMember_828946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_828945" xlink:to="loc_us-gaap_PurchaseCommitmentMember_828946" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentAxis" xlink:label="loc_itci_ResearchAndOtherCommitmentAxis_1309234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_itci_ResearchAndOtherCommitmentAxis_1309234" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_ResearchAndOtherCommitmentDomain" xlink:label="loc_itci_ResearchAndOtherCommitmentDomain_1309235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_ResearchAndOtherCommitmentAxis_1309234" xlink:to="loc_itci_ResearchAndOtherCommitmentDomain_1309235" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_SiegfriedCampaignAndLonzaCampaignMember" xlink:label="loc_itci_SiegfriedCampaignAndLonzaCampaignMember_1309236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_itci_ResearchAndOtherCommitmentDomain_1309235" xlink:to="loc_itci_SiegfriedCampaignAndLonzaCampaignMember_1309236" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_495" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeAgreementUpfrontPayments" xlink:label="loc_itci_CollaborativeAgreementUpfrontPayments_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeAgreementUpfrontPayments_502" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementMilestonePayments" xlink:label="loc_itci_CollaborativeArrangementMilestonePayments_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementMilestonePayments_503" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementAmountPayable" xlink:label="loc_itci_CollaborativeArrangementAmountPayable_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementAmountPayable_504" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementRemainingPotentialMilestonePayments" xlink:label="loc_itci_CollaborativeArrangementRemainingPotentialMilestonePayments_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementRemainingPotentialMilestonePayments_505" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_RoyaltyPaymentPercentage" xlink:label="loc_itci_RoyaltyPaymentPercentage_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_RoyaltyPaymentPercentage_506" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_CollaborativeArrangementLicenseExpirationDescription" xlink:label="loc_itci_CollaborativeArrangementLicenseExpirationDescription_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_CollaborativeArrangementLicenseExpirationDescription_507" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="itci-20211231.xsd#itci_PaymentOfMilestoneAmount" xlink:label="loc_itci_PaymentOfMilestoneAmount_613655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_itci_PaymentOfMilestoneAmount_613655" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_828927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_CostOfRevenue_828927" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_828929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_828929" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_828930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_828930" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_828931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_828931" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_828943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_494" xlink:to="loc_us-gaap_Cash_828943" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" xlink:to="loc_us-gaap_Revenues_537" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_828744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" xlink:to="loc_us-gaap_OperatingExpenses_828744" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_828747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" xlink:to="loc_us-gaap_InvestmentIncomeInterest_828747" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_828742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_828742" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" xlink:to="loc_us-gaap_NetIncomeLoss_538" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_536" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_539" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g234590g00d00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234590g00d00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &$2^8A(X0DE-! 0      "\< @   @  ' )0  AR<C,U.3 Y,QP"!0 6
M36EC<F]S;V9T(%=O<F0@+2!)3E1200 X0DE-!"4      !#N)-0A),:1M(6;
MV4K A3V-.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F
M   .             #^    X0DE-! T       0   !:.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      -#
M!@             #5P  !S8    ' $D 3@!4 %( 00 M #$    !
M                  $             !S8   -7
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   -7     %)G:'1L;VYG   '
M-@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #5P    !29VAT;&]N9P  !S8    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     #>8
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M_P#-1[_]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MX?$S1%1B976$A96GQL<I271VI;=SAJ;_Q  = 0$  @,! 0$!
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M=BXC\.U5K+O9JW(H-(.[0&/9!P@R?OD26BR1D?-1[5$[)LN5RT2B))"2DY-
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M"&%Q"<J'" 9CJ8#:&T-%+_M:B^5#0F&0A_>?<6]*MST&4XO=PZXXZ\^F4$I
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MWMN/P";Z*_ZNG?ZQ^6+7Z?%];3W4?#3Z06%/6E1_IS3O;<?@$WT5_P!73O\
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M_4]\+>.<^#UY'2F!S_[_ %8!ZM?GIWBO8_F>Y^@2O5?HI[F_B+]'[./JEO\
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M2OT^U:<J>YOXB_1^SCZI;_\ R?TZ?;_*$+3^^V-.?_/[<=G6//3O%>_)%S]
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M]:XVUQR+NOFF8 K]JZ=QB2#A/QHW$$CF$!,( &MT1Y42? GH 4J"^\\&SH'
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MF-O;G2([S&_C>W \VILJW<C.[O9QD9QSKSYD_H?Q I2E]U0X'E*4O[#Z/78
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M'<?3^4"ARQBW#X_APY'E\^E/@_J [_U4[CU/H_P_=&Z]-1X>GR6GX^EGZO\
M;%/8?3^4"_HT?7J?!_4-O[*=QO\ YGT=OR>V-_KU/AZ?)2?-[K5IIC3VC[?%
M3V'D>7U<L?@P<O3O-3X/ZAZ4[CU/H_6-IX?'R6,=G2SC_-_B^:GL/I_*!7//
MX-'/K/W]S\_74_!_4/2G<^I]'ZQM/#T^2D\\CW6=#V_P'/\ K-/8?'+O^K!&
MOO: ?\]_;4?!_6^VWNIW'S>T^CMV[]GMC?/^/^&/#W_JI/Q=+/J*>P^G\H%?
M1HY<OAW9I0?Z'];^E.X^7?#Z([__ #%#3P]/DL>EGYOO?KQ\?GJ?8?3G_A O
MX^]HSGK_ );R^4]=/@_K?TIW'J?1^L7YOR?D>'I\ECTL_5ZCV'T^7U8_P:/D
M_EWG/V-/@_K?TIW'D_M/H_6-\VWF^74^'I'*U@=F)9TR<G'N?K.<_&:#N/I\
MOK^2W#EV??OQ4^#^H>E.X]3Z/9ZQM1X>GR6GTL_5\4]A]/Y0*^C1Y_[^\Y^<
MT^#^M^SW4[C;S>T^C^/^V-M_!J?#TZCO6G7^^SUZ_B/UU/L/IZ]H%D=8[VCS
M_P!_'K)^<GXWP?U#TIW'J?1^L;3P]/DM.O\ ?9^K_; \^8]A]/Y0*^C1\O\
M+J?!_4/2G<>I]'ZQM/#X^2D^EJ]13V'D>7U?1H^O4^#^H>E.X]3Z/UC:>'I\
MEI]+/U>GL/(\OJ^C1]>I\']0]*=QZGT?K&T\/3Y+3\72SZCY:>P\CR^KZ-'U
MZGP?U#TIW'J?1^L;4>'I\EI]+/U?Y/BI[#R/+ZOHT?7J?!_4/2G<>I]'ZQM3
MX>GR6D?Y6?VL4]AY'E]7T8/KU/@_J'I3N/4^C]8VGA\?)2?2U>HI[#R/+ZOH
MT?7J?!_4/2G<>I]'ZQM/#T^2T^EGU%/8>3Y?5G_!H_7TT?J^>GP?U#TIW'J?
M1^L;4>'I\ECTL_5Z>P\CR^KZ,'UZGP?U#TIW'J?1^L;].GAZ?)8]+/U?Y?\
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M\1#V#\_[:"Z,'=]SW'QCC6V3M-"<GVC08',_KJ?; BOB?:6\?9#F('Z@K?\
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MH:-_7D?ZK=/8B1Y>5]&CZ[3V=W/R:3U_SFKJ_P AZ^JGPH%YZ&C?KV?=R/\
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M&1&?F2D6T/Y8F,Q6U/Q[3LX&HBD-PEK4Z_.E7DR'5'C.F&E.0ZEYUW3:\5\
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M<^=0'<Q.  ! 0[L=P^@(=0_4&VZ?_-73PMVDR<;#W0?Y2G]'N(#YJ> NR/\
MRCVOT%?UW3Y!^NI-W,7@!,(F-W8_A],81$3&-1&PF$1'J(F'*NXB(CN/4=QZ
MZGPMVD P-A[F!U#I"-/FA5/@-LD<D]T>UD\\F"LGLZYOZN794>]B< '^6.X?
M?WAM?K5^3\6GA;M)^0]TT_OE'U+6H&PNR/\ RC6KT%9ZO/-^VORS[V)P !O_
M /C'</G7??\ 4&U^M7\@_DT\+=I/R'N?I"/J7VZZ'879'7_ZCVKT%75R_ENG
MQCXQF@=S&X 2[\O=D.'X.8.4VU$;@!B[@/*8 RML8NX .P[AN #MN&GA=M+R
M\![IC/+I"3_\+09U[,X/,"G@-LB#D=T>U@D8/N%8SYOOW4?LTY5'O8G !V>_
M'</O7I_6&U\_E^ZKT[/YAIX7;2?D/=---9"//VPOM\U/ 79'_E'M7H*\?+[M
MP-?T?I>]B<  ?_G'</O[PVH__=7;3PNVE'_$BZ:]?2$_I/0OUT\!MD?^4:U:
M9_D2_KFOVQ3WL3@ _P L=P^_O#;?+_SJZCPMVD.?[![IZ2D?_"\W+Y:CP%V0
MT_\ J-:N6/O%?Q8^_>SM\WF-/>Q.  /_ ,X[A]_>&V^3_G5Z:>%VTFG]@]T]
M(3YN?N+]?G\]2=A=D?\ E&M6=.4%?R?RWX\C]M/>Q. #_+'</O[PVWUJZ#:[
M:3\A[IZ0G]L+3E_7S%/ 79'_ )1[7K_>*_KNGR5/O8G !V>_'</O[Q&OS=OM
MJ_+_ *]3X7;2=6P]T^60CZEY_EZN5/ 79'7_ .HUJ[/O%6/\\QU_8"H][$X
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M=V)P L"[IN@**-(8HK+ JJ4G>D5ELIJ))** /(FJH0Z:9A*8Y#% 2C"MKMI
ME2O >YZ)5SD)P, ZD"&#\VI'(UDG839%2@D]T:U8*@-(12>>F"J;N@^<Y YG
M(KV@\+W#QB'A=PI2\0X2BVC&CPD:@Y0DT%$';RUR#Y%-=];9B4;@!):4GE!!
MZN^*(H"F=)!F1%BBV03^"WBZ3;Q<)$Z>LJD.+(*""$L(22$L(0K5"&]4A)US
MDJRHDG],[/V6VV&U1;?:D)$5MM*@Z"%KE+6 5277!_"+=T5O [N[A* E"4I'
M8+7,KM4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5UJXJ\U6' V-H.XUF'AYN4F<JX
MGQZ#2=4>IL$6F1+U#5)X_$T>JDX%PP;R9W38H'%,ZR12JD.03%'=$8,RXV^
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M6.#9RCAFV,X44<^#H+.5$D!<',L*9 %0PFW'6Z[0D6^YSH3:UN-193K#;C@
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M>U^P;+S;[4]MI3;$F,VVW"G(8:;F*:7+*(Z& PAR46&4R'4MAQ]#3:'5*0D
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M@@\E\G/'"3) RBAD6I%"H)&4.*:91.81VM;<;$1]_H]P88XJRX[P;?+;XCA
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M.\UF\D6KZ/B>IIX0[0>7+MZ?)]94CQ;\58"._$UQ"?(/MTY(ZB/E']4H=/\
MM[>NT=YK/Y(M?T?$]33PAV@\N7;T^3ZRH]UOQ5[_ -DWQ!B&W;[=&2?E\GLF
M$?E_CVT[S6?R1:_H^)ZFGA%M!Y<NWI\GUE/=;<5?8'$UQ!B/D^[1D@-]A_\
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M2"LE&;9 K.3:Q$5N:B3V61JSINE"VN"N#)TREHQL]5*<7\$W:N43MS%59KK
MFJ@MWM4OZMN5M$]5M=#ZX[]KN*;E'4&TNH4Z(4V#N/-K*=]I3,YTD)6A6\$D
M*&-?P_;;@(!FI7'$AJ? <MSZ.(ME:6ERX<S?;<2E00XEV"T$[Z%H*5+!0<@C
MO73NZ@6QN_@4;S2TPKD(6X,BQ]!L$C6R+UJ9AK4A7:PJV,J+I52!DIU@W;VE
M2=-+-H:+0.1JZED"NU?.W#8UB4W)6F279<EI:W79;:%)7<7A(2_. :0&VN*)
M<E;C"8ZFUJ<*<)2X\%>JB[=2VEPTKC)1&A2H*FFXJW&%BVP.@"/ =<"@])X2
M+;%2B2X^A\%M*U.*6AI3>/H[NBU]B9*LECJ;%-JO6(NT5YK!^RB=?R;B$L5(
MQU1VZCBRRY9%9>T1$?C:*<(VAW&.G#L9*78KL4XU=)HC><V88=<FOO25*DS>
MBN*<0PTPAE^-=WKN%--,I3PVG'74M/LMN)#R6&WBL/\ ME5!MC,;5"0U%:3%
MA%Y*&%%3I<:>M9M*^,ZL>.\EIV0MB2I&]&XHCM)5%:0R:VGW2.QN&14;%BJ"
MMSU9C88Z8D[1:Y&4<V",FI LHV@)PRT4*TE68J0*$BVCWCE:5;R9$WL-/P)B
M 0:QV/BI1PV):XJ PTTA,=A#:6WVF&X_3T *3NS0V@I:=2$A+;BV'TR6=Q(R
M&V4A:PY(BF6OI#SBU29*W5.1WGWWU0%J=;<+D-;CP6ZVZ7 76D2(PBR%+<52
M(SNC^2HZ30D2TBH&$\Q;5IA1!W)I2TG5;-!3<2QIJ4JX,](RCZC(VNWV6M.S
M,':J,U85Q>HNV;5%J-Z1LY%DEXN27QQF"@A(1N]*[XL3VYB\I2I;K3<6/;@E
M2MQ4!#C*4M*=XB>=;]HY-O8@L(CLN&"ZQPW5E_>Z(U:%VIZ$$AWAMLRE.NW)
M10@;ERX<@AT-(0;%IO&Q9*O.9.GG]0;V5YD*[S.0&RSVZ6B.=P]BF*G9J4J$
MR\BEFREVC$8*S..6-G")HGD6Q'1A!!W(,G>;EA:<BPHZ9 :5$BSH96(K"VW6
M+BY#=E%,=Q+K<=\N0FE,R6SQ6LN#*BH*1,;:)V/<)L\QB[TQVU24-+D/H4T]
M9NE=!*WVN$I]D)FO)D,K2$/;K80&B@A5_+=T/FW\,YAIG%%?DDY0UD92<DG;
MK!%SK&NV=5X\D:_3)^,1;S-2;N)1PVD'IC/IMH[4:+))QS-*7F ?:7]FVGIB
M9:)CS.XXS(2VAMLI=E1I;4R,N6% "0RPMHH0R"TH(6E/&(99"+$+:EZ'!3!,
M-B0D,&(7'2HJ:B.VU=KDHA^*51'I,=>^MY#BDI=2A8:(W]_:1[HO?'5Y2N-B
MH\1+-6OL=>,*[&W"XUMFQF:IE"T93AWR,A'2!WYF+F6M+AA9(=0QD;(V8L7S
MUPG*HD>%R\&XR8KC+4@H><,<F2J+&<*@U8/!]:5,*0&"%1E./LI" (CSA2RH
MLA3:\6MJ9#;\9Q4<+8BM3FD1S+F!1$N_M[1)6I_C%UQUJ4TTPMY96N0P@K61
M**'VJ=9.Z&Y,L-;1@ @VL*)Z6E2I):"L<M$L%FC12EH-).*BF"38(>4/#4Q&
M)DUA>R!9()60<"5LGWAD26-FXC$D2.*IW=FP9Z \A+CB78;R));XRPI7!=D(
M0ZEH EHMMCB+#;>+4G;.;)CSV3%80;A$O$-PI6X&VVKHU<6$.(924I5)BM7%
M8XRU*#RF]\MMN/25O\%GQY62'SK)9V@L<5>.G92L5:O/V!Y61,>1>UF]05\&
MTRDG'(Q N[#*R,"W:/GB+!F"K4?"5B.)8%I!QB=FV56>79ES'@Q*D*>0IIM"
M!%!MCUL#4=I96E#24ON2 C>W$NG<:0Q'W645/"=Y%VC7=J&UTB-%Z.LN+<<7
M*4J<B<7Y+J>$7'0IMN.%D;ZF4)4^MV05OKQO'<5UE2ERR<U7VLX5Q@1? 4T"
MU@FFLC.0HV-S:&5B>3 *.7?CEG(FCV_>5"KLUXN-38&(0BQE"7N]$=*7 TH-
M;UVLMX:"6D!MF598UJCL@-@%*FY MA+X.ZLF2ZM*TJ2G-2+?YC,B,^Z.E<*)
M>H$CCNNEZ5%O<N\S'T*?*E+0MA5X4W'6D$(;BLA39)4!GB/[I?E)H6[@XK$6
MLXN5NN=T"7:6*9:6."D[1*,I6.CXN=<$D7:-=KSANY!&(2!N+X'@K"[9NFZ*
MP<)6Q<(L,L]+?4&8,>!AU"'&7FVEW=;CC[.$H=<>3=W4$JR$!AK 6VMYM?63
MMK-Z<_,5%;]T2'I/"0Z\A4<NIL00W&?45+:0VNPQUX3@GI#Y!2ZW&=9L'&W'
M=?<:XNIV,(ZMQ+QE3%YXC-T:4>,6<Q$STC.3:S*R0S5N)9AZSFYY9XRDU)!(
MJ;=FQ9J,5!0!UKJR]GXLJ<J>IQ27%Q>CE"DA]+;B8LB&B1'#A"6"(\AQ"TI0
M4J!5A*0XX%T+;M-*MT-N(AAM:6;HS<TJ)4UQ.',@SC&DAL9D-E^WLJ25*WV]
MX94O@L!O)K/NF5TCW+E=ACB)8#,+6Z6L+AM>+2O*+V6X3M"LSV1K,C*A)FIT
M0TE\?QHLJ[%H+(H1[UXU1?).$F#YISW-D(K@6D37@E*(K45*F6EEIN*[?5($
MI0W')ZEMW^6EPNN("E-,.;I7Q"OHM;:RFW4N]":*G!)5,(<=2EPR(]C8)AMD
M*:MNZJP0UI$5L8#DAK&ZILM4VD=T"DT+!8I_(T$,XBYCJ^\85Y%,]@BK#.4S
M%".-JK#6+QU/,"0]91F6D5DAR[BV4N\0LT0@W912;=R=RWVO[-I:MYAVQWHZ
M^/<G67B4H7#5=+E;Y_26%)8<*Y%L3;F8T(+W0ZPI33SB4Y!HP=HEBZB?=$.3
M650K1$D1U[[R9C%GA7F'T%]*Y#83&O+=[G&XG>6&G5)D,L..937SJE)1_-R<
MA,RSM5_*2[YW)R3]RH*KEZ_?N%'3MVX54,8ZJ[EPJHNJ<PB8ZBAA$>8=P]&P
MRU&89C,(2VQ':;89;0,)0TTD(;0D=02D!('8!7GY,AZ7(D2I"U.R)+SLA]Q0
M\9QUU:G'%JTYJ4HG]5< !Z=H=.G:4?./E'IMT'Y=@_%MK33</()?+]]T$ Z;
M  #V?(/9V;[=-*:_%\8_W?[:GR=H#TV$-P >T?,/D[-M]NT-P\JGS_*"/UTZ
M>??KT 1#;?YM]N@>0-NP=]*?/\Q_3V<_GTYU',(= $/SB^?<.FX;= $!VZ#L
M/SZ4^?YC]O\ ;ISJ-P\@E ?(',7Y=Q[?(.X!TW#8/,(:4P>SX_EK4&WD$ \H
M#N ^?MZ]?DV[-]*<NWYC]ODJ Z /4-]AV !#IN/D#L_& _BTI3IU[ W_ /.#
MM$0'KU#H/9TZ_/TTIS[>6>1^W[14[_* !U[1 1Z^3J/EZ;!OY]Q'II3Y^6>1
MJ V[-R[_ #@/3;;?J.^W7LZ]0[ WTI\_S'[9TY<Z!V\H" "(@ !S!N(CTV H
M=HB.W+T =]@#KI09/($GJT.OZ*]A/<,>Y3R>/QKO&OQ!1#Z*M[QF9Y@R@/B+
M,7E>BI1HLV6OUF;#WM8DE,1SDZ5:AURD!E%N5I)^DJY>LDF'Q#NB;9(D<79^
MV+2M@'=N,E)2M+JT+!$9E6,;K:D@NN)/C*\1)P"3^C.Y5W/W(I8VHO#:VWRG
M?M4-84A3:' 0)CZ3@[RT'##2AHE1=6,EL#U*:^/5]\II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4JT)2[1,0^5CW4?;%ED1*!U8VD7"79&YTB*@*4A%PCQBN %.!3"
MBX.!%0.B?E5(<A;;<-UU <2N* >0<F16E\R-4./)4DZ9\8#(((T(J@_<6([B
MFEM3E*3C)9MTY]LY (W768ZVU<\'"C@Y!P17 #)$$.VT5>Q$=^GM;7_R>?\
M4WT_GY=9][WQS=A =O3X77_C_P!=:N^\7\1<OHBY_5-/EQ0,CP0[;15[Z_\
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M[^/: 9Q?D:Y&F/=FNG/&ORB@@[)G']C3 SG&=EGA]SG.<V[3EIG&001G(H7
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MER'4.6!00=DSNXV:8\8D#.RKXP4\][-N&X.PJP%?VI.M03 _!<H5$Q>$K&X
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MSC>TQG(R3R3!*BD!8B^AWXQR%[YC6_I 42=O?15K9 1*;_<SJ\A5.U,3  B
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M]Z<P@0_3E,.X:=[WAGVZ#H,_A"%R_I]?B&O+M%.^\;EP+GJ2/P/=!RYY/1,
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M/A<'\]_U-/WUVQOY.[3#/+Q+5Y]=+ER&.7.M7O\ !PX]GM09NW__ $U$^?\
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M\DW;2O$8*2PLH%JZ@H)M,2CV$M$BP\.$Q&: )[/(-RFK;9>3'X*5*? :6K&
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MNRGM#3NT)079\2W,2&I%N]N3<;E=(L>[R-Z2\UT%,:%%GI99X*^ASFD.R Z
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M&N))NZ^$PT"&F6]ZV'<:;!PVVG"4#1( KA^\0\3?;[:6"Q';EW%_>1$"]0V
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MJ\*;82ZYQ7$M(-L*6PMPEQ80 %+)61O$FN(/<(N)P0$#92P6(#V@,A>A 1V
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M1_F/Z==!_5H.V?9E[J/Y:WKD?XQCY_O?D/Z_-A[XKQQ>DOD@/,(N(?KV=/\
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M5XV*25.N<JX&-T&8;B%3@XX?=$IA:'&UJ:><1&M5OMO&=4@IP](5"6^L(&Z
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ML.]0W']1>5.SJ/\ @7IY1\G7Y0U/!VS_ +J7_2Q_]*H[X?N5OQ.SWT=?A_\
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MP_<K:89V>/\ X=?_ *OK]L4]E7<)>WQ;AW]Y65/XO$G_ &Z<';3^[E_TL?\
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M&,^43G.!RC/TT12*4 $JAMI_8P'$1 I2"8X;")BE#4]&B^46>0_B)>I.<C^
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MIT[R/*YD9Z5;M!KJ?=>F1@_**GV56[XGW,I_XQA*;[?TWX@  B!A^W_Q@,(
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MP\Q;FO%O==A,*1S]P[D'*4$+C'T]4Y.<,@^(Q5<*)G;PCPK$3,R"NH9$IP1
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MP/&1'4L+ENW2W! 5@/D7+1#05Q#+ERPMM;#CZ4QV8Y0L+WBA"G%/*5C&"4H
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M'0#4Z5XQDNXB=T012513H5,33<)$2<I)Y5JQ$W!"'(J5)<A7@%6(15,BI2J
M8I5"$.  8H"'ZO/=?V%)253)2BA14@JMDH[JBE2-Y.6]%;JE)R-<$CD2*_$B
M>X3W2$[VY;H8"A@^^L$%2=X*P</C3>2E6Z=,I2<!2154+W%_NE1&C6/3KD"F
MQ9<_@3(F9((K-GWPQC'!JU+(@@WYS'.8_>4R<PF,)MQ$=]9[K6P!67#(?+B@
M IPVJ05J"=TI!66MXA)2G )TW4XY#&Q/</[IJ6TL="CAE!4I+0N\(-A3F\%J
M2GI&Z%+WUA9&"H*5DG>(.TV[BQW2-FZ;/F=4KC-\R!8&;UMF&OH.V@.#*G<
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M=P+I2# DHZ>9"&>*^HM-%#"\$CZ%O+0C/8O>7&ON%DT9>BN;%"N4RB5RF5[
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MA7JZ1.Z;L];1?I=ILSECB2W6$WY=BB/2^_I965*1;;AT]]44%'05&.'D:%]
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M[=1U']>?E[?CH4I))*4DJ&Z20,E.OBD]8U.ATU-:BD(4@)E(4J92@4I"E "
M4 V H% .4"@'0  -@#IMIDYSG7GGKSVU. !@ 8QC&-,<L8Y8QIBA"$3*4B92
MD(0 *4A"@4I2AT I2E    #H    &G/G0      #  & !V #0"H!-,#F4 A
M4.!2G4 I0.<I-^4IC@',8"[CR@(B ;CMMN.F3RSH.0[,\Z;J02H !1P"<#)
MY GF<=6>5;2K1JN<JB[9NLH3]8=5%-0Y-AW#E,<HF+L/7H(=>O;J02- 2 >8
M!(K%3;:R%+0A1'(J2E1'Q$@D?)1VS:/T#M7S5L];*;=\;NT$G""G*(&+SHK%
M.F;E, &#F*.P@ AU#0*4DY22D]H)!^<:T<;;=06W6T.H.,H<0E:#@Y&4J!!P
M0",C0C-;J222"9$44TT44B%3322(5--,A0V*0A" !2$*  !2E    V  #4$D
BDDG).I)YD]IK)*4I2$I2$I2 $I2 $I T  &  !H -!7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846468136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001567514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Intra-Cellular Therapies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ITCI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4742850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">430 East 29th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-9333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,593,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Baltimore, MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067839190968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 92,364,990<span></span>
</td>
<td class="nump">$ 60,045,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available-for-sale</a></td>
<td class="nump">319,968,348<span></span>
</td>
<td class="nump">597,402,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">20,155,994<span></span>
</td>
<td class="nump">10,764,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,948,126<span></span>
</td>
<td class="nump">7,056,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">25,443,372<span></span>
</td>
<td class="nump">14,235,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">467,280,830<span></span>
</td>
<td class="nump">690,904,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,790,724<span></span>
</td>
<td class="nump">1,998,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">20,764,458<span></span>
</td>
<td class="nump">24,324,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">86,084<span></span>
</td>
<td class="nump">86,084<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">489,922,096<span></span>
</td>
<td class="nump">717,313,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,691,220<span></span>
</td>
<td class="nump">5,501,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">11,072,996<span></span>
</td>
<td class="nump">7,896,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_AccruedCustomerProgramsCurrent', window );">Accrued Customer Programs</a></td>
<td class="nump">5,963,610<span></span>
</td>
<td class="nump">3,005,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, short-term</a></td>
<td class="nump">6,731,792<span></span>
</td>
<td class="nump">5,541,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">20,896,860<span></span>
</td>
<td class="nump">14,907,479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">53,356,478<span></span>
</td>
<td class="nump">36,853,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">18,674,943<span></span>
</td>
<td class="nump">23,600,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,031,421<span></span>
</td>
<td class="nump">60,453,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 175,000,000 and 100,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; 81,886,965 and 80,463,089 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">8,189<span></span>
</td>
<td class="nump">8,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,639,475,837<span></span>
</td>
<td class="nump">1,593,475,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,221,229,698)<span></span>
</td>
<td class="num">(937,104,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated comprehensive (loss) income</a></td>
<td class="num">(363,653)<span></span>
</td>
<td class="nump">480,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">417,890,675<span></span>
</td>
<td class="nump">656,860,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 489,922,096<span></span>
</td>
<td class="nump">$ 717,313,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_AccruedCustomerProgramsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued customer programs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_AccruedCustomerProgramsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067839130664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">81,886,965<span></span>
</td>
<td class="nump">80,463,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">81,886,965<span></span>
</td>
<td class="nump">80,463,089<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846342376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 83,803,017<span></span>
</td>
<td class="nump">$ 22,812,979<span></span>
</td>
<td class="nump">$ 60,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_Costofproductsales', window );">Cost of product sales</a></td>
<td class="nump">8,034,589<span></span>
</td>
<td class="nump">1,895,029<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">88,845,513<span></span>
</td>
<td class="nump">65,782,137<span></span>
</td>
<td class="nump">89,124,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">272,611,040<span></span>
</td>
<td class="nump">186,363,444<span></span>
</td>
<td class="nump">64,947,625<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">369,491,142<span></span>
</td>
<td class="nump">254,040,610<span></span>
</td>
<td class="nump">154,072,463<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(285,688,125)<span></span>
</td>
<td class="num">(231,227,631)<span></span>
</td>
<td class="num">(154,011,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,568,090<span></span>
</td>
<td class="nump">4,235,481<span></span>
</td>
<td class="nump">6,291,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(284,120,035)<span></span>
</td>
<td class="num">(226,992,150)<span></span>
</td>
<td class="num">(147,720,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(5,631)<span></span>
</td>
<td class="num">(13,513)<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (284,125,666)<span></span>
</td>
<td class="num">$ (227,005,663)<span></span>
</td>
<td class="num">$ (147,722,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic &amp; Diluted</a></td>
<td class="num">$ (3.50)<span></span>
</td>
<td class="num">$ (3.23)<span></span>
</td>
<td class="num">$ (2.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average number of common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic &amp; Diluted</a></td>
<td class="nump">81,253,394<span></span>
</td>
<td class="nump">70,364,800<span></span>
</td>
<td class="nump">55,186,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 81,707,874<span></span>
</td>
<td class="nump">$ 22,530,753<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,095,143<span></span>
</td>
<td class="nump">$ 282,226<span></span>
</td>
<td class="nump">$ 60,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_Costofproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Product Sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_Costofproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846388216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (284,125,666)<span></span>
</td>
<td class="num">$ (227,005,663)<span></span>
</td>
<td class="num">$ (147,722,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on investment securities</a></td>
<td class="num">(844,237)<span></span>
</td>
<td class="nump">352,267<span></span>
</td>
<td class="nump">796,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (284,969,903)<span></span>
</td>
<td class="num">$ (226,653,396)<span></span>
</td>
<td class="num">$ (146,926,104)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840888488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Comprehensive Gain (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 317,714,881<span></span>
</td>
<td class="nump">$ 5,490<span></span>
</td>
<td class="nump">$ 880,753,339<span></span>
</td>
<td class="num">$ (562,376,191)<span></span>
</td>
<td class="num">$ (667,757)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,895,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Exercise of stock options and issuances of restricted stock (Value)</a></td>
<td class="nump">3,235,601<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">3,235,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Exercise of stock options and issuances of restricted stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">194,205<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">194,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,788,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,788,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(147,722,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,722,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">796,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,074<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">195,007,271<span></span>
</td>
<td class="nump">$ 5,551<span></span>
</td>
<td class="nump">904,971,772<span></span>
</td>
<td class="num">(710,098,369)<span></span>
</td>
<td class="nump">128,317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,507,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common shares issued</a></td>
<td class="nump">652,712,011<span></span>
</td>
<td class="nump">$ 2,341<span></span>
</td>
<td class="nump">652,709,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,409,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Exercise of stock options and issuances of restricted stock (Value)</a></td>
<td class="nump">11,464,918<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">11,464,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Exercise of stock options and issuances of restricted stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">214,103<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">214,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">24,115,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,115,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(227,005,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227,005,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">352,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,267<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">656,860,104<span></span>
</td>
<td class="nump">$ 8,046<span></span>
</td>
<td class="nump">1,593,475,506<span></span>
</td>
<td class="num">(937,104,032)<span></span>
</td>
<td class="nump">480,584<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,463,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Exercise of stock options and issuances of restricted stock (Value)</a></td>
<td class="nump">11,518,911<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">11,518,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Exercise of stock options and issuances of restricted stock (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,419,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">178,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">34,303,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,303,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(284,125,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284,125,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">(844,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 417,890,675<span></span>
</td>
<td class="nump">$ 8,189<span></span>
</td>
<td class="nump">$ 1,639,475,837<span></span>
</td>
<td class="num">$ (1,221,229,698)<span></span>
</td>
<td class="num">$ (363,653)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,886,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840970632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (284,125,666)<span></span>
</td>
<td class="num">$ (227,005,663)<span></span>
</td>
<td class="num">$ (147,722,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">533,360<span></span>
</td>
<td class="nump">528,118<span></span>
</td>
<td class="nump">477,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">34,303,029<span></span>
</td>
<td class="nump">24,115,197<span></span>
</td>
<td class="nump">20,788,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock issued for services</a></td>
<td class="nump">178,534<span></span>
</td>
<td class="nump">214,103<span></span>
</td>
<td class="nump">194,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on investment securities, net</a></td>
<td class="num">(4,079,828)<span></span>
</td>
<td class="num">(648,248)<span></span>
</td>
<td class="num">(1,131,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(9,391,411)<span></span>
</td>
<td class="num">(10,764,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(891,741)<span></span>
</td>
<td class="num">(7,056,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(11,207,917)<span></span>
</td>
<td class="num">(7,921,670)<span></span>
</td>
<td class="nump">1,465,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Long term deferred tax asset, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264,609<span></span>
</td>
<td class="nump">264,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,189,395<span></span>
</td>
<td class="num">(1,923,199)<span></span>
</td>
<td class="num">(6,536,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other</a></td>
<td class="nump">12,123,870<span></span>
</td>
<td class="nump">198,036<span></span>
</td>
<td class="nump">3,327,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent', window );">Lease liabilities, net</a></td>
<td class="num">(175,110)<span></span>
</td>
<td class="num">(73,160)<span></span>
</td>
<td class="nump">889,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(259,543,485)<span></span>
</td>
<td class="num">(230,072,845)<span></span>
</td>
<td class="num">(127,983,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows (used in) provided by investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(224,574,687)<span></span>
</td>
<td class="num">(755,629,547)<span></span>
</td>
<td class="num">(80,720,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">505,244,056<span></span>
</td>
<td class="nump">275,601,271<span></span>
</td>
<td class="nump">258,857,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(325,738)<span></span>
</td>
<td class="num">(266,724)<span></span>
</td>
<td class="num">(700,395)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">280,343,631<span></span>
</td>
<td class="num">(480,295,000)<span></span>
</td>
<td class="nump">177,436,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">11,518,911<span></span>
</td>
<td class="nump">11,464,918<span></span>
</td>
<td class="nump">3,235,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds of public offerings, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">652,712,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,518,911<span></span>
</td>
<td class="nump">664,176,929<span></span>
</td>
<td class="nump">3,235,601<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">32,319,057<span></span>
</td>
<td class="num">(46,190,916)<span></span>
</td>
<td class="nump">52,689,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">61,445,933<span></span>
</td>
<td class="nump">107,636,849<span></span>
</td>
<td class="nump">54,947,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">93,764,990<span></span>
</td>
<td class="nump">61,445,933<span></span>
</td>
<td class="nump">107,636,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">5,631<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets under operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,917,935<span></span>
</td>
<td class="nump">$ 219,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=itci_VehicleFleetLeaseMember', window );">Vehicle Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets under operating leases</a></td>
<td class="nump">$ 107,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=itci_RealEstateLeaseMember', window );">Real Estate Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets under operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilitites, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=itci_VehicleFleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=itci_VehicleFleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=itci_RealEstateLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=itci_RealEstateLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846400264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 92,364,990<span></span>
</td>
<td class="nump">$ 60,045,933<span></span>
</td>
<td class="nump">$ 107,636,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 93,764,990<span></span>
</td>
<td class="nump">$ 61,445,933<span></span>
</td>
<td class="nump">$ 107,636,849<span></span>
</td>
<td class="nump">$ 54,947,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842879416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intra-Cellular Therapies, Inc. (the &#8220;Company&#8221;), through its wholly-owned operating subsidiaries, ITI, Inc. (&#8220;ITI&#8221;) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (&#8220;CNS&#8221;). In December 2019, the Company announced that CAPLYTA<div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">TM</div> (lumateperone) had been approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of schizophrenia in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA in late March 2020. Additionally, in December 2021, the Company announced that CAPLYTA had been approved by the FDA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate (42mg/day). As used in these Notes to Consolidated Financial Statements, &#8220;CAPLYTA&#8221; refers to lumateperone approved by the FDA for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder in adults, and &#8220;lumateperone&#8221; refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and depressive episodes associated with bipolar I or II disorder. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0&#160;million. On September&#160;15, 2020, the Company completed <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div> public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8&#160;million. On January&#160;7, 2022, the Company completed a public offering of common stock in which the Company sold 10,952,381 shares of common stock at an offering price of $42.00 per share for aggregate gross proceeds of $460.0&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $433.7&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Possible sources of funds include public or private sales of the Company&#8217;s equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company&#8217;s product candidates and technology and, to a lesser extent, grant funding. On August&#160;30, 2019, the Company filed a universal shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was declared effective by the SEC on September&#160;12, 2019, on which the Company registered for sale up to $350&#160;million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which included up to $75&#160;million of common stock that the Company could issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August&#160;29, 2019 for the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program. On September&#160;10, 2020, the Company terminated the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program sales agreement with SVB Leerink LLC. During the year ended December&#160;31, 2020, the Company issued an aggregate 742,791 shares of common stock under the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div></div> equity program which resulted in the Company receiving net proceeds of $17.9&#160;million. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on January&#160;6, 2020, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company</div> filed an automatic shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a &#8220;well-known seasoned issuer&#8221; under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842555256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing, and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the consolidated balance sheets. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Investment Securities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment securities may consist of investments in U.S. Treasuries, various U.S. governmental agency debt securities, corporate bonds, certificates of deposit, and other fixed income securities with an average maturity of twelve months or less. Management classifies the Company&#8217;s investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> Such securities are carried at estimated fair value, with any unrealized holding gains or losses reported, net of any tax effects reported, as accumulated other comprehensive (loss) income, which is a separate component of stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other-than-temporary, if any, are included in consolidated results of operations. A decline in the market value of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security below cost that is deemed to be other-than-temporary results in a reduction in fair value, which is charged to earnings in that period, and a new cost basis for the security is established. Dividend and interest income are recognized as interest income on the consolidated statements of operations when earned. The cost of securities sold is calculated using the specific identification method. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors its investment portfolio for overall risk, specifically credit loss, <div style="letter-spacing: 0px; top: 0px;;display:inline;">quarterly</div> or more frequently if circumstances warrant. The Company has estimated the expected credit loss over the lifetime of the asset and has determined an allowance for credit losses is not material with respect to the investment portfolio. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2&#8212;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#8212;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has no assets or liabilities that were measured for significant unobservable inputs (Level 3 assets and liabilities) as of December&#160;31, 2021 and December&#160;31, 2020. The carrying value of cash held in money market funds of approximately $56.5&#160;million as of December&#160;31, 2021 and $27.9&#160;million as of December&#160;31, 2020 is included in cash and cash equivalents and approximates market value based on quoted market price or Level&#160;1 inputs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value measurements of the Company&#8217;s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">376,507</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56,539</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">319,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">625,319</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,917</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">597,402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Financial Instruments </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits, and lease liabilities, short term, to approximate their fair value because of their relatively short maturities at December&#160;31, 2021 and December&#160;31, 2020. Management believes that the risks associated with the Company&#8217;s financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Restricted Cash </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash is collateral used under the letter of credit arrangement for the Company&#8217;s vehicle lease agreement (see Note <div style="display:inline;">6</div>). The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-18,</div> &#8220;Restricted Cash&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18&#8221;)</div> and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Accounts Receivable, net </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers&#8217; credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a Customer&#8217;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of December&#160;31, 2021 and 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable. As of December&#160;31, 2021 and 2020, our credit loss reserve on receivables was not significant. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">years ended December&#160;31, 2021 and 2020, approximately $20.1&#160;million and $10.8&#160;million, respectively, of the Company&#8217;s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 60 days. For the years ended December&#160;31, 2021 and 2020, the Company had a grant receivable of approximately $0.1&#160;million and $0, respectively. For the years ended December&#160;31, 2021 and 2020, 96% of sales were generated from three major industry wholesalers. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">Three individual customers accounted for approximately 40%, 28%, and 28% and 39%, 29%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div>&#160;28% of product sales for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company believes that such customers are of high credit quality. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Inventory </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (&#8220;FIFO&#8221;) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes inventory costs associated with the Company&#8217;s products after regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Property and Equipment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:hidden37872336">three</span> to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC&#160;Topic No.&#160;360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date. </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2019, the Company adopted FASB ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC Topic 842&#8221;). The Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. Payments for identified leases are recognized in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2018, the Company adopted FASB ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Revenue from Contracts with Customers </div></div>(&#8220;ASC Topic 606&#8221;). The Company did not generate any product related revenue prior to January&#160;1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company&#8217;s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service.&#160;The reported results for the years ended December&#160;31, 2021 and December&#160;31, 2020 reflect the application of ASC Topic 606. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div>(below). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company&#8217;s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company&#8217;s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products. The Company recognizes revenue on product sales when the customer obtains control of the Company&#8217;s product, which occurs at a point in time (upon delivery). Product revenues are </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company&#8217;s sales of its product. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company&#8217;s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company&#8217;s estimates utilizing payer mix are based on CAPLYTA&#8217;s actual channel mix in 2021. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of December&#160;31, 2021 and 2020, therefore, the transaction price was not reduced further during the years ended December&#160;31, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>&#8212; The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the consolidated statements of operations for the years ended December&#160;31, 2021 and December&#160;31, 2020, as well as a reduction to accounts receivable, net on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>&#8212; Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product&#8217;s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>&#8212; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the years ended December&#160;31, 2021 and December&#160;31, 2020, these amounts were not significant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>&#8212; The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>&#8212; The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>&#8212; Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost of Product Sales </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (&#8220;BMS&#8221;), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-9%</div> on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the FDA approval of CAPLYTA, the Company ex<div style="letter-spacing: 0px; top: 0px;;display:inline;">pen</div>sed all costs associated with the manufacturing of lumateperone as part of research and development expenses. The cost of product sales in the years ended December&#160;31, 2021 and 2020 are lower than incurred because of previously expensed inventory. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors, among other factors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the year ended December&#160;31, 2021 the Company had no material change in estimate which related to the prior year estimates of accrued expenses for clinical trials. For the years ended December&#160;31, 2020 and 2019, we recorded a change in estimate of approximately $2.3&#160;million and $5.3&#160;million, respectively, both related to the prior year estimates of accrued expenses for clinical trials that resulted in a reduction of research and development expenses. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Advertising Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the FDA approval of CAPLYTA, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. The Company incurred $82.5&#160;million, $36.3&#160;million, and $0 in advertising costs during the years ended December&#160;31, 2021, 2020, and 2019, respectively, related to its marketed product, CAPLYTA. </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s effective tax rate for the years ended December&#160;31, 2021, 2020, and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (&#8220;AMT&#8221;) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December&#160;31, 2021.&#160;The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $0.3&#160;million to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December&#160;31, 2019 and received the refund in July 2020. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or losses on its investment securities in a separate statement of comprehensive loss for each period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Share-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payments are accounted for in accordance with the provisions of ASC Topic&#160;718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>. The fair value of share-based payments related to stock options is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the &#8220;Black-Scholes Model&#8221;). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 accounts for forfeitures as they occur. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes Model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes Model, require the input of subjective assumptions, and changes </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected volatility rates for quarterly periods prior to December&#160;31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company&#8217;s common stock. In the fourth quarter of 2019 and for all periods thereafter, expected volatility rates are based entirely on the historical volatility of the Company&#8217;s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the &#8220;simplified method,&#8221; which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A restricted stock unit (&#8220;RSU&#8221;) is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company&#8217;s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2020, the Company granted performance-based RSUs for approximately 86,000 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;the approval of a planned supplemental new drug application (&#8220;sNDA&#8221;) by the FDA (the &#8220;2020 Milestone RSUs&#8221;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#8217;s peers (the &#8220;2020 TSR RSUs&#8221;). In the fourth quarter of 2021, the Company received approval from the FDA for the sNDA for the use of CAPLYTA for the treatment of bipolar depression. In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;certain operational milestones (the &#8220;2021 Milestone RSUs&#8221;, and collectively with the 2020 Milestone RSUs, the &#8220;Milestone RSUs&#8221;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#8217;s peers (the &#8220;2021 TSR RSUs,&#8221; and collectively with the 2020 TSR RSUs, the &#8220;TSR RSUs&#8221;). The Milestone RSUs are recognized when it is probable that the performance metrics will be obtained. The TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the respective agreements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic&#160;718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date&#160;or the date the required services are completed and are marked to market during the service&#160;period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2018, the Company&#8217;s stockholders approved the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2018 Amended and Restated Equity Incentive Plan (the &#8220;Amended 2018 Plan&#8221;) pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. </div>   <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement <div style="letter-spacing: 0px; top: 0px;;display:inline;">Award</div> Plan (the &#8220;2019 Inducement Plan&#8221;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&#160;Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of December&#160;31, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Loss Per Share </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock option grants and RSUs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,451,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,517,622</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,039,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,598,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,600,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,268,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TSR RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Issued Accounting Standards </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-to-maturity</div></div> debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January&#160;1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January&#160;1, 2020 and for the years ended December&#160;31, 2021 and 2020. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842891944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investment [Text Block]</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Investment Securities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment securities consisted of the following (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,955 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,394 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(249</td>
<td style="white-space:nowrap;vertical-align:bottom">) </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">320,333 </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(386</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">319,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">596,921</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">650</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(169</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">597,402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has classified all of its investment securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale,</div></div> including those with maturities beyond one year, as current assets on the consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of December&#160;31, 2021 and 2020, the Company held $67.2&#160;million and $188.5&#160;million, respectively, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities with contractual maturity dates more than one year and less than two&#160;years, with the remainder of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities having contractual maturity dates less than one year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate related fair value of investments with unrealized losses as of December&#160;31, 2021 was $263.5&#160;million, which consisted of $71.7&#160;million from U.S. government agency securities, $49.9&#160;million of commercial paper, and $142&#160;million of corporate notes/bonds. $9.5&#160;million of the aggregate fair value of investments with unrealized losses as of December&#160;31, 2021 has been held in a continuous unrealized loss position for over than 12 months, with the remaining $254.1&#160;million held in a continuous unrealized loss position for less than 12 months. As of December&#160;31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3&#160;million and had been held in a continuous unrealized loss position for less than 12 months. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842527304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Inventory </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory consists of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,483,801</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2,483,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in process</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,407,165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1,781,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,057,160</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2,791,483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,948,126</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">7,056,385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842528424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and Equipment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:64%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408,751</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">423,097</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Scientific equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,287,228</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,127,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,240,315</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,240,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,359,391</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,034,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less accumulated depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,568,667</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,036,549</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,790,724</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,998,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $0.5&#160;million, respecti<div style="letter-spacing: 0px; top: 0px;;display:inline;">v</div>ely. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842888296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right Of Use Assets and Lease Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right Of Use Assets and Lease Liabilities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Right of Use Assets and Lease Liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Real Estate Leases </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2014, the Company entered into a long-term lease with a related party which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company&#8217;s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October&#160;1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March&#160;1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions. The Company has no other significant leases. In addition, no identified leases require allocations between lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the real estate lease balances within the consolidated balance sheet, weighted average remaining real estate lease term, the weighted average discount rates, and operating cash outflows related to real estate leases as of December&#160;31, 2021 and 2020: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:43%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets and Liabilities &#8211;Real Estate</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,680,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,029,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,680,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,029,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,325,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,284,540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current&#160;operating&#160;lease&#160;liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,997,469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,562,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total&#160;lease&#160;liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,322,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,846,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.09</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,448,323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,346,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,553,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,192,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maturity analysis under the lease agreements are as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:79%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,491,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,566,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,675,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,787,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,902,726</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,937,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,359,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Present value discount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,036,924</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,322,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,325,475</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,997,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense for the year ended December&#160;31, 2021, 2020 and 2019 was approximately $3.3&#160;million for each year, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vehicle Fleet Lease </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;17, 2019, the Company entered into an agreement (the &#8220;Vehicle Lease&#8221;) with a company (the &#8220;Lessor&#8221;) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contractual period of each lease is 12 months, followed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4&#160;million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4&#160;million is recorded as restricted cash on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nature of the lease is one commonly referred to as &#8220;TRAC&#8221; lease, as it contains a terminal rental adjustment clause, or &#8220;TRAC&#8221; clause.&#8221; The TRAC clause limits lessee<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>exposure, or likelihood of having a variable lease payment<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period increments. The vehicle leases entered into since March 2020 represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Vehicle Lease balances within the consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of December&#160;31, 2021 and December&#160;31, 2020: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:36%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities &#8211; Fleet</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">5,083,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">7,295,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,083,792</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,295,515</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,406,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,257,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current&#160;operating&#160;lease&#160;liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,677,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,038,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total&#160;lease&#160;liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,083,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,295,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.0 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.69</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.74</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,325,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,183,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,122,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">511,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the maturity of the Company&#8217;s fleet lease liability as of December&#160;31, 2021: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,471,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,681,294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,152,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Present value discount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,083,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,406,317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,677,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Right of use assets and lease liabilities for all operating leases were approximately $20.8&#160;million and $25.4&#160;million, respectively, as of December&#160;31, 2021, and approximately $24.3&#160;million and $29.1&#160;million, respectively, as of December&#160;31, 2020. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842881848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Share-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the total number of shares reserved under all equity plans was 17,787,390 and the Company had 5,855,106&#160;shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (&#8220;ISOs&#8221;) as defined by the Internal Revenue Code of 1986, as amended, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally <span style="-sec-ix-hidden:hidden37872734">one</span> to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of&#160;grant. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense related to all of the Company&#8217;s share-based awards, including stock options and RSUs granted to employees, directors and consultants recognized during the years ended December&#160;31, 2021, 2020, and 2019, was comprised of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:52%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventoriable costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,624,098</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1,342,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,832,088 </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7,072,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">9,411,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,846,843</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">15,700,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11,377,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,303,029 </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">24,115,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">20,788,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table describes the assumptions used for calculating the value of options granted during the years ended December&#160;31, 2021, 2020, and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:56%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">89.4%-94.9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.6%-95.5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">85.7-96.5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.87</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.32</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of December&#160;31, 2021, and changes during the period then ended, are summarized as&#160;follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:62%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,347</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant date fair value for awards granted during the years ended December&#160;31, 2021, 2020, and 2019 was $0, $12.84 and $0 per share, respectively. The total intrinsic value of the options exercised during the years ended December&#160;31, 2021 was $0.1&#160;million, and $0, respectively, for the years ended December&#160;31, 2020 and 2019. The total intrinsic value of the options outstanding as of December&#160;31, 2021 was $1.3&#160;million. The total intrinsic value of the options exercisable as of December&#160;31, 2021 was $0.2&#160;million. The total fair value of shares vested during the years ended December&#160;31, 2021 was $0.1&#160;million and $0 for the years ended December&#160;31, 2020 and 2019, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized share-based compensation expense related to stock option awards at December&#160;31, 2021 was $0.2&#160;million and will be recognized over a weighted-average period of 1.2&#160;years. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding RSU awards under the 2019 Inducement Plan during the period then ended are summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82,355</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs cancelled in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,545</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151,967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151,967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">The total intrinsic value of the time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $2.7&#160;million, $0 and $0, respectively. The total intrinsic value of the time based RSU&#8217;s outstanding as of December&#160;31, 2021 was $8.0&#160;million. The total fair&#160;value of time based RSUs vested during the years ended December&#160;31, 2021, 2010 and 2019 was $1.3&#160;million, $0 and $0, respectively. The fair value of time based RSUs is based on the closing price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">As of December&#160;31, 2021, there was $1.4&#160;million of unrecognized compensation costs related to unvested time based RSUs which will be recognized over a weighted-average period of 1.2 years. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">During the year ended December&#160;31, 2020, the Company issued options and time based RSUs totaling 314,138 shares in the 2019 Inducement Plan. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of December&#160;31, 2021, and changes during the year then ended, are summarized as&#160;follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,477,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">683,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30.82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(696,325</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.7 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options canceled or expired 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(49,149</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.4&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,416,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.1 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,416,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,838,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">The weighted-average grant date fair value for awards granted during the years ended December&#160;31, 2021, 2020 and 2019 was $29.01, $17.98 and $9.17 per share, respectively. The total intrinsic value of the options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $19.6&#160;million, $11.1&#160;million and $3.1&#160;million, respectively. The total intrinsic value of the options outstanding as of December&#160;31, 2021 was $172.4&#160;million. The total intrinsic value of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">options exercisable as of December 31, 2021 was</div>&#160;$127.9&#160;million. The total fair value of shares vested during the years ended December&#160;31, 2021, 2020 and 2019 was $10.6&#160;million, $13.4&#160;million and $12.0&#160;million, respectively. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized share-based compensation expense related to stock option awards at December&#160;31, 2021 was $18.4&#160;million, and will be recognized over a weighted-average period of 1.7&#160;years. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding time based RSU activity, including with respect to grants to employees as of December&#160;31, 2021, and changes during the year then ended, is summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:52%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,311,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.7&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">725,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(629,540</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.8 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs cancelled in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30,631</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.8&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,377,685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.5 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total intrinsic value of the time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $22.3&#160;million,&#160;$14.6&#160;million and $3.1&#160;million, respectively. The total intrinsic value of the time based RSU&#8217;s outstanding as of December&#160;31, 2021 was $72.1&#160;million. The total fair value of time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $11.1&#160;million, $7.2&#160;million and $4.6&#160;million, respectively. The fair value of time based RSUs is based on the closing price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, there was $24.4&#160;million of unrecognized compensation costs related to unvested time based RSUs which will be recognized over a weighted-average period of 2.0 years. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> share-based compensation expense related to Milestone RSU&#8217;s for the years ended December&#160;31, 2021, 2020 and 2019 of approximately $0.6&#160;million, $0, and $0.9&#160;million, respectively. The total fair value of shares vested with respect to Milestone RSUs during the years ended December&#160;31, 2021, 2020 and 2019 was $0, $0 and $0.9&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to the Company&#8217;s Milestone RSUs and the TSR RSUs during the year ended December&#160;31,&#160;2021 are summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.1 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Milestone RSUs and TSR RSUs granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.1 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Milestone RSUs and TSR RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total intrinsic value of the Company&#8217;s Milestone RSUs and the TSR RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $0, $1.6&#160;million, and $2.2&#160;million, respectively. The total intrinsic value of the Company&#8217;s Milestone RSU&#8217;s and the TSR RSUs outstanding as of December&#160;31, 2021 was $7.2&#160;million. The total fair value of the Company&#8217;s Milestone RSUs and the TSR RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $0, $1.1&#160;million, and $0.9&#160;million, respectively. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, there was $3.2&#160;million of unrecognized compensation costs related to unvested Milestone RSU grants and TSR RSU grants which will be recognized over a weighted average period of 1.6 years. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average estimated fair value per share of the 2020 TSR RSUs granted was $32.56, and the 2021 TSR RSUs granted was $51.18, which were derived from Monte Carlo simulations. Significant assumptions utilized in estimating the value of the 2020 awards granted include an expected dividend yield of 0%, a risk-free rate of 1.4%, and expected volatility of 91.3%. Significant assumptions utilized in estimating the value of the 2021 awards granted include an expected dividend yield of 0%, a risk-free rate of 0.2%, and expected volatility of 95.8%. The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#8217;s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date. Similarly, the 2021 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#8217;s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company&#8217;s total shareholder returns, expressed as a percentile ranking of the Company&#8217;s total shareholder return as compared to the Company&#8217;s peer group. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company&#8217;s common stock over the 30 trading days preceding the settlement date by the average share value of the Company&#8217;s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period. The Company&#8217;s peer group included companies that compromised the Nasdaq Biotechnology Index at December&#160;31, 2019 and 2020, respectively. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842349016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2017, former President Donald Trump signed into law the &#8220;Tax Cuts and Jobs Act&#8221; (&#8220;TCJA&#8221;) that significantly reforms the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). The TCJA, among other things, includes changes to U.S.&#160;federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating loss carryforwards, allows for the expensing of capital expenditures, and puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system. While the TCJA provide for a territorial tax system, beginning in 2018, it includes two new U.S. tax base erosion provisions, the global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income (&#8220;GILTI&#8221;) provisions and the base-erosion and anti-abuse tax (&#8220;BEAT&#8221;) provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. As of the year ended December&#160;31, 2021, the Company&#8217;s foreign operations do not generate positive income and the Company is not currently subject to the GILTI provisions. The Company has not made an accounting policy election for GILTI and will analyze and formulate its GILTI accounting policy in the period which the Company becomes subject to the GILTI provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BEAT provisions eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The Company has not made any qualifying payments and the BEAT tax is not applicable in 2021. Therefore, the Company has not included any tax impacts of BEAT in its consolidated financial statements for the year ended December&#160;31, 2021. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss before income taxes is as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:49%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S.</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(221,215,855</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(155,615,614</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(56,121,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(62,904,180</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(71,376,536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(91,599,320</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total loss before taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(284,120,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(226,992,150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(147,720,578</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total income tax expense for the years ended December&#160;31, 2021, 2020 and 2019 is allocated as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,631</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(53,070,458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40,049,094</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,484,822</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,070,458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,049,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,484,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxe<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,631</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the difference between the statutory federal income tax rate and the effective income tax rate for the years ended December&#160;31, 2021, 2020 and 2019 is as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:70%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax at statutory federal rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.00</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other permanent differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.60</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.01</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign rate differential</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4.63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6.60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.02</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in effective state tax rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(0.31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.04</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowanc<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18.70</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17.65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.0</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effect of temporary differences that exist between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. As of December&#160;31, 2021, the Company had $543.4&#160;million of federal net operating loss carryforwards, of which $131.1&#160;million expire at various dates through 2037 and $412.3&#160;million do not expire. The gross amount of the state net operating loss carryforwards is equal to or less than the federal net operating loss carryforwards and expires over various periods based on individual state tax law. In general, businesses with U.S. net operating losses (&#8220;NOLs&#8221;) are considered loss corporations for U.S. federal income tax purposes. Pursuant to Section&#160;382 of the Code, loss corporations that undergo an ownership change, as defined under the Code, may be subject to an annual limitation on the amount of NOLs (and certain other tax attributes) available to offset taxable income earned after such ownership change. For the years ended December&#160;31, 2015 through 2021, the Company performed a Section&#160;382 ownership analysis and determined that an ownership change occurred (within the meaning of Section&#160;382 of the Code) in 2015 but not in subsequent periods. Based on the analysis performed through December&#160;31, 2021, however, the Company does not believe that the Section&#160;382 annual limitation will impact the Company&#8217;s ability to utilize the tax attributes that existed as of the date of the ownership change in a material manner. If the Company experiences an ownership change in the future, the tax benefits related to the NOLs and tax credit carryforwards may be further limited or lost. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020, respectively: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:59%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred&#160;tax&#160;assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,561,289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85,751,154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,154,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,363,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,321,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,321,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,947,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,137,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,660,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">850,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,177,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,461,587</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred tax liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset&#8212;capital lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,049,103</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,228,138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(123,049</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset before valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,572,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,290,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166,572,615</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113,290,682</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the Company&#8217;s historical operating performance and the reported cumulative net losses to date, the Company presently does not have sufficient objective evidence to support the recovery of its net deferred tax assets. Accordingly, the Company has established a full valuation allowance against its net deferred tax assets in 2021 and 2020, for financial reporting purposes because it is not more likely than not that these deferred tax assets will be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The open years subject to tax audits vary depending on the tax jurisdictions. In the U.S federal jurisdiction, we are no longer subject to income tax audits by taxing authorities for years before 2017. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amount of unrecognized tax benefits was $1.7&#160;million as of December&#160;31, 2021 and December&#160;31, 2020. If recognized, none of these tax benefits would affect the effective tax rate due to valuation allowances. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842532296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Commitments and Contingencies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Royalty Commitments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company, pursuant to which the Company holds a license to certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of BMS relating to lumateperone and other specified compounds. The agreement was amended on November&#160;3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop, or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement, the Company made an upfront payment of $1.0&#160;million to BMS in 2005, a milestone payment of $1.25&#160;million in December&#160;2013, and a milestone payment of $1.5&#160;million in December&#160;2014 following the initiation of the Company&#8217;s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">obligated to pay BMS a $2.0&#160;million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December&#160;20, 2019 and as a result the Company accrued an additional milestone liability of $5.0&#160;million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0&#160;million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75&#160;million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 &#8211; 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> payments made in consideration of any sublicense. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement extends, and royalties are payable, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited.&#160;In connection with the transfer, the Company guaranteed ITI Limited&#8217;s performance of its obligations under the BMS agreement. The Company expensed approximately $4.1&#160;million and $1.1&#160;million in cost of product sales to satisfy its obligation under the BMS agreement for the years ended December&#160;31, 2021 and 2020, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Other Commitments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the Company has committed to purchasing production campaigns for active pharmaceutical ingredients (API) from each of our supply vendors &#8211; Siegfried Evionnaz SA (&#8220;Siegfried&#8221;) and Lonza Ltd. (&#8220;Lonza&#8221;). As of December&#160;31, 2021 and 2020, the Company had paid deposits totaling $9.5&#160;million and $3.0&#160;million, respectively, for the Siegfried and Lonza campaigns which are recorded within prepaids and other current assets on the consolidated balance sheets. Over the course of the vendors&#8217; manufacturing period, the Company will remit payment to the vendor based on the executed agreements. Upon title transfer of the product, the Company will recognize the material as inventory. The API campaigns are expected to be received into inventory during 2022 or the first half of 2023. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Retirement savings plan 401(k) contributions </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined contribution 401(k) plan covering all full-time employees. Participants may elect to contribute their annual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> earnings up to the federally allowed maximum limits. The Company made a matching contribution of 100% on the first&#160;6% of contributions made by participants in the year ended December&#160;31, 2021, 2020 and 2019. Participant and company contributions vest immediately. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded matching contribution expense of $3.0&#160;million, $1.8&#160;million and $0.7&#160;million, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the normal course of our business, we are occasionally involved with various claims and litigation. Reserves are established in connection with such matters when a loss is probable and the amount of such loss can be reasonably estimated. At December&#160;31, 2021 and 2020, no material reserves were recorded. The determination of probability and the estimation of the actual amount of any such loss are inherently unpredictable, and it is therefore possible that the eventual outcome of such claims and litigation could exceed the estimated reserves, if any. However, we believe that the likelihood that any such excess might have a material adverse effect on our financial statements is remote. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067928228840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><div style="font-weight:bold;display:inline;">10. Related Parties </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">The Company has no other related party transactions other than the real estate lease for the Company&#8217;s headquarters in New York, New York disclosed <div style="letter-spacing: 0px; top: 0px;;display:inline;">in Note 6.&#160;</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842480008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No other subsequent events have occurred since the balance sheet date other than the public offering of common stock completed by the Company on January&#160;7, 2022, as disclosed in Note 1. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842528984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Quarterly Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Unaudited Quarterly Financial Information</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Unaudited Quarterly Financial Information </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables herein set forth the Company&#8217;s unaudited condensed consolidated 2021 and 2020 quarterly statements of operations. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following table sets forth the Company&#8217;s unaudited condensed consolidated statements of operations for the 2021 quarters ended: </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:40%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2021&#160;Quarter&#160;Ended</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,670,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,207,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,046,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,878,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(111,675,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(99,531,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89,187,615</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(69,097,022</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">270,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">392,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">421,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">483,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,756</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85,733,937</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76,908,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,743,782</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52,739,943</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per share</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following table sets forth the Company&#8217;s unaudited condensed consolidated statements of operations for the 2020 quarters ended: </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:39%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2020&#160;Quarter&#160;Ended</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,454,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,368,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,906,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,083,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73,787,606</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,305,048</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(66,778,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(50,169,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">644,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">752,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,160,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,678,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60,699,178</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55,183,625</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,712,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47,410,602</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per share</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.96</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840980072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing, and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the consolidated balance sheets. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Investment Securities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment securities may consist of investments in U.S. Treasuries, various U.S. governmental agency debt securities, corporate bonds, certificates of deposit, and other fixed income securities with an average maturity of twelve months or less. Management classifies the Company&#8217;s investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale.</div></div> Such securities are carried at estimated fair value, with any unrealized holding gains or losses reported, net of any tax effects reported, as accumulated other comprehensive (loss) income, which is a separate component of stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other-than-temporary, if any, are included in consolidated results of operations. A decline in the market value of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security below cost that is deemed to be other-than-temporary results in a reduction in fair value, which is charged to earnings in that period, and a new cost basis for the security is established. Dividend and interest income are recognized as interest income on the consolidated statements of operations when earned. The cost of securities sold is calculated using the specific identification method. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors its investment portfolio for overall risk, specifically credit loss, <div style="letter-spacing: 0px; top: 0px;;display:inline;">quarterly</div> or more frequently if circumstances warrant. The Company has estimated the expected credit loss over the lifetime of the asset and has determined an allowance for credit losses is not material with respect to the investment portfolio. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2&#8212;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#8212;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has no assets or liabilities that were measured for significant unobservable inputs (Level 3 assets and liabilities) as of December&#160;31, 2021 and December&#160;31, 2020. The carrying value of cash held in money market funds of approximately $56.5&#160;million as of December&#160;31, 2021 and $27.9&#160;million as of December&#160;31, 2020 is included in cash and cash equivalents and approximates market value based on quoted market price or Level&#160;1 inputs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value measurements of the Company&#8217;s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">376,507</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56,539</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">319,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">625,319</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,917</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">597,402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Financial Instruments </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits, and lease liabilities, short term, to approximate their fair value because of their relatively short maturities at December&#160;31, 2021 and December&#160;31, 2020. Management believes that the risks associated with the Company&#8217;s financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Restricted Cash </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash is collateral used under the letter of credit arrangement for the Company&#8217;s vehicle lease agreement (see Note <div style="display:inline;">6</div>). The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-18,</div> &#8220;Restricted Cash&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18&#8221;)</div> and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable, net</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Accounts Receivable, net </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers&#8217; credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a Customer&#8217;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of December&#160;31, 2021 and 2020. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable. As of December&#160;31, 2021 and 2020, our credit loss reserve on receivables was not significant. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">years ended December&#160;31, 2021 and 2020, approximately $20.1&#160;million and $10.8&#160;million, respectively, of the Company&#8217;s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 60 days. For the years ended December&#160;31, 2021 and 2020, the Company had a grant receivable of approximately $0.1&#160;million and $0, respectively. For the years ended December&#160;31, 2021 and 2020, 96% of sales were generated from three major industry wholesalers. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">Three individual customers accounted for approximately 40%, 28%, and 28% and 39%, 29%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div>&#160;28% of product sales for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company believes that such customers are of high credit quality. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Inventory </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (&#8220;FIFO&#8221;) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes inventory costs associated with the Company&#8217;s products after regulatory approval when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Property and Equipment </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:hidden37872336">three</span> to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC&#160;Topic No.&#160;360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2019, the Company adopted FASB ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC Topic 842&#8221;). The Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. Payments for identified leases are recognized in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2018, the Company adopted FASB ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Revenue from Contracts with Customers </div></div>(&#8220;ASC Topic 606&#8221;). The Company did not generate any product related revenue prior to January&#160;1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company&#8217;s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service.&#160;The reported results for the years ended December&#160;31, 2021 and December&#160;31, 2020 reflect the application of ASC Topic 606. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div>(below). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company&#8217;s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company&#8217;s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products. The Company recognizes revenue on product sales when the customer obtains control of the Company&#8217;s product, which occurs at a point in time (upon delivery). Product revenues are </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company&#8217;s sales of its product. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company&#8217;s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company&#8217;s estimates utilizing payer mix are based on CAPLYTA&#8217;s actual channel mix in 2021. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of December&#160;31, 2021 and 2020, therefore, the transaction price was not reduced further during the years ended December&#160;31, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>&#8212; The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the consolidated statements of operations for the years ended December&#160;31, 2021 and December&#160;31, 2020, as well as a reduction to accounts receivable, net on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>&#8212; Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product&#8217;s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>&#8212; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the years ended December&#160;31, 2021 and December&#160;31, 2020, these amounts were not significant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>&#8212; The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>&#8212; The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>&#8212; Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of product sales</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Cost of Product Sales </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (&#8220;BMS&#8221;), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-9%</div> on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the FDA approval of CAPLYTA, the Company ex<div style="letter-spacing: 0px; top: 0px;;display:inline;">pen</div>sed all costs associated with the manufacturing of lumateperone as part of research and development expenses. The cost of product sales in the years ended December&#160;31, 2021 and 2020 are lower than incurred because of previously expensed inventory. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development, including Clinical trial expenses</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors, among other factors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the year ended December&#160;31, 2021 the Company had no material change in estimate which related to the prior year estimates of accrued expenses for clinical trials. For the years ended December&#160;31, 2020 and 2019, we recorded a change in estimate of approximately $2.3&#160;million and $5.3&#160;million, respectively, both related to the prior year estimates of accrued expenses for clinical trials that resulted in a reduction of research and development expenses. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expense</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Advertising Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the FDA approval of CAPLYTA, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. The Company incurred $82.5&#160;million, $36.3&#160;million, and $0 in advertising costs during the years ended December&#160;31, 2021, 2020, and 2019, respectively, related to its marketed product, CAPLYTA. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s effective tax rate for the years ended December&#160;31, 2021, 2020, and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (&#8220;AMT&#8221;) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December&#160;31, 2021.&#160;The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $0.3&#160;million to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December&#160;31, 2019 and received the refund in July 2020. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or losses on its investment securities in a separate statement of comprehensive loss for each period. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Share-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payments are accounted for in accordance with the provisions of ASC Topic&#160;718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>. The fair value of share-based payments related to stock options is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the &#8220;Black-Scholes Model&#8221;). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 accounts for forfeitures as they occur. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes Model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes Model, require the input of subjective assumptions, and changes </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected volatility rates for quarterly periods prior to December&#160;31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company&#8217;s common stock. In the fourth quarter of 2019 and for all periods thereafter, expected volatility rates are based entirely on the historical volatility of the Company&#8217;s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the &#8220;simplified method,&#8221; which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company&#8217;s common stock on the date of grant. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A restricted stock unit (&#8220;RSU&#8221;) is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company&#8217;s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2020, the Company granted performance-based RSUs for approximately 86,000 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;the approval of a planned supplemental new drug application (&#8220;sNDA&#8221;) by the FDA (the &#8220;2020 Milestone RSUs&#8221;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#8217;s peers (the &#8220;2020 TSR RSUs&#8221;). In the fourth quarter of 2021, the Company received approval from the FDA for the sNDA for the use of CAPLYTA for the treatment of bipolar depression. In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;certain operational milestones (the &#8220;2021 Milestone RSUs&#8221;, and collectively with the 2020 Milestone RSUs, the &#8220;Milestone RSUs&#8221;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#8217;s peers (the &#8220;2021 TSR RSUs,&#8221; and collectively with the 2020 TSR RSUs, the &#8220;TSR RSUs&#8221;). The Milestone RSUs are recognized when it is probable that the performance metrics will be obtained. The TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the respective agreements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic&#160;740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic&#160;718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date&#160;or the date the required services are completed and are marked to market during the service&#160;period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2018, the Company&#8217;s stockholders approved the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2018 Amended and Restated Equity Incentive Plan (the &#8220;Amended 2018 Plan&#8221;) pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement <div style="letter-spacing: 0px; top: 0px;;display:inline;">Award</div> Plan (the &#8220;2019 Inducement Plan&#8221;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&#160;Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of December&#160;31, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Loss Per Share </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock option grants and RSUs. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,451,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,517,622</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,039,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,598,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,600,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,268,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TSR RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Issued Accounting Standards </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-to-maturity</div></div> debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January&#160;1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January&#160;1, 2020 and for the years ended December&#160;31, 2021 and 2020. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840287016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value measurements of the Company&#8217;s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">376,507</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56,539</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">319,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reporting&#160;Date&#160;Using</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets&#160;for<br/> Identical<br/> Assets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money Market Funds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 46%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">625,319</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27,917</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">597,402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 46%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,451,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,517,622</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,039,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,598,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,600,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,268,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TSR RSUs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842571704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment securities consisted of the following (in thousands): <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,955 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,919 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,394 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(249</td>
<td style="white-space:nowrap;vertical-align:bottom">) </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,164 </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">320,333 </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(386</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">319,968</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. Government Agency Securities</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Certificates of Deposit</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial Paper</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">124,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 57%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Notes/Bonds</div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">596,921</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">650</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(169</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">597,402</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842892776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory consists of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,483,801</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2,483,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in process</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,407,165</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1,781,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,057,160</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2,791,483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,948,126</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">7,056,385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842566536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:64%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">408,751</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">423,097</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Scientific equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,287,228</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,127,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,240,315</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,240,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,359,391</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,034,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less accumulated depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,568,667</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,036,549</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,790,724</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,998,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846595784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right Of Use Assets and Lease Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Maturity Analysis Under Lease Agreements</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maturity analysis under the lease agreements are as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:79%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,491,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,566,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,675,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,787,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2026</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,902,726</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,937,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,359,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Present value discount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,036,924</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,322,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,325,475</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,997,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember', window );">Vehicle Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Maturity Analysis Under Lease Agreements</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the maturity of the Company&#8217;s fleet lease liability as of December&#160;31, 2021: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,471,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,681,294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,152,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Present value discount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,083,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,406,317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,677,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock', window );">Schedule Of Quantitative Information About Operating Leases</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Vehicle Lease balances within the consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of December&#160;31, 2021 and December&#160;31, 2020: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:36%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities &#8211; Fleet</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">5,083,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">7,295,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,083,792</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,295,515</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,406,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,257,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current&#160;operating&#160;lease&#160;liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,677,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,038,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total&#160;lease&#160;liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,083,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,295,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.0 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.69</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.74</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,325,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,183,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,122,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">511,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_ItciRealEstatesLeaseMember', window );">ITCI Real Estates Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock', window );">Schedule Of Quantitative Information About Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the real estate lease balances within the consolidated balance sheet, weighted average remaining real estate lease term, the weighted average discount rates, and operating cash outflows related to real estate leases as of December&#160;31, 2021 and 2020: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:43%">&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:2%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets and Liabilities &#8211;Real Estate</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use assets, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,680,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,029,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,680,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,029,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, short-term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating&#160;lease&#160;liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,325,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,284,540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current&#160;operating&#160;lease&#160;liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,997,469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,562,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total&#160;lease&#160;liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,322,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,846,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.3 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.09</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,448,323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,346,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,553,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,192,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of quantitative information about operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_ItciRealEstatesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_ItciRealEstatesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846567896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Total Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense related to all of the Company&#8217;s share-based awards, including stock options and RSUs granted to employees, directors and consultants recognized during the years ended December&#160;31, 2021, 2020, and 2019, was comprised of the following: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:52%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventoriable costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,624,098</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1,342,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,832,088 </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7,072,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">9,411,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,846,843</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">15,700,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11,377,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,303,029 </div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">24,115,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">20,788,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used for Calculating Value of Options Granted</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table describes the assumptions used for calculating the value of options granted during the years ended December&#160;31, 2021, 2020, and 2019: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:56%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">89.4%-94.9</div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.6%-95.5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">85.7-96.5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.87</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.32</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.9</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of December&#160;31, 2021, and changes during the year then ended, are summarized as&#160;follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:61%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,477,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">683,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30.82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(696,325</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.7 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options canceled or expired 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(49,149</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.4&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,416,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.1 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,416,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,838,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_TimeBasedRestrictedStockUnitsRSUMember', window );">Time Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Information Regarding RSU Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding time based RSU activity, including with respect to grants to employees as of December&#160;31, 2021, and changes during the year then ended, is summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:52%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,311,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.7&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">725,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(629,540</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.8 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs cancelled in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30,631</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.8&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,377,685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.5 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember', window );">Milestone and Total Shareholder Return Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Information Regarding RSU Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to the Company&#8217;s Milestone RSUs and the TSR RSUs during the year ended December&#160;31,&#160;2021 are summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.1 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Milestone RSUs and TSR RSUs granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.1 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Milestone RSUs and TSR RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember', window );">Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of December&#160;31, 2021, and changes during the period then ended, are summarized as&#160;follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:62%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,347</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Information Regarding RSU Activity</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding RSU awards under the 2019 Inducement Plan during the period then ended are summarized as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value&#160;Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs vested in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82,355</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.2&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Time based RSUs cancelled in 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,545</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151,967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.2 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151,967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at December&#160;31, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_TimeBasedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_TimeBasedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067844775672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss before income taxes is as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:49%">&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:3%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S.</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(221,215,855</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(155,615,614</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(56,121,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(62,904,180</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(71,376,536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(91,599,320</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total loss before taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(284,120,035</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(226,992,150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">(147,720,578</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Total Income Tax Expense</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total income tax expense for the years ended December&#160;31, 2021, 2020 and 2019 is allocated as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%">&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:10%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,631</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(53,070,458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40,049,094</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,484,822</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,070,458</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,049,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,484,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxe<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,631</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the difference between the statutory federal income tax rate and the effective income tax rate for the years ended December&#160;31, 2021, 2020 and 2019 is as follows: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:70%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax at statutory federal rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.00</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other permanent differences</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.60</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.01</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign rate differential</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4.63</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6.60</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.02</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in effective state tax rates</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(0.31</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.04</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowanc<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18.70</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17.65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.0</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020, respectively: <br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:59%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred&#160;tax&#160;assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,561,289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85,751,154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,154,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,363,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,321,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,321,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,947,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,137,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,660,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">850,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,177,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,461,587</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred tax liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset&#8212;capital lease</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,049,103</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,228,138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(123,049</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset before valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,572,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,290,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166,572,615</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(113,290,682</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842554424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Quarterly Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following table sets forth the Company&#8217;s unaudited condensed consolidated statements of operations for the 2021 quarters ended: </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:40%">&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:4%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2021&#160;Quarter&#160;Ended</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,670,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,207,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,046,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,878,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(111,675,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(99,531,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(89,187,615</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(69,097,022</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">270,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">392,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">421,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">483,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,756</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85,733,937</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(76,908,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,743,782</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52,739,943</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per share</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following table sets forth the Company&#8217;s unaudited condensed consolidated statements of operations for the 2020 quarters ended: </div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:39%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2020&#160;Quarter&#160;Ended</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,454,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,368,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,906,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,083,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73,787,606</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,305,048</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(66,778,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(50,169,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">644,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">752,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,160,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,678,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(60,699,178</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55,183,625</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,712,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47,410,602</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per share</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.96</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067836049128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
<th class="th"><div>Sep. 12, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,666,667<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering, Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="nump">$ 29.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Initial public offering, Gross proceeds</a></td>
<td class="nump">$ 460,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering, Net proceeds</a></td>
<td class="nump">$ 433,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 652,712,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,886,965<span></span>
</td>
<td class="nump">80,463,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, Number of shares</a></td>
<td class="nump">10,952,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering, Price per share</a></td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,409,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Initial public offering, Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,000,000.0<span></span>
</td>
<td class="nump">$ 295,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering, Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,800,000<span></span>
</td>
<td class="nump">$ 277,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SecuritiesAuthorizedAmountForIssuance', window );">Universal shelf registration statement, effective date value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_SecuritiesAuthorizedAmountForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities Authorized Amount For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_SecuritiesAuthorizedAmountForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067835644808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_CashAndCashEquivalentMaximumMaturityPeriod', window );">Maturity of highly liquid investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_AvailableForSaleSecuritiesMaturityPeriod', window );">Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">more than three months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Carrying value of cash held in money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,500,000<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Assumed expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_GrantReceivable', window );">Grant Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=itci_AmtTaxCreditMember', window );">Amt Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=itci_CaplytaMember', window );">CAPLYTA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,500,000<span></span>
</td>
<td class="nump">$ 36,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=itci_CustomerOneMember', window );">Customer one [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=itci_CustomerTwoMember', window );">Customer two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=itci_CustomerThreeMember', window );">Customer three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=itci_ClinicalTralMember', window );">Clinical Tral [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ChangeInAccountingEstimateAmount', window );">Reveral of accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured using quoted prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured using quoted prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=itci_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Additional shares of common stock reserved for future equity grants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember', window );">Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,138<span></span>
</td>
<td class="nump">314,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_PerformanceBasedRestrictedStockUnitsMember', window );">Performance Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">64,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Product [Member] | Bristol Myers Squibb Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_RoyaltyPaymentPercentage', window );">Royalty Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Product [Member] | Bristol Myers Squibb Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_RoyaltyPaymentPercentage', window );">Royalty Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issuance of shares, Inducement Award Plan | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_AvailableForSaleSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_AvailableForSaleSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_CashAndCashEquivalentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Maximum Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_CashAndCashEquivalentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ChangeInAccountingEstimateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in accounting estimate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ChangeInAccountingEstimateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_GrantReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_GrantReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=itci_AmtTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=itci_AmtTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=itci_CaplytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=itci_CaplytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=itci_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=itci_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=itci_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=itci_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=itci_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=itci_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=itci_ClinicalTralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=itci_ClinicalTralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=itci_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=itci_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=itci_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=itci_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067835596072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">$ 376,507<span></span>
</td>
<td class="nump">$ 625,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">56,539<span></span>
</td>
<td class="nump">27,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">71,652<span></span>
</td>
<td class="nump">259,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">26,233<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">55,919<span></span>
</td>
<td class="nump">124,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Notes/Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">166,164<span></span>
</td>
<td class="nump">203,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">56,539<span></span>
</td>
<td class="nump">27,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">56,539<span></span>
</td>
<td class="nump">27,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">319,968<span></span>
</td>
<td class="nump">597,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">71,652<span></span>
</td>
<td class="nump">259,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">26,233<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">55,919<span></span>
</td>
<td class="nump">124,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | Corporate Notes/Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Available-for-sale investment securities</a></td>
<td class="nump">$ 166,164<span></span>
</td>
<td class="nump">$ 203,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840715192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,451,398<span></span>
</td>
<td class="nump">5,517,622<span></span>
</td>
<td class="nump">6,039,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,598,250<span></span>
</td>
<td class="nump">1,600,083<span></span>
</td>
<td class="nump">1,268,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=itci_TotalShareholderReturnRestrictedStockUnitsMember', window );">Total Shareholder Return Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">68,598<span></span>
</td>
<td class="nump">36,339<span></span>
</td>
<td class="nump">67,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=itci_TotalShareholderReturnRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=itci_TotalShareholderReturnRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842741496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available-for-sale</a></td>
<td class="nump">$ 319,968,348<span></span>
</td>
<td class="nump">$ 597,402,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate related fair value of investments with unrealized losses</a></td>
<td class="nump">263,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Investment securities, held in continuous unrealized loss position for less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</a></td>
<td class="nump">254,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember', window );">Contractual Maturity More Than One Year And Less Than Two Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available-for-sale</a></td>
<td class="nump">67,200,000<span></span>
</td>
<td class="nump">188,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available-for-sale</a></td>
<td class="nump">71,652,000<span></span>
</td>
<td class="nump">259,276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate related fair value of investments with unrealized losses</a></td>
<td class="nump">71,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available-for-sale</a></td>
<td class="nump">55,919,000<span></span>
</td>
<td class="nump">124,370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate related fair value of investments with unrealized losses</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available-for-sale</a></td>
<td class="nump">166,164,000<span></span>
</td>
<td class="nump">$ 203,256,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate related fair value of investments with unrealized losses</a></td>
<td class="nump">$ 142,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846373464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment Securities - Summary of Investment Securities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 320,333,000<span></span>
</td>
<td class="nump">$ 596,921,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)</a></td>
<td class="num">(386,000)<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">319,968,348<span></span>
</td>
<td class="nump">597,402,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">71,752,000<span></span>
</td>
<td class="nump">259,304,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(31,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">71,652,000<span></span>
</td>
<td class="nump">259,276,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">26,232,000<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">26,233,000<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">55,955,000<span></span>
</td>
<td class="nump">124,368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">55,919,000<span></span>
</td>
<td class="nump">124,370,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes/Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">166,394,000<span></span>
</td>
<td class="nump">202,749,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">624,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)</a></td>
<td class="num">(249,000)<span></span>
</td>
<td class="num">(117,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 166,164,000<span></span>
</td>
<td class="nump">$ 203,256,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840830920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory, Current (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,483,801<span></span>
</td>
<td class="nump">$ 2,483,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,407,165<span></span>
</td>
<td class="nump">1,781,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,057,160<span></span>
</td>
<td class="nump">2,791,483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 7,948,126<span></span>
</td>
<td class="nump">$ 7,056,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067835595528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 6,359,391<span></span>
</td>
<td class="nump">$ 6,034,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(4,568,667)<span></span>
</td>
<td class="num">(4,036,549)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property Plant and Equipment Net</a></td>
<td class="nump">1,790,724<span></span>
</td>
<td class="nump">1,998,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">408,751<span></span>
</td>
<td class="nump">243,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">423,097<span></span>
</td>
<td class="nump">423,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">4,287,228<span></span>
</td>
<td class="nump">4,127,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 1,240,315<span></span>
</td>
<td class="nump">$ 1,240,315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067844941976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 533,360<span></span>
</td>
<td class="nump">$ 528,118<span></span>
</td>
<td class="nump">$ 477,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840685784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right Of Use Assets and Lease Liabilities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">$ 20,764,458<span></span>
</td>
<td class="nump">$ 24,324,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net lease liabilities</a></td>
<td class="nump">25,400,000<span></span>
</td>
<td class="nump">29,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember', window );">Vehicle Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">5,083,792<span></span>
</td>
<td class="nump">7,295,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net lease liabilities</a></td>
<td class="nump">$ 5,083,792<span></span>
</td>
<td class="nump">$ 7,295,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of long term lease</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Guarantee Obligations</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths', window );">Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths', window );">Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=stpr_NY', window );">NEW YORK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of long term lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=stpr_MD', window );">MARYLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of long term lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum net proceeds of capitalized costs in first twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum net proceeds of capitalized costs later than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067839179352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right Of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease liability</a></td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="nump">$ 29,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(6,731,792)<span></span>
</td>
<td class="num">(5,541,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">18,674,943<span></span>
</td>
<td class="nump">$ 23,600,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_RealEstatesLeaseMember', window );">Real Estates Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2022</a></td>
<td class="nump">3,491,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2023</a></td>
<td class="nump">3,566,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2024</a></td>
<td class="nump">3,675,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2025</a></td>
<td class="nump">3,787,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Year ending December 31, 2026</a></td>
<td class="nump">3,902,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix', window );">Thereafter</a></td>
<td class="nump">9,937,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">28,359,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="num">(8,036,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease liability</a></td>
<td class="nump">20,322,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(3,325,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 16,997,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year six.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_RealEstatesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_RealEstatesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842744440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">$ 20,764,458<span></span>
</td>
<td class="nump">$ 24,324,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, short-term</a></td>
<td class="nump">6,731,792<span></span>
</td>
<td class="nump">5,541,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">18,674,943<span></span>
</td>
<td class="nump">23,600,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease liability</a></td>
<td class="nump">25,400,000<span></span>
</td>
<td class="nump">29,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember', window );">Vehicle Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">5,083,792<span></span>
</td>
<td class="nump">7,295,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, short-term</a></td>
<td class="nump">3,406,317<span></span>
</td>
<td class="nump">2,257,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">1,677,475<span></span>
</td>
<td class="nump">5,038,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease liability</a></td>
<td class="nump">$ 5,083,792<span></span>
</td>
<td class="nump">$ 7,295,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">1.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,325,987<span></span>
</td>
<td class="nump">$ 1,183,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,122,896<span></span>
</td>
<td class="nump">511,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_ItciRealEstatesLeaseMember', window );">ITCI Real Estates Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">15,680,666<span></span>
</td>
<td class="nump">17,029,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, short-term</a></td>
<td class="nump">3,325,475<span></span>
</td>
<td class="nump">3,284,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">16,997,469<span></span>
</td>
<td class="nump">18,562,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease liability</a></td>
<td class="nump">$ 20,322,944<span></span>
</td>
<td class="nump">$ 21,846,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="nump">9.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,448,323<span></span>
</td>
<td class="nump">$ 3,346,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 1,553,338<span></span>
</td>
<td class="nump">$ 1,192,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_ItciRealEstatesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_ItciRealEstatesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067839214072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="nump">$ 29,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(6,731,792)<span></span>
</td>
<td class="num">(5,541,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">18,674,943<span></span>
</td>
<td class="nump">23,600,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember', window );">Vehicle Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">Year ending December 31, 2022</a></td>
<td class="nump">3,471,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">Year ending December 31, 2023</a></td>
<td class="nump">1,681,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">Year ending December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">Year ending December 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">5,152,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="num">(68,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">5,083,792<span></span>
</td>
<td class="nump">7,295,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(3,406,317)<span></span>
</td>
<td class="num">(2,257,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 1,677,475<span></span>
</td>
<td class="nump">$ 5,038,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=itci_VehicleFleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067836828776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,787,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.01<span></span>
</td>
<td class="nump">$ 17.98<span></span>
</td>
<td class="nump">$ 9.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of the options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">1.29%<span></span>
</td>
<td class="nump">2.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Similarly, the 2021 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#8217;s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date.<span></span>
</td>
<td class="text">The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#8217;s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total instrinsic value of stock units outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total instrinsic value of stock units exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate', window );">Share based compensation arrangement by share based payment award vesting start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate', window );">Share based compensation arrangement by share based payment award vesting end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2024<span></span>
</td>
<td class="text">Feb. 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">&#160;Requisite Service Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=itci_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,855,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_TimeBasedRestrictedStockUnitsRSUMember', window );">Time Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total instrinsic value of stock units vested,other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Total instrinsic value of stock units outstanding other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of time based vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100,000<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_MilestoneRestrictedStockUnitsMember', window );">Milestone Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-cash stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of time based vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense related to employee stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options, vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options, vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember', window );">Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,138<span></span>
</td>
<td class="nump">314,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12.84<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of the options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense related to employee stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total instrinsic value of stock units outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total instrinsic value of stock units exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total instrinsic value of stock units vested,other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Total instrinsic value of stock units outstanding other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of time based vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_TotalShareholderReturnRestrictedStockUnitsMember', window );">Total Shareholder Return Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="nump">$ 32.56<span></span>
</td>
<td class="nump">$ 51.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.80%<span></span>
</td>
<td class="nump">91.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Total shareholder return will be determined by dividing the average share value of the Company&#8217;s common stock over the 30 trading days preceding the settlement date by the average share value of the Company&#8217;s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">&#160;Requisite Service Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember', window );">Milestone And Total Shareholder Return Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total instrinsic value of stock units vested,other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Total instrinsic value of stock units outstanding other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of time based vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Vesting End Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Vesting Start Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=itci_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=itci_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_TimeBasedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_TimeBasedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_MilestoneRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_MilestoneRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_TotalShareholderReturnRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_TotalShareholderReturnRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840869608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 34,303,029<span></span>
</td>
<td class="nump">$ 24,115,197<span></span>
</td>
<td class="nump">$ 20,788,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=itci_InventoriableCostsMember', window );">Inventoriable Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share-based compensation expense</a></td>
<td class="nump">1,624,098<span></span>
</td>
<td class="nump">1,342,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share-based compensation expense</a></td>
<td class="nump">9,832,088<span></span>
</td>
<td class="nump">7,072,545<span></span>
</td>
<td class="nump">9,411,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 22,846,843<span></span>
</td>
<td class="nump">$ 15,700,390<span></span>
</td>
<td class="nump">$ 11,377,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=itci_InventoriableCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=itci_InventoriableCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067844715816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">89.40%<span></span>
</td>
<td class="nump">91.60%<span></span>
</td>
<td class="nump">85.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">94.90%<span></span>
</td>
<td class="nump">95.50%<span></span>
</td>
<td class="nump">96.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">1.29%<span></span>
</td>
<td class="nump">2.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840445768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period, Number of Shares</a></td>
<td class="nump">5,477,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted, Number of Shares</a></td>
<td class="nump">683,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, Number of Shares</a></td>
<td class="num">(696,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period, Number of Shares</a></td>
<td class="nump">5,416,017<span></span>
</td>
<td class="nump">5,477,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at end of period, Number of Shares</a></td>
<td class="nump">5,416,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period, Number of Shares</a></td>
<td class="nump">3,838,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 18.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price</a></td>
<td class="nump">30.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted-Average Exercise Price</a></td>
<td class="nump">16.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">21.11<span></span>
</td>
<td class="nump">$ 18.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">21.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 18.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2', window );">Options granted, Weighted-Average Contractual Life</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-Average Contractual Life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm', window );">Options exercised, Weighted-Average Contractual Life</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-Average Contractual Life</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember', window );">Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period, Number of Shares</a></td>
<td class="nump">39,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted, Number of Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, Number of Shares</a></td>
<td class="num">(4,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period, Number of Shares</a></td>
<td class="nump">35,381<span></span>
</td>
<td class="nump">39,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at end of period, Number of Shares</a></td>
<td class="nump">35,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period, Number of Shares</a></td>
<td class="nump">4,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 17.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted-Average Exercise Price</a></td>
<td class="nump">19.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">16.83<span></span>
</td>
<td class="nump">$ 17.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">16.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 19.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2', window );">Options granted, Weighted-Average Contractual Life</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-Average Contractual Life</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm', window );">Options exercised, Weighted-Average Contractual Life</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-Average Contractual Life</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options grants in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangements by share-based payment award options exercises in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067836781576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation- Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year, Number of Shares</a></td>
<td class="nump">251,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.05<span></span>
</td>
<td class="nump">$ 16.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember', window );">Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Time based RSU's granted, Number of Shares</a></td>
<td class="num">(82,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Time based RSU's cancelled, Number of Shares</a></td>
<td class="num">(17,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year, Number of Shares</a></td>
<td class="nump">151,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest, Number of Shares</a></td>
<td class="nump">151,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Exercisable, Number of Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Time based RSU's granted, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Time based RSU's cancelled, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">15.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest, Weighted- Average Exercise Price</a></td>
<td class="nump">16.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited', window );">Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options granted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment arrangement other than options weighted average contractual term of instruments forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067840655880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period, Number of Shares</a></td>
<td class="nump">5,477,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted, Number of Shares</a></td>
<td class="nump">683,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, Number of Shares</a></td>
<td class="num">(696,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired, Number of Shares</a></td>
<td class="num">(49,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period, Number of Shares</a></td>
<td class="nump">5,416,017<span></span>
</td>
<td class="nump">5,477,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at end of period, Number of Shares</a></td>
<td class="nump">5,416,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period, Number of Shares</a></td>
<td class="nump">3,838,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 18.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted-Average Exercise Price</a></td>
<td class="nump">30.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted-Average Exercise Price</a></td>
<td class="nump">16.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired, Weighted-Average Exercise Price</a></td>
<td class="nump">28.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">21.11<span></span>
</td>
<td class="nump">$ 18.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">21.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 18.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2', window );">Options granted, Weighted-Average Contractual Life</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm', window );">Options exercised, Weighted-Average Contractual Life</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm', window );">Options canceled or expired, Weighted-Average Contractual Life</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-Average Contractual Life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-Average Contractual Life</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options grants in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangements by share-based payment award options exercises in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067835575208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year, Number of Shares</a></td>
<td class="nump">251,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.05<span></span>
</td>
<td class="nump">$ 16.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year, Number of Shares</a></td>
<td class="nump">1,311,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Time based RSU's granted, Number of Shares</a></td>
<td class="nump">725,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Time based RSU's vested, Number of Shares</a></td>
<td class="num">(629,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Time based RSU's cancelled, Number of Shares</a></td>
<td class="num">(30,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year, Number of Shares</a></td>
<td class="nump">1,377,685<span></span>
</td>
<td class="nump">1,311,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 18.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Time based RSU's granted, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">36.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Time based RSU's vested, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">16.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Time based RSU's cancelled, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">30.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 28.16<span></span>
</td>
<td class="nump">$ 18.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options forfeited average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options granted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067935622856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year, Number of Shares</a></td>
<td class="nump">251,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 16.05<span></span>
</td>
<td class="nump">$ 16.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember', window );">Milestone and Total Shareholder Return Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year, Number of Shares</a></td>
<td class="nump">72,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Milestone RSUs and TSR RSUs granted, Number of Shares</a></td>
<td class="nump">64,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Time based RSU's vested, Number of Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year, Number of Shares</a></td>
<td class="nump">137,196<span></span>
</td>
<td class="nump">72,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 28.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value</a></td>
<td class="nump">44.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Time based RSU's vested, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of year, Weighted-Average Grant Date Fair Value</a></td>
<td class="nump">$ 35.67<span></span>
</td>
<td class="nump">$ 28.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options grants in period remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067835593880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 543.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_FederalNetOperatingLossCarryForwardExpirationPeriod', window );">Federal net operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=itci_IndefinitePeriodCarryForwardMember', window );">Indefinite Period Carry Forward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">412.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=itci_ExpireIn2037Member', window );">Expire In 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 131.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_FederalNetOperatingLossCarryForwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal net operating loss carry forward expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_FederalNetOperatingLossCarryForwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=itci_IndefinitePeriodCarryForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=itci_IndefinitePeriodCarryForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=itci_ExpireIn2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=itci_ExpireIn2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067844722504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss before Income Taxes (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (221,215,855)<span></span>
</td>
<td class="num">$ (155,615,614)<span></span>
</td>
<td class="num">$ (56,121,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S.</a></td>
<td class="num">(62,904,180)<span></span>
</td>
<td class="num">(71,376,536)<span></span>
</td>
<td class="num">(91,599,320)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (284,120,035)<span></span>
</td>
<td class="num">$ (226,992,150)<span></span>
</td>
<td class="num">$ (147,720,578)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067841654232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Total Income Tax Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,631<span></span>
</td>
<td class="nump">$ 13,513<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,070,458)<span></span>
</td>
<td class="num">(40,049,094)<span></span>
</td>
<td class="num">(8,484,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,070,458<span></span>
</td>
<td class="nump">40,049,094<span></span>
</td>
<td class="nump">8,484,822<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 23,125<span></span>
</td>
<td class="num">$ (23,756)<span></span>
</td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="num">$ (10,232)<span></span>
</td>
<td class="num">$ (3,281)<span></span>
</td>
<td class="nump">$ 5,631<span></span>
</td>
<td class="nump">$ 13,513<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067844878184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax at statutory federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">Other permanent differences</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(1.01%)<span></span>
</td>
<td class="num">(0.67%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(4.63%)<span></span>
</td>
<td class="num">(6.60%)<span></span>
</td>
<td class="num">(13.02%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in effective state tax rates</a></td>
<td class="num">(0.31%)<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
<td class="num">(0.16%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense</a></td>
<td class="nump">2.04%<span></span>
</td>
<td class="nump">3.14%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(18.70%)<span></span>
</td>
<td class="num">(17.65%)<span></span>
</td>
<td class="num">(5.75%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067842821720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 137,561,289<span></span>
</td>
<td class="nump">$ 85,751,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Accrued employee benefits</a></td>
<td class="nump">1,154,766<span></span>
</td>
<td class="nump">1,363,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit</a></td>
<td class="nump">9,321,214<span></span>
</td>
<td class="nump">9,321,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">15,947,281<span></span>
</td>
<td class="nump">15,137,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,660,441<span></span>
</td>
<td class="nump">850,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease', window );">Capital lease</a></td>
<td class="nump">6,177,924<span></span>
</td>
<td class="nump">7,461,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_Deferredtaxliabilitiesrightofuseassetcapitallease', window );">Right of use asset&#8212;capital lease</a></td>
<td class="num">(5,049,103)<span></span>
</td>
<td class="num">(6,228,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment', window );">Unrealized gains on investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(123,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(201,197)<span></span>
</td>
<td class="num">(244,058)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_DeferredTaxAssetsLiabilitiesGross', window );">Net deferred tax asset</a></td>
<td class="nump">166,572,615<span></span>
</td>
<td class="nump">113,290,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(166,572,615)<span></span>
</td>
<td class="num">(113,290,682)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Capital Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_Deferredtaxliabilitiesrightofuseassetcapitallease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Right Of Use Asset Capital Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_Deferredtaxliabilitiesrightofuseassetcapitallease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_Deferredtaxliabilitiesunrealizedgainsoninvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Unrealized Gains On Investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_Deferredtaxliabilitiesunrealizedgainsoninvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067837059416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2019</div></th>
<th class="th"><div>May 31, 2005</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Contributions made by participants for which the company makes matching contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember', window );">Purchase Commitment [Member] | Siegfried Campaign and Lonza Campaign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Bristol-Myers Squibb Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_CollaborativeAgreementUpfrontPayments', window );">Company made an upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_CollaborativeArrangementMilestonePayments', window );">Company made milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_CollaborativeArrangementAmountPayable', window );">Obliged to make milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_CollaborativeArrangementLicenseExpirationDescription', window );">License expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Bristol-Myers Squibb Company [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_RoyaltyPaymentPercentage', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Bristol-Myers Squibb Company [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_RoyaltyPaymentPercentage', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Bristol-Myers Squibb Company [Member] | National Democratic Alliance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_CollaborativeArrangementRemainingPotentialMilestonePayments', window );">Company remaining milestone payment</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Bristol-Myers Squibb Company [Member] | ITCI National Democratic Alliance Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_itci_PaymentOfMilestoneAmount', window );">Payment of milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_CollaborativeAgreementUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_CollaborativeAgreementUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_CollaborativeArrangementAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement amount payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_CollaborativeArrangementAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_CollaborativeArrangementLicenseExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement license expiration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_CollaborativeArrangementLicenseExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_CollaborativeArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_CollaborativeArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_CollaborativeArrangementRemainingPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement remaining potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_CollaborativeArrangementRemainingPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_PaymentOfMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_PaymentOfMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>itci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_itci_ResearchAndOtherCommitmentAxis=itci_SiegfriedCampaignAndLonzaCampaignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">itci_ResearchAndOtherCommitmentAxis=itci_SiegfriedCampaignAndLonzaCampaignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=itci_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=itci_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=itci_NationalDemocraticAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=itci_NationalDemocraticAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=itci_ITCINationalDemocraticAllianceMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=itci_ITCINationalDemocraticAllianceMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140067846619864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Quarterly Financial Information - Schedule of Quarterly Financial Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue, net</a></td>
<td class="nump">$ 25,670,926<span></span>
</td>
<td class="nump">$ 22,207,201<span></span>
</td>
<td class="nump">$ 20,046,561<span></span>
</td>
<td class="nump">$ 15,878,329<span></span>
</td>
<td class="nump">$ 12,454,270<span></span>
</td>
<td class="nump">$ 7,368,594<span></span>
</td>
<td class="nump">$ 1,906,636<span></span>
</td>
<td class="nump">$ 1,083,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="num">(111,675,480)<span></span>
</td>
<td class="num">(99,531,025)<span></span>
</td>
<td class="num">(89,187,615)<span></span>
</td>
<td class="num">(69,097,022)<span></span>
</td>
<td class="num">(73,787,606)<span></span>
</td>
<td class="num">(63,305,048)<span></span>
</td>
<td class="num">(66,778,953)<span></span>
</td>
<td class="num">(50,169,003)<span></span>
</td>
<td class="num">$ (369,491,142)<span></span>
</td>
<td class="num">$ (254,040,610)<span></span>
</td>
<td class="num">$ (154,072,463)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">270,617<span></span>
</td>
<td class="nump">392,695<span></span>
</td>
<td class="nump">421,028<span></span>
</td>
<td class="nump">483,750<span></span>
</td>
<td class="nump">644,390<span></span>
</td>
<td class="nump">752,829<span></span>
</td>
<td class="nump">1,160,059<span></span>
</td>
<td class="nump">1,678,203<span></span>
</td>
<td class="nump">1,568,090<span></span>
</td>
<td class="nump">4,235,481<span></span>
</td>
<td class="nump">6,291,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,125<span></span>
</td>
<td class="num">(23,756)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(10,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,281)<span></span>
</td>
<td class="nump">5,631<span></span>
</td>
<td class="nump">13,513<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,733,937)<span></span>
</td>
<td class="num">$ (76,908,004)<span></span>
</td>
<td class="num">$ (68,743,782)<span></span>
</td>
<td class="num">$ (52,739,943)<span></span>
</td>
<td class="num">$ (60,699,178)<span></span>
</td>
<td class="num">$ (55,183,625)<span></span>
</td>
<td class="num">$ (63,712,258)<span></span>
</td>
<td class="num">$ (47,410,602)<span></span>
</td>
<td class="num">$ (284,125,666)<span></span>
</td>
<td class="num">$ (227,005,663)<span></span>
</td>
<td class="num">$ (147,722,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
<td class="num">$ (3.23)<span></span>
</td>
<td class="num">$ (2.68)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>d234590d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:itci="http://www.intracellulartherapies.com/20211231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="itci-20211231.xsd" xlink:type="simple"/>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P10_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_10_2020To01_10_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-01-10</startDate>
            <endDate>2020-01-10</endDate>
        </period>
    </context>
    <context id="P09_15_2020To09_15_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="PAsOn09_15_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="PAsOn01_10_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2020-01-10</instant>
        </period>
    </context>
    <context id="P01_07_2022To01_07_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="PAsOn02_25_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">itci:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IndefinitePeriodCarryForwardMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">itci:IndefinitePeriodCarryForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ExpireIn2037MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">itci:ExpireIn2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:TimeBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:RealEstatesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:VehicleFleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="itci:ResearchAndOtherCommitmentAxis">itci:SiegfriedCampaignAndLonzaCampaignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:VehicleFleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="itci:ResearchAndOtherCommitmentAxis">itci:SiegfriedCampaignAndLonzaCampaignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InventoriableCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">itci:InventoriableCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:TimeBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">itci:VehicleFleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:VehicleFleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerThreeMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">itci:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">itci:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">itci:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CaplytaMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">itci:CaplytaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InventoriableCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">itci:InventoriableCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RealEstateLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">itci:RealEstateLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ITCINationalDemocraticAllianceMemberMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">itci:ITCINationalDemocraticAllianceMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">itci:ClinicalTralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">itci:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">itci:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CaplytaMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">itci:CaplytaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:ItciRealEstatesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">itci:VehicleFleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">itci:ClinicalTralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CaplytaMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">itci:CaplytaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_10_2020To01_10_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-10</startDate>
            <endDate>2020-01-10</endDate>
        </period>
    </context>
    <context id="P09_15_2020To09_15_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2018_NYsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2019_MDsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-05-31</startDate>
            <endDate>2005-05-31</endDate>
        </period>
    </context>
    <context id="P12_01_2013To12_31_2013_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="P12_23_2019To12_23_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_NationalDemocraticAllianceMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">itci:NationalDemocraticAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-23</startDate>
            <endDate>2019-12-23</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:TotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_12_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="PAsOn01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="P01_07_2022To01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="P12_01_2014To12_31_2014_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">itci:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_27_2020_AmtTaxCreditMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">itci:AmtTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="P03_31_2020To03_31_2020_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2018_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">itci:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2020_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">itci:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="P09_12_2019To09_12_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Segment">
        <measure>itci:Segment</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2021To12_31_2021">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2021To12_31_2021">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      id="hidden37872734">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis"
      id="hidden37872336">P3M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:EntityCentralIndexKey contextRef="P01_01_2021To12_31_2021">0001567514</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2021To12_31_2021">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P01_01_2021To12_31_2021">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2021To12_31_2021">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2021To12_31_2021">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2021To12_31_2021">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2021To12_31_2021">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2021To12_31_2021">001-36274</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2021To12_31_2021">Intra-Cellular Therapies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2021To12_31_2021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2021To12_31_2021">36-4742850</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2021To12_31_2021">430 East 29th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2021To12_31_2021">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2021To12_31_2021">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2021To12_31_2021">10016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2021To12_31_2021">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2021To12_31_2021">440-9333</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2021To12_31_2021">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2021To12_31_2021">ITCI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2021To12_31_2021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2021To12_31_2021">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2021To12_31_2021">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2021To12_31_2021">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2021To12_31_2021">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2021To12_31_2021">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2021To12_31_2021">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2021To12_31_2021">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2021To12_31_2021">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="P01_01_2021To12_31_2021">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn06_30_2020"
      decimals="-8"
      unitRef="Unit_USD">3200000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn02_25_2022"
      decimals="INF"
      unitRef="Unit_shares">93593748</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="P01_01_2021To12_31_2021">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="P01_01_2021To12_31_2021">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P01_01_2021To12_31_2021">Baltimore, MD</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">92364990</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">60045933</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">319968348</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">597402126</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">20155994</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">10764583</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">7948126</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">7056385</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">25443372</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">14235455</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">467280830</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">690904482</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1790724</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1998346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">20764458</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">24324762</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">86084</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">86084</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">489922096</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">717313674</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">8691220</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">5501825</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">11072996</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">7896942</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <itci:AccruedCustomerProgramsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5963610</itci:AccruedCustomerProgramsCurrent>
    <itci:AccruedCustomerProgramsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">3005175</itci:AccruedCustomerProgramsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">6731792</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">5541802</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">20896860</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">14907479</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">53356478</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">36853223</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">18674943</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">23600347</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">72031421</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">60453570</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">81886965</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">81886965</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">80463089</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">80463089</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">8189</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">8046</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1639475837</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1593475506</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-1221229698</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-937104032</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-363653</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">480584</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">417890675</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">656860104</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">489922096</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">717313674</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">81707874</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">22530753</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_GrantMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">2095143</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_GrantMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">282226</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_GrantMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">60613</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">83803017</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">22812979</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">60613</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <itci:Costofproductsales
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">8034589</itci:Costofproductsales>
    <itci:Costofproductsales
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1895029</itci:Costofproductsales>
    <itci:Costofproductsales
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</itci:Costofproductsales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">88845513</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">65782137</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">89124838</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">272611040</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">186363444</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">64947625</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">369491142</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">254040610</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">154072463</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-285688125</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-231227631</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-154011850</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1568090</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">4235481</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">6291272</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284120035</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-226992150</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-147720578</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5631</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">13513</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284125666</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-227005663</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-147722178</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.68</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">81253394</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">70364800</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">55186206</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284125666</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-227005663</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-147722178</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-844237</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">352267</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">796074</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284969903</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-226653396</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-146926104</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">54895295</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">5490</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">880753339</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-562376191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-667757</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="0"
      unitRef="Unit_USD">317714881</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">596558</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">59</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">3235542</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">3235601</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">15644</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">2</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">194203</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">194205</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">20788688</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">20788688</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-147722178</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-147722178</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">796074</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">796074</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">55507497</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">5551</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">904971772</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-710098369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">128317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">195007271</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">23409458</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">2341</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">652709670</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">652712011</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">1536797</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">153</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">11464765</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">11464918</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">9337</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">214102</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">214103</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">24115197</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">24115197</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-227005663</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-227005663</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">352267</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">352267</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">80463089</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">8046</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">1593475506</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-937104032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">480584</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">656860104</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">1419331</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">143</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">11518768</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">11518911</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">4545</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">178534</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">178534</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">34303029</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">34303029</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-284125666</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284125666</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-844237</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-844237</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">81886965</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">8189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">1639475837</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-1221229698</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_USD">-363653</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">417890675</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284125666</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-227005663</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-147722178</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">533360</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">528118</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">477121</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">34303029</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">24115197</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">20788688</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">178534</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">214103</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">194205</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">4079828</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">648248</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">1131597</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">9391411</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">10764583</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">891741</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">7056385</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">11207917</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">7921670</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-1465384</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-264609</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-264609</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">3189395</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-1923199</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-6536036</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">12123870</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">198036</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">3327095</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-175110</itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent>
    <itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-73160</itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent>
    <itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">889468</itci:IncreaseDecreaseInOperatingLeaseLiabilititesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-259543485</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-230072845</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-127983241</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">224574687</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">755629547</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">80720301</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">505244056</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">275601271</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">258857683</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">325738</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">266724</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">700395</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">280343631</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-480295000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">177436987</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">11518911</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">11464918</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">3235601</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">652712011</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">11518911</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">664176929</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">3235601</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">32319057</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-46190916</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">52689347</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">61445933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">107636849</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="0"
      unitRef="Unit_USD">54947502</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">93764990</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">61445933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">107636849</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5631</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1600</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">1600</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis"
      decimals="0"
      unitRef="Unit_USD">107809</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">8917935</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2020To12_31_2020_RealEstateLeaseMemberusgaapPropertySubjectToOrAvailableForOperatingLeaseAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">219703</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">92364990</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">60045933</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">107636849</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">93764990</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">61445933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">107636849</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Organization &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Intra-Cellular Therapies, Inc. (the &#x201c;Company&#x201d;), through its wholly-owned operating subsidiaries, ITI, Inc. (&#x201c;ITI&#x201d;) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (&#x201c;CNS&#x201d;). In December 2019, the Company announced that CAPLYTA&lt;div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px"&gt;TM&lt;/div&gt; (lumateperone) had been approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for the treatment of schizophrenia in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA in late March 2020. Additionally, in December 2021, the Company announced that CAPLYTA had been approved by the FDA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate (42mg/day). As used in these Notes to Consolidated Financial Statements, &#x201c;CAPLYTA&#x201d; refers to lumateperone approved by the FDA for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder in adults, and &#x201c;lumateperone&#x201d; refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and depressive episodes associated with bipolar I or II disorder. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0&#160;million. On September&#160;15, 2020, the Company completed &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt; public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8&#160;million. On January&#160;7, 2022, the Company completed a public offering of common stock in which the Company sold 10,952,381 shares of common stock at an offering price of $42.00 per share for aggregate gross proceeds of $460.0&#160;million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $433.7&#160;million. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Possible sources of funds include public or private sales of the Company&#x2019;s equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company&#x2019;s product candidates and technology and, to a lesser extent, grant funding. On August&#160;30, 2019, the Company filed a universal shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3,&lt;/div&gt; which was declared effective by the SEC on September&#160;12, 2019, on which the Company registered for sale up to $350&#160;million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which included up to $75&#160;million of common stock that the Company could issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August&#160;29, 2019 for the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;at-the-market&#x201d;&lt;/div&gt;&lt;/div&gt; equity program. On September&#160;10, 2020, the Company terminated the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;at-the-market&#x201d;&lt;/div&gt;&lt;/div&gt; equity program sales agreement with SVB Leerink LLC. During the year ended December&#160;31, 2020, the Company issued an aggregate 742,791 shares of common stock under the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;at-the-market&#x201d;&lt;/div&gt;&lt;/div&gt; equity program which resulted in the Company receiving net proceeds of $17.9&#160;million. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In addition, on January&#160;6, 2020, the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&lt;/div&gt; filed an automatic shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3&lt;/div&gt; with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a &#x201c;well-known seasoned issuer&#x201d; under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_10_2020To01_10_2020"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn01_10_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">29.50</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_10_2020To01_10_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">295000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_10_2020To01_10_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">277000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_15_2020To09_15_2020"
      decimals="INF"
      unitRef="Unit_shares">12666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn09_15_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">30.00</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P09_15_2020To09_15_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">380000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P09_15_2020To09_15_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">357800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_07_2022To01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">10952381</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn01_07_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">42.00</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_07_2022To01_07_2022"
      decimals="-5"
      unitRef="Unit_USD">460000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_07_2022To01_07_2022"
      decimals="-5"
      unitRef="Unit_USD">433700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <itci:SecuritiesAuthorizedAmountForIssuance
      contextRef="PAsOn09_12_2019_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_USD">350000000</itci:SecuritiesAuthorizedAmountForIssuance>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_12_2019To09_12_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-6"
      unitRef="Unit_USD">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">742791</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">17900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing, and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Investment Securities &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Investment securities may consist of investments in U.S. Treasuries, various U.S. governmental agency debt securities, corporate bonds, certificates of deposit, and other fixed income securities with an average maturity of twelve months or less. Management classifies the Company&#x2019;s investments as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale.&lt;/div&gt;&lt;/div&gt; Such securities are carried at estimated fair value, with any unrealized holding gains or losses reported, net of any tax effects reported, as accumulated other comprehensive (loss) income, which is a separate component of stockholders&#x2019; equity. Realized gains and losses and declines in value judged to be other-than-temporary, if any, are included in consolidated results of operations. A decline in the market value of any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; security below cost that is deemed to be other-than-temporary results in a reduction in fair value, which is charged to earnings in that period, and a new cost basis for the security is established. Dividend and interest income are recognized as interest income on the consolidated statements of operations when earned. The cost of securities sold is calculated using the specific identification method. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company monitors its investment portfolio for overall risk, specifically credit loss, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;quarterly&lt;/div&gt; or more frequently if circumstances warrant. The Company has estimated the expected credit loss over the lifetime of the asset and has determined an allowance for credit losses is not material with respect to the investment portfolio. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies the fair value method under ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements and Disclosures&lt;/div&gt;&lt;/div&gt;. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;2&#x2014;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#x2014;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has no assets or liabilities that were measured for significant unobservable inputs (Level 3 assets and liabilities) as of December&#160;31, 2021 and December&#160;31, 2020. The carrying value of cash held in money market funds of approximately $56.5&#160;million as of December&#160;31, 2021 and $27.9&#160;million as of December&#160;31, 2020 is included in cash and cash equivalents and approximates market value based on quoted market price or Level&#160;1 inputs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; investment securities are identified in the following tables (in thousands): &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reporting&#160;Date&#160;Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&#160;for&lt;br/&gt; Identical&lt;br/&gt; Assets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money Market Funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;376,507&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,539&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;319,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reporting&#160;Date&#160;Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&#160;for&lt;br/&gt; Identical&lt;br/&gt; Assets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money Market Funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;625,319&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,917&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;597,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits, and lease liabilities, short term, to approximate their fair value because of their relatively short maturities at December&#160;31, 2021 and December&#160;31, 2020. Management believes that the risks associated with the Company&#x2019;s financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash is collateral used under the letter of credit arrangement for the Company&#x2019;s vehicle lease agreement (see Note &lt;div style="display:inline;"&gt;6&lt;/div&gt;). The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-18,&lt;/div&gt; &#x201c;Restricted Cash&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-18&#x201d;)&lt;/div&gt; and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable, net &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers&#x2019; credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a Customer&#x2019;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of December&#160;31, 2021 and 2020. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable. As of December&#160;31, 2021 and 2020, our credit loss reserve on receivables was not significant. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;years ended December&#160;31, 2021 and 2020, approximately $20.1&#160;million and $10.8&#160;million, respectively, of the Company&#x2019;s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 60 days. For the years ended December&#160;31, 2021 and 2020, the Company had a grant receivable of approximately $0.1&#160;million and $0, respectively. For the years ended December&#160;31, 2021 and 2020, 96% of sales were generated from three major industry wholesalers. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;Three individual customers accounted for approximately 40%, 28%, and 28% and 39%, 29%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt;&#160;28% of product sales for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company believes that such customers are of high credit quality. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; (&#x201c;FIFO&#x201d;) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company capitalizes inventory costs associated with the Company&#x2019;s products after regulatory approval when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:hidden37872336"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC&#160;Topic No.&#160;360, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property, Plant and Equipment&lt;/div&gt;&lt;/div&gt;. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date. &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2019, the Company adopted FASB ASC Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC Topic 842&#x201d;). The Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. Payments for identified leases are recognized in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2018, the Company adopted FASB ASC Topic 606,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Revenue from Contracts with Customers &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC Topic 606&#x201d;). The Company did not generate any product related revenue prior to January&#160;1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company&#x2019;s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service.&#160;The reported results for the years ended December&#160;31, 2021 and December&#160;31, 2020 reflect the application of ASC Topic 606. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Sales, net &lt;/div&gt;&lt;/div&gt;(below). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To date, the Company&#x2019;s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Sales, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company&#x2019;s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#x2019;s products. The Company recognizes revenue on product sales when the customer obtains control of the Company&#x2019;s product, which occurs at a point in time (upon delivery). Product revenues are &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reserves for Variable Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company&#x2019;s sales of its product. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company&#x2019;s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company&#x2019;s estimates utilizing payer mix are based on CAPLYTA&#x2019;s actual channel mix in 2021. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#x2019;s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of December&#160;31, 2021 and 2020, therefore, the transaction price was not reduced further during the years ended December&#160;31, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade Discounts and Allowances&lt;/div&gt;&lt;/div&gt;&#x2014; The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the consolidated statements of operations for the years ended December&#160;31, 2021 and December&#160;31, 2020, as well as a reduction to accounts receivable, net on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;&#x2014; Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product&#x2019;s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Provider Chargebacks and Discounts&lt;/div&gt;&lt;/div&gt;&#x2014; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;period-end&lt;/div&gt; that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the years ended December&#160;31, 2021 and December&#160;31, 2020, these amounts were not significant. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Government Rebates&lt;/div&gt;&lt;/div&gt;&#x2014; The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Payer Rebates&lt;/div&gt;&lt;/div&gt;&#x2014; The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Incentives&lt;/div&gt;&lt;/div&gt;&#x2014; Other incentives which the Company offers include voluntary patient assistance programs, such as the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-pay&lt;/div&gt; assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payments&lt;/div&gt; required by payers. The calculation of the accrual for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-pay&lt;/div&gt; assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost of Product Sales &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-9%&lt;/div&gt; on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prior to the FDA approval of CAPLYTA, the Company ex&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;pen&lt;/div&gt;sed all costs associated with the manufacturing of lumateperone as part of research and development expenses. The cost of product sales in the years ended December&#160;31, 2021 and 2020 are lower than incurred because of previously expensed inventory. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development, Including Clinical Trial Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors, among other factors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#x2019;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the year ended December&#160;31, 2021 the Company had no material change in estimate which related to the prior year estimates of accrued expenses for clinical trials. For the years ended December&#160;31, 2020 and 2019, we recorded a change in estimate of approximately $2.3&#160;million and $5.3&#160;million, respectively, both related to the prior year estimates of accrued expenses for clinical trials that resulted in a reduction of research and development expenses. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Advertising Expense &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the FDA approval of CAPLYTA, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. The Company incurred $82.5&#160;million, $36.3&#160;million, and $0 in advertising costs during the years ended December&#160;31, 2021, 2020, and 2019, respectively, related to its marketed product, CAPLYTA. &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s effective tax rate for the years ended December&#160;31, 2021, 2020, and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (&#x201c;AMT&#x201d;) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December&#160;31, 2021.&#160;The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $0.3&#160;million to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December&#160;31, 2019 and received the refund in July 2020. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or losses on its investment securities in a separate statement of comprehensive loss for each period. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Share-based payments are accounted for in accordance with the provisions of ASC Topic&#160;718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt;. The fair value of share-based payments related to stock options is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the &#x201c;Black-Scholes Model&#x201d;). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 accounts for forfeitures as they occur. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company utilizes the Black-Scholes Model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes Model, require the input of subjective assumptions, and changes &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Expected volatility rates for quarterly periods prior to December&#160;31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company&#x2019;s common stock. In the fourth quarter of 2019 and for all periods thereafter, expected volatility rates are based entirely on the historical volatility of the Company&#x2019;s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the &#x201c;simplified method,&#x201d; which defines expected life as the midpoint between the vesting date and the end of the contractual term. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A restricted stock unit (&#x201c;RSU&#x201d;) is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company&#x2019;s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the first quarter of 2020, the Company granted performance-based RSUs for approximately 86,000 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;the approval of a planned supplemental new drug application (&#x201c;sNDA&#x201d;) by the FDA (the &#x201c;2020 Milestone RSUs&#x201d;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#x2019;s peers (the &#x201c;2020 TSR RSUs&#x201d;). In the fourth quarter of 2021, the Company received approval from the FDA for the sNDA for the use of CAPLYTA for the treatment of bipolar depression. In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;certain operational milestones (the &#x201c;2021 Milestone RSUs&#x201d;, and collectively with the 2020 Milestone RSUs, the &#x201c;Milestone RSUs&#x201d;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#x2019;s peers (the &#x201c;2021 TSR RSUs,&#x201d; and collectively with the 2020 TSR RSUs, the &#x201c;TSR RSUs&#x201d;). The Milestone RSUs are recognized when it is probable that the performance metrics will be obtained. The TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the respective agreements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic&#160;740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Equity instruments issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; for services are accounted for under the provisions of ASC Topic&#160;718 and ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;505-50,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity/Equity-Based Payments to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Employees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date&#160;or the date the required services are completed and are marked to market during the service&#160;period. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2018, the Company&#x2019;s stockholders approved the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company&#x2019;s stockholders approved the Company&#x2019;s 2018 Amended and Restated Equity Incentive Plan (the &#x201c;Amended 2018 Plan&#x201d;) pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. &lt;/div&gt;   &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Award&lt;/div&gt; Plan (the &#x201c;2019 Inducement Plan&#x201d;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&#160;Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of December&#160;31, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock option grants and RSUs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,451,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,517,622&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,039,945&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,598,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,600,083&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,268,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;TSR RSUs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently Issued Accounting Standards &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;held-to-maturity&lt;/div&gt;&lt;/div&gt; debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January&#160;1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January&#160;1, 2020 and for the years ended December&#160;31, 2021 and 2020. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing, and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the consolidated balance sheets. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <itci:CashAndCashEquivalentMaximumMaturityPeriod contextRef="P01_01_2021To12_31_2021">P3M</itci:CashAndCashEquivalentMaximumMaturityPeriod>
    <itci:AvailableForSaleSecuritiesMaturityPeriod contextRef="P01_01_2021To12_31_2021">more than three months</itci:AvailableForSaleSecuritiesMaturityPeriod>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Investment Securities &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Investment securities may consist of investments in U.S. Treasuries, various U.S. governmental agency debt securities, corporate bonds, certificates of deposit, and other fixed income securities with an average maturity of twelve months or less. Management classifies the Company&#x2019;s investments as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale.&lt;/div&gt;&lt;/div&gt; Such securities are carried at estimated fair value, with any unrealized holding gains or losses reported, net of any tax effects reported, as accumulated other comprehensive (loss) income, which is a separate component of stockholders&#x2019; equity. Realized gains and losses and declines in value judged to be other-than-temporary, if any, are included in consolidated results of operations. A decline in the market value of any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; security below cost that is deemed to be other-than-temporary results in a reduction in fair value, which is charged to earnings in that period, and a new cost basis for the security is established. Dividend and interest income are recognized as interest income on the consolidated statements of operations when earned. The cost of securities sold is calculated using the specific identification method. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company monitors its investment portfolio for overall risk, specifically credit loss, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;quarterly&lt;/div&gt; or more frequently if circumstances warrant. The Company has estimated the expected credit loss over the lifetime of the asset and has determined an allowance for credit losses is not material with respect to the investment portfolio. &lt;/div&gt; </us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies the fair value method under ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements and Disclosures&lt;/div&gt;&lt;/div&gt;. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;2&#x2014;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#x2014;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has no assets or liabilities that were measured for significant unobservable inputs (Level 3 assets and liabilities) as of December&#160;31, 2021 and December&#160;31, 2020. The carrying value of cash held in money market funds of approximately $56.5&#160;million as of December&#160;31, 2021 and $27.9&#160;million as of December&#160;31, 2020 is included in cash and cash equivalents and approximates market value based on quoted market price or Level&#160;1 inputs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; investment securities are identified in the following tables (in thousands): &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reporting&#160;Date&#160;Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&#160;for&lt;br/&gt; Identical&lt;br/&gt; Assets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money Market Funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;376,507&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,539&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;319,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reporting&#160;Date&#160;Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&#160;for&lt;br/&gt; Identical&lt;br/&gt; Assets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money Market Funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;625,319&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,917&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;597,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">56500000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">27900000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; investment securities are identified in the following tables (in thousands): &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reporting&#160;Date&#160;Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&#160;for&lt;br/&gt; Identical&lt;br/&gt; Assets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money Market Funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;376,507&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,539&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;319,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reporting&#160;Date&#160;Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&#160;for&lt;br/&gt; Identical&lt;br/&gt; Assets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money Market Funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 46%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;625,319&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,917&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;597,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 46%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">56539000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">56539000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">71652000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">71652000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26233000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26233000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">55919000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">55919000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">166164000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">166164000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">376507000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">56539000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">319968000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">27917000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">27917000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">259276000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">259276000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">10500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">10500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">124370000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">124370000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">203256000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">203256000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">625319000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">27917000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">597402000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, right of use asset, net, other assets, accounts payable, accrued liabilities, accrued employee benefits, and lease liabilities, short term, to approximate their fair value because of their relatively short maturities at December&#160;31, 2021 and December&#160;31, 2020. Management believes that the risks associated with the Company&#x2019;s financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash is collateral used under the letter of credit arrangement for the Company&#x2019;s vehicle lease agreement (see Note &lt;div style="display:inline;"&gt;6&lt;/div&gt;). The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-18,&lt;/div&gt; &#x201c;Restricted Cash&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-18&#x201d;)&lt;/div&gt; and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable, net &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers&#x2019; credit profiles. The Company reserves against accounts receivable for estimated losses that may arise from a Customer&#x2019;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated collectability losses was not significant as of December&#160;31, 2021 and 2020. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a credit loss reserve against uncollectible accounts receivable as necessary. We extend credit primarily to pharmaceutical wholesale distributors. Customer creditworthiness is monitored and collateral is not required. Historically, we have not experienced credit losses on our accounts receivable. As of December&#160;31, 2021 and 2020, our credit loss reserve on receivables was not significant. &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;years ended December&#160;31, 2021 and 2020, approximately $20.1&#160;million and $10.8&#160;million, respectively, of the Company&#x2019;s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 60 days. For the years ended December&#160;31, 2021 and 2020, the Company had a grant receivable of approximately $0.1&#160;million and $0, respectively. For the years ended December&#160;31, 2021 and 2020, 96% of sales were generated from three major industry wholesalers. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;Three individual customers accounted for approximately 40%, 28%, and 28% and 39%, 29%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt;&#160;28% of product sales for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company believes that such customers are of high credit quality. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. &lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">20100000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">10800000</us-gaap:AccountsReceivableNet>
    <itci:GrantReceivable
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">100000</itci:GrantReceivable>
    <itci:GrantReceivable
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</itci:GrantReceivable>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerThreeMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerOneMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerTwoMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomerThreeMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; (&#x201c;FIFO&#x201d;) basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company capitalizes inventory costs associated with the Company&#x2019;s products after regulatory approval when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:hidden37872336"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC&#160;Topic No.&#160;360, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property, Plant and Equipment&lt;/div&gt;&lt;/div&gt;. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2019, the Company adopted FASB ASC Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC Topic 842&#x201d;). The Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. Payments for identified leases are recognized in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2018, the Company adopted FASB ASC Topic 606,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Revenue from Contracts with Customers &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC Topic 606&#x201d;). The Company did not generate any product related revenue prior to January&#160;1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact on the Company&#x2019;s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service.&#160;The reported results for the years ended December&#160;31, 2021 and December&#160;31, 2020 reflect the application of ASC Topic 606. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Sales, net &lt;/div&gt;&lt;/div&gt;(below). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To date, the Company&#x2019;s only source of product sales has been from sales of CAPLYTA in the United States, which the Company began shipping to customers in March 2020. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Sales, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company&#x2019;s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#x2019;s products. The Company recognizes revenue on product sales when the customer obtains control of the Company&#x2019;s product, which occurs at a point in time (upon delivery). Product revenues are &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reserves for Variable Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company&#x2019;s sales of its product. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include the Company&#x2019;s best estimates that take into consideration a range of possible outcomes which are considered more likely in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. The Company&#x2019;s estimates utilizing payer mix are based on CAPLYTA&#x2019;s actual channel mix in 2021. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#x2019;s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined it was probable that a significant reversal of revenue would not occur in a future period for the estimates detailed below as of December&#160;31, 2021 and 2020, therefore, the transaction price was not reduced further during the years ended December&#160;31, 2021 and 2020. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade Discounts and Allowances&lt;/div&gt;&lt;/div&gt;&#x2014; The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of product sales, net within the consolidated statements of operations for the years ended December&#160;31, 2021 and December&#160;31, 2020, as well as a reduction to accounts receivable, net on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;&#x2014; Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product&#x2019;s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any expired product returns to date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Provider Chargebacks and Discounts&lt;/div&gt;&lt;/div&gt;&#x2014; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who purchase the product directly from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recognized, resulting in a reduction of product revenue and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;period-end&lt;/div&gt; that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the years ended December&#160;31, 2021 and December&#160;31, 2020, these amounts were not significant. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Government Rebates&lt;/div&gt;&lt;/div&gt;&#x2014; The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Payer Rebates&lt;/div&gt;&lt;/div&gt;&#x2014; The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Incentives&lt;/div&gt;&lt;/div&gt;&#x2014; Other incentives which the Company offers include voluntary patient assistance programs, such as the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-pay&lt;/div&gt; assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payments&lt;/div&gt; required by payers. The calculation of the accrual for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-pay&lt;/div&gt; assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company applies the claims for vouchers for product that is in the distribution channel and reduces recognized revenue accordingly. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost of Product Sales &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-9%&lt;/div&gt; on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prior to the FDA approval of CAPLYTA, the Company ex&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;pen&lt;/div&gt;sed all costs associated with the manufacturing of lumateperone as part of research and development expenses. The cost of product sales in the years ended December&#160;31, 2021 and 2020 are lower than incurred because of previously expensed inventory. &lt;/div&gt; </us-gaap:CostOfSalesPolicyTextBlock>
    <itci:RoyaltyPaymentPercentage
      contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</itci:RoyaltyPaymentPercentage>
    <itci:RoyaltyPaymentPercentage
      contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis"
      decimals="2"
      unitRef="Unit_pure">0.09</itci:RoyaltyPaymentPercentage>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development, Including Clinical Trial Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors, among other factors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#x2019;s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the year ended December&#160;31, 2021 the Company had no material change in estimate which related to the prior year estimates of accrued expenses for clinical trials. For the years ended December&#160;31, 2020 and 2019, we recorded a change in estimate of approximately $2.3&#160;million and $5.3&#160;million, respectively, both related to the prior year estimates of accrued expenses for clinical trials that resulted in a reduction of research and development expenses. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <itci:ChangeInAccountingEstimateAmount
      contextRef="P01_01_2020To12_31_2020_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2300000</itci:ChangeInAccountingEstimateAmount>
    <itci:ChangeInAccountingEstimateAmount
      contextRef="P01_01_2019To12_31_2019_ClinicalTralMemberusgaapChangeInAccountingEstimateByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5300000</itci:ChangeInAccountingEstimateAmount>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Advertising Expense &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the FDA approval of CAPLYTA, the Company began to incur advertising costs in connection with the subsequent commercial launch of CAPLYTA in 2020. Advertising costs are expensed when services are rendered. The Company incurred $82.5&#160;million, $36.3&#160;million, and $0 in advertising costs during the years ended December&#160;31, 2021, 2020, and 2019, respectively, related to its marketed product, CAPLYTA. &lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2021To12_31_2021_CaplytaMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">82500000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2020To12_31_2020_CaplytaMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">36300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2019To12_31_2019_CaplytaMembersrtProductOrServiceAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s effective tax rate for the years ended December&#160;31, 2021, 2020, and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (&#x201c;AMT&#x201d;) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, and a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the year ended December&#160;31, 2021.&#160;The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $0.3&#160;million to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December&#160;31, 2019 and received the refund in July 2020. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn03_27_2020_AmtTaxCreditMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;All components of comprehensive loss, including net loss, are reported in the financial statements in the period in which they are incurred. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or losses on its investment securities in a separate statement of comprehensive loss for each period. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Share-based payments are accounted for in accordance with the provisions of ASC Topic&#160;718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt;. The fair value of share-based payments related to stock options is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the &#x201c;Black-Scholes Model&#x201d;). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For all awards granted with time-based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 accounts for forfeitures as they occur. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company utilizes the Black-Scholes Model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes Model, require the input of subjective assumptions, and changes &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Expected volatility rates for quarterly periods prior to December&#160;31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company&#x2019;s common stock. In the fourth quarter of 2019 and for all periods thereafter, expected volatility rates are based entirely on the historical volatility of the Company&#x2019;s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the &#x201c;simplified method,&#x201d; which defines expected life as the midpoint between the vesting date and the end of the contractual term. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A restricted stock unit (&#x201c;RSU&#x201d;) is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company&#x2019;s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the first quarter of 2020, the Company granted performance-based RSUs for approximately 86,000 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;the approval of a planned supplemental new drug application (&#x201c;sNDA&#x201d;) by the FDA (the &#x201c;2020 Milestone RSUs&#x201d;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#x2019;s peers (the &#x201c;2020 TSR RSUs&#x201d;). In the fourth quarter of 2021, the Company received approval from the FDA for the sNDA for the use of CAPLYTA for the treatment of bipolar depression. In the first quarter of 2021, the Company granted performance-based RSUs for 64,518 shares of common stock, which vest based on the achievement of a service component and certain milestones that include (i)&#160;certain operational milestones (the &#x201c;2021 Milestone RSUs&#x201d;, and collectively with the 2020 Milestone RSUs, the &#x201c;Milestone RSUs&#x201d;) and (ii)&#160;the achievement of certain comparative shareholder returns against the Company&#x2019;s peers (the &#x201c;2021 TSR RSUs,&#x201d; and collectively with the 2020 TSR RSUs, the &#x201c;TSR RSUs&#x201d;). The Milestone RSUs are recognized when it is probable that the performance metrics will be obtained. The TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the respective agreements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic&#160;740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Equity instruments issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; for services are accounted for under the provisions of ASC Topic&#160;718 and ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;505-50,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity/Equity-Based Payments to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Employees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date&#160;or the date the required services are completed and are marked to market during the service&#160;period. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2018, the Company&#x2019;s stockholders approved the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company&#x2019;s stockholders approved the Company&#x2019;s 2018 Amended and Restated Equity Incentive Plan (the &#x201c;Amended 2018 Plan&#x201d;) pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Award&lt;/div&gt; Plan (the &#x201c;2019 Inducement Plan&#x201d;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&#160;Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of December&#160;31, 2021, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. &lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P03_31_2020To03_31_2020_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">86000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_PerformanceBasedRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">64518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2018_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn05_31_2020_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">314138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock option grants and RSUs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,451,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,517,622&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,039,945&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,598,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,600,083&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,268,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;TSR RSUs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the net loss for the years ended December&#160;31,&#160;2021, 2020 and 2019: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,451,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,517,622&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,039,945&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,598,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,600,083&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,268,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;TSR RSUs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">5451398</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">5517622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">6039945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1598250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1600083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1268679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">68598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">36339</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">67080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently Issued Accounting Standards &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;held-to-maturity&lt;/div&gt;&lt;/div&gt; debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January&#160;1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January&#160;1, 2020 and for the years ended December&#160;31, 2021 and 2020. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Investment Securities &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Investment securities consisted of the following (in thousands): &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; (Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,752&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,955 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,394 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;) &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;320,333 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(386&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;319,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; (Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;624&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;596,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;650&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(169&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;597,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has classified all of its investment securities as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale,&lt;/div&gt;&lt;/div&gt; including those with maturities beyond one year, as current assets on the consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of December&#160;31, 2021 and 2020, the Company held $67.2&#160;million and $188.5&#160;million, respectively, of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; investment securities with contractual maturity dates more than one year and less than two&#160;years, with the remainder of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; investment securities having contractual maturity dates less than one year. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The aggregate related fair value of investments with unrealized losses as of December&#160;31, 2021 was $263.5&#160;million, which consisted of $71.7&#160;million from U.S. government agency securities, $49.9&#160;million of commercial paper, and $142&#160;million of corporate notes/bonds. $9.5&#160;million of the aggregate fair value of investments with unrealized losses as of December&#160;31, 2021 has been held in a continuous unrealized loss position for over than 12 months, with the remaining $254.1&#160;million held in a continuous unrealized loss position for less than 12 months. As of December&#160;31, 2020, the aggregate related fair value of investments with unrealized losses was $372.3&#160;million and had been held in a continuous unrealized loss position for less than 12 months. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. &lt;/div&gt; </us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Investment securities consisted of the following (in thousands): &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; (Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,752&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,955 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,919 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,394 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;) &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,164 &lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;320,333 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(386&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;319,968&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; (Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt; Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. Government Agency Securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Certificates of Deposit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial Paper&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;124,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Notes/Bonds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;624&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;596,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;650&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(169&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;597,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">71752000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">71652000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">26232000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">26233000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">55955000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">55919000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">166394000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">249000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">166164000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">320333000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">386000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">319968000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">259304000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">259276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">124368000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">124370000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">202749000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">624000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">117000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">203256000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">596921000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">650000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">169000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">597402000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">67200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2020_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">188500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">263500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_USGovernmentAgenciesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">71700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">49900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">142000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">9500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">254100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">372300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Inventory &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Inventory consists of the following: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw materials&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,483,801&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2,483,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Work in process&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,407,165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,781,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,057,160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2,791,483&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,948,126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7,056,385&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Inventory consists of the following: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw materials&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,483,801&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2,483,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Work in process&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,407,165&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,781,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,057,160&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2,791,483&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,948,126&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7,056,385&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">2483801</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">2483801</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">2407165</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1781101</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">3057160</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">2791483</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">7948126</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">7056385</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Property and Equipment &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of the following: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:64%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;408,751&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;243,532&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;423,097&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;423,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Scientific equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,287,228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,127,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,240,315&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,240,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,359,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,034,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,568,667&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,036,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,790,724&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,998,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $0.5&#160;million, respecti&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;v&lt;/div&gt;ely. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of the following: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:64%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;408,751&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;243,532&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;423,097&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;423,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Scientific equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,287,228&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,127,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,240,315&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,240,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,359,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,034,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4,568,667&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,036,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,790,724&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,998,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">408751</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">243532</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">423097</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">423097</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">4287228</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">4127951</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">1240315</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      unitRef="Unit_USD">1240315</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">6359391</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">6034895</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">4568667</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">4036549</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1790724</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1998346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Right of Use Assets and Lease Liabilities &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Real Estate Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In 2014, the Company entered into a long-term lease with a related party which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company&#x2019;s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02&lt;/div&gt; for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October&#160;1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March&#160;1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions. The Company has no other significant leases. In addition, no identified leases require allocations between lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the real estate lease balances within the consolidated balance sheet, weighted average remaining real estate lease term, the weighted average discount rates, and operating cash outflows related to real estate leases as of December&#160;31, 2021 and 2020: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:43%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease Assets and Liabilities &#x2013;Real Estate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use assets, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,680,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,029,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,680,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,029,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities, short-term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating&#160;lease&#160;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,325,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,284,540&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&#160;operating&#160;lease&#160;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,997,469&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,562,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&#160;lease&#160;liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,322,944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,846,634&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.09&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,448,323&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,346,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,553,338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,192,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Maturity analysis under the lease agreements are as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,491,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,566,466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,675,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,787,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,902,726&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,937,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,359,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Present value discount&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,036,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Lease liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,322,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,325,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,997,468&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Lease expense for the year ended December&#160;31, 2021, 2020 and 2019 was approximately $3.3&#160;million for each year, respectively. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Vehicle Fleet Lease &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;17, 2019, the Company entered into an agreement (the &#x201c;Vehicle Lease&#x201d;) with a company (the &#x201c;Lessor&#x201d;) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The contractual period of each lease is 12 months, followed by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;month-to-month&lt;/div&gt;&lt;/div&gt; renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4&#160;million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4&#160;million is recorded as restricted cash on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The nature of the lease is one commonly referred to as &#x201c;TRAC&#x201d; lease, as it contains a terminal rental adjustment clause, or &#x201c;TRAC&#x201d; clause.&#x201d; The TRAC clause limits lessee&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;exposure, or likelihood of having a variable lease payment&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-month&lt;/div&gt; period increments. The vehicle leases entered into since March 2020 represent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; transactions. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Vehicle Lease balances within the consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of December&#160;31, 2021 and December&#160;31, 2020: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:36%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease Assets and Liabilities &#x2013; Fleet&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use assets, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5,083,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7,295,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,083,792&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,295,515&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities, short-term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating&#160;lease&#160;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,406,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,257,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&#160;operating&#160;lease&#160;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,677,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,038,253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&#160;lease&#160;liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,083,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,295,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.0 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.0 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,325,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,183,072&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,122,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;511,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the maturity of the Company&#x2019;s fleet lease liability as of December&#160;31, 2021: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,471,479&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,681,294&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,152,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Present value discount&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(68,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,083,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,406,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,677,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Right of use assets and lease liabilities for all operating leases were approximately $20.8&#160;million and $25.4&#160;million, respectively, as of December&#160;31, 2021, and approximately $24.3&#160;million and $29.1&#160;million, respectively, as of December&#160;31, 2020. &lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn09_30_2018_NYsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">P14Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn02_28_2019_MDsrtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">P3Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock contextRef="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the real estate lease balances within the consolidated balance sheet, weighted average remaining real estate lease term, the weighted average discount rates, and operating cash outflows related to real estate leases as of December&#160;31, 2021 and 2020: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:43%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease Assets and Liabilities &#x2013;Real Estate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use assets, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,680,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,029,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,680,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,029,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities, short-term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating&#160;lease&#160;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,325,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,284,540&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&#160;operating&#160;lease&#160;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,997,469&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,562,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&#160;lease&#160;liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,322,944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,846,634&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.3 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.09&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,448,323&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,346,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,553,338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,192,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">15680666</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">17029248</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">15680666</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">17029248</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3325475</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3284540</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">16997469</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">18562094</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">20322944</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">21846634</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="4"
      unitRef="Unit_pure">0.0910</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="4"
      unitRef="Unit_pure">0.0909</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3448323</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3346375</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2021To12_31_2021_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1553338</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2020To12_31_2020_ItciRealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1192739</us-gaap:VariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Maturity analysis under the lease agreements are as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,491,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,566,466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,675,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,787,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2026&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,902,726&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,937,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,359,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Present value discount&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,036,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Lease liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,322,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,325,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,997,468&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3491166</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3566466</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3675196</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3787248</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3902726</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <itci:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">9937065</itci:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">28359867</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">8036924</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">20322943</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3325475</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">16997468</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:RestrictedCash>
    <itci:PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths
      contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</itci:PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths>
    <itci:PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths
      contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</itci:PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths>
    <itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Vehicle Lease balances within the consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of December&#160;31, 2021 and December&#160;31, 2020: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:36%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease Assets and Liabilities &#x2013; Fleet&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use assets, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Operating&#160;lease&#160;right&#160;of&#160;use&#160;assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5,083,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7,295,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,083,792&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,295,515&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities, short-term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating&#160;lease&#160;liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,406,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,257,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Current&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&#160;operating&#160;lease&#160;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,677,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,038,253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&#160;lease&#160;liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,083,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,295,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.0 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.0 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,325,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,183,072&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,122,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;511,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">5083792</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">7295515</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">5083792</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">7295515</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3406317</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">2257262</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1677475</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">5038253</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">5083792</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">7295515</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="4"
      unitRef="Unit_pure">0.0169</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="4"
      unitRef="Unit_pure">0.0174</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">2325987</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1183072</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1122896</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2020To12_31_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">511471</us-gaap:VariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2021To12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the maturity of the Company&#x2019;s fleet lease liability as of December&#160;31, 2021: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,471,479&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,681,294&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,152,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Present value discount&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(68,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,083,792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,406,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,677,475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3471479</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1681294</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">5152773</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">68981</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">5083792</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">3406317</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_USD">1677475</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">20800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">25400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">24300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">29100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Share-Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, the total number of shares reserved under all equity plans was 17,787,390 and the Company had 5,855,106&#160;shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (&#x201c;ISOs&#x201d;) as defined by the Internal Revenue Code of 1986, as amended, or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally &lt;span style="-sec-ix-hidden:hidden37872734"&gt;one&lt;/span&gt; to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of stock options granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of&#160;grant. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total share-based compensation expense related to all of the Company&#x2019;s share-based awards, including stock options and RSUs granted to employees, directors and consultants recognized during the years ended December&#160;31, 2021, 2020, and 2019, was comprised of the following: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Inventoriable costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,624,098&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,342,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,832,088 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7,072,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,411,056&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Selling, general and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,846,843&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;15,700,390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;11,377,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,303,029 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;24,115,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;20,788,688&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table describes the assumptions used for calculating the value of options granted during the years ended December&#160;31, 2021, 2020, and 2019: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:56%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;89.4%-94.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;91.6%-95.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85.7-96.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.87&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of December&#160;31, 2021, and changes during the period then ended, are summarized as&#160;follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:62%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options granted in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercised in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19.98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average grant date fair value for awards granted during the years ended December&#160;31, 2021, 2020, and 2019 was $0, $12.84 and $0 per share, respectively. The total intrinsic value of the options exercised during the years ended December&#160;31, 2021 was $0.1&#160;million, and $0, respectively, for the years ended December&#160;31, 2020 and 2019. The total intrinsic value of the options outstanding as of December&#160;31, 2021 was $1.3&#160;million. The total intrinsic value of the options exercisable as of December&#160;31, 2021 was $0.2&#160;million. The total fair value of shares vested during the years ended December&#160;31, 2021 was $0.1&#160;million and $0 for the years ended December&#160;31, 2020 and 2019, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The unrecognized share-based compensation expense related to stock option awards at December&#160;31, 2021 was $0.2&#160;million and will be recognized over a weighted-average period of 1.2&#160;years. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding RSU awards under the 2019 Inducement Plan during the period then ended are summarized as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&#160;Per&#160;Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;251,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs vested in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(82,355&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs cancelled in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15.81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151,967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151,967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;The total intrinsic value of the time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $2.7&#160;million, $0 and $0, respectively. The total intrinsic value of the time based RSU&#x2019;s outstanding as of December&#160;31, 2021 was $8.0&#160;million. The total fair&#160;value of time based RSUs vested during the years ended December&#160;31, 2021, 2010 and 2019 was $1.3&#160;million, $0 and $0, respectively. The fair value of time based RSUs is based on the closing price of the Company&#x2019;s common stock on the date of grant. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;As of December&#160;31, 2021, there was $1.4&#160;million of unrecognized compensation costs related to unvested time based RSUs which will be recognized over a weighted-average period of 1.2 years. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;During the year ended December&#160;31, 2020, the Company issued options and time based RSUs totaling 314,138 shares in the 2019 Inducement Plan. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of December&#160;31, 2021, and changes during the year then ended, are summarized as&#160;follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,477,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options granted 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;683,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30.82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercised 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(696,325&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.7 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options canceled or expired 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(49,149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.4&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,416,017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.1 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,416,017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,838,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;The weighted-average grant date fair value for awards granted during the years ended December&#160;31, 2021, 2020 and 2019 was $29.01, $17.98 and $9.17 per share, respectively. The total intrinsic value of the options exercised during the years ended December&#160;31, 2021, 2020 and 2019 was $19.6&#160;million, $11.1&#160;million and $3.1&#160;million, respectively. The total intrinsic value of the options outstanding as of December&#160;31, 2021 was $172.4&#160;million. The total intrinsic value of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;options exercisable as of December 31, 2021 was&lt;/div&gt;&#160;$127.9&#160;million. The total fair value of shares vested during the years ended December&#160;31, 2021, 2020 and 2019 was $10.6&#160;million, $13.4&#160;million and $12.0&#160;million, respectively. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The unrecognized share-based compensation expense related to stock option awards at December&#160;31, 2021 was $18.4&#160;million, and will be recognized over a weighted-average period of 1.7&#160;years. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding time based RSU activity, including with respect to grants to employees as of December&#160;31, 2021, and changes during the year then ended, is summarized as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&#160;Per&#160;Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,311,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.7&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs granted in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;725,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs vested in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(629,540&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.8 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs cancelled in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.8&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,377,685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.5 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total intrinsic value of the time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $22.3&#160;million,&#160;$14.6&#160;million and $3.1&#160;million, respectively. The total intrinsic value of the time based RSU&#x2019;s outstanding as of December&#160;31, 2021 was $72.1&#160;million. The total fair value of time based RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $11.1&#160;million, $7.2&#160;million and $4.6&#160;million, respectively. The fair value of time based RSUs is based on the closing price of the Company&#x2019;s common stock on the date of grant. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, there was $24.4&#160;million of unrecognized compensation costs related to unvested time based RSUs which will be recognized over a weighted-average period of 2.0 years. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; share-based compensation expense related to Milestone RSU&#x2019;s for the years ended December&#160;31, 2021, 2020 and 2019 of approximately $0.6&#160;million, $0, and $0.9&#160;million, respectively. The total fair value of shares vested with respect to Milestone RSUs during the years ended December&#160;31, 2021, 2020 and 2019 was $0, $0 and $0.9&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information related to the Company&#x2019;s Milestone RSUs and the TSR RSUs during the year ended December&#160;31,&#160;2021 are summarized as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&#160;Per&#160;Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72,678&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.1 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Milestone RSUs and TSR RSUs granted in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.1 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Milestone RSUs and TSR RSUs vested in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total intrinsic value of the Company&#x2019;s Milestone RSUs and the TSR RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $0, $1.6&#160;million, and $2.2&#160;million, respectively. The total intrinsic value of the Company&#x2019;s Milestone RSU&#x2019;s and the TSR RSUs outstanding as of December&#160;31, 2021 was $7.2&#160;million. The total fair value of the Company&#x2019;s Milestone RSUs and the TSR RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $0, $1.1&#160;million, and $0.9&#160;million, respectively. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, there was $3.2&#160;million of unrecognized compensation costs related to unvested Milestone RSU grants and TSR RSU grants which will be recognized over a weighted average period of 1.6 years. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The weighted average estimated fair value per share of the 2020 TSR RSUs granted was $32.56, and the 2021 TSR RSUs granted was $51.18, which were derived from Monte Carlo simulations. Significant assumptions utilized in estimating the value of the 2020 awards granted include an expected dividend yield of 0%, a risk-free rate of 1.4%, and expected volatility of 91.3%. Significant assumptions utilized in estimating the value of the 2021 awards granted include an expected dividend yield of 0%, a risk-free rate of 0.2%, and expected volatility of 95.8%. The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#x2019;s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date. Similarly, the 2021 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#x2019;s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company&#x2019;s total shareholder returns, expressed as a percentile ranking of the Company&#x2019;s total shareholder return as compared to the Company&#x2019;s peer group. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company&#x2019;s common stock over the 30 trading days preceding the settlement date by the average share value of the Company&#x2019;s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period. The Company&#x2019;s peer group included companies that compromised the Nasdaq Biotechnology Index at December&#160;31, 2019 and 2020, respectively. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">17787390</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_TwoThousandEighteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5855106</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total share-based compensation expense related to all of the Company&#x2019;s share-based awards, including stock options and RSUs granted to employees, directors and consultants recognized during the years ended December&#160;31, 2021, 2020, and 2019, was comprised of the following: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Inventoriable costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,624,098&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,342,262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,832,088 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7,072,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,411,056&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Selling, general and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,846,843&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;15,700,390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;11,377,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,303,029 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;24,115,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;20,788,688&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_InventoriableCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">1624098</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_InventoriableCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">1342262</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">9832088</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">7072545</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">9411056</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">22846843</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">15700390</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">11377632</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">34303029</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">24115197</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">20788688</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table describes the assumptions used for calculating the value of options granted during the years ended December&#160;31, 2021, 2020, and 2019: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:56%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;89.4%-94.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;91.6%-95.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85.7-96.5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.87&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of December&#160;31, 2021, and changes during the period then ended, are summarized as&#160;follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:62%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options granted in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercised in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19.98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">39728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">17.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P9Y2M12D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">4347</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">19.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">35381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <itci:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P8Y2M12D</itci:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">35381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">4658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">19.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding RSU awards under the 2019 Inducement Plan during the period then ended are summarized as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&#160;Per&#160;Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;251,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs vested in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(82,355&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.2&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs cancelled in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15.81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151,967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151,967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">251867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">82355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P1Y2M12D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">17545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <itci:ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P1Y2M12D</itci:ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">151967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">16.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">151967</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.05</itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</itci:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">8000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2020To12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2019To12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2020_InducementAwardPlanMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">314138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of December&#160;31, 2021, and changes during the year then ended, are summarized as&#160;follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:61%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,477,894&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options granted 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;683,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30.82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercised 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(696,325&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.7 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options canceled or expired 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(49,149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.4&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,416,017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.1 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,416,017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,838,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">5477894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">683597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">30.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021">P9Y2M12D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">696325</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <itci:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2021To12_31_2021">P4Y8M12D</itci:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">49149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">28.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2021To12_31_2021">P8Y4M24D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">5416017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">21.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">5416017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">21.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">3838799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2021To12_31_2021">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">29.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">17.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">19600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">11100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">172400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">127900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">10600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">13400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">12000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">18400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information regarding time based RSU activity, including with respect to grants to employees as of December&#160;31, 2021, and changes during the year then ended, is summarized as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:52%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&#160;Per&#160;Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,311,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.7&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs granted in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;725,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.2 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs vested in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(629,540&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.8 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Time based RSUs cancelled in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.8&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,377,685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.5 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1311877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">725979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">36.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P2Y2M12D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">629540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P0Y9M18D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">30631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">30.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y9M18D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1377685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">28.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">22300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">14600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">72100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">7200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">24400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021_TimeBasedRestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2020To12_31_2020_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2019To12_31_2019_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Information related to the Company&#x2019;s Milestone RSUs and the TSR RSUs during the year ended December&#160;31,&#160;2021 are summarized as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&#160;Per&#160;Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72,678&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.1 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Milestone RSUs and TSR RSUs granted in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.1 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Milestone RSUs and TSR RSUs vested in 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">72678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">28.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">P2Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">64518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">44.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">P2Y1M6D</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <itci:HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">P0Y</itci:HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">137196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">35.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">P1Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="P01_01_2019To12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="PAsOn12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">7200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2020To12_31_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2019To12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2021_MilestoneRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">32.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">51.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To03_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2020To12_31_2020">The 2020 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#x2019;s common stock determined over a three-year performance period ending and vesting after December 31, 2022 but before February 18, 2023, provided the grantee remained in the service of the Company on the settlement date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="P01_01_2020To03_31_2020_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate contextRef="P01_01_2020To12_31_2020">2022-12-31</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate contextRef="P01_01_2020To12_31_2020">2023-02-18</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2021To12_31_2021">Similarly, the 2021 TSR RSUs granted will entitle the grantee to receive a number of shares of the Company&#x2019;s common stock determined over a three-year performance period ending and vesting after December 31, 2023 but before February 23, 2024, provided the grantee remained in the service of the Company on the settlement date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="P01_01_2021To12_31_2021">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate contextRef="P01_01_2021To12_31_2021">2023-12-31</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate>
    <itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate contextRef="P01_01_2021To12_31_2021">2024-02-23</itci:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="P01_01_2021To12_31_2021_TotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis">Total shareholder return will be determined by dividing the average share value of the Company&#x2019;s common stock over the 30 trading days preceding the settlement date by the average share value of the Company&#x2019;s common stock over the 30 trading days beginning on January 1, 2020 and 2021, accordingly, with a deemed reinvestment of any dividends declared during the performance period.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;22, 2017, former President Donald Trump signed into law the &#x201c;Tax Cuts and Jobs Act&#x201d; (&#x201c;TCJA&#x201d;) that significantly reforms the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;). The TCJA, among other things, includes changes to U.S.&#160;federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating loss carryforwards, allows for the expensing of capital expenditures, and puts into effect the migration from a &#x201c;worldwide&#x201d; system of taxation to a territorial system. While the TCJA provide for a territorial tax system, beginning in 2018, it includes two new U.S. tax base erosion provisions, the global intangible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-taxed&lt;/div&gt; income (&#x201c;GILTI&#x201d;) provisions and the base-erosion and anti-abuse tax (&#x201c;BEAT&#x201d;) provisions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s tangible assets. As of the year ended December&#160;31, 2021, the Company&#x2019;s foreign operations do not generate positive income and the Company is not currently subject to the GILTI provisions. The Company has not made an accounting policy election for GILTI and will analyze and formulate its GILTI accounting policy in the period which the Company becomes subject to the GILTI provisions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The BEAT provisions eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The Company has not made any qualifying payments and the BEAT tax is not applicable in 2021. Therefore, the Company has not included any tax impacts of BEAT in its consolidated financial statements for the year ended December&#160;31, 2021. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Loss before income taxes is as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:49%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S.&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(221,215,855&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(155,615,614&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(56,121,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-U.S.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(62,904,180&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(71,376,536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(91,599,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total loss before taxes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(284,120,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(226,992,150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(147,720,578&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total income tax expense for the years ended December&#160;31, 2021, 2020 and 2019 is allocated as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,631&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,513&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(53,070,458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(40,049,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,484,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53,070,458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,049,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,484,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for income taxe&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,631&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,513&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the difference between the statutory federal income tax rate and the effective income tax rate for the years ended December&#160;31, 2021, 2020 and 2019 is as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax at statutory federal rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other permanent differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.60&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign rate differential&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4.63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in effective state tax rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State income tax expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.04&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowanc&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18.70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for income taxes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Deferred income taxes reflect the net tax effect of temporary differences that exist between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. As of December&#160;31, 2021, the Company had $543.4&#160;million of federal net operating loss carryforwards, of which $131.1&#160;million expire at various dates through 2037 and $412.3&#160;million do not expire. The gross amount of the state net operating loss carryforwards is equal to or less than the federal net operating loss carryforwards and expires over various periods based on individual state tax law. In general, businesses with U.S. net operating losses (&#x201c;NOLs&#x201d;) are considered loss corporations for U.S. federal income tax purposes. Pursuant to Section&#160;382 of the Code, loss corporations that undergo an ownership change, as defined under the Code, may be subject to an annual limitation on the amount of NOLs (and certain other tax attributes) available to offset taxable income earned after such ownership change. For the years ended December&#160;31, 2015 through 2021, the Company performed a Section&#160;382 ownership analysis and determined that an ownership change occurred (within the meaning of Section&#160;382 of the Code) in 2015 but not in subsequent periods. Based on the analysis performed through December&#160;31, 2021, however, the Company does not believe that the Section&#160;382 annual limitation will impact the Company&#x2019;s ability to utilize the tax attributes that existed as of the date of the ownership change in a material manner. If the Company experiences an ownership change in the future, the tax benefits related to the NOLs and tax credit carryforwards may be further limited or lost. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following summarizes the significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020, respectively: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&#160;tax&#160;assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,561,289&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85,751,154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued employee benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,154,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,363,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development credit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,321,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,321,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,947,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,137,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,660,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;850,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capital lease&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,177,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,461,587&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use asset&#x2014;capital lease&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,049,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,228,138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unrealized gains on investment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(123,049&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(244,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset before valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,572,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,290,682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166,572,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113,290,682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Based upon the Company&#x2019;s historical operating performance and the reported cumulative net losses to date, the Company presently does not have sufficient objective evidence to support the recovery of its net deferred tax assets. Accordingly, the Company has established a full valuation allowance against its net deferred tax assets in 2021 and 2020, for financial reporting purposes because it is not more likely than not that these deferred tax assets will be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The open years subject to tax audits vary depending on the tax jurisdictions. In the U.S federal jurisdiction, we are no longer subject to income tax audits by taxing authorities for years before 2017. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total amount of unrecognized tax benefits was $1.7&#160;million as of December&#160;31, 2021 and December&#160;31, 2020. If recognized, none of these tax benefits would affect the effective tax rate due to valuation allowances. &lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Loss before income taxes is as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:49%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S.&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(221,215,855&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(155,615,614&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(56,121,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-U.S.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(62,904,180&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(71,376,536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(91,599,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total loss before taxes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(284,120,035&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(226,992,150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(147,720,578&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-221215855</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-155615614</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-56121258</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-62904180</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-71376536</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-91599320</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-284120035</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-226992150</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-147720578</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total income tax expense for the years ended December&#160;31, 2021, 2020 and 2019 is allocated as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,631&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,513&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(53,070,458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(40,049,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,484,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53,070,458&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,049,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,484,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for income taxe&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,631&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,513&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5631</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">13513</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">1600</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-53070458</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-40049094</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-8484822</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-53070458</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-40049094</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">-8484822</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5631</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">13513</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the difference between the statutory federal income tax rate and the effective income tax rate for the years ended December&#160;31, 2021, 2020 and 2019 is as follows: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax at statutory federal rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other permanent differences&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.60&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign rate differential&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(4.63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in effective state tax rates&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State income tax expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.04&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowanc&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18.70&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for income taxes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0060</itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.0101</itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.0067</itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0463</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.0660</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.1302</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0031</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0112</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.0016</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0204</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0314</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.0140</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.1870</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.1765</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">-0.0575</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">543400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_ExpireIn2037MemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">131100000</us-gaap:OperatingLossCarryforwards>
    <itci:FederalNetOperatingLossCarryForwardExpirationPeriod contextRef="P01_01_2021To12_31_2021">2037</itci:FederalNetOperatingLossCarryForwardExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_IndefinitePeriodCarryForwardMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">412300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following summarizes the significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020, respectively: &lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&#160;tax&#160;assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,561,289&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85,751,154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued employee benefits&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,154,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,363,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development credit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,321,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,321,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,947,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,137,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,660,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;850,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capital lease&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,177,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,461,587&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use asset&#x2014;capital lease&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,049,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,228,138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unrealized gains on investment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(123,049&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(244,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset before valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166,572,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,290,682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166,572,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(113,290,682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">137561289</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">85751154</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1154766</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1363082</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">9321214</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">9321214</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">15947281</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">15137990</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1660441</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">850900</us-gaap:DeferredTaxAssetsOther>
    <itci:Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">6177924</itci:Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease>
    <itci:Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">7461587</itci:Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease>
    <itci:Deferredtaxliabilitiesrightofuseassetcapitallease
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5049103</itci:Deferredtaxliabilitiesrightofuseassetcapitallease>
    <itci:Deferredtaxliabilitiesrightofuseassetcapitallease
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">6228138</itci:Deferredtaxliabilitiesrightofuseassetcapitallease>
    <itci:Deferredtaxliabilitiesunrealizedgainsoninvestment
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</itci:Deferredtaxliabilitiesunrealizedgainsoninvestment>
    <itci:Deferredtaxliabilitiesunrealizedgainsoninvestment
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">123049</itci:Deferredtaxliabilitiesunrealizedgainsoninvestment>
    <itci:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">201197</itci:DeferredTaxLiabilitiesDepreciation>
    <itci:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">244058</itci:DeferredTaxLiabilitiesDepreciation>
    <itci:DeferredTaxAssetsLiabilitiesGross
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">166572615</itci:DeferredTaxAssetsLiabilitiesGross>
    <itci:DeferredTaxAssetsLiabilitiesGross
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">113290682</itci:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">166572615</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">113290682</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License and Royalty Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company, pursuant to which the Company holds a license to certain patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; of BMS relating to lumateperone and other specified compounds. The agreement was amended on November&#160;3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop, or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the agreement, the Company made an upfront payment of $1.0&#160;million to BMS in 2005, a milestone payment of $1.25&#160;million in December&#160;2013, and a milestone payment of $1.5&#160;million in December&#160;2014 following the initiation of the Company&#x2019;s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;obligated to pay BMS a $2.0&#160;million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December&#160;20, 2019 and as a result the Company accrued an additional milestone liability of $5.0&#160;million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0&#160;million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75&#160;million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 &#x2013; 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-royalty&lt;/div&gt; payments made in consideration of any sublicense. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The agreement extends, and royalties are payable, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt;&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-product&lt;/div&gt;&lt;/div&gt; basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited.&#160;In connection with the transfer, the Company guaranteed ITI Limited&#x2019;s performance of its obligations under the BMS agreement. The Company expensed approximately $4.1&#160;million and $1.1&#160;million in cost of product sales to satisfy its obligation under the BMS agreement for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Other Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, the Company has committed to purchasing production campaigns for active pharmaceutical ingredients (API) from each of our supply vendors &#x2013; Siegfried Evionnaz SA (&#x201c;Siegfried&#x201d;) and Lonza Ltd. (&#x201c;Lonza&#x201d;). As of December&#160;31, 2021 and 2020, the Company had paid deposits totaling $9.5&#160;million and $3.0&#160;million, respectively, for the Siegfried and Lonza campaigns which are recorded within prepaids and other current assets on the consolidated balance sheets. Over the course of the vendors&#x2019; manufacturing period, the Company will remit payment to the vendor based on the executed agreements. Upon title transfer of the product, the Company will recognize the material as inventory. The API campaigns are expected to be received into inventory during 2022 or the first half of 2023. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Retirement savings plan 401(k) contributions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company sponsors a defined contribution 401(k) plan covering all full-time employees. Participants may elect to contribute their annual &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; earnings up to the federally allowed maximum limits. The Company made a matching contribution of 100% on the first&#160;6% of contributions made by participants in the year ended December&#160;31, 2021, 2020 and 2019. Participant and company contributions vest immediately. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded matching contribution expense of $3.0&#160;million, $1.8&#160;million and $0.7&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the normal course of our business, we are occasionally involved with various claims and litigation. Reserves are established in connection with such matters when a loss is probable and the amount of such loss can be reasonably estimated. At December&#160;31, 2021 and 2020, no material reserves were recorded. The determination of probability and the estimation of the actual amount of any such loss are inherently unpredictable, and it is therefore possible that the eventual outcome of such claims and litigation could exceed the estimated reserves, if any. However, we believe that the likelihood that any such excess might have a material adverse effect on our financial statements is remote. &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <itci:CollaborativeAgreementUpfrontPayments
      contextRef="P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">1000000.0</itci:CollaborativeAgreementUpfrontPayments>
    <itci:CollaborativeArrangementMilestonePayments
      contextRef="P12_01_2013To12_31_2013_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">1250000</itci:CollaborativeArrangementMilestonePayments>
    <itci:CollaborativeArrangementMilestonePayments
      contextRef="P12_01_2014To12_31_2014_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">1500000</itci:CollaborativeArrangementMilestonePayments>
    <itci:CollaborativeArrangementAmountPayable
      contextRef="PAsOn01_31_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">2000000.0</itci:CollaborativeArrangementAmountPayable>
    <itci:CollaborativeArrangementRemainingPotentialMilestonePayments
      contextRef="P12_23_2019To12_23_2019_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_NationalDemocraticAllianceMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">5000000.0</itci:CollaborativeArrangementRemainingPotentialMilestonePayments>
    <itci:PaymentOfMilestoneAmount
      contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ITCINationalDemocraticAllianceMemberMemberusgaapRegulatoryAgencyAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000.0</itci:PaymentOfMilestoneAmount>
    <itci:CollaborativeArrangementAmountPayable
      contextRef="PAsOn12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">14750000</itci:CollaborativeArrangementAmountPayable>
    <itci:RoyaltyPaymentPercentage
      contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</itci:RoyaltyPaymentPercentage>
    <itci:RoyaltyPaymentPercentage
      contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_ProductMembersrtProductOrServiceAxis"
      decimals="2"
      unitRef="Unit_pure">0.09</itci:RoyaltyPaymentPercentage>
    <itci:CollaborativeArrangementLicenseExpirationDescription contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis">through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product</itci:CollaborativeArrangementLicenseExpirationDescription>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2021To12_31_2021_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">4100000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2020To12_31_2020_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:CostOfRevenue>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis"
      decimals="-5"
      unitRef="Unit_USD">9500000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2020_PurchaseCommitmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_SiegfriedCampaignAndLonzaCampaignMemberITCIResearchAndOtherCommitmentAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000.0</us-gaap:Cash>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">3000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Related Parties &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;The Company has no other related party transactions other than the real estate lease for the Company&#x2019;s headquarters in New York, New York disclosed &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in Note 6.&#160;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;No other subsequent events have occurred since the balance sheet date other than the public offering of common stock completed by the Company on January&#160;7, 2022, as disclosed in Note 1. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Unaudited Quarterly Financial Information &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tables herein set forth the Company&#x2019;s unaudited condensed consolidated 2021 and 2020 quarterly statements of operations. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The following table sets forth the Company&#x2019;s unaudited condensed consolidated statements of operations for the 2021 quarters ended: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:40%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&#160;Quarter&#160;Ended&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,670,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,207,201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,046,561&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,878,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(111,675,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(99,531,025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(89,187,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(69,097,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;270,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;392,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;421,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;483,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85,733,937&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76,908,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(68,743,782&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52,739,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The following table sets forth the Company&#x2019;s unaudited condensed consolidated statements of operations for the 2020 quarters ended: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&#160;Quarter&#160;Ended&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,454,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,368,594&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,906,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,083,479&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73,787,606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,305,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(66,778,953&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(50,169,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;644,390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;752,829&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,160,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,678,203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60,699,178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55,183,625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,712,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47,410,602&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The following table sets forth the Company&#x2019;s unaudited condensed consolidated statements of operations for the 2021 quarters ended: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:40%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&#160;Quarter&#160;Ended&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,670,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,207,201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,046,561&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,878,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(111,675,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(99,531,025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(89,187,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(69,097,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;270,617&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;392,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;421,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;483,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85,733,937&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(76,908,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(68,743,782&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52,739,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The following table sets forth the Company&#x2019;s unaudited condensed consolidated statements of operations for the 2020 quarters ended: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&#160;Quarter&#160;Ended&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,454,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,368,594&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,906,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,083,479&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating expenses&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73,787,606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,305,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(66,778,953&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(50,169,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest income&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;644,390&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;752,829&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,160,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,678,203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(60,699,178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55,183,625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,712,258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47,410,602&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="P10_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">25670926</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P07_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">22207201</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P04_01_2021To06_30_2021"
      decimals="0"
      unitRef="Unit_USD">20046561</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">15878329</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="P10_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">111675480</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">99531025</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2021To06_30_2021"
      decimals="0"
      unitRef="Unit_USD">89187615</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">69097022</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P10_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">270617</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P07_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">392695</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="0"
      unitRef="Unit_USD">421028</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">483750</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">23125</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To06_30_2021"
      decimals="0"
      unitRef="Unit_USD">-23756</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">-5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-85733937</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">-76908004</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="0"
      unitRef="Unit_USD">-68743782</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">-52739943</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P10_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P07_01_2021To09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2021To06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:Revenues
      contextRef="P10_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">12454270</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P07_01_2020To09_30_2020"
      decimals="0"
      unitRef="Unit_USD">7368594</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P04_01_2020To06_30_2020"
      decimals="0"
      unitRef="Unit_USD">1906636</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_USD">1083479</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="P10_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">73787606</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2020To09_30_2020"
      decimals="0"
      unitRef="Unit_USD">63305048</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="0"
      unitRef="Unit_USD">66778953</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_USD">50169003</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P10_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">644390</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P07_01_2020To09_30_2020"
      decimals="0"
      unitRef="Unit_USD">752829</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="0"
      unitRef="Unit_USD">1160059</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_USD">1678203</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P10_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-10232</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_USD">-3281</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-60699178</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="0"
      unitRef="Unit_USD">-55183625</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="0"
      unitRef="Unit_USD">-63712258</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_USD">-47410602</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MEBX8\:U*NG+B.!Y+Q;ZOD^G&_CMLVC.(GY."W8B;Z 2<\R$/%Y:&& /6XN+
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M!8#_-TJ9TZ!Z0??]9O$_4$L#!!0    ( ,L]851=O=;%V0(  - '   8
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MR#049*;Q@375BH@%F8H:;U)I2KP!\D4H13Z0IUE*+MY=CER-P8V$F[>!;IM
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MW^IF0\S&F^=I6?^/[K>V7(VB^::L\JQQ-@BR9+5]C;\T1.PY8-KC (T#. X
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M$O6174\47]LS:<&5/N'LL-"W' @#T.^7G*N/B3GFVGLS_0]02P,$%     @
MRSUA5'.;K?C(!0  DPP  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R=
M5VEOW#80_2O$-BA:0-[+=IS#-K!V$B1%TAA9MT51] -7&DFL*5(AJ5UO?WW?
MD*L]<KA!/M@6CQF^F3?S2)^OK+OS-5$0]XTV_F)0A] ^&XU\7E,C_="V9+!2
M6M?(@*&K1KYU)(MHU.C1=#Q^/&JD,H/+\SAWXR[/;1>T,G3CA.^:1KKU%6F[
MNAA,!OW$!U75@2=&E^>MK&A.X;?VQF$TVGHI5$/&*VN$H_)B,)L\NSKA_7'#
M[XI6?N];<"0+:^]X\*:X&(P9$&G* WN0^+.D:]*:'0'&QXW/P?9(-MS_[KV_
MBK$CEH7T=&WU'ZH(]<7@R4 45,I.AP]V]9HV\9RRO]QJ'W^+U6;O>"#RS@?;
M;(R!H%$F_97WFSQ\B\%T8S"-N--!$>4+&>3EN;,KX7@WO/%'##5: YPR3,H\
M.*PJV(7+]ZZ21OTK.47GHP"//#_*-]97R7KZ%>O)5+RS)M1>O#0%%8<.1H"R
MQ3/M\5Q-'_3X@O*A.)YD8CJ>3A[P=[R-[SCZ._Z&^#)Q;8VW6A4R580IQ(TC
M3R:D"5N*5\I(DRNIQ1R3A/(+7OPU6_C@4$!_/X#H9(OH)"(Z^<Z,/VP]&8I]
M!^*- ; CKNI.2R=N:W*R5>0SK""3/X6:Q(\_/)E.Q\^O;=-*LXZCR?.?,Q%J
M9[NJ%@HAKFJK]?K(K@P5 BWOX-Y4Z-6%5X62+KF\?=/[W?C$3.\OIA-C\58U
M*E"1">6%% MEVUJB?W+J@LJ1V#SA$*5%??-I1C#*0OG<+LFM,Y$CZKBUH"5D
MHV46HGN8-N28GCY^4*:,L4O)S9T)WTBM16/1])V&3]=5'MXES(L"5'O1H5"=
M)[?$R0T5\1A#5'C1.@5=4GH-CYCJG&W].J^5#$[E\?@XJ6V5L"EO'?L2B[4(
MTE44,Z:8D+SGPZO* "SF&\IKT.8;Y%J%6J6@<^+MC, M;>>%7WL4W3:]U[_.
M^_0.D7B![J!F00[=,7F:10\;5H'/V,[DB"J&>SV[>?OG[4S<OA/OC?A%F@Z2
M*R;CV%CC0U,F1!,H UUMM]"(UI8E.8:-_'+2D6E(47['J5G5*J\/'*"G"O8]
M'L<?X4$X^<]LF06S<XU\Y\2;'DV?#D_' D67+%$93LBJ<E2A!47EK&=V;!YI
M2@:GPS'D4&O4P%#,R@!;"%"71PXBQRNGXB#658<VSB(:Y?D^\9'/+12ZQR7G
MN<0Y+(.[<'M<L >AK@CX9(OE>U1+(%3+H^G9V3X:Y'M.;4A$34[_+^.@-=81
MGU1V#MM<[,A=K:>K"]%0@LV2)1TX (I_<+NE6=^UK75A8ZNU7%@7>\0?GKT"
M3KCXV"F.I"@4[\$A95*^F+Z@-/PQR[B T<BE0".Z+)66P[?I"*3B%8!R9L9\
M5Y8J5]RG"*,BPP*"\L;I"A6-Z=9ZQ3TJ<NEK4>(Q($IGFUYKL''(ZK5+4><<
M[)#?;93Q]!@>7&3)$<>QE#K*-&=!F27YD&0[1KKX%%S9F7V%ZZE/^@+M#,A%
MG$1F.B[C6(U!:)(^0*Q(K)']!#[J%@<:H6'DJ<\CO/C=#1*K6FD0SLT?[>:0
M*+<C]>4]ZT,5$[ IT@/UGK^\WDG!#3I"+2!PWG8N3ZW&<7G$G^NNH&T?.VZS
M)4/TR%+<N%<,['%R]MS'- 8T\A93MMM?T"(<K+ #G!,)2AT<M\2,[%4M2&%Y
MS+A0  "J^5E= B*_[T #E ?%&Q4=V09O7P&*8N N!U/@AU.?LA>@KH:EF840
M5P]XE@#@(?0@DPLP@XY(5 "G"0?&-IUU%5Y8XCBJXJ>"FNB2Z 94K?/,9TVZ
M1/E7*D:DHK!M*.9;C)^)8GYTG/6<R7 $CT>X5>XH;-C[[C7H1-^M&9_6:_KC
M+PD,4'SIJ3+:>RB"IBH^AUDNT/+IS;B=W;ZX9^FAN=N>GNOO<.,IZ*BF$J;C
MX=GI0+CT!$Z#8-OX[%S8@$=L_*SQ7P,YWH#UTMK0#_B [?\AE_\!4$L#!!0
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M_@!O-B$9LK!(=.';@D!I E%L=&I:AV.\]OO*E(:<:.O2&H\D 4$Y%KB)M7M
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M:>N.S&$54+6%;9U2P#19E0OKKE: V<[HL:WMSJ3?K5 8-H"DB47W[8.3"UT
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MO/'AICFW,PDEQD.A[,UP9O:A.!T4YUARXT"]2F]3.QT<*-EE4%FX4;OVR/Q
M'?ZI-T:JH'6N*DVT<^T*/2S!ESQ-)8[-NTV%HX!W'W)C^XWB%>,*Y)[(J@^5
MM:<2;CT=/X9N^]2#XC&*/<3&R(+2,K""/8Q; T(0N=37I:(+E8^S@Z"ON9Q9
M X(XH*[3+2&P''@ :\,^9NG P"H0TL&3;6\OILR+=6<GLD(?.+!W[ H"QK&
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M(KP .EZ YZ4%S.Z"#QB^A5W\!U!+ P04    " #+/6%4'D*D7DP"   3!0
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M,2YX;6S-?5MSW%:2YKM^!4)C;\@1(,4JBJ3HMAU!47*/)JRV5I2[8V)C'U#
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M39<\LW]]]\/SGAZ-!9[G^IA7\ICE@<<LELF[IN[ONN1-79@B7N YP>P 7UK
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M]TCXF(M&"8VQO3-TELY9%6[0V "5[)XN2(; -5C+,1.+X+":0,LA;&.$J^W
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M>^O13#E>&ORPY:X>$JTGX\-9:YQW=C1<YVKWFM99&%^B]]3U=")P+T$,+O9
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MRN*1ZX<;O.- NP3\OE+8Z6'B"+I;<_H-4$L#!!0    ( ,L]851SB1. :0(
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MCV7;Q99YK[;KU>T"A+5V =HUC"K>/]0Z#VI;$!#7@1?&<&ED$8Y(Y.U:[VW
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M>G8]=#RQSH^%-+DN;Z1QM! ##=>=AOE 0QRTZ;3L^-W1^GLY>KQ+M;?EIBQ
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M7P^?-Y>B]\.;N^4/0L]+"/!*WH*H#\>>*9S-W75MT[%JY:Y(;Y2U:NF:"RF
M:C@ OM\J9;L.3M!?FI_]%U!+ P04    " #+/6%4O=JFIZ8%  #$#0  &0
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MBX.K8B#9+C\W63$I69)?;@F."-<&ZOZ:,?DZT$<QU?'A^']02P,$%     @
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M",0J&ITJ&AVEU6V+QHX0_.TK"* [09+L=\-T;C6=JZ;S6J;[)4\6A,O8AUS
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M^B[+<E5&PVF@J/C.6OPT5(2W0=N#R[<GUF'M+3KYWN8]YBN:9B@F2Y"T/HU
M!2]>A2PN!-NH%^L63,#N45_7!$>$RP'P^Y(Q\7HAW]6K7DB]^@M02P,$%
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M<FMS:&5E=',O<VAE970S-"YX;6S%6&UOVS80_BN$L \MD$0B]685M@''P;8
M"6;4S8JBV =:.MM"*=$C*;O=KQ\I*9(2V:K1(JD_6")U+\]S=[HS/3YP\45N
M 13ZFK%<3JRM4KMWMBWC+6147O$=Y/K)FHN,*KT4&UON!-"D5,J831PGL#.:
MYM9T7.XMQ'3,"\72'!8"R2++J/AV#8P?)A:V'C?>IYNM,AOV=+RC&UB">M@M
MA%[9C94DS2"7*<^1@/7$FN%W<T*,0BGQ=PH'V;E'ALJ*\R]F<9M,+,<@ @:Q
M,B:HONQA#HP92QK'O[51J_%I%+OWC]9_+\EK,BLJ8<[9QS11VXDULE ":UHP
M]9X?_H2:D&_LQ9S)\AL=:EG'0G$A%<]J98T@2_/J2K_6@>@H8.^$ JD5R+D*
M;JW@ED0K9"6M&ZKH="SX 0DCK:V9FS(VI;9FD^8FC4LE]--4ZZGI;;X'J71>
M%%I"7(A4I2#1)9HE26KB3!FZS:MJ,5%_<P.*INRMEGA8WJ WO[T=VTK#,,;L
MN'9Y7;DD)US>0'R%7'R!B$/P$?7Y^>K.4W5;DV\B0)H(D-*>>]+>JLO] LWV
MFB%=,;C4O"\E98 ^WVDE=*L@D_\,N'0;EV[ITOM^T&7',>TY/A;<RG18FC8O
MZ7[JXB@*1JXW&MO[;AS[DGX4>CKH)&@DG^#W&OS>(/[99B-@0Q7H%YGI2X+6
M-!5H3UD!B*]1VO"3NIS5%A6Y;C$L_4]+,BXER&/$*I]^!RX)7-\QG^-P_0:N
M_R/AW@)+-%04\URE><$+^1PGVG%9O@5()P0QT#MJ2W.$"<JTTO88C;G?H^&&
MQ!V@$30T@D$:9Q3J!9JW9!Y:,G>&S*(F<X'NNDSN3S&Y#OH)\3T\P"1LF(2O
MQ*3!CW2"[GB^ 7&,2=AC$@T5UJCA,1KD82 */8@*W27OJ3)TOFD\ M '$]R_
M=,_X!%2@69Y4,2^W/QQXN2W1YWO(5B"&6DK40(E>JXMAIYT=SLOUL=IV-RE!
M2)YFI9X'?4D\&@TE$'?&'QZD\+!$?_ ]B+QD,=M 'IL!^"R<YV0*MP,'O]K$
MP>W(P2\X<VK;W0R$./#)D5SU)8D?D3 XG:MVZN!?,79P?^Z$.!PJKG;NX.'!
M,^=9!B).=7M8T!V(L\JH'0<X>+4R:CLW'F[=/U=&_3[L^Q&.CI117Q(3SPT'
MLM(V;3S<M5^HC$8]Q%X4#951V]IQ])TR$CLN#. ?:$ND[>;$>:UZ(FW_)</]
M]Z?JJ;;]I$J"  =>OZ!JT>Z/8>*XQ#_=ETCG $%^04'53KN(L5?-Q^>([<[Y
MSQR^[ZG8I+G4OUC76M>Y"G6$1'6>K1:*[\HCX8HK?< L;[= $Q!&0#]?<ZX>
M%^:4V?RK,/T?4$L#!!0    ( ,L]851I.^]'8 0  .H3   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;+U86X_:.!3^*U:T#U.I0^+C7$@%2#.P[8[4
MKD9%TWVH]L& @:A)S-H&VOWUZX0T"6LG$ZFC>8%<SN4[/OX^.YZ<N?@F]XPI
M]#U+<SEU]DH=WKFN7.]91N6('UBNWVRYR*C2MV+GRH-@=%,Z9:D+GA>Z&4UR
M9S8IGSV*V80?59KD[%$@><PR*G[<LY2?IPYV?C[XG.SVJGC@SB8'NF-+IIX.
MCT+?N76439*Q7"8\1X)MI\X=?C<G7N%06GQ)V%FVKE%1RHKS;\7-PV;J> 4B
MEK*U*D)0_7=B<Y:F122-XY\JJ%/G+!S;US^COR^+U\6LJ&1SGOZ5;-1^ZHP=
MM&%;>DS59W[^@U4%!46\-4]E^8O.%]LH=-#Z*!7/*F>-($ORRS_]7@U$RP'[
M'0Y0.<!0!U(YD++0"[*RK 55=#81_(Q$8:VC%1?EV)3>NIHD+]JX5$*_3;2?
MFCWD)R:5[HM"2[8^BD0E3*);M+RT%?$MLIO<+)BB2?I&VSXM%^CFMS<35VE
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MRZ%03!1$PFKJW/HWL]C$VX#?#&JU9Q.C9"G$JW$>LJGC&4+ (=4F \7/%F;
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MT#)5=WS^'18.^49?PE-9_:)Y+1N$%DI*J7BV &L&&<OK)WU=!*(%P-X[ +(
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M2YH@+RV*81]HZ6P3I427I.-DOWXDI<B.+3/>T'R(1>J>A\\=3W?D8"WD=[4
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M09#6P+R?":%?!W:!^GXY_!=02P,$%     @ RSUA5&OW+SYZ P  KPL  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&ULG9;;;N,V$$!_A1#ZL LTD4C=
M ]O KM.B!1(T2)H61=$'VAK;Q%*B2U+QYN]+RHHL1Y3@Q@^6*,WES&@XG-E!
MR&]J!Z#1]Y)7:N[MM-[?^+Y:[Z"DZEKLH3)O-D*65)NEW/IJ+X$6C5+)?1($
MB5]25GF+6?/L02YFHM:<5? @D:K+DLK7K\#%8>YA[^W!(]ONM'W@+V9[NH4G
MT,_[!VE6?F>E8"54BHD*2=C,O2_X9HD3J]!(_,'@H'KWR(:R$N*;7?Q:S+W
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M#=(*F/<;(?3;PLYLW8R^^ ]02P,$%     @ RSUA5*$X&_3A!   GA0  !D
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MEAOHYXLT5:^#_ 7UD>3D7U!+ P04    " #+/6%4JMT6E)X#  "(#   &0
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MK>3G/LFSQ'VZ\?.N:@'#$N\;[E%G+75VEMKI<XL&2Z6@-F@AE9,F1+H)D^\
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MT9A@=4&1Z,.R]0_?3ZD=_%RTRW_$H=^ 4D$K.=1?,%,NH#_?K3D39,F%HCR
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M0Z:.AB3G0"#)U9#DXI"TG3J;78M]4Z?'3C70,)<T_K@X_NSODWIV#^@35R.
M2P^D3W3Q=O'B/;Q/<#O].RENXUP8WT_ZD$6KD#>B'KJ)XNHJ[GH'TA.ZAKMX
M^51FT5-DM[LH<&S7=G9.B*_ZY=HNZBKLXE7X#4[&W6Z]W>4VM4CK7)R.I^X.
MOT$MM0/6)=O%2_;7GXO7#;2/C@W$U""W2^!0D7: &B7<GOVQ+SD-KVUZO3%U
MY3HQ82+MVQL:9KQOM_*IFVKO,2!LP-/(X[U@7^[-*%N/$S5EH\,IFZ?!SGO%
M';VOH6Q>=V&#+4X]C8T>CFFO>@I8M]6:- [FIH9+#X?+5SD#]+JWJ= D-BY3
M??,MPKK%EJ^!J0 9!'<+$"K2#EDCN?>_V13TNK@^Q>X,>1K8O3?:$_1,%YZ,
M7='=Z>MT!2;2#DP#N#<$P!6+6^1)!$F^X^5*9%^Q*^AI</4.9 GF:VST<6Q\
M?09W7K?8I&<.'7M^NW<O#&*>/;;W<%)?XZA_"#C:XT2-H\$&1_T^&/4UC/HX
MC Z_T'?>8VG?U;R+E^NU8]& ZO><B0V^G7?>8\D:TSVQX'KVV,5CT:CKXZB[
M[9>G')A+G,3EVA@';F7FC:=[ NE1M,<.'HE&:+\'H7NO#/894$6V:!194159
M=65MSIOWRZ#<J8&LMAI@$;69AM45E];Z"KVRINZI22G'(J5@RIZ<<V0I[\)M
MS>_<#I/-OTFK<_X89YF"\HS\E675/;?JZK^Z)R?O41X1%H:YD%KR>N5S7"X(
M@^2 ?Q&D+%:+$>6K[(QLO9WR!0B%";@*56 E-K%U+^9AE]_\QEUPE+Z\TM6;
M"[R5 1M&OJ8O/DY?]&'?&:3Z#3#?UX3#GQX(YFL:X@]9X[\J Z];Q'9M?,,F
M@?%PWB!(L:5'H,E.T'.7]HUX>- ]#MT]WFY[K,E,,.3>Z1?P\*![,Z?S:H+A
M&JKQQ0N#H/&@<-)XORWEXE&]B2@+YBHKJ]>2MM]NWW8\4^_X[7Q_;K^_L W?
M7]KOKZMW&;7YZM7*&R:@WA8DX0_0E#4.H"]$];9B]:',E^KMNGE>EGFJ'A><
M02V0 O#[0YZ7FP^R@>T[HZ?_!5!+ P04    " #+/6%4+@2: $X#  #)"P
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MAU)8\UVA;\7A?V@2&EB^1!3*_:)#$XL]E.R4%F4#-@K*O*K_^7U3B Z A*\
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MAIGIM4': /-\+81^G-@-VNY]\A=02P,$%     @ RSUA5"Q342$F P  5PH
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M%FM68;DOL: 6+!"!1Y;)I0 ?LXA&AP$L1:QFAW;L[I$QX@.=]0&&'P"R$6P
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M3?A0+O\SEQ-B)VS'"FJLX)KM!'E\[48*6C82]BS<W+WR+]NVKF?#A;6 L%?
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M!>KW%6/R-- !ZO<]D_\ 4$L#!!0    ( ,L]852:'.1EB00  /H3   9
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M"C-!C\\X5]N&62!_[NO_ U!+ P04    " #+/6%4O\W<#&,$  #)$0  &0
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MLW""YF9G7#NFD[2D.U1"]'B+,JKN#_56,1L6Z$&4'LN[X/-MY6'K%46>5:2
MI9HJ%3WW?$'"[.1UST/%_:;L^5'F^6S=<Q;>Z?C;DN/AWA;3P0ZN!^^F?JF[
MZ13<[]5S_Z]RQ.?TSG<9PPW*0!SLDE?,V#]5G-*E.$*YM-\*%,Q%$NOTBIC/
MYM\CSNTM_(?Y$3L=IU\5"C7I1XXK+HFQ%(2X()5NLT>=4*;?#=*!%FM[]9X)
M31=Y^[A"3L=0LX#>+X303P.S0?[U9O@O4$L#!!0    ( ,L]853M\$U@I@(
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MN!-SSF3;IEM#BZIIC1NA3:-MAH5YV5!:![.>":$/ADW0O97Q+U!+ P04
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MPQ7>?: L -\OI#3[B0W0WJ;COU!+ P04    " #+/6%4\M;LISL#  !&"P
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M2"$6R@*1ERV,($V5(1G&[\JF5;M4X/[]A_6)SEWF,B<<1C3]D2S$NF]U++2
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M/E7^!CB_T3+.7@_.I=8RS"X#P%%5&0/\?B&EWMR8-X[;]_"C?P%02P,$%
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M#3@B;?\;2_DR3YI9=Y"(>E;;_PK+Z\;-/=#&XC)E*Y9.ZJ&>3ZMN8#LV:MW
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #+/6%4O24 A(($   -)@  #P
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M4$L! A0#%     @ RSUA5#'\EUSN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ RSUA5)E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #+/6%4XI^LJA,&  #*&0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ RSUA5!+,3D(&!@  ;!8
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M965T-BYX;6Q02P$"% ,4    " #+/6%4!^^'%JX'  !V'P  &
M    @(&K)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
MRSUA5+U8:G.( @  0P<  !@              ("!CRT  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,L]851SFZWXR 4  ),,   8
M          " @4TP  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " #+/6%4S&2WKL\G  #"?@  &0              @(%+-@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,L]850O^0*4A04  (D-
M   9              " @5%>  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ RSUA5-<F%2I5 @   P4  !D              ("!#60
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #+/6%4.(B>
MZ.,"   G!@  &0              @(&99@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( ,L]852M88#WYP<  #D6   9
M  " @;-I  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
MRSUA5-TVM!*Y"P  ="T  !D              ("!T7$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " #+/6%4%K$2Z.$+  "1'0  &0
M            @('!?0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( ,L]853>NN-&%@@  !<3   9              " @=F)  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ RSUA5!Y"I%Y, @
M$P4  !D              ("!)I(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " #+/6%4 SHK<5,"   E!0  &0              @(&I
ME   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,L]8536
MLITQ(@0  .8)   9              " @3.7  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ RSUA5)1'TLRB*0  GXH  !D
M     ("!C)L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,L]852,G@X6E04  ,<1   9              "
M@1W3  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ RSUA
M5*T0'B,/!P  0!<  !D              ("!Z=@  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " #+/6%4O=JFIZ8%  #$#0  &0
M        @($OX   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( ,L]850RVE$&% 0  $ )   9              " @0SF  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ RSUA5(X(N[%X!   2A0
M !D              ("!5^H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " #+/6%4.(<QR@\(  "<*@  &0              @($&[P
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,L]853V?&>X
M[P0  $(;   9              " @4SW  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ RSUA5# KA(%1 P  W0H  !D
M ("!<OP  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #+
M/6%4B@Z\[@ $  !A$   &0              @('Z_P  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,L]851I.^]'8 0  .H3   9
M          " @3$$ 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#
M%     @ RSUA5+DQ31]P @  4P8  !D              ("!R @! 'AL+W=O
M<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #+/6%4)(;S4S(#   8
M#   &0              @(%O"P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;%!+ 0(4 Q0    ( ,L]8508E% _4@(  +,%   9              " @=@.
M 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ RSUA5!-K
MZ4<(!   :PX  !D              ("!81$! 'AL+W=O<FMS:&5E=',O<VAE
M970S.2YX;6Q02P$"% ,4    " #+/6%4:_<O/GH#  "O"P  &0
M    @(&@%0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M ,L]852A.!OTX00  )X4   9              " @5$9 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ RSUA5*K=%I2> P  B P  !D
M             ("!:1X! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " #+/6%4FR#<D30*   _.@  &0              @($^(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,L]850N!)H 3@,
M ,D+   9              " @:DL 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ RSUA5"Q342$F P  5PH  !D              ("!
M+C ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #+/6%4
M^&/VBBD%  #-&P  &0              @(&+,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,L]851D Q'/B 0  -01   9
M      " @>LX 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ RSUA5!_VZ-HV!   ^Q$  !D              ("!JCT! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #+/6%4FASD98D$  #Z$P
M&0              @($70@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( ,L]852_S=P,8P0  ,D1   9              " @==& 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ RSUA5.WP36"F
M @  -P<  !D              ("!<4L! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " #+/6%4YIE&SK0"  !9!P  &0
M@(%.3@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,L]
M853RUNRG.P,  $8+   9              " @3E1 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ RSUA5.$>[-YG P  5@P  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( ,L]852])0"$@@0   TF   /
M  "  3IK 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #+/6%4\R"+>>D!
M   2(@  &@              @ 'I;P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #+/6%4LFA)V-4!  "_(0  $P
M@ $*<@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     00!! +X1   0= $
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>204</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/InvestmentSecurities</Role>
      <ShortName>Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Right Of Use Assets and Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities</Role>
      <ShortName>Right Of Use Assets and Lease Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Unaudited Quarterly Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation</Role>
      <ShortName>Unaudited Quarterly Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables</Role>
      <ShortName>Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/InvestmentSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Right Of Use Assets and Lease Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables</Role>
      <ShortName>Right Of Use Assets and Lease Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/ShareBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Unaudited Quarterly Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables</Role>
      <ShortName>Unaudited Quarterly Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Investment Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Investment Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail</Role>
      <ShortName>Investment Securities - Summary of Investment Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail</Role>
      <ShortName>Inventory - Schedule of Inventory, Current (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Property and Equipment - Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Right Of Use Assets and Lease Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Right Of Use Assets and Lease Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail</Role>
      <ShortName>Right Of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail</Role>
      <ShortName>Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail</Role>
      <ShortName>Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail</Role>
      <ShortName>Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail</Role>
      <ShortName>Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail</Role>
      <ShortName>Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Share-Based Compensation- Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail</Role>
      <ShortName>Share-Based Compensation- Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail</Role>
      <ShortName>Share-Based Compensation - Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Income Taxes - Loss before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Loss before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Income Taxes - Total Income Tax Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail</Role>
      <ShortName>Income Taxes - Total Income Tax Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d234590d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Unaudited Quarterly Financial Information - Schedule of Quarterly Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail</Role>
      <ShortName>Unaudited Quarterly Financial Information - Schedule of Quarterly Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="d234590d10k.htm">d234590d10k.htm</File>
    <File>d234590dex1013.htm</File>
    <File>d234590dex108.htm</File>
    <File>d234590dex231.htm</File>
    <File>d234590dex311.htm</File>
    <File>d234590dex312.htm</File>
    <File>d234590dex321.htm</File>
    <File>d234590dex42.htm</File>
    <File>itci-20211231.xsd</File>
    <File>itci-20211231_cal.xml</File>
    <File>itci-20211231_def.xml</File>
    <File>itci-20211231_lab.xml</File>
    <File>itci-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g234590g00d00.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="809">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d234590d10k.htm": {
   "axisCustom": 1,
   "axisStandard": 25,
   "contextCount": 204,
   "dts": {
    "calculationLink": {
     "local": [
      "itci-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "itci-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d234590d10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "itci-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "itci-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "itci-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 508,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 5
   },
   "keyCustom": 41,
   "keyStandard": 365,
   "memberCustom": 25,
   "memberStandard": 32,
   "nsprefix": "itci",
   "nsuri": "http://www.intracellulartherapies.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.intracellulartherapies.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Investment Securities",
     "role": "http://www.intracellulartherapies.com/role/InvestmentSecurities",
     "shortName": "Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Inventory",
     "role": "http://www.intracellulartherapies.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Property and Equipment",
     "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Right Of Use Assets and Lease Liabilities",
     "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities",
     "shortName": "Right Of Use Assets and Lease Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Share-Based Compensation",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Income Taxes",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "role": "http://www.intracellulartherapies.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Related Parties",
     "role": "http://www.intracellulartherapies.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Subsequent Events",
     "role": "http://www.intracellulartherapies.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Unaudited Quarterly Financial Information",
     "role": "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation",
     "shortName": "Unaudited Quarterly Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Investment Securities (Tables)",
     "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables",
     "shortName": "Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Inventory (Tables)",
     "role": "http://www.intracellulartherapies.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Right Of Use Assets and Lease Liabilities (Tables)",
     "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables",
     "shortName": "Right Of Use Assets and Lease Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Unaudited Quarterly Financial Information (Tables)",
     "role": "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables",
     "shortName": "Unaudited Quarterly Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P09_15_2020To09_15_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P09_15_2020To09_15_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)",
     "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)",
     "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail",
     "shortName": "Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Investment Securities - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
     "shortName": "Investment Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)",
     "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
     "shortName": "Investment Securities - Summary of Investment Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)",
     "role": "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail",
     "shortName": "Inventory - Schedule of Inventory, Current (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Property and Equipment - Property and Equipment (Detail)",
     "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment - Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Right Of Use Assets and Lease Liabilities - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
     "shortName": "Right Of Use Assets and Lease Liabilities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "us-gaap:OperatingLeaseExpense",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)",
     "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
     "shortName": "Right Of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)",
     "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail",
     "shortName": "Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)",
     "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
     "shortName": "Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail",
     "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_InventoriableCostsMemberusgaapIncomeStatementLocationAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail",
     "shortName": "Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail",
     "shortName": "Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Share-Based Compensation- Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail",
     "shortName": "Share-Based Compensation- Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_InducementAwardPlanMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
     "shortName": "Share-Based Compensation - Stock Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
     "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)",
     "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
     "shortName": "Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Income Taxes - Loss before Income Taxes (Detail)",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Loss before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Income Taxes - Total Income Tax Expense (Detail)",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail",
     "shortName": "Income Taxes - Total Income Tax Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate (Detail)",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail",
     "shortName": "Income Taxes - Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "4",
      "lang": null,
      "name": "itci:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P10_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Unaudited Quarterly Financial Information - Schedule of Quarterly Financial Information (Detail)",
     "role": "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail",
     "shortName": "Unaudited Quarterly Financial Information - Schedule of Quarterly Financial Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P10_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Organization",
     "role": "http://www.intracellulartherapies.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d234590d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "itci_AccruedCustomerProgramsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued customer programs current.",
        "label": "Accrued Customer Programs Current",
        "terseLabel": "Accrued Customer Programs"
       }
      }
     },
     "localname": "AccruedCustomerProgramsCurrent",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_AmtTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amt Tax Credit [Member]"
       }
      }
     },
     "localname": "AmtTaxCreditMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_AvailableForSaleSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Securities Maturity Period",
        "label": "Available For Sale Securities Maturity Period",
        "terseLabel": "Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesMaturityPeriod",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb Company [Member]"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_CaplytaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPLYTA [Member]"
       }
      }
     },
     "localname": "CaplytaMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_CashAndCashEquivalentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Maximum Maturity Period",
        "label": "Cash And Cash Equivalent Maximum Maturity Period",
        "terseLabel": "Maturity of highly liquid investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentMaximumMaturityPeriod",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ChangeInAccountingEstimateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in accounting estimate amount.",
        "label": "Change In Accounting Estimate Amount",
        "terseLabel": "Reveral of accrued expenses"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateAmount",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_ClinicalTralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical tral [member].",
        "label": "Clinical Tral [Member]"
       }
      }
     },
     "localname": "ClinicalTralMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_CollaborativeAgreementUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Upfront Payments",
        "label": "Collaborative Agreement Upfront Payments",
        "terseLabel": "Company made an upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementUpfrontPayments",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_CollaborativeArrangementAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement amount payable.",
        "label": "Collaborative Arrangement Amount Payable",
        "terseLabel": "Obliged to make milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementAmountPayable",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_CollaborativeArrangementLicenseExpirationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement license expiration description.",
        "label": "Collaborative Arrangement License Expiration Description",
        "terseLabel": "License expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseExpirationDescription",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_CollaborativeArrangementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Milestone Payments",
        "label": "Collaborative Arrangement Milestone Payments",
        "terseLabel": "Company made milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayments",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_CollaborativeArrangementRemainingPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement remaining potential milestone payments.",
        "label": "Collaborative Arrangement Remaining Potential Milestone Payments",
        "terseLabel": "Company remaining milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRemainingPotentialMilestonePayments",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Maturity More Than One Year And Less Than Two Years [Member]",
        "label": "Contractual Maturity More Than One Year And Less Than Two Years [Member]"
       }
      }
     },
     "localname": "ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_Costofproductsales": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Product Sales.",
        "label": "CostOfProductSales",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "Costofproductsales",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "terseLabel": "Customer one [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Three [Member]",
        "terseLabel": "Customer three [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "terseLabel": "Customer two [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_DeferredTaxAssetsLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets liabilities gross.",
        "label": "Deferred Tax Assets Liabilities Gross",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation.",
        "label": "Deferred Tax Liabilities Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Capital Lease.",
        "label": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCapitalLease",
        "terseLabel": "Capital lease"
       }
      }
     },
     "localname": "Deferredtaxassetstaxdeferredexpensereservesandaccrualscapitallease",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_Deferredtaxliabilitiesrightofuseassetcapitallease": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Right Of Use Asset Capital Lease.",
        "label": "DeferredTaxLiabilitiesRightOfUseAssetCapitalLease",
        "negatedLabel": "Right of use asset\u2014capital lease"
       }
      }
     },
     "localname": "Deferredtaxliabilitiesrightofuseassetcapitallease",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_Deferredtaxliabilitiesunrealizedgainsoninvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 11.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Unrealized Gains On Investment.",
        "label": "DeferredTaxLiabilitiesUnrealizedGainsOnInvestment",
        "negatedLabel": "Unrealized gains on investment"
       }
      }
     },
     "localname": "Deferredtaxliabilitiesunrealizedgainsoninvestment",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation other permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Other Permanent Differences",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "itci_ExpireIn2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expire In 2037 [Member]",
        "terseLabel": "Expire In 2037 [Member]"
       }
      }
     },
     "localname": "ExpireIn2037Member",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]",
        "label": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_FederalNetOperatingLossCarryForwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal net operating loss carry forward expiration period.",
        "label": "Federal Net Operating Loss Carry Forward Expiration Period",
        "terseLabel": "Federal net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "FederalNetOperatingLossCarryForwardExpirationPeriod",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "itci_GrantReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant receivable.",
        "label": "Grant Receivable"
       }
      }
     },
     "localname": "GrantReceivable",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.",
        "label": "hare Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms"
       }
      }
     },
     "localname": "HareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ITCINationalDemocraticAllianceMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ITCI national democratic alliance [member].",
        "label": "ITCI National Democratic Alliance Member [Member]",
        "terseLabel": "ITCI National Democratic Alliance Member [Member]"
       }
      }
     },
     "localname": "ITCINationalDemocraticAllianceMemberMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilitites, current.",
        "label": "Increase Decrease In Operating Lease Liabilitites Current",
        "terseLabel": "Lease liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilititesCurrent",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_IndefinitePeriodCarryForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite period carry forward.",
        "label": "Indefinite Period Carry Forward [Member]",
        "terseLabel": "Indefinite Period Carry Forward [Member]"
       }
      }
     },
     "localname": "IndefinitePeriodCarryForwardMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_InducementAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Award Plan [Member]",
        "terseLabel": "Inducement Award Plan [Member]"
       }
      }
     },
     "localname": "InducementAwardPlanMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_InventoriableCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InventoriableCostsMember.",
        "label": "Inventoriable Costs [Member]",
        "terseLabel": "Inventoriable Costs [Member]"
       }
      }
     },
     "localname": "InventoriableCostsMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_Investment1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment1 [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "Investment1Axis",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_Investment1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment1 [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "Investment1Domain",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_ItciRealEstatesLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ITCI real estates lease.",
        "label": "ITCI Real Estates Lease [Member]"
       }
      }
     },
     "localname": "ItciRealEstatesLeaseMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year six.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Six",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone and total shareholder return restricted stock units.",
        "label": "Milestone And Total Shareholder Return Restricted Stock Units [Member]",
        "terseLabel": "Milestone and Total Shareholder Return Restricted Stock Units [Member]",
        "verboseLabel": "Milestone And Total Shareholder Return Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_MilestoneRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Restricted Stock Units [Member]",
        "label": "Milestone Restricted Stock Units [Member]",
        "terseLabel": "Milestone Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "MilestoneRestrictedStockUnitsMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_NationalDemocraticAllianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National Democratic Alliance.",
        "label": "National Democratic Alliance [Member]",
        "terseLabel": "National Democratic Alliance [Member]"
       }
      }
     },
     "localname": "NationalDemocraticAllianceMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_PaymentOfMilestoneAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of milestone amount.",
        "label": "Payment Of Milestone Amount",
        "terseLabel": "Payment of milestone amount"
       }
      }
     },
     "localname": "PaymentOfMilestoneAmount",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum net proceeds of capitalized costs in first twelve months.",
        "label": "Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months",
        "terseLabel": "Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months"
       }
      }
     },
     "localname": "PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum net proceeds of capitalized costs later than twelve months.",
        "label": "Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months",
        "terseLabel": "Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months"
       }
      }
     },
     "localname": "PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "itci_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_RealEstateLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate Lease [Member]"
       }
      }
     },
     "localname": "RealEstateLeaseMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_RealEstatesLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estates lease.",
        "label": "Real Estates Lease [Member]",
        "terseLabel": "Real Estates Lease [Member]"
       }
      }
     },
     "localname": "RealEstatesLeaseMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_ResearchAndOtherCommitmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and other commitment.",
        "label": "Research and Other Commitment [Axis]"
       }
      }
     },
     "localname": "ResearchAndOtherCommitmentAxis",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_ResearchAndOtherCommitmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and other commitment.",
        "label": "Research and Other Commitment [Domain]"
       }
      }
     },
     "localname": "ResearchAndOtherCommitmentDomain",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_RoyaltyPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment Percentage",
        "label": "Royalty Payment Percentage",
        "terseLabel": "Royalty payment, percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentPercentage",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative information about operating leases.",
        "label": "Schedule Of Quantitative Information About Operating Leases [Table Text Block]",
        "terseLabel": "Schedule Of Quantitative Information About Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "itci_SecuritiesAuthorizedAmountForIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Authorized Amount For Issuance",
        "label": "Securities Authorized Amount For Issuance",
        "terseLabel": "Universal shelf registration statement, effective date value"
       }
      }
     },
     "localname": "SecuritiesAuthorizedAmountForIssuance",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited average remaining contractual terms.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options granted average remaining contractual terms.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period remaining contractual terms.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, number.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Number",
        "terseLabel": "Vested or expected to vest, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Options canceled or expired, Weighted-Average Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award options grants in period weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term 2",
        "terseLabel": "Options granted, Weighted-Average Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Vesting End Date",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting End Date",
        "terseLabel": "Share based compensation arrangement by share based payment award vesting end date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingEndDate",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Start Date",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Start Date",
        "terseLabel": "Share based compensation arrangement by share based payment award vesting start date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingStartDate",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangements by share-based payment award options exercises in period weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercised, Weighted-Average Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment arrangement other than options weighted average contractual term of instruments forfeited.",
        "label": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited",
        "terseLabel": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited"
       }
      }
     },
     "localname": "ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Number.",
        "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Number",
        "terseLabel": "Exercisable, Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Weighted Average Exercise Price.",
        "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding Weighted Average Exercise Price.",
        "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest, Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "itci_SiegfriedCampaignAndLonzaCampaignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Siegfried campaign and lonza campaign.",
        "label": "Siegfried Campaign and Lonza Campaign [Member]"
       }
      }
     },
     "localname": "SiegfriedCampaignAndLonzaCampaignMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "itci_TimeBasedRestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time based restricted stock units.",
        "label": "Time Based Restricted Stock Units R S U [Member]",
        "terseLabel": "Time Based Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "TimeBasedRestrictedStockUnitsRSUMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_TotalShareholderReturnRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total shareholder return restricted stock units.",
        "label": "Total Shareholder Return Restricted Stock Units [Member]",
        "terseLabel": "Total Shareholder Return Restricted Stock Units [Member]",
        "verboseLabel": "Total Shareholder Return Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "TotalShareholderReturnRestrictedStockUnitsMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "itci_VehicleFleetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicle fleet lease.",
        "label": "Vehicle Fleet Lease [Member]",
        "terseLabel": "Vehicle Fleet Lease [Member]"
       }
      }
     },
     "localname": "VehicleFleetLeaseMember",
     "nsuri": "http://www.intracellulartherapies.com/20211231",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r105",
      "r232",
      "r236",
      "r241",
      "r368",
      "r369",
      "r374",
      "r375",
      "r444",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r105",
      "r232",
      "r236",
      "r241",
      "r368",
      "r369",
      "r374",
      "r375",
      "r444",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r53",
      "r103",
      "r104",
      "r244",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r169",
      "r257",
      "r259",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r243",
      "r250",
      "r271",
      "r273",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r499",
      "r502",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r243",
      "r250",
      "r271",
      "r273",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r499",
      "r502",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r169",
      "r257",
      "r259",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r257",
      "r258",
      "r464",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r257",
      "r258",
      "r464",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r243",
      "r250",
      "r261",
      "r271",
      "r273",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r499",
      "r502",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r243",
      "r250",
      "r261",
      "r271",
      "r273",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r499",
      "r502",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r103",
      "r104",
      "r244",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r117",
      "r121",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r117",
      "r121",
      "r225",
      "r272",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r170",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND"
       }
      }
     },
     "localname": "MD",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r447"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r22",
      "r484",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r22",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on investment securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r44"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r216"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r55",
      "r56",
      "r57",
      "r488",
      "r510",
      "r514"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r65",
      "r66",
      "r67",
      "r107",
      "r108",
      "r109",
      "r373",
      "r505",
      "r506",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Comprehensive Gain (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r317",
      "r318",
      "r319",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r110",
      "r111",
      "r112",
      "r113",
      "r121",
      "r178",
      "r179",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r231",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r350",
      "r351",
      "r352",
      "r353",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r437",
      "r466",
      "r467",
      "r468",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r274",
      "r276",
      "r323",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r276",
      "r309",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Non-cash stock-based compensation expense recognized"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r156",
      "r159",
      "r165",
      "r189",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r368",
      "r374",
      "r404",
      "r445",
      "r447",
      "r472",
      "r485"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r50",
      "r97",
      "r189",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r368",
      "r374",
      "r404",
      "r445",
      "r447"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured using quoted prices",
        "verboseLabel": "Available-for-sale investment securities"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r180",
      "r198"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Investment securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r277",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r37",
      "r447",
      "r517",
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r37",
      "r88"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r89",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r413"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r117",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r117",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r122",
      "r123",
      "r124",
      "r126",
      "r128",
      "r137",
      "r138",
      "r139",
      "r189",
      "r232",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r248",
      "r249",
      "r252",
      "r253",
      "r404",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r226",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Additional shares of common stock reserved for future equity grants"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r447"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value: 175,000,000 and 100,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; 81,886,965 and 80,463,089 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r73",
      "r478",
      "r494"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r169",
      "r402",
      "r403",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r169",
      "r402",
      "r403",
      "r516",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r169",
      "r402",
      "r403",
      "r516",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r142",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r146",
      "r147",
      "r169",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r169",
      "r402",
      "r403",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r262",
      "r269",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Notes/Bonds [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r74",
      "r97",
      "r189",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r347",
      "r356",
      "r358"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r145",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r185",
      "r200",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r185",
      "r200",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r185",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Investment securities, held in continuous unrealized loss position for less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r184",
      "r199",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Aggregate related fair value of investments with unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.",
        "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r98",
      "r348",
      "r356",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r343",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "itci_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Contributions made by participants for which the company makes matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r86",
      "r214"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic &amp; Diluted",
        "verboseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r100",
      "r333",
      "r360"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax at statutory federal rate",
        "verboseLabel": "US statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r333",
      "r360"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r333",
      "r360"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in effective state tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r333",
      "r360"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r333",
      "r360"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateAndTheEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense, weighted-average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation costs related to unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized share-based compensation expense related to employee stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options [Member]",
        "verboseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Scientific Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r65",
      "r66",
      "r67",
      "r107",
      "r108",
      "r109",
      "r111",
      "r118",
      "r120",
      "r136",
      "r195",
      "r254",
      "r255",
      "r317",
      "r318",
      "r319",
      "r352",
      "r353",
      "r389",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r505",
      "r506",
      "r507",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r393",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r395",
      "r396",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r245",
      "r262",
      "r263",
      "r268",
      "r269",
      "r393",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r262",
      "r263",
      "r268",
      "r269",
      "r393",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r393",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r212",
      "r465",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue [Member]"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of guarantee.",
        "label": "Guarantor Obligations, Nature [Axis]"
       }
      }
     },
     "localname": "GuaranteeObligationsByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Current Carrying Value",
        "terseLabel": "Guarantee Obligations"
       }
      }
     },
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Nature [Domain]"
       }
      }
     },
     "localname": "GuaranteeObligationsNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r86",
      "r213",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment losses recognized"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r99",
      "r359"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r470",
      "r475",
      "r479",
      "r496"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r99",
      "r359"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Non-U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r334",
      "r336",
      "r342",
      "r354",
      "r361",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r119",
      "r120",
      "r155",
      "r332",
      "r355",
      "r362",
      "r497"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail",
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r330",
      "r331",
      "r336",
      "r337",
      "r341",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Long term deferred tax asset, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r207",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r207",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r204"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r48",
      "r447"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r49",
      "r93",
      "r132",
      "r202",
      "r203",
      "r205",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r204"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r30",
      "r204"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r76",
      "r154"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Stock issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Year ending December 31, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of long term lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Right Of Use Assets and Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r97",
      "r160",
      "r189",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r369",
      "r374",
      "r375",
      "r404",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r97",
      "r189",
      "r404",
      "r447",
      "r474",
      "r490"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r97",
      "r189",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r369",
      "r374",
      "r375",
      "r404",
      "r445",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities measured using quoted prices"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Carrying value of cash held in money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r58",
      "r61",
      "r67",
      "r71",
      "r87",
      "r97",
      "r110",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r125",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r189",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r391",
      "r404",
      "r476",
      "r492"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r156",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r429",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "presentationGuidance": "Total Lease liability",
        "terseLabel": "Net lease liabilities",
        "verboseLabel": "Total Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: Current portion",
        "verboseLabel": "Lease liabilities, short-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "presentationGuidance": "Lease liabilities",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r366",
      "r367",
      "r372"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized (loss) gain on investment securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r62",
      "r65",
      "r66",
      "r68",
      "r72",
      "r254",
      "r414",
      "r419",
      "r420",
      "r477",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r277",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Initial public offering, Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds of public offerings, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r312"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]",
        "verboseLabel": "Product sales, net [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r58",
      "r61",
      "r67",
      "r81",
      "r97",
      "r110",
      "r119",
      "r120",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r189",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r366",
      "r370",
      "r371",
      "r376",
      "r377",
      "r391",
      "r404",
      "r479"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r40",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r220",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r215"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r217",
      "r447",
      "r481",
      "r491"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property Plant and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r217",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r18",
      "r473",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r18",
      "r473",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentMember": {
     "auth_ref": [
      "r18",
      "r473",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.",
        "label": "Purchase Commitment [Member]",
        "terseLabel": "Purchase Commitment [Member]"
       }
      }
     },
     "localname": "PurchaseCommitmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Unaudited Quarterly Financial Information"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivables, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable, net"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RegulatoryAgencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of regulatory agency.",
        "label": "Regulatory Agency [Axis]"
       }
      }
     },
     "localname": "RegulatoryAgencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegulatoryAgencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization that establishes and ensures compliance with rules or regulations.",
        "label": "Regulatory Agency [Domain]"
       }
      }
     },
     "localname": "RegulatoryAgencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r328",
      "r463",
      "r552"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development, including Clinical trial expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r91",
      "r471",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r91"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r255",
      "r320",
      "r447",
      "r489",
      "r509",
      "r514"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r107",
      "r108",
      "r109",
      "r111",
      "r118",
      "r120",
      "r195",
      "r317",
      "r318",
      "r319",
      "r352",
      "r353",
      "r389",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r256",
      "r257",
      "r464"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r69",
      "r97",
      "r152",
      "r153",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r189",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r404",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue, net"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationScheduleOfQuarterlyFinancialInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r431",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right of use assets under operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Initial public offering, Gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Total Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Statutory Federal Income Tax Rate and the Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r276",
      "r308",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r276",
      "r308",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Total Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/UnauditedQuarterlyFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r277",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r285",
      "r297",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used for Calculating Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Information Regarding RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "verboseLabel": "Requisite Service Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Options, vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Time based RSU's cancelled, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Time based RSU's cancelled, Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "negatedLabel": "Time based RSU's granted, Number of Shares",
        "terseLabel": "Time based RSU's granted, Number of Shares",
        "verboseLabel": "Milestone RSUs and TSR RSUs granted, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Time based RSU's granted, Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of year, Number of Shares",
        "periodStartLabel": "Outstanding at beginning of year, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value",
        "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Time based RSU's vested, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of time based vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Time based RSU's vested, Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "positiveLabel": "Expected dividend yield",
        "terseLabel": "Assumed expected dividend rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate",
        "verboseLabel": "Weighted-average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Issuance of shares, Inducement Award Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Awards granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of the options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled or expired, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled or expired, Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Total instrinsic value of stock units outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r287",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period, Number of Shares",
        "periodStartLabel": "Outstanding at beginning of period, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price",
        "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest at end of period, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Terms of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r275",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, exercise price",
        "verboseLabel": "Options granted, Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r277",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Initial public offering, Price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Total instrinsic value of stock units outstanding other than options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Total instrinsic value of stock units vested,other than options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options, maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r303",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Total instrinsic value of stock units exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of period, Weighted-Average Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r96",
      "r97",
      "r122",
      "r123",
      "r124",
      "r126",
      "r128",
      "r137",
      "r138",
      "r139",
      "r189",
      "r232",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r404",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r47",
      "r65",
      "r66",
      "r67",
      "r107",
      "r108",
      "r109",
      "r111",
      "r118",
      "r120",
      "r136",
      "r195",
      "r254",
      "r255",
      "r317",
      "r318",
      "r319",
      "r352",
      "r353",
      "r389",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r505",
      "r506",
      "r507",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r136",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanysFleetLeaseLiabilityDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail",
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Stock issued for services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common shares issued, shares",
        "verboseLabel": "Initial public offering, Number of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Exercise of stock options and issuances of restricted stock (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r254",
      "r255",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised, Number of Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail",
      "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r254",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Exercise of stock options and issuances of restricted stock (Value)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r97",
      "r174",
      "r189",
      "r404",
      "r447"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets",
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r421",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r421",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r421",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r110",
      "r111",
      "r112",
      "r113",
      "r121",
      "r178",
      "r179",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r231",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r350",
      "r351",
      "r352",
      "r353",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r437",
      "r466",
      "r467",
      "r468",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r102",
      "r262",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail",
      "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryOfInvestmentSecuritiesDetail",
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r329",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/IncomeTaxesTotalIncomeTaxExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r430",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic &amp; Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average number of common shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.intracellulartherapies.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r556": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r557": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r558": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r559": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r561": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r562": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001193125-22-059849-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-059849-xbrl.zip
M4$L#!!0    ( ,L]852'6T%U]LT" .E4'@ /    9#(S-#4Y,&0Q,&LN:'1M
M[+UI<]M&UBC\_:EZ_@-*SV2N/47*7+3:B6_)DIQHQI;T2O)D<F_=<C6!)HD8
M!&@LDIA?_YZE&VB H$3)I A*F)HD(@GT=DZ???GY?]^./.M:AI$;^+]LM#=;
M&Y;T[<!Q_<$O&TG<;^YM6/_[_7__U\_#&!Z$A_WHK1O;[B\;PS@>OWWSYN;F
M9M/UXU#8TO,23X3Q4(9B[,IHTPY&;SJM3KO=Z;8WU+N>ZW_+O7O;"[W-(!S
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M)S*T@%=N[^QNM[>FIGN3Q_90]B5R!QF]_QE)Q-N(V"L,;Q%3?AO#\?^R$;D
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MW"!:%[5]NJ*V%0-]7<3Z)0"]O9\!O;U?5V"H1 6&]O[\6 '/+ATKZ@H,5:W
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MG?:<I'VKV[*.111;G?UX:%W&H93QTC20RA[<(?QY%EX%-_Z<QX9+_2,(OSW
MY92;D CZ67@.@A"0NX4)4[.6->>JS@,8T?L_[GA^ >\]"/CMG>>DLZJS0(5U
M' )PW+'P+'DK[03KX,'70&5D]-IZ!>=DX4'-5E@?2EB>?K>9_>+O_[/7:>^^
MBV!43XZ'@:_-;@W0SVTO09W1 CE= %HXTGHUV]>+^ 3//0"'=K:F,.CU;)3]
M% #'/L<5/DB(7;C(O;75:NYWNUT-_27Y?_>?/O(1<#UT8Q>&9Y.-#*5CC9,P
M2M!V$P<6/(%\EL6J=N=5[S5>%_0@'=_:U,';.K"!F]<FC7M-&MVM^4T:LRT9
MW<Y"#2/9<*O0Y"RU3JOTFBI@9[BQN8T1[0N1V^<TZ!4B\)L]+["_55$LOG)C
MCMB7PAY:MB>BZ$'Z4PJ)\D.?K5CE#[*]V6JE1_D_+?I?,8!"S?1,U:^K4.#Y
M/3.MZW(R@A]>10]3RFND6M#QGRJ_"EUNJ1CO,T,Q4.:!"\#^,DGD*:R-ZVR\
M5^+;I-WI$?V?4S[FW'Z+DONGU=J_M38Q!=8Z%Z'U;^$ETCJ7H479>ZNVR*WH
MF!5)9QHXK^?WZO#DA3DZ[L-2K3#,[S^?,H,@Z=,6D"O004Y%Y(COUJ]>T /5
M_1+T63NV,)=AVK2U/"/AT^OR#U?;!C/4ME/4_FLO_"SXEX"?H$^CNCZ:HC%"
MN* \WL5Z,";$0>.UM'H3RQY*^QM.\,UR&3Q&Y(0;6<*Z 26W^0TT(M^*I(@
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MI5#V@0#ZMD0ZSO9O%S[ G!PIA5_EC@AMVQ[Z9*( SDI$>A?T74_)]NBMN0/
MHR!"RHG.<F_";%GB>B()=\#1!>B^)Y3"3S.*,?#>6Q=07\(;?U/WZB.9PF%I
MQ8MU3N3\HQ>(HFT<6P.T=KYV6]2^;L/":MKT2U9'WI$V3.1%OVPT]T 8AZ7
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M^>#H(D]\J%NME-\ HPM; GH9$+VD'N9SK5\OZIN<J'ZT)J%45EKLRQMDVO[
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MACD='BX2^]0IJD*M6,P;!$RY5? &^7'=B*5PPL<B%NI\Q5 ;T3FQ$8Y>I;W
M8OGT4X4MNSB:U7/VO08TO8@W$W6W7V$\OMR@I\.JQ(#C, UXDGB/*\1C9V:&
M#D\O9Q<O^@S4?>*KVV#X8R(BYD$VR#3E2<X\EZ#4$)IS#SYT+0!E$6S_2(\5
MV!0&C^'IVJI,C$:HU6L/JZ+,7',!KH?M)1$AQDT0>LX-TM#IY"4R'I=D_/D<
M%(LK1CQ!DHFEHU0LW8<0+D+@-3]/T#AX^3UQ>SU+E2FPQDD88=-=-JUD"[&
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M*OUXF)4BRB.$XTJ==6?T#E0N4S0'YN^C3?[*H8X#SN=C_*W;VMR=H75P6:&
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M':&5JBC(X4,F_\E& 'UL*/A,>PE P5>'R9@+R!3*6]U],0V$*%:D-W?84%S
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M=-/KNHQ4$TV'?GP^.JJ)14TL:F+Q/(B%O!WK4&BCF59F]B[2C![&F5UC\.R
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M.U)TIOL\X^8:2EFCY [G;P$P(QD2 S-D3>-.P&T?N^-0_!5@Q-Q0(!\)72<
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M7N0E-]QMC?N-F=*,\TUN&741+YG@S[M7>R$'Q!\C+;QTS.3\<#=Z(71T 5O
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M9JK5<H3):@7Q5O^V_OF&#TJF%#GFHFWZ?6<':Z0GAIPL.ZHVT1VRV3Q&C5^
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MK'?SG19G.4-]X.6%/]X1Q6/'J6<4A?.6#W=ZO8Q8,<L4,^!L$R^;;#ZY(U#
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ME&0DMT+6YITEG"0=MZ1NH089RW!X3$8-,7U@:_N#7 AVW432IFZF+SJ%VTJ
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MRZ;@I5M4%W4I0L',G9I%!#?]Q55^V0<1G+7;"/_?/N^8CBXO=C9RGL1V+Y!
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MPS\N?H#(IXL_S1)Y$*&F+$O5PU.:W7@>'KL0=SVQ"A<#N/JKQEQYV:M@P59
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M7ABWT[ZHB'8NTU85/?+'RVZV]W_YS[.R\W9D>TY6GNABMY7X4160?S29'%J
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M*0AB;[4_.E8^X'Y*+@>\\5/AH.[4$C=ZB7]\XZ@_2)J*SHN]MK(4NWU>-%&
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M:!T.Y\KO_H'$++\HGUPD)V0.SDU?,>USC5Z@9/IQK_@K_Y7SHDF.71E@%HN
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M>G^HIA)D@=9;[\@K.,S>I+(BM'FC"[-G>6ZBKH7'<*)95AKM!\X/%A/''X&
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M0FH\&C!>'F8_-ZW%_<^]:1^W(G%?# ,!I%U)^I<0,L 7\3N6)!^Y@YC-5:3
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MANQQ_LRX\)H6&IM\K:FD^BGF454T?7@PA15.?GXK(]:J?^Y50(I8A#I8X2=
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M:ZVKY-;'2U(00.RR0B&VVM'T:$?06Z6HC,,PZ&"S\93N";7BUOSQT3"\3_I
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MA6[(]*LL"UJRD?T!PL . A9PEAN]V<)*+)/<X4[5#.<K"V_]^94%H46:0FZ
M[#-'%Z[9B&BA>&IY=![#GJMA$R_04D)8FK5DHW7)+'!-RW>>0#KQG'BB$4;*
M01HYGJQ>'&F%IZ'BJ$4#IJ*9!\H!%<%F/O7 &V\0I$'>0F3L2PIHZ*^(BQW&
M]=?3-R<G>1Q,L#55JC(^QS+(D9B$7@GH#K-?QM=8+3^Z',Y2Q798(@K2R*T9
MB*MA\6S"QE)+V>H>'12RWKG*5]'S=JLM&^C4S/G2>YLO/9KSI=?G2R<-)09_
MO&TF]>/G=.]Q"O<+OR"3EK3V=?J28HZ9<[S$%)@>(KN/$BL4*W%#7U#<!#(_
M4L<V5_BR6WO'$VA4JBV]H]E1T)C\$L&TXFXRRD@U-9>WHLJL,,A4#+[H1JJV
ML+!,OGQV J3$E^R,$Z">IIHC/T[AS0G#!@<!BT$=$U;KZ\PD-A(\#@VBNL%P
ML&C@I$T(+:UM1YTD8KZ(H1$,2+*)TC *0\-)L]#;1C*6'<?\#3_EV@? ^ULI
M;0^H-KHCP>H4SX'VI$E=VIQ!KZ*^V,0F0FB;>L5N.:PT6SK>LTX.ZI5:CE3L
M%1E!:G".:ZV"BYU _OAO#+H)M1=48*,&.'O!;J43(^<-OW^%-G XUQQ6G5MA
M/JPVY,[C'$]?__WTV<'1C[+\V!IE,8>IWDN(RI/[$"6D0C(JC7E-%)ZH'T$P
M)GAT]EJC4:?7P,.6GO6AG!+ST__:=?"P>];U<SJ E,',9 U7K:)H04DW\/[C
MJ,:I5;:BST_.S@^>-G\_.,Z3%19%AIE:%V=D4::1'KCSL>&J\IB^T0/])QDD
M2%#$^"MD;+#:O_9K Y+RZ1H.ZF%V7J(:N?_+?^</!)E<CS:2_PV7BG_0Q>1_
MH028N% .[I\I EIF20V/4ITS)&X?U"[?^:Q 2$X-7>6:#%GE&G,D7S;5I6!T
M8.@#M2^V(50ATSS&FE-+4*JY;2+)@J-_P+577'N.K<$U=6.W!F^_]I -4@#2
M$B%!>F=6&$/6N T91OI2'9[LP/T_<W<?IE_=\@3+2;^:.L"DV; D'*.<DI@?
M%KDW*S!GP=<E2.Q0IJ*%*61CKZDWZQ2#,&!3+Z7S!+$K4LT6T+0&F&1E"DF&
M<&2_'8;# X?E(\T:Y9XBY(L )4'@J<,/CFR!894C&O!%'$6#G=38UA1+T;)W
MH"25-B-^O :B-@)JNFFD5#%JNP"-TO7<\N CLGQAEQ]'QX!:Y[EY37+K^:'=
M3ND[ F&CBB%?W4?@1E)\XJLLFU *)8M#$6@XCBP.#K/G6#$ER0$M09"C>JO=
MI+9<B=\S>NV'[YM'@* '^)4GCVOZ<4DUQL?0:%.RWY5P4"B?(CN7N):??!1>
MZ#@QB;E-R<#BB)LLIZ'NR6+$R+3D;;%0C)WG",[=TVA1<6;<MO>IIJ;*5:Q
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MJ"Y.SF=\L,)"1?5#R(2R[PS3J'#IP0PB8Q-!W@IL=..V#OP3(A)0P3,:#AS
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M"Q-B\HG*-(:S$'0/M9#9;&:HCJ@\(RFF1">KUL@!8GCR:Q5'/>:_6ZXQ=XV
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M<#1,7NK!H,=2.XXIY42D7-,4*>:#QA<=Z0W%27Q0NN_8XD T*U /1;FD]-C
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M$,R"X&$( LW?M1:+/+$2P8?^Z,X'?I&(0*0-_"),_N&I2V;1,(N&630\#-%
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M5<KIP+>*ZCK>*(:)JLI_]65!" 3<"@]C+&@ZM'+^W @\8_Q!";3K)R-\ CF
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MMMN:;+]:=H3(\D_X.)PX>@7XQ&BZ4W@B3G7"GQ5<EX-^6\[E^V ')E8E.$:
M46P2^"LA;JX_*!H8T:V^71;UZS0!3W#QDP7<Y9ZI1!)U?,NBW8VO=64OJ)9D
M22Z](GVQ"%,//B%%X//@7 -B#^\L[7(Z NFEYZT*<1O*G 6"EGVCFWZ#,B($
M6'K&^B?!$+\E'FP2-9(X$)ND;,0]>?0DFBZ1#7 @0RH"SDV[,""8#UZ_K^PN
M.UF"*TQQJ@I)73B>E)48OL%7L-"3Z)YB$UT':4SP1SNMS"9Q;M]+&6;#7<?M
M06%-!7_& R,WQ^U<9S<A,K@/(+;"8&&AJHOSPQ3]\AL;]@ &/KR&(J]U)UGX
M3BP^58'@PW1717(4K:&@*_D9!#E+-3,4.9OE\FWE,D=15D@5A#X6DHA@9)*;
MT%.: #XP-1LNB-$+=V'@HW$BW>)U[UO&BBXH< M;%&R9*!KJ?74XY0:N4G%;
MX3QZ-7_"C@T@9KX AU.1."Y+>T57L)]%/&MF)C\A649&$NM8R8\,!=I>V77X
M 9_5U[FQ6(B/X?ZS1Z0XT9GR@H0LV;C:$*-XF D62T_%&QX-I8:Q%,_S(<+.
M<AC7\ZS<\M44Z:BP:C4R7RAPB!]0T];/J8Y* C]L>L%0OQIO'HE)L>TMQE%Q
M%%%J1Q8\TLBK$I8%J\U<I_64OW>0SY$ZC99$HO%,%U; ./&2^B>%+U-F)XQ)
M14S8IX*BP2B;*K/$-+U_-E;0C"3/I+C!#59YM#"N9-JLN! /_WB )8$]P9+"
M.C2MYA30AM#2*!!9<FJ(, #F19RNA]E)%(J.^9]X-K0,5*6)I&U42T@R*M+Q
M>(B* I&.M1K*F\KXJ??"JD+<?+TE,"$PM_CP#HV:E,)0,EN#IDW/L/)KS$TK
M-'*\;778,-,C2\U%V_3;A.].UV6-I6Y1.'Y@^"6[LEKQ,"E7M$5$1CNT]$)-
M<*C(HE%'S\7L7&6+"ZLY@9$VN_6))O]:ORY2L(S.#-QK<-V#YS%,&^XSZI@<
M(; B?MC5Q(Q'5ZXPK<EDD$L)17R@=-*L0X$Y'CW%GL#ORIIWN#:<YRI_&\\?
MGR+Z8M40&Q,K7QS="N=!S%W,$$0W=;G3+!\E*>/-&<YAY+CQT1P/J+LV/2"'
M=BI+X.!]OFZ3AZXT46C!LJV=QR8XV]814+'INW7CT]N<61=Z&"X#-5/R04B1
M5&? Y8=A+YD4-)+VI>0922BYH:8>8)&A5YS'+C'?5PS.%Z8%1[LHJ<[,)YDQ
M2W>IO9L=%^@L=O'D,*5%ACD>IT53X$<UPK]9E!<]?SL*MVQ;?"JRQ$VOD60?
MX6>\_.0L:C(9WN&&I=V)<:<\%2#-L&SR*R7X>)V:P0+*SY2S7JVD"P</J,.M
MVV?G>0N-"Y<7R.DE+'QP'U&.B% 4S;U?[9)0X/2,U]F),HVK,F#,R,'KD^EY
MJB#YE&N:3JY.]%(R[KBD5TT&GJG(=U(+-1' QDL2<:&!"J]1U%;&4S;YMVNQ
M2RYH7FV_511ASPY72JEXKA?2UFM#32U3@VO:R)L*)>>#,G+:6%\5.L5VBXAB
ME*KG=ID/4@QE-']6LYX]ETI&P&:KRE5IB\B2'6M.DB._P>YTP7K=$T*YQN/
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M3*3?_'3[?MMR632Z<.@R>I_(V6MV%0RO!FL:!6 DSQ9]1S:&0A=A/99 ^BS
MIX,7Y@K@([_F K7A;X,5-_J\ZPC>9OA[-AV'OX5-&/X*R_!&OVL(\]54HS^T
MR$8]&IZ ( Q_W<']Q%S1X-?DSX[&@0G8T>_0U!S^<CGU2[9*QQ_E1*;_/7G,
ML!>5:763M=!VNVX-51V+ >GQONE>8:ITWQ>&OKLOE-Y_4"*(3C+2J^HZ68'3
MD )RK".3QU/S*1XW,-+U85<8<J-S-6AYD)9D4LK<<H 6IC6( ;KOQ?I>[:[S
M HX3-H;1:-%DC<(QT;!Q71;4,R#EV3%6AD@KN:F^*#PJ@]XC;N0W=R-Q/KY(
MR(.HXJY$T O+MDS@1?ZLU2..BQ0ZRJN>8G_0$==YG\',LQ<RN>13M"W\T1,?
M*?S91Q)\ZN99Z98]'5[ZU FECTO:AQ=>\C]5* #ZS%D *GD=BD#'8_P^[A;U
M!#P1HD!T< H>!GAM&P^,GFR:))(Q_%."]%2F#F=E$0F!2L-"U]P9T<$Y1A51
MM]*P4.5>$%YO.*28&O^O6]5)SEP<,Q?'S,7Q,8WHI"%'X>S$P(DK@T++OO2?
MH1'J!([58'B? EP8;[HTE540ORA(%</I:=%TTD:EH"74'("Z<MPQ4U_,%&&S
M[)EESQW+'L:P#"AJ@XK T$U:_MNCOCX]>?/R'V]/8E0,Z9@QG'6Y\\CNT]=_
M/WUV</2CW(K&)]_V#LY;9W&"JC!;Z>? [E/#N)11)^I/V2Q;9MDRRY8[DBU4
M-=E'E1)$=22][!\%;WP@)[;P4HLL8V2/="[J"HNKP.=K/U_[^=H_!'?&]=NM
M=B<SVC4K?T*O5[@YWYDB*!BS7S$+@5D(? 3=+Q@/5%^"<#LYED%3CQ_Q<BA8
M5P31C+<R CF-X"GRNS<6ZJ8^P+887&*Y%J[K"XUQZY^R#A->LY$PRX=9/CP(
M(X&%D-H$0TA!;;LL I14#&.#P8)+1#?%WM1^L4$JTQI_76&%.#HZ#'$Y]8U5
M5O487-W:MJFM?[L"HTH;UIB8,*<T^P1A84I_0V*36\ 8,)6KBSUCAU DPI C
M;"!LU[S2XD8ID0"S29)UM8[?%A/OGPVG63#.@O%A"$;RARI3"V$M=]#G*E4\
M*Y.&6^UUHDQQE<G7XI*#67C,PF,6'@]5>%#/3<55*-1U1AP-RL+%>!;;OG4$
M73H0+9[:?)S-"=[?+"QF83$+BX<A+*8=+E]$7&X6("FLB@7T3V!4""A;4U,5
M%XQXX,%8S,QB8A83LYAXF&+"=!W""J?WG<%/(D,BA1R>-"H(7;PKG9V%Q2PL
M9F'Q((7%5! 7>T8J]%%ZAAM'*4!!U4[\ED%6> Y5S))BEA0/75(DT/FW#G#.
M(F(6$;.(>*@B@@K)4 +@I1?B<2E8549>M!4^2#Y,I9H)#52Z7>7!LQB9Q<@L
M1AZ.&/%\F(6]0"!5$","-HXT(MN.FY^YT$*SIDT[2)K.4F&6"K-4>$!209P.
M939G0.*B[2]<@&9H$,82 =NTD+V: Y:S&)C%P ,1 U&:(DI?^ K,7VH",#KO
M@N_ E56(V=O.!1&S+)AEP8.1!01(&H,A<1],MR[;X@!9S7?<UU9:082&C_4(
MXP,^0CL96=#\1T5\C82K)>2RQ")MKCR.VR<4)#-XZF<!3WTR@Z=^>>"ILZJ;
M5=U#5'5[]-0,]C0;N/.M?]"WGH!!5P*^WRRM+:(BWI@W%F$GL1EQ%@"S )@%
MP,,0 -R.'-J0%8 I,@44.+A&(E[&OZTOD##594O3MCL!GYW%PBP69K'P0,2"
M8$\VKF>RY@@Q%L''<\_AQGET_!T7]0N$K*32\?<,-C^+AEDTS*+AH8B&B>X?
MAHNBH,$[N\O<LB1VAG*91WQ^!,UB*JO!<A02!*QB6]?4M:V&A']W+"@^$?7.
MK]:3JC'; @+?,8D"NUF(YL RM.Z41B.!^D5Z *2D+Y1%[EH*#5C+ 2,=$TWW
M=4%]W<)ZW-STJ$/DRHG((6A8ET*]P<RIDU0STW/"8>V?E'#3[:4%PB5\9P.O
MM? 8% @4VK1(E:K,&Z;=90GA0<JT@&D:9#XU;>6Y0??32""1 TN+(R$=@D>=
M,&GU&;,:P3*^@#MX]ZAG1X\._B>74ZOX0<IB(G00Q.)A]FW2?C*@&U8[H!7A
MDK^^]I $^OI510PE1)TJ/#D1TG3$/Q3QC<(1V=CVPB+O.RY XW_]SP;.3H83
MZ9$7D#ACU>AP"J7$ _SJ2+7^$6XWZ-\B/N >H+]HEGVZF[!#S!,RN!/T%;I4
MJ[)".EAD=5F7BY*/4/Q)X@FVG17D3FKJQ)>!9($M[$PM$..FB[EE4MJI3*@J
MHS.I%"8=G\XK&3!+"Z:'N9D&:$3'0]59&U-8XE_AB%8AW-")2*"I!&90YV#A
M^+<.!D",TCQ*D%>FW##(5[, E<^-JN@4;PLN(+V>W>AJ;:DZQ 3V4!Q-#2>D
MK"FMS!B,8T(RY5B^B0)7CM7O3^$>W54.]RLT?,L")-#[X\=/OOWQT?_WY ]#
MN_31[8W<>'-^-V7PM;2*D:;[\V%*6?BPS>3[2#;YRZNSY^>O7_[]^3,DDGSQ
M(GOZ^N?]9)+WV"K>3^C\F5;V55//,O2+DZ'??FDR]'@6H9]9A+XY>_WF^=G;
MT^>SS/R]2XD.X!K\C'_UX#M3(2/8IE6S)-!:,-6?/'Z4/3>NRXY_!'_@O&NM
M!:L:Q_&/IGT7?D*I<_0=6<'P +"XF^6RWPIP[7MB,P,S^_%Q?OS#]YG#MX'=
M;RV9R.#H2O'7JA3^78\N _X^>MKL*,  -VKMPQXZM.1AQ!NB(<W1IRC1GP17
MX6=$M\N.'QW_2&$%4[F&OP&VN=L@]ZC98!4WE7GR:^D]^-VWS95#0QV>L:M@
M,+-*^=)4RG=?FDIY/*N4SZQ27C[_R\G+#!3+T^?/D?1]UBR_=T51[(*0Q["+
MR!2,+&5<2H_9A'KGXT3P\ L&!,*:)"P\FH7NER9TO__2A.Z36>A^9J'[\^FK
MY]GYR8OG;_^1/3L]?_KR]?DO9[-1?P>!D$[),&"=;B=*Y\:@S](8].W<&/3E
M-0;10Q/E]\,?;GUB[UX%?"'2_LW)V=OL]'12NN\Y4<>_W[P[GLV[.S'O?OS2
MS+MO9_/N<YMW)V?_\_QM]N+U67;V_"^GYV_/3EZ]Q=*^H^]_.J>TU^M7V?/_
M^Y?3M__(X1,O3]Y23NSUT__YZ^N7SYZ?93^?O'W[_.P\.WGU+#L]/_\%?O7F
ME[.G?STY!R/Q]0OY;G;^_.DO9Z>?*AQ\1QO^ 4;CO=Q;KOH]#94--\GU!VUQ
MOR82A,T&EL&!U?(N*UW6M0:+V!JN0WME7&'^E?VE:A:FRLZ)J"635:02&_J4
MVVU@FS.J?WWTT^G;IZ>']//1L./B[@]D$DOY D_D.:[[&D:$68RO^2R>4$74
M"[MH>]/N)&?Y;8[9D.,<4S-K4V0_/LZ_A?]]_^2'K.D[7][EUJ:UBHD53C.F
M9.IFSR>W5'S6VH(_?)A=/X!.,D18+)@DAWXXSG3[$!_#+L&(41B.F\=XDY<[
M7Y!?ZM9>E Z;.8KLG$JS80W/0]?GUWQI/BQD,A^F4^=ZT%EO^G:Y-HZ/TO-_
M]=@I,)^HWQR$F_,9]\?A/7KTI7F\W\T>[V>6BO_/V?/SYV=_?_[L__UDGN@<
MO?^,T?OOYNC]EQ>]_^H5V]&7IMB^GQ7;YP[WG;PZ^<MS;%/P\5M,V/]R?G[Z
M^A7%9^$#+_]Q?DIQV1>GKTY>/3T]>9D]??WJV>E;_0QHQU]>OJ6/8 'O"?[A
M(6?[Z6>_U1^\Z'N>AZ@+Y7+\<6ZEJZKFBI#,2[?LG</ K%3,"JJ;J;"KCK'>
MI)5;FDLEU,*X+]C%*WV("\NMB&6-W_QG7S-5F^\0# ^..O>T5[%N$#R9>@V1
M8B7^Q'8+FXACM96S7#BL77Z?L U79$OV%M_KA(;N^G9@_%IV86M8*&T>A*7&
M:=)J.)!$V0[FYC*J3,Z>V:7=+&PKQ9Y'% H[HB6"'QYE,),-KQA^"Q>+_HL=
MF;! #K=B8;LK:^O?^ 8NGXZ.A&F;?K#U8=N15V?PGFM><_0CO<9$P]6CI(^?
M>."U W\D X='ERYJ!^>>[>Q[K,U6G &11RY[%LT.OGU2FVKG2@Y%^@/Z-#GY
M9V'ZK_WT<QW]-7N/$[K=ZAP_RJ7UUE^7\^=/Z6D2'\TD-'ITF)TCTX#<UJAG
M=*(+MD@G:_QDVZC'?7RMM"N6EQ2O7OP:&B'LV99ZO1OF8<1>?^Z7[1#_Y8*:
M8.E/B][!F)S3QUEW8]]Y65\VU26#R/!309B [D9ZR-*ZPVS<_7R?._A%<N""
MF(' #= %*QDY+< UO?W7=_3KIV"5EVVY$+2(%M]3E?"OQ>ZFQO_!(=JC*^+3
M='BK4HTY%OH:S,_+$AY[+\*=4G=MLD79;-<&+O?2]F0=LX2F-G;8[I":Q.UO
M8 Z[/%O"E.BC$1_"'@IG/.1UW5P2LGDN736;IK++'GRKF$BE*%HD6F$@ :1;
M*[*-+>@U-4%0;ML2IE(R:$=M^[;9NMUR71K$JN/D$_ZR:BYX;*!C6LH3X:F'
M-6!D&9 AK4$?#@% ,@>&/0P6?K^QR[6I2[=AIFHY_>ADMC2"]K+I0;#L'-R4
M'._4TU?GA]EI[>4Y::(\>WKRYN4_WIYDW\2<<W_*KHSC1-9EN(:_',(37C1-
M08-_!FN1G10;6%H2H@0# .]Y\>PD][JQ WG'J%NPL XF_V_8/? U2Y,1."_=
M_F^>'&\N_K,PNS\IL $\LRNI68LFY7<IJPR(5J+,TW'#8RH$,O"]48]HEHAJ
M3Y*2M=X$5_<*!:ZCU*$%<=-@&7]M!"N8,7[@$]BDE2[:\5%8M*E5@OE/3W]1
M;AO<P\)N\>3@(*;6X#!,C4VOIH8C=.>2'H9YH$-7R!8_6AR_#A,4F]W"V41-
M:)QKEKPQI%9U2J>X\:>G_@QGWXPG^Z=HMK!LFZ8FB BS960.7,F"K7 &&:*_
MT%LJ/-_]!M]Q:2H8,@R &N ^X)A\P([0<4HV?'BB]KXMX6V\Y2LE>7U)Z"&&
M3"["K0TGD/5EFE8^?O)(/M+2D^#Q)+)(XP[;$_=\E'+:O1O!D.1:J2&+I[4:
ME!&G%Z3\E+>] /ON/V[_!]\8ACN1@<;C&8U6VS=#VBI<8(/ /-@WZ6ZQ=Z#D
MX/OL32SLKD'S,9D2CF@\YJ\0[N=EO);D[&1O,*&:/=ZCBQ%=!K2NK09":&/^
MF8HBE3"D:GY^]NPP>P,[@A^W->C2BKX)KSOO^F*7??N(O47]UW%.=^N"RY5&
M0^J(MB2S(&5Z 8F-)_+D.-M<T%CK*5E%W5]=*8,U=>0B)L<(1@WWW;$$ 4>A
M(%G&T$'X$'2L\!7N%5PD[U_IK>+;!H,=BIL[&1>L' B\)R3PV+=M79=)&S5^
MB'T_>!=VO*EV3<8Q<6G] L/0+UJSR5,=[QEI$J6@N^-P[W+9PB>/'N=[]V>@
M5<0D2N8X.D][5=N?8]7F_Q%4'%I"ZFDP@A@"@5T&GT9P[Z(-H9D(N-5@!6^U
M:+H$7.\D#>)A87"C96GL-1.EV6W*]_#5%:Q,+[WE?@2JPN%W6[Y:[G8KPI"(
MHP>G#Z$KFQQW1>B*)B([YRR&]."N5"LY>L>B*W3AY;ODYEN&[BO8Y237+_$Q
MDYN$G['8> _RRF-<14<L;L"_*BO:A$NX0FH%D"@RG1$O.<#'>>0PS\$&UQF'
MRE>.9*%JD6NJ)SX=SB-9'H0D$"ZD22_?W@NG8@0.V26#)G*-&V5YQGN?*$L.
MWO'S2]2GO)\ULM*R1;+"1=YR'0[\ 5QW&@$B\\&C6@M/0>3--2$FW+E];*3Z
M 'QS^R[G?S1;6Q_,;6?W-G']_9RX_O(2UWL/R\<XC7<B&BJSL!7?M;:O04SS
MSR2)9"V+GE) \#IP##&$%$G""J.C2XO2C2W*H24'_P'E C:/^0@!WN.10*/I
MR+A=1\C($B.A&=W)7'["4'+3P^$[6,!(BL@JXY<<?Y?AN,AB@!?R^Y,W^[?J
M"VU)6OO:]Z*I0E#"BR;[YNB_CC)Z,L>9[GQM/Y8.XBWCGYU9V4ZJS]D..NBW
MB=2C]3R4Q-\UZM4LL12=<)5).U->I'%=\# "O#6Z*B5O%^4\V8CBS&EM!XG3
MV$.Y-OPR<)X=!;QV6S)ZR:X"DX)"IDU7+MU7Z$;_&@*[Z>$&"Q0VOVS8$6C%
M@!./&C?,9%537QR8I<20_XD@UA3Y@'5]>7)*$=H-FJ@"!ZOV[:9IDUW:<K@#
M/Z'WS_7"H\1Q*?P<XB97%:;- MZUVO6%FHB3GC_A+..(D@'A]2S3J.NCU&=4
M$_4H<S 2=)@=Z"E*_A6<D<>3/Y0*-'.3O&KX$7"10(M9<B,6\%@)<%-[@>L7
MR[XSM6UZ)X#"\*D-YOD,[Q-<<TI+P%;#'-UD3!#</P3MPBP>KG?=K8>W-;*W
M:>TXWX&Y+XLW(<]8"L@ *GBKP-E/S'?"#.<Z,;?;;.&(N]%-9&PQ KFY0C\-
MK!<Z4L+X"M\L.RZ-YW,57?[2I=L8HFODQ*(KBA8\R>WH@TX6@/0)..*PWEE/
MJB!:"=A6SOU1PK:T/F[H7Z<I7(O09V:YHP6E!"RZ&A<-BR22<^Q2D\#Q]V9X
M"C71@[#&<.*7DA&"I9<T!0R65]\'#<+%41W&50BZT8P"!S<3XP=_@>?QY;;U
M$D9E+FC#X_TD%Q-'B,O.4AJS._$>YS'(.@^8[Q-?W9SW7Q'D<\*RKM!-+CMG
MP;&F8T[[6\?IW6A90?XBDARNKF2U_8&Z%QXL;E D^NZ_6K_S!YZ^/3TX.O[A
MR<'K9V\/SE].)&RGP^L6!'5))PH>V?7M JV!B:!-0<GVTN3C9^B?#M#KQWO
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M)$/B,7 3Z:]I;PRR[:U]@N_5KG]HJ R +!EBDJ9<XS\R:0LVG+-1$+E-YSI
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MUW &"[7_>./PM4%N*N><XC4C&@ Z2A.=)$'PWSA51A<W%POGD2P2ZN@].&]
M-TZ'E)%UD+KFD=TFB/Q(^@AD')MIY=#;RWE'@=L1!*3B;T&3!@&3(M7S(% B
MP+5/Z9]R-W*1:M@"Z+L+*.0E+QH(_8+Q3 #5=\Z_G)H6!/9;DR:3D@CDR^3B
M;6T(1<J<0C6 %X3 $&VOP2Z*[%::I-2$24T'VE<Q;LR25#>@RU=#SE$K+I6/
MJP;BS"J-T,C6&@LQ=;Z+606L4;7U'.%#58L9.S0GU3J2)@^_O?QX2C^Z1/@Q
MX>@P8.*0 R?(I2J%ID=5O B24>$9%7EYH[G92WG;\_ !F,)C]SO""&U]DO\W
M94),Y+J$2#5$$(Q5@XLW!)M4A+,<AAG\&.H":W)-@&*<\ ^O,]?63V]A 2V3
MPU>9R*F8#ESO.Q73:\U6<(HT"S0ETSCT\[PQ2JF:<E$ZWH(!=IW 2I2)FW K
M$_UDPDDP<S@4(0JNR"\LQ%A  !\[(F$<7B\NY12PC81[7S$\1]X\0$'0%TF1
M%I3/GI]+(3[AWLP+RQ869JE30X.U'R)3*6NS06L]1J0H^!%[?@/BTM34DPO@
M2U/AES>7 WE-#27AJ.:M+ B[J.6+!,2EH!MGN7.,%+<@>""7M2!_V!F#H1)S
M@SQP-TP)NJBDXD6'RJ<P>2$W13N <O]>7O<WC;T8K'AUZTPA)\][CAN-DR^/
M02:X/2MV#]%JE=91 CMR DBU-&1]A\TW7%\:>NZTV(H4!<UWJF.AI705&D,I
M[$&NOD&RZRH#<];0@LN'?E.<O*^_F,LB*:JG03B_K(4U;3K7L/:^\ +%<$6
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M3>4D7YO)'.0.()F2$K@*/#7PWO-:H#HUEK)!U$0@DOD%%YX.N8:W@A8:Q\E
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M*>'LU!V*Z0R?('6?_*@W*\1@0'T*5VK)21)/8O*4JIC)RRD_"[BM:+&B93N
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MDW)I9+(G#\(>')S"-@58ED\,:\9%RGU_\A;/QW/!K$D"/+BP+)5,KKUN^8M
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M&//<:2QI Q3M4#H"%YL%/D+*7,FJ>,%#:2:&<\L4*[FD:#I?M3ZK_H3&#\C
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M/Z+,$_#1CZ2 OA=&R'T#Z".;[$FM&'&'$TB[IQB((\6R2*?8CXP"BR;J<O-
MH@H;DBS45")YS!%]Z_*3O!ZX2.3@).>\*:$7>.W?IGO9AG*>%LKY8R2/KM;*
MJH_30RU5J-T>^<>A@AY3O2I:\N'QEK ,LAM]UO<@B[@]#]HJ)GR <& VUA5;
M*!_'Y'57BTJM61X,!*&ZY@9UQ9YZ'$G(@S>$')O.:;$56-ZR,*<[(QE=Z",S
MR9(T$\4F?F7!ND*?.@V@%SLLC:*%>;S,UE[1ORQX!?4"$OM$QOFV!-B,QFA&
MO0E UX4-%;?M?OP#3JKXCJ]#Z;-T"N&@JG==$$7(0]_886M$1S&G#O@7W<<(
M TAXH&+@NXCO.;H GP6OO*^2RV \S2$R92=C<*=K8C@4S[1Z>2X%9'>X=W%"
M5HA4 ')=?Y=',,3#Z.99BP69SQD;%9'Q>T[C@)FC4Q3)LV;X7HS7<4'HS4HI
M.,A_01DXVG>-D0FY>M-9(4E _]X7@[GT 0SY4,X(_AIG:09V03I#$UAT@HA;
M.70AL0:JV%!74HZ1SK=,%"?*0_PP>9F=_&>#-2_T/$VHP\J44X74%F"JXFEV
MFZ535A,M3%0\QL4<!B'F!&91 )8E,(J-1#@$ YA=.!B!U,F0D0/4#>O''-=[
M785WC2)X"4LQB]UH@C##XW9]?@9ST>G"S"7146\&,$HE$-&KB(3;BR()$7O1
MN[W6G/)A J,!(!7#JV4&8R$V+H8"(1W_8.Z8W+L))FPU5/ZOW*U].;Q<:)7%
MA8PF<'_@OXBP0/,$JM-?3(A))[ B"O8%H:AR3U0=&#CJ5>A?(XZL'D9,+T$*
MTAWS>4'FSDVKH:_0]3]^<3X+B !_=SY_/E,6%I>6L4*_Q>.'.@-.(,L&7/$2
M* 3Y'=&F2'E" J<P1EP\M)UCVEJ=LE?_["1. 7:G>W(1]B@,PYF_!<W"TD<W
M3V28I[+.">G]+8N$>7V14@+PF-S$COQ1J]4RL@<*.TXI?Z]YS32Y1FY!D",.
MC"3T7IGY$DAA4)&:_+<LG'$6<N46E(1-81_P'J$U9IBG/2F/CH[;;WA?*#9?
MG1W>[E28"N9&H>(J2WAST8T<UNDFNM779A6UZ)R3DE(2XS)QVA$MTJ&Q1JS?
M(XP;0:6^MST%K_2[\F]():ZTV$!X;J'9438!Y!A0"?ECVAPSJT(JYC%L@0I-
M#KKWN9J\L7Y5GL;LMIRST12^I7()(WT'B?#Y0&&GC>]R9X AR$UCB)B@1$I4
MI0G)&D!-219R0\Q4+#@$'&&CZ@QT5E&T =:;4(8$!4+1'N@ 2DY9X!!<98ZV
MXL[:.O-:Y@ <V1R W<X!6*=/8O'Q+%"#YH33;'DKHU\76NC*0<I15=YK--Z#
M:4DL0KC2X&#$KQ )%G-QHC]$/MG(B]0=T4ELXP#D&X/'QD/%^VB4 Q)+HH J
M3\,S@?-#P5UR@.EPGTKTI(")\J#DS@;*%\^UCUX,B*8&4$''EE3!]5! A#K\
M;+RA+R#M"[TX8U!H1!1N!G:HD3OLB5*!T[C!J5^W4D5!E@2LA!I6Q^#1-I-"
MG]\<X08S@IL.B"K':*-R"1H+W4#DQZ%W4\RT:#?B>Z.FU'Y-GA*'FE4>*Z&E
M%')-M=/I+@8G%!2Z%J+3.0\N?ZFA$!7Y><%CHV.]W/C9#Z#7%!3FZNR!IG.J
ML7S('N \%L?]W#<1 "SE6L"D<_I>9GH!WVU !QK>@/E=BTD0S :#IT:]+]HV
MRD9IX.^R*+\'9$(9E<@/Y,?2O/+O%D)C"3'/J@>5SU:E)YU<$HM2'E1J251^
M3;I=9BB7CLP;C!#=Q!PXG)J.ED4+I"62=M+(W>&;0B$(Y$JGO2V!8O@*%-4G
MZ2B8Y $;Y5!5B>YXOT=2GT)H5:D%/P@S++O/(QD@K<=NWE>=,EI<Y195T0*
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M5\<8<VH;45*[M.;SC]0)ZF@ME!O'J)QY[O4E_"8IN+]E_BV]Z#B#^A HVAR
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M!M,G9IQ-] JH+5*59]-YZ;9(_/Z\P]3&+\N'?V7>M8_F7;O0=TWWG+_!N_9
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M_ (U);>7QL**B-)TIDD<8GU"*E<S394/5='&ER/1N(;2:F9OA[0:[[$XHA"
MYJ)G/G^+G-_RG1:NU+)MXUN/I8:VGV^LM-=EK?S?__-G(HGPY'9,(,L\NOW+
MN]8[_#<_&/_-<Q@@N3,.H IP$&V?. 4X_@Q40B/L82WL))4_5G_3ORJ\[SMZ
M!VT5&#:$%-:!#S;$71SXZH-2+?@2)_SH= ]ZQZW_K]UY-V=/R/ECN;:T8A7"
MEHMZ<F) ;D3<Q=UY=BS_06!\(0\I;=_1:;,(0J>^>C-^VI*37VA^D#FQ8<O
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M'GZ6@] R!*A)RM3VT"/T38 _HD)SBY5$O^/G7=2',4A\1]H!">9P/=1>&BV
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M/WVZ.#N_HBXI9U^OOGV].KTY=W[]^H_S*^A$99M/K2.GG'.D!06\@M0)Y,6
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MY[=%X/4;Q2)PZXO>" #O6E^T]477'^2]ZK?9\6%J , W)T%V'QV_.0!^4 G
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M*6S*,TXB=UJ53PW=22I_K/ZF?U4XI.\6V]O&K_V5KT@E%.%W[,@W?'8Y<.4
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MI9O=;J_?[7?V_=YQJW70(A1W1##N2OAB7$Y%\]%I)M%5/'1.L]LL93W2.6Z
M*ZWK#&;H7QN(Z;T0$?K=KL1MD$X35WX=?G7Y^9>/%S?PZ99S+9*[P!-IP_G\
M^:QI@=K; FJVK',EG':T3:!VO-^#LL[-E,B_)%!K[?4.^L>'%JC98=[>,'4
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M_+.D?U3 + ;Q\3W6Z7LLDK:_?;8_X>5-RLH_6+1#%V!HJM[KJ:-15_J !ON
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M$O::F_(;9OD/'HU"5KU5L-'0U,%PJ/:'<LNJQ8HHB=1*(K7 3K7(S,AD<T5
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MU"&GG!IVZ]?^94CZR28S1 JC%,;&,$0*HQ3&QC!$YCL;VP!LK6O:BMG)QO0
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M>R/M1Z?SKF36_7IF?9YW2&F^-R11,,.)\M7UG\(RE<CKJ+%H.LL=TYPC0I!
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ME0TR7=F*(.7MPE-+M-+OJOJ@KXX,>>-?C;R3&<PCRF B!G!$.V?EO2T:.G_
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MBG!GRJ9P\@_?.\F=9LCU>/9LV;*Q*=4\<C$R2U*+];G!WW&?.0Z98H8ABT+
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M^_63LEB:/R_6G[)OC$Z[F,"Y^RY$^KT;3\$(@)SX'ON@3$Q;N6?,4\P9'F_
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M!WQ9&"/D/EXR^."1>&$1T=PGRIQI,5.8RU \33 K!//'!Q/6\;D=SJDM':[
M%9NN)=0G#I/"$,SXHS%5<,I1EBB;,HB*[&5N>^46=,4MP.2.]HH=[9'<T3[X
M?E!K[XWWNZM [MD,"][3C_[0WW'TO=[0PYJWW?,!.$ P)_(#GG/-4!65CX_!
M)OID@Q$[8H >..%/-;5CM(MA@?F' !8]MOJF;?K_Q"; C\!--NJQWP(&2^.
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M/]^=)$PLTJ_B[*:FS2A-R_<>"=B0$BB)0N%C?S(VXX/Q8\OX#0<\+R*M)#P
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MNFG%]R%=X1"YO-\5>)*5I6Y84H1I#M,%)RK:![TDD7B _<;P&*)+#4%YH5+
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MNK*A+[ OR&W,!TDIB)3@3!/.8&S]2F^FXO6(=_&2OHNUF9C<WF#AAVHV0HM
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M17AG+V)$AF,1I1<;GY,:?1\.K2BZRMD4?A&LH!M-6/S 31:SAAHFS,K+TZ4
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MX&*/:Y?'TX.6JU@66A7F@KS=7S%(0W)Z,=OD,T[A6RX%+>I@>$SD<6!-\[L
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MR5*Y<J=?=B6'I8:N%Z &(87H'#RHUIA:<U%L0'!Q8=PP#0XMUS(5W#,![2)
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MN4XB$\_[SE)##+E3Q>8-1Q*KE3@K9;N.YP[]+"9^1W!S-^FLU-Q 0=W_F""
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M3OF.+A39E6GM?JN1[#M-!D\S<W+HCDCE8%$.H(R77?9LL9<PK1(-]CWAY[Q
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M1A\\TI[>'J2E)6I?HVY:K+:W<:G\2&LB#<N)?HW_OO\+*%F50>08.5%$J6A
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M<Z#WNW7Y9%ZIS/UE.R>):Y9%XEJ=MMYMIV%KEKQ&Y\SLT,>E"UQ$M"P,NJ;
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MVR7U"$L@8UDYCQUP'GMZMY,VROT(N7I3>X^U#U)[CV?%N3KM5HREO/@6B(+
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MX;CA:/2SV3E;G)%C\+C/#XN[]CIJKZ/V.G;3G8[]2!,51 %HCFAN92VI.Q(
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ML?;IMM@)<IV'[;.9RTXP[W"/8OR!H;>&&2<^:RM7U!;LU%MPVQ;\Z"S=$NW
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M#,519\H3("1D*:G'MO9RLW!6%(J6V9WMZ+WNN11R5,N;502DJF[KL-'/>'+
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M4$[E +6\6B0M(11IK@"VN5#Q]/BV:<,X]IQX$%4QY)WVW^8 6UXDUY1T>/E
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M/LQ7? OA5:Z4]& M7/1XX49BI^* 'IX=BA1FR%0Y7_$$%V/BC? X"%.NZVY
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M[>8>Q1:;=L6-#:MB]^;W]Y:'4Q8A(-QO$DAL<H<FGLTF(S]V.BW/I5MKQWN
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MX=24\B2DR2@$6V#ELIQ$D"@)#0EDAN^>NRA4  8D$:->_I)$H$N?^09> I
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M#J]@D&[;Y&>8S+(,B#YNA)JE3^G1&&DQK$3XCE[B/LT"J5QBS"$ H8''@2$
M*".6UHS.O;.5)[[VZ0R@%S1,4]$' ?!DEE3(#IDC)@D87\*1+4M>Q%'*Q\+!
M*SCGAXT8+IB"E;%T%/N[+W?*1VN%%V<=@0KOR S9(@(CXKN4>227D%[8'/PR
MD$T.3TT\*0HL)[/KY'IEK 5SEW8M.FVP95-1LQRVCW--//#L'E%F@YVPJ#G]
M59$SUN]DVW5OI0^!4%=!FDH08Y.DZ1:2AO"51\YC: 4$:,0L3)!(;[;9DM"=
MIVHF];:P/B)1X: Y]H5:)2<5Z<VE\*3&0U%O]-?,X+G=DUB73:(U:*%A2#B
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M0.O7W@4N .#3O3CSCM]>7HPL7LUUKO:S93!11W%REP;+G9.+RXO]T\OW5SW
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M_\FD;/S*M7$BGW=_[=4=R\->]ZQ^;73>;Y3\=3<E4IYVA[VW-X-!H\3:R0V
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MO8"!T^/BJ"ZCO(1WP%ZAG9F@=-:T.V7^N#7U&"1!@9.A>8]AZCPM>%'X>Z9
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M$1@^85;UN<*@_ _RJ*5ODEWHVL.^,_UZ>*'7]3R5/=GAB:SDL9BSF3TV1@5
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M]IJ-_I:8@>>>DG+,>7KVQKL'B40=I#=<,.RIU84Y3J0VC<$N;Q)?%XFVY^"
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M 7DXB78W^^+?@_C_!E!$VT^N3HF!1/EX^$_X\MWY^Y.]_P]02P,$%     @
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ME1PAL*A*0V6/O]1Z=\DH_BHDT-O,*U+?3M/';S&D###W4VN1<#H-Z#2[^5+
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M7GYY=SG=H4_T6+1?]O\!4$L#!!0    ( ,L]853=^ _[(@<  %<8   1
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M9]$Q;N'7(:Z7WXK%&=Y2'Y6XJ+]%_P)02P,$%     @ RSUA5%>^AP*W#@
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M.!Q# OQ$AABDZ._X\  ,:9MO$X+1)[:>_]8# )8@%(*$)QI[DCQ_9(6-CTW
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MO[3Y]Z:HU7]KR/_[Z[!_">!W\;?8Z_UE08<:!RTC(LJ3A#*F_O2H&04!*T+
M$&5[B+(61%U+$2*KJ$I-+1V%O]7\G0T\T1Z/Q^C9V&WGB:H\$H,1=401 [8R
M1E4>(@_YR<J?=?]FQ@J/1'N'_L85%64M1;6?7?FIYM]M4$<2TI/D^1]9^;GN
M3W:H*:=E0\0C Q$HHIX!@HCW\B2)&J,#2&@,!D4455*4IR:6FJCT830.B0\.
M .DH_*+QDR4D0@OQK;UZOW3<]I"R0Q%^Y7X78-!ZW]]6ZBC\R?A57>&?^CH*
MOP7;<H&$)F%0OW'  $/Z-P>V4DL+XXGST14+ ?_Y2%9,[_>O3?\G'W^%V/;Q
M[]YL>>B-)V(]27IHK*</2@'E'^"]7?-/[J\];&6E!<4%D#QQ6T_Q]:@,>30:
MJ:6H[NVMJ:E*[6U-;U7J7*F" FNJ*ZN O9!(10C26XD:RF^=_JOZ/TP;XQ&!
M6W,'5?9M<D;B$53S/\:0EI>GAI<Z0A$%1JDC-,#>2!5EL*:GH@984=$;I:B*
M]%145U?_#O23L7\ ?7N9X(GYJ<Y66Y!4,(2*$D1%5549[(5250.C%%74P%X(
M-66PM[JWE[<:4@7IK?$#XC=F_@%E3LU</#'T_RP#MR=Y?T]BP/:;#%VQ[Y.0
MV#\4MG2VIT4M3\36\J 7X!F$0NHH_,+[=R7T/SOS/PO /]3_'2/8%X7[GR:#
MGVK]NY&MO _V)*(,?*AQUONV0O_U+Q$@RO)*/\\(O]/Y=]L(7^I00R'U%+XK
M?F?\HW=^.];^5[H-B2*B_T\ZCHKB2;UNH<[P>@@\;NO5#@HIZDW$8T4]_?TQ
M:(3GEKY"$ [YYUKT8PR)DO"B/X_T?YC[O]CH_SI7_[.)9R=7_\;]^]KU;S/5
M]VGY6VZ:;F77?];9.MN75__-[/(W]=]91_Z_G;S_H?X[Z_C_=HGX5S/_C/Q/
M ?[E2NC'NK?]PI5ZV8724]%1^!W[^\V"PM_N%K[=BBC\>2]"O0]2^'$C]+LD
M^]^G'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0
M'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =D!V0'9 =
MD!V0'9#_91"6O_YK,0J'U!4+%CNH]W4*8 2@^2]IR\A_:X-F^QM@--RTA^AH
MN+Y_ ZP3L!]  Z"A8Z#YZ5N - R,NVCIZ)E8F%FI%4B<   C#2T=#;7,PL'&
MQDA'\^T#8%1KW$ E9AY>/@-;IPS^/0*">\4\"6/WQ24/&!X^DT(>DH*HPRGI
MEVK'7[!(2*MIF)G;.3@Z!S?=4E$U,C%%>OM$I\YN*!O;>Z$"(R+32KI[0%!2
M4%%S0%0Q%56$9NL[8S]]=HSJ%CTMW?9WQZCB8UQ4I^EHZ.F86)F9V-CI ;NV
MG (P< $9N7F4> UL=_'QBSEX4D;VB$M(VA/.I*2-OH"HJ-HYDB_5WF(24#8R
M-DD=DC*$(P//1C0,C\UNJ)D>]D*@2.&1!87UG0?4B1T!C4%UWOD+OW[>Z^U&
MD4Q_KR!_5KSLL:G+];&'5Y</QL7MZ6],/ADH\41"J+.CIPG!/_3J;#,98CT%
M\9VH<$AS#DP%0EM6I89+/-!1P_:K*RXN^DN-:B/G6G8=CAF0;\TWIV&"Q[9;
MLP#9=3:35BU%-3;OQ&)9 IO@1:'QU4T/NJ'P8<!XZ2O,8/RFZV5 _D/@VKEP
M!E:9RDS!6^Y-D00EL(=X257NQ? U>^L@%B_)D3T1!A]!3/>Q'JH&]@GN6*+R
M.M!:8\(";0>2ITT3S6)[%<7B2(8WM/4T-37P <U'I<<+KP_W<^^9E^ME-F"!
MO>3KGDQFX:4E%^<&-E3) !)?Y>*2C]W.G,L!W+JIV:C;NQ%_W]E=DC"U'!(R
MQ1"9(]0F_DJLT ]/"8M)Y2="H9J86[S3:6*Z08NM;/;$_&7>%]/!>4]/JO"1
MWM!GFH',*;<(5KL$940U6.[5<),=+T:6@4!0<<F6"-+%QJ/M)&6YHVEF_G42
MN-9D9G.V,GD0$B?!U7:15(KO4J/W]Y.?8*X@@4JKJXH-#3F&!+GH"Y#SHQYZ
MIL=,N2IA/!*"3@LGC15,?>\\:D::,@9=!)8IG6?BH&>0/,3/U=(T7I)G60+D
M58P 620?M[-62H?/R /U><+].%^B/ 6!;GHRX>1"QBFN$;FJ13#( F#JLE]R
M43V*PN^?FCVK.S<?;?ZTI2\ZRU"2'W[9I^">0KP<[*#OL\J)^"FQ  +(Z+QC
MBY,:Q/;Y(G]-7;Q)ZJZJ(_*7]LIG=Y^/%0\%S9YIZSLIW=+K6Y>1*F(QGT$G
M8!E9%,DAM>DN64?;'G8&F$^^F.^_(OB0R=F_95XV>1)^[Q#?25,AUT'*Q<BF
MO%=D,G.;U07%6\ 2.7'RBA&S2Z.A[1.)>)G8*3-73+EAB<<9IX4E'G.K["[F
MN89AF<B34+5R-:W87$NNH<(]XJJW N+![[D*U&P,'Z5P/9GO1S%KZ)@_-TV.
M)ON[SH(MVAE?:ZP]TWO")ZQ1.YD!/'&SJ/1R#\YN=YF1-<]MG9%$.>X,]6$*
MN?ZJ<W"SBVR@2I%*D>MAZ![_5ZO(>@:: T.!91/\L,Q(FS)M%/_R (I!.2QY
MQH0,C(BF 85I6M+2 HMDVD:7'"I0'-IYQER:/4?9;Y/Z$1RW[JES[3LS G/\
M0BFF;I7XE+JB(WN*/%0306]Q6#M6 WU3QXIZ?C1:D'\(PI,$-]3B*VC6J9KS
M*MQ77M8+I\4FV"A1E)BPB6KN+LEDRC/(0C1_([W:%!C44.7G4L--FX<5KRS3
M9UEREZ^M8C<-@DEJ>5L=>\P78^N1!7Q_2!7X2BW*"99NQBC[#(RD!X+)16QA
MA!.GY1532Z#%$6O#*?U ^LMUBJ43UQ(DE@:.J)[GD.Q\VG66?P1.D%S"\L\:
MY\6/\*OTI>LO8OQDSP ;=!I?1--;V)J'UC5SL6@3%S5%@&:%:J.'>42K\EX4
M&^::;MKD:ZQCBR+?<SU +\,L(Z9JI6]F9EI>#0KL??-NN+ L>1H-EV@H;=?N
MXA"#&G'0:\UQ5]L'\SZH<V'A/JZK?;5AG65SS,O5!HRK= SJC#4EW$Z0H'/J
M6A3IJHWW/UO&3(/)<73_W,I::L;!"84&/92,3A.Y-^R&Y6AYXVZZ1H*L"#@G
M7UOOOBO8J1+FT#8WUOK <26F6VIRPL?@G'^"O'R]ZKAS<U,.ID-FKF2^W(5-
M^E+^QUY+^W*C 6F8$UKR$*\O^[3;:N(@#;(NV]% H#61?,VVAC53L.FR^!I_
M1(6%L:*C[@#OA8!R5XR@6Z;09JUM?YD.+Z_OTS(_I7W0!":#Y:1>;RWRO)]%
M?"+XG0*@ 01]R"VN0ZG,ZRH"=O(!H;;+(09^7,_@]JN]Q^Z)YH01Y=(?GGLL
MP"E/@!>[H>73RB7O[!T/"V]RG,L.E XL@<?KWN#/%)F6/J1\Y1TFQ-S-RXW5
M/#:8PZG?IJ1 -BCD/2.Z;H^E.R0U*X&>FQ1G>KIO#B)WXJ-X^'Q.T#).7@B-
MP1_R9HN)* ,J*!,#F[S ,@=(#%HK0@$AX?WMY*<&AK5&'5:Y3S<7BF?X1YF#
M6Y0U,-?G4XHP;]ZW0E;-,:V1=1$;0@S[EK'8ZH-\'*+E\ZA.*<CIO++-W4\L
M/$IJZGH'I@^73;@.IYF>OS(Y81?7*"O@Y!RL)$]V+Q^<?UB=_\SUBDFFIG9@
M6#:?R"ADI-^:KB^IR:5WF2/?F59FZMQYY=C4MO [<[QN%HE5HI<Z08>S)X40
M=V^C&V^TGQDQK@C/-S>I:IPBRK/'Q^5P\2Y( CNAS*2H\8'!A:H,>-R@L@IB
MX&/_P-[*X6%Y["B**"?FDT#VEAF[EX9F7.RXS'8L.NR@G\P&OWR^1S@W-D.F
MT[F,@2%439?%.!#*(2F>KRG8'.=F%'N[TSP(DN/"6Z@U-=@=BB;4%?)&5(B"
M-7."AERJ\R<]]9JU5VG=^SG=0MG*;"^:1_/[\"FH19J=UHG=R I2"9N.:"DJ
M;$[/?=B?7>'>BH9]VQHJN"\C+SSD#+HHG:O;L&')0@]BD#)PJS:G]>8.8SD[
M"^>@/-%;FM"7^E0H39L6M+RM%(2&K=J=!RM6,#SA3LVZ$(]G "+BX-:P"]X^
MNT% F]K&<N?)F_VR FQ+:1'9(7&[8[H<3%2T5X=I)O+K.MNZ6NW/[ FG@.UX
MN# 7M1[S1&K.[E6^(UH**LX]9>Y;=3,YLN5!0'!,PGNH$-HK9G&0.R]+\*K=
M??--Y%5\9F:2>3UM10X7,BH>?CXF0F-N"EEF@2[)]06SM19.!\F+OUAWJ+PZ
M44&45CE[51\QL8L)<OH]MXM<2LI+VW5;;:F!M 'C?(ED<FJJOOVY&&3J?8BU
MJUC7Q/!HIR9$.&[$2C96B9B3E#;+<"S*,:/^1N*MSD/,10HDG<U)5'ZS"%:F
M6?F8G+]3CI3Q@C]V4]2$/&].>)%1#47W]N+#TS9J!JY);HZ_BQ=L7C 'UXLL
M%IPYV#D.JF9_;7:W4E:Q.TZPZ+JW5@&"?-93QB3?]3RSH#=AI>Z$FH./..O<
MF_+RFK<O8S7;!.^&]F7"]ULZ $%O_?J\9.P;+N%!<+?8M@CI2/Z(J%RT-8(@
MR2(1INQ2C$5E<U^F>2)1Q<_4GQ)T*H9X))&W6)8G(5!OZA@6G@"U?6Q)(L_=
MVU2G36NC3,LN?7#5>@T;$GTT),@3T&0Z/,?QI4(E?-GJMMX&TADE% )*BT-^
MT+?S?62R#/<.=#!G@)^YJ0_4*0/%A \_=MUM#H-O*MJ*1$NTYLT9AH1K6^L(
M28#-#4"[](-#S "NSJTMTTN>-[3 ;> 'W/"F!:O,L>LRY_W\6T:#B_4Z"4"C
M\ P10_O:W/&C8[#G(S [ZN90W%;0[N%U"59*?R([]U-^[R:OI4^"MRQ62(8%
M>\=&C%L^3H*.QE*&)H%60CH\+>A;SJZNGXU=@QZN<_93K@NX+3QZ02LVBP(O
M0N@20-UINWV.Z:O72 J'- ?X5- 43IF)SJQJT0K6^]L^"#XS/<6A*6!A.HN&
M)C?0-D2[&4/=.6!3R.2Y>QWO+2)!VJ4LI"1N^]HG2*Q),;CKH]\*)1JA,;"[
M]RD\C>$*!)BU9F+?V>3$O2].(['I<!K(J@&R&H-UFZB6J%FCETSO /I)=]E7
M\,EBAM<*"@N3*%:S(V\"R:KX?6/]SQ<6<GNTC&O91ER@/)2P>J_@T;>3I1";
M%6>[$]4R)]+OL9!W05'LK<_LS0\Q%.=95!\\SR+$H5$4H59';JKNS*R38K[4
M+38)/++/#JSS881V[E7FBV87%&L@L? @U[AK!$40YM^0/.Z!/V%?PA72"G&$
M24@L%@XRVQNN:DON<LW+CCA[62?BA->Y4+""<%>0W* DYZV.)B;IYE-$1EP*
MBZSVL>S)Z815*_/ >^DI>^V2<^>D1;.P_'2U4_2+/4++<L^+!$45+)]5"+ZS
M0$,$$T;N]-F-C^,6']1>.*W-ORP=VEM7J!=1UN1*R7PN\+&3[QF"+E1[^AUF
MWO9"@4)R@=AEZZ-VI*$"[V5;N57K/I'W>TO'?'L9-U9AVKY$'>-^'7%_S#2-
M)S%?TL16GNBES?6JYV1#AKT;"\TH;X,SQQZ-@5V!%Y.'7SL#DI/)]@T,"/RD
MTQX+1',(QBTW)FD/N^YZND3__*7(.B^3V8P%AECV<)LS+;"6G%C#T9PW6?Z7
M'Z_<"Y:I'TJ^_*!@B!P?Y/ULKW0%ZDH8C6/UL,D(:D33FKP^+9'=*Y<U;!^I
M:4QGMZ8I,@9Y2H-^J"=#;BB3-70SO-? )VGNPIM6I)\,-Q!>+<-?X%]FS[HW
M[I;TSM; S@^-AO,73V.[<V%NV/$\P\G QD(0!Q JRG58K]%A\EO:UDOC'_49
MZOI_;D_*L)XZ@33AX^3A*\2.G]:-HZD!!#=5YHA.B$[Y6XD!8F*8XM)"E_^<
MHML=K44WJJR?KL1K; 965AY/&]\D@L9*IL?SS[N>F7$4Z',6JG$$IO9U9<F-
MA<NV*IP*"EHW[G3NI[=#8$'C(F1RDI"UI6\D&$3 N<[FSRHUN4J %VN9.WOA
MKC"*ZZ-I%KC]+D:/85?1Z:YR TJ64/KKUDU@'Y'7,Y#R2M8_38F]+&;)K9B_
MP\WDS(VKU^'\Y) R@FQ4QAG=+%GB,:.B1#.PW*S&>SY>6-HLDZIXHTOQ@V>Q
M4O49TNIX6J0A*G!4!@J!A#.(W&U/%>EQ"<SGOUV:G$YY]SY5TSI?V7?Z+F=+
ML9NUZR.8N5 GGFWFSNB#0E.<J]V])I&&N]<B(RY+-[M:>BH]L;W:B<8*8@ #
ML19W0# +7Y?DB^I<<PK\UU(JNSK[!NYH-8S.70;3<C=J2U-0UI@[J?$Y-95C
M<;$W58*N[JGJZ/8*+Y,;[-MC);])8 J2O2U%?,2$O7J<,IW!NWI2<4[0/GS*
MFH%7JZX]I)0]#5]D]8S;'2,W/NIRA#@^&BQA'O2<Z\J&B[=P6LOH ?<9*?OQ
M=Y[^V=SJ!95]%L?02X^,RJ#HAX/]07\4/$;#LVBKVY>!+@E>=\R3&+/T)A;J
M]_0*]G-XBN<J6ZUE'YVF"?S8KK,^I,GK5 AJ1<D+U5 H,+!*$=C<\66ICEC>
MPT4= V##@9/<]7-AO-";4K6-6-WKKSGL5P/4]\QW8;322,P@^X:*V%8@T)R5
MW,C8QX3A\[1:GB]1?Z1SX_#F*2W^UPZ"RH?7F*170,Z^64QF27N+9[V[ N;>
MFZ[GI5P]*X;*ED>>.8"UCB]^8MO:)WV*B-#F&QZ8RM6/&C?D3PL3P<I?Y"8'
M.W(V/+_DY'JLGY]2)2E>@&[MNJ;OO<AT< BYQ\C4,ABA4<U:@3HVJT-1\*]J
MY)\&-*VHNZ,ML&C;:ZKYK?;#E-]L:9$ONT7?/"MH*(JL<Z$$9;B(],FRL099
M2^V];-9D/&EK>K ;5-UU-3HZGK$P:+%B-)OEX:?;>;2G%CXBM!"6L8KL\WQP
MZZ7@D'!+YF1><J7(:,2 K".-#-.T@ R+M<*!1 Z,49B4XI3V@D]T1Q:_DY-U
M3H]2N+X$S;74W*,S,8^XUC0^/-;V[1"TO6;S9I+EU4>[^$;=Q0]]DBIO'A);
M^SR&SF,)96J&74!-TNG%=HL.[3C+P>SBH53O0L9;5XA&+QXU7Y^P/,QFTRY6
MJ5A:99*P8-\PG)X1RV)1X=]2>;7;V;_*>*GQQ6B64M$EU^=U97ZA< ,2U*W$
M4S.#EM6U#,OIXLE>$$B3S T .$A=NEEIQ=*H;5&-<DWM;_B8JR"_F%A&4:DO
M;I+3]8G-LG;.*2U^O?"^<H,SI8;X2&!L_J5(0:@Z]Z%TR]ZRQF#:^2$WI0E#
MX/1@-V0O@U",'9,G@;D_FHD1418V*61DHO#1)7[1R- S.?KM!0(>UJS+:!?_
ML*-:8_5NL0U,'^Z^&Y;>')Q^7<P=36/.EKB:9'96>L_MNO*RQ\_ F%!6><G,
M2PNL"CI+M?!:$Z>5-_USR)Y#/M/#*)J(08=DZ VFS/?0= X15>WN:$UA'N-0
M7!=N,AT^Y- (IT2V3@K+QQ*KS^DD;IY7MBK7'7HZ5=D:SIL"9)"?B>>HFWHV
M;?_L*X!CIM-WU<C/[D1L(NU#KL9W)80>^.LK9336:A<-GJZR^H0(<3^\6?EP
MLT/V1-Y=-5_+2)3?23RJQD:6BZ_TB>\4VB%.@F2/,<ZY*C9T+T5Q+.*06#89
M[U,\?<V?Z)0?%P]1'X2X8"--C)%7^+H?653"G -W5UL^A2]L#$ ]3=*:F5M*
MT75#1BAK$$ZKF?<:*K+:")(;DF_$T6UWR,P<BVGD5^U+-P+>@6A,N^9LVK\L
M(_'1-Z0/#]M07O _\Y]/.WSRL[9;PXD>QQ!6J+BXDU2B,7+%M!QH<_K#]<67
M/=S*?$PAFKTRHW5URY7]6N-K'I*B*VI*)'75@- RIF2>ZX5W3@>Y.=I']K<-
MMMZ> 0%!GGV),&_Z$N[P#(&XO$XUD4"9ZHH O[A7)M*2'#>-V1K"<AL&TT7*
M-4*DJPXU[S5V<'M@F,Y*O' D2;_O@P9UY0@]BPWPNZ@""&)!VUF!'!>[E4;'
M3,<X.@N5)XXM+" @I?Y6REI_""Q7$$LOAIUADBG75^JD9W&_#1R!.1#*O:'U
MI'/-6KX264TB'9FQE.(')R^U<'0L#J?=* )1-UD>E)RVVX ??#>"7&]69%:G
M55<GZ77K@%/0^X'6M4&L:9+WT6FE7,P]%ZLK-HOQY*-U/98QU>55O.ZM5YU(
M-?-)DNQ7.A->.0 7)+L'\."TRK+&\&@.)W-F@@R>1:*P5+3D7&A=]W55AJQ#
MEBA.G)7;E)L@_M;)Z[>=4SC/R,A,4OI9I%J*!)ZK-/)&@%!%&I,OZI^Q$& C
M?A:F-YH-ZAA65Q3+>ZRE57I?R9("GZ;$'G ,,E-\]JCQZ(W$O7?[U$(]?53(
MUE,PJ103.F>';MAD:"-%KM>DBT.K.&=>PBW36[EM#ZUAI@46(F1DR3]I)TN(
MYFQ*N^(&K DR/G1.,](J2:R\OUBT6>DEEK8;6:Z^CS7>+?0<> )&+DOE_-2]
MV-"9+J&RPI)67M6N$@C9EW^GGBQ7P],@]4Q\):A4IEHEAHS>+<XJPJR\1_Y6
MHJJ&]H$DSIC8H$VXM^KM%O/N1E+\Z$T^J'N=O%_RQ[LM_4H@CGP[-[/1J3ZW
MB'Z\/[A+H%M[%N839L,M3)!A@<7P5>4P#A8S7!?6;BCV: #5^YV_S:H3RG4/
M&,,M1$X75>OJM$Q([XP<1-^W2(!L"AO%])<G:;B93&:8/MO,6YYF?W/7L=7I
M8@8"QAG@6UYD)8Z&PTJ<3*V IX_;'[\\R753F4_D!G]O,YVZC(#4#'=,#)>
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M:E(QZLA8'V>W/MW'DLR]LWNK:O-YX;2R8].\TP[9_%)=]*]!TLZ]2\0A"%-
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MSMPQS39A, 2'=J7E?(_8VW\9CIRS'DT(7*IY[3(:X.!@,O+^U11,.B3(*MT
MZ::5S/A4K%RF^%(_Z0[-Q:89%(2%7^#(;L)<FG]:M[DK4!Y!,!D%R6)H0V)M
MX! FU38PP[PP2'*C<T!3V/:62PZ)_\L:?WH:\*993"&E@GZOVF (84XU PSI
M5B,]6JE;+QMH;AMW-!V?K6@0T#1L*B=Z2\P-/M;"#)(*V!:-W35,&%@<'(!6
M64GO7*;D=(2Q-9M3X$HP6YFLB[L++)@\8823T]"'6OC9:!C&W-3I3Q:VJ"JK
MJWO@Y )CC04QU%ST=V2YQT+SJ)^L-,^VH7N]!A^W4*)[A7 DUK.8]IJ"POI9
MNPVD_?M4_S)/B2/OIFXY6V1)55/D M+L0I!3U?[&,'*X6XCUL[IJGIPZSF8!
MQ[EF#Z.CH*X&0C1W1')1&7U$820W#6/]8P.[4A:HJR1S*""\F#+W#AO-,\B
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MS29 ?B/).1*^V,,R3$LXQ9^B;N*I-;[-0#W04K"5&C"ZUEF5AE5XEG"*WL;
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M?KQ:NR8@68"CECQN=9@OQ$)=A\209$+667$2*]E]W)=V]>A"R\&$7MZJVF0
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M?^IP7QE2D0IIO7^+@, 'L26RHK@DD['%V,.XS76<=A>-[H<$0Y+=NL&9'H\
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M;F:S_EHC_J$4TA^V6E?_5M2J'J]JSK]+)58WM[JD;+W,N42?-774=F$419R
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M.9%!YXF5*<@(Z&8T@+7S]FLQ3+1;/S88]R=PK" @:/L=(N .056IYXW/>C9
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M/\A/Z&QVA6;O!:!77PF>7"(WK8#5HH[WG"ZC\.EX 6BY"6^.D?T 9L6HOCJ
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MZY]-,1,Q@4Q!AZ3<D.DE1B%6EA\2H>!MMGBZ+S7$V;!O9Z.RHHA,+14H;3D
M%(4T6LV/S'"N^>ZVEAVLZ03,EBI%.[C(S$XDD4Y,:/F,V+-T^HQ+,AA8'# "
MD"5(XQH9TJ[S'37Y>^_]&3R0A%CA?%_ K[;TT((ICBQ!B5\XACEB(6_-F%X
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M!S]'$[VW@N@CQQV.H#BG&+L)TH)@6(4?U.>Q=9$MD?8PRFS5/=4I[#:TH[\
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M6CD)M;4B9;B6A^U=/?VS ?V*0?547-8*N=UZ6.LILW[@W-_R%""@2=H+1L7
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M(J,8BD45TW;.>^>C )H=9'_:,K/0_-O/??4MF4ED6SZ:1_[RFWV#A *",2R
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M*DUC(U&NSKDRJY RK]:WI)[0LU!L].+JLIOG,XL3B6.NB>FILR'9@(NGLK#
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M-+7''^)XW!OP@NBF1=XR\ICT6L[G/I'P;J1#<*_70Y[J\;[I!?\ZE*ONQC/
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MR<I[AEKPV5?06NDSH%I5N)H-3X6<'2NKRU='&D=1.;L[M2I)^F:XT/F8(M>
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M=EJ/LZ6,L%I2H3V8"0F3_1DH0F^(X-J$-AX/(XUDI5U8X^^M(01*_/)U.N_
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MU-U^XWLC]@PXGKS^!YW6Z?F%C/'02$DL#+DP,D1<I\,:#0FZ%B^OTU(U?J:
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MJ4WLW78S+ZGVU)?93_;\7G+I> _)'0C=#?_^\V<M(YH,?Y_S+.\Q)W4$(@(
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M2>#EEI+1D,[O#:W6-Q[/ +^($#XWC"OH.+/J7&@.JGM4^@TA?6L-#&[R7Z-
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M5@CX$*&\4;9;]DSO]ZLYSYQ,ZZ&%765W]YGKWBCU15K>IT[NAGZB PVFZ&?
M-5%:B?'&?[]D(NA@V>TA#^+<>LD%%52[<M&&CHYPR+W"UO+"I,(S8)\I1O#3
M?UJD 7>J B)[&]>\?!)X[W"IXOK QW5<4X4,NO7,SFNA>B@_?XH@WOTGW?S0
M="O?[SNRG;F:^B?VB9<0/0-8[FVWL_F?&/$Y'P/MK([,J$[O62%#^2>4JR>U
M@LE03:'):\"[%:QL&8,(3K,+O' 0],9?O/\5\B!80)@6H?B?5OK'?9P7+_Z^
M__X/8:M#T:1JE)LJ[%O]W/\0W[+[21[$!'U2\-%P*NQ'X\6_DN7V##C0H+YX
MO(7:1&+@?[YB"LT71]W3^ SD">V6Y_(F\*_YXE&W5F[GQT1OWFP^W'\\H7V!
MGOK7#D6S0X)EASD/ [IWO0XN$0>Y+6T=\;IUR% /59@Q)3T#EG0\Q\[^0YZ7
M:FB)?A&TY3*^[W2___?RZNK B6B2JUN829/H0,U>KR>3GNG_? %:/K*]GJ;F
M$_S--Y<.P6F> 0%$;<B6CT-B#RTS$<8#_SOMPQ?:E['_Y9^&:W:H-!MGM_7'
MLSS_5,"(Y^3HT]YBV$N=[4#-23)2<#&QO+(ZD/Z&9 AR^ R(&G/SJ;G9(.KF
MA_T/ONF/4PVX,W_MT#)Q'/2B3:"G&3[DW)D=P_-BX%'CW]$GKF<LC#>N)ASV
MZ\Q[!$_BU70/>/YVKL"7; 5LF8L_,1GQWK9$_'?=1_Q5ID'^-J[D,E;B179C
MJ,N6K1[B0FX]2QA'F'KQ+L__[60S3VAU><@=<G;5F8VH/1I"KO;_5N/N/P7?
M,L"8:I4L>MKXG^7"!BV7TV? *K2-?GUHK(.1A^K(U 9U,J>Y^'E$]%Q\7\TP
M3.[_J%_C)^1##L$'!L]]HEF7OPH-0%UL!'60&5-TS1,N2OS_UKA2YCT'J]S2
MAG6/S]4HTIRL_*L6J\2':8<L-.E7,9,%%,,8[.?2,[-(AV/$J^K4WJ+5O3.4
MB4)(,404)C5@Z03H'6BWOA++DR9&1W]_) 4#7C(EHQH6-UH^*IS-KO6M^S;_
M)4EI_/VJV7SIO!3P,XUXVV<%(?*8; KI11(R<K7907=P?IU2"HQGSQ7\OOBG
MP2YN>)>$KOX*8VHBVV1_Y&!.^SD%7J?0!30JF47* F/JK'IC$K??!_RXFZ5W
MF)"BE*D,4047GUEA'.)0;WCBM1:)N>/W X_5%$MC+(G3NT,4.^/J7\[>^]G!
MXM,@DPAE=$^CKUM22&J(1(GK:$QH\_R?_1^KSL1GP!7<4-I6-+EGQ@1/%=SQ
MK.=5WC/@OK>$OZKN1,VT;*1M?UI X*JOY.U-G-?T,T!K #0:S#=4CYP(1R?U
MW6>=PSDK*MYL'4'YHQ%R4I1,W\QB7W#1I.R(BQ"FLUBP/5#$_<<ZQ4U_55$V
M)O/FV+OAKY_N%)$4&.F4DK_LW9B@)X6LW]0J@9=.UK[I#O G5I0Y1U06Q?T0
M;V<(0R\\A*N5H[5NTL"Q\YUSR" QK6GAUB)K?O4J96'@F\E!<OP[9XZF#WT7
MP\J5O<GF4S/%ROZ(#1SCY<H3D]3L<=Z>U,JH8Z/&U8,TM(.:?8R)!>:4+BI8
M2L+PP4=:&Q=/ 80\;RWEF6?=.XN$*ZVT!NR(I%'"")6_7"U^DXU3PB !,$S&
M+=C-<Y<VT+U9"*HXKEAT:)!Q&6%Y)RQB*.4R@,$D[G^^;9,+.F,<QXGKVPT>
MQ'Z/;VH*[G2_&<8IG4ATFCS;0,!5__H,^.9!Q-HW*!2Y$7.!="8+D3[%H:&G
M3]>H]_8&L5!?H8^1=G3X=AIY457T<M(4@.*CB;QC:4X^:)1Y!<89GY/,H/J/
MQ]"N4B"9X[ZU9:KNE7Y?1CC?D'90@4*[O%R3TQS]VK+_6^^?Y?6&2I!U1AFN
M+;Z%T0B6[8*F&K:&D2O==]HXWQQ='B>?09=71B;-=>KH8#Y,K8'WL*D]X4WE
M610TY]5LTRP5&VJD!BX?GE@%V*42XX9QI7XS+CK28]@6FM/P&YU2A>9 PKHD
M'4 T)#4*M4,9CJ7YX^!&RVX18RG-PM\N&X'2BPYB4FC6KG5%O]@494(JXU)^
MX+N$97VNY)F:NT5CBDCB3UE;-U6I7JCJ!&'HO W?J:U.[\=GGD_ILVHOQ@7A
M?3,K.EUH"+#,6$\_\B]35F]MEVGJ1::##K+P3RK]3342XI666>O;M$5:M*R;
M+OA1LM&FY.LTV A!-O!Z)(;P#IW5 TQ%:LR+P=O\-62&35N9O!P?G4VD1Z29
M"+HLN4K["R'W:0>)EAI&2_CPSJV&V-A4FJA#46(I.540HIH^$#H@VBG ROU6
M24M*!?GMS^DD9=E$L@^S7+8][']^ 9G<XD1)F[)G+7XCJTV1M0L-JI;%?KDG
MT4HBE5.+5+Q(SMJ_*U0"+1 W.)U"Z$-J3.N,-#\GGZ6 \\(J#R0'])D8&(\E
M#>\K74UV5JD1:#];-M"8\_:M<D:E=-F@M467O:=66*VA/27!3KS:]\WZA SQ
M-4$'W?-LGO9>HUAH[JH$1(68,Y!SG.G:D<<GL4S9*[ 4O]>'\UW6*&#&&+:,
M3BA+"3-'^C. &1+H6E"8PV&*B>%3)7R#IJ=2+-01NROSI7"15:TCBJ=D9)DY
MC?([%C]:1]%[,JWIT061J<Z0"@BGK?\:T&2S3IE1&1Q#0[M&PAN&KH'\Y3"U
MPF+&]>J'[/ [;CDM2SS&P7B*X13<7-)%QVB+HGA#$I:MKD6.FSA7,WR7MPP2
M3BXS7B@Q2;C5?!GS##<I/#&J1#W8///R.OKJ"/M_L)S0(QCB V=0#"Q6];0?
M8 UMT1E)90?UDT2E3"D/H^E8M#N]<%TI>A)9QZL:U^E9@#T4OA]SR3@:".KM
M:S1-J:5B]G+X*?P337-5XF,^K(+#QH9D,R>L78V2:[JK<AP&9=^6U7&L!"JE
MR4TL%17FB&T.V#CVEA65K4J[VU+V*(^-YWZP<V]539! .EGF-PH,M[ZK";XM
MJJ,M(<(R^=7XZLI8JB&;)8<W1;Z;K;A@S,:C-Z<0P7NXH%]&[%.IOPNQ*49+
M].? Q&L=_*ZJ+L^EO./*I?77BJKC5FW7G_-$04T,:*"360=?.$V,-!G_WSA^
ML@53#16\J 6^\"-UR/TQ2R6HB$92];[:V.US!IH*9RKG9WJ:]:I+ZSR\X;3X
M 44L&,AB$Q\9O_,TN?:H.)O>N6(Q1$Y.8^!45QBXW9Q>F=.[UDTM](ES:WM;
MJ#?%B6>'-4I_J2:^Q$03SFHW)4^R%V^P=4R(V2^H=56TKF#Q_=A*(QJ:*5Z^
MS&VSJ!$3@_V]A:6W7V&[ RA61*OJ]G1H4"WVHW]^JP8D5H M'<E@DL3*5Z=X
MC&VN8=@M:O%'!*=.HJ;"VH2FDH3&[2@;7@F=-96KYT; "G<:3\-@]YW%-;=F
MBGOR?1+!N,!>Z!['ATE#!HA)Y^!>")8R)F%O"=?1%$[2>/E)-@376!:2Z993
MK";MG[ 3%;DT8%^3:,"\KB4N7^?4E8_,0.'Z^(I7MEM,'.N/]%<%:?#9^0X#
M1UBTD^%: _N]FIOQXI7W=)"5;!V+M91A" ^]?%?P>"CUR9U!CW8MOT-XV.SK
M2PK#G1VA/L-5.Z :0QEX&C\U/VEVM!RM(7^70_:[R:'Z]]=%OG'5OFR?ICG'
M%1V[QDSZ69)5K$(#)UH7>JA/Q7$*!HZS9M9E5ID_V/CF"Z_,J3MHGU1F5':#
M/BN+RW4GW\MA:]M4+X2OU8R#L\MV(4=.9:-&HC*0'7>,FT)_"IEO_D7!''B=
M5=*U_XNUMXR*J]NV10N7X &"NVMPA^#N!)?@6EB0X.[N+@GN7A0>W"%0!"M<
M@D-PA\NW]V[WG"=_WKFO9OVJ-L<<H_?1UQASKFI5JXVP6=4=# &>5( 6HTB'
MOYTO:[)5B)?M.]U9]YV@H!/<O#R'5A?WVLTXZBIKKE)88^YQ5KK,=RB\\"2:
M%0O\J' ?MN4+)N@C#,LJ\/MF+;(+N5.>]XD3OHL"@Y9R*(=(),LB?E$,)._P
MSAH !\?=;_,CNK4,V!NUH0HR!I7^PQV,)^A"S;0(2^>L$W)VTAW0%)<V(ZKA
MCI&UY$LC!([OTOGI>AMUWZ=L,48P A^SB_F5A]#5\4*H%4I#(K43QG8G:I0[
MHK<M*1UF49=/$Q,2XWS( 8?&V&FNHE24 U5IA@I\_LO]=-+;V6*-.;'!]S:-
MR[ 6W6LW^%M\:N5FW!;@)28NVE+)*J!* RDH#6^.?\:)K33$;_J865&!+XM!
MLMY4;MUED:4-CY.PC<EHULWZURP4).&/Z_$.*P\L?)<-J5'4B%'JZ>6%Z37_
M*A/UWK)ABC>GQ?AP7R\U+4+#F':-BU*+$'&2(J<G@=:)HH*+()@]?T!5.%B&
M3AR"N]MQ,!*>>2O0J'8XX4*HU!OEHF"("FR5&IT]Z7L_)1 * O=Q6M7\TE=(
MW%86^&E3J1YE0-[8X.AR$FM88DB4Y]ZQ%-O<0>I*U6$>@KJ[CCS9MPT"9WQE
M@29&Z*:"^X1FLW!6![0@#=TTWYFQSG.?53JL'?JYC0\\J_ISQF_LU<Z?T/VQ
M9? SA__>,&2/=]]<3_3_45U?*-77(^%2X8AQ:DP"ZV:P6K$@)3[6/R@G:VVV
MD;!TN"@%4PUILB%I\T>A%PY++#N7_&;WHZ4TMTRQK-[,JI9O-3B=&H2Z+;&]
M)^EF+89ZN$FY:-16C\5PTM"Z6=*JEIK/D,=OQR'R,[W;S#GH0='U-Q],F!EE
M'FYPCK9V2Y$]KXFC.6ZN(VL.*N/XMC;0.3>0&XQ:_#Q#N\*.OW_XD2A+7'>[
M3D]'/JZ#D3E:ZSW51GI2W"V?;F<'/'\A' (X5G(E-1B;4K5Y.2IU:<VC)G^O
M@X]6G<3JAMAT0)Q=8- V?-4 RKTZ@TU):6:3)&JQ4TO=?014IQ'H4VY8MU,
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M-M4)8JZ4@+;3'BW#,V>.RB%-?TW8>;Z2W:+=52?IQM-P87SP;0=F-RE[-@G
MS(XVF2WQ.N@G25=$<!APVD2SZE/ K>7PRG-C,[ZG5,#>+&EB$L&PTBIAE76/
MK;#7OI@O&CY/;?DVKCZJ_ELJ>W)ZI:ZU]M3%(\'*<),;BNY"L_:ASS(5GGN,
MKR;"O?07K %0J$)"YDT7!+?(X%S2E\-O7.4!H>R2%P%1I#G(-V<]UE9OHO;:
MPS=]!8"'.,[=$G*:Z$'USX<^+KO/Z9<^[E#),G;O5X!L;A[ZIW]KHB@X9'SF
M>5_PK/N9D;3C5-3Y7X*PVGL%#":(BB5<OG1K/1\:. N8@'0>[!N.#\^,!;S:
M<B%KE%M?30%CN@Q\1S//>\T>ZR_P'LB(4-\UH#!O*^9.T]=Y3]U1N/1._SJQ
M E!!EZ*C<$]CE]?-$:CX<KK+.X%OP.OHTRF6"R]IEB)"A!H65H 7S(IP!P*-
M8,((9>MXO>UF3<=&"D=M3K7[*R#A^!$U8:T$]&*\9%RW7=LY3'W'/@DM$%%]
MNS@63^%2ZW53??/)O<@F01C-<2!,^IQ1T%L2N]]QB73$>@UO/V("5<\TH0'L
M#G57K2;7.NQ\E+_51/K(Z.$_R3)LU'XY)L?L<B3U1(]8E-EL-6'/*.V%J*+7
M+$U+YTR+N0[7[>62;)=[P)+_@Z&KL>VRR^/2]H[%P]TL_QSIO9__(3]SG=/5
M\[[G>JO+#0YIT<+NBI1WY.G?^=6_>EV&R3]WQU7$=*"5;Q0 [V-NQA+.6XU7
MMO_J/ K/D6UBOC?O695%<*2L3X@P]HZP6I^7_8((!5RAMWOQODGYCF8BX*[A
M]_C=B^_U'U<?E2_^NZRM)'50YF?6A=:G#]/B=8XME/]H&5Z*,QT-9A'..;'S
M&G"!^=;W7T2N_BZO_]4KR)R>%[X6>W/^4 =E$D GZW /V QP-&RNN(WB+WAB
M^M(C]BAZ_10%Z3=PZK7V<+5>@-Q6G QGW.AD;->N/ 8@^J_/E*AV*@[</+N6
MHI$_;WICOD3=OZBM%QX*<X.NI;-%9>3NVS^5O?&;P.[0>K7@=&V$!%8<N OO
M3W-V>@5@=2&] J2N[SM$_1"7#<1'HO@N=<7X6@_4WXK,]O@C\S,/]%E'_!3'
M15BD31/1]^5CE]>C]ZSOFBI[AC@(-#/&,G/!M?0*.'^[FA\/ _Y=FWM*.P(J
M7]:K2?M4Z$/J0/EH*T*\B5U(T]US!7S6F;[9*2#0J1&^(Z9PN.K@4Y$J5/PQ
M]6;;).!&ZQ40W_X*J'QKE%Q+ZF<X+B)W6KU='0G0=PM__7](>=[[YB2H3+YU
ME2=\)Q:_<;$RZ#698_>R_[4(^.)EW#?!J&'Z"3] KZQ3?N!6M;T4#;WG*NPH
M@,^I/C^/%_W1V^[-\NA4KR=[2LB=E+J5'O=?5]U)^DOVR4M5X2T*?S[4"6A(
M" 6_85F+F%YP*4XX]Q=1#0>M[/V8//[%R7T\\^!_S?J/KP!ECU? Y[G'@4[5
M^W]HYWL+<7M%)EE4M4!]LZ2UDN:-E4=RTF__IOVX=>0:^JSM??VOR#8U$9$F
M*;TQ"TQ1539W+F_L?/\!9'O73[\W_G#]EEW@6W8-'NQ;'^J:'IY^DYW3OW\\
M.ZD($;L+.YKNN4NY>SA;J'/,)X+ZO^/[8[WU%&!5@)_Z5@'^*2#_@O*FG&_Y
M&!,5(7"O@&_&'8(!(_$]8BE^LN&@[2D6R"O O:#:=[ON6LP['WKO\^]D'25.
M@Z4'ON>!J)^:PK#,K)'QMB965G,[I,O+U9RKK,;FB*@V>W'>9^'BN2WQ:,$F
M'A5K$FP(V3OV#NB%Z?*OH9OS\\.?CQ)MT\ M(UBMGVI )9J1/$*L-&;T):.!
MXS_F4W'X4D.95I:UB\MH&=@H& )1 P7J)%;8_W;$\JL-)=V=D<@$DJ?Q:?LH
M#D"XG_N<-6';,K+<U%:@F4HR+)HX37'V(TN5E@"!N;^M0KDYQ6ERB36BNZ4I
M>4,&)(E!Y^9,@N6']C>(?<>T,6W/23D\:4&YM%_+VE.S,@@_F6K0@!'E1BE+
M@S8;U["";A5TS*^GZFS_YX\=-2([#16W9&;'E.\WO<O)/6D[U>X_J'LO7;]8
MJ<E^)+KXT7\L1Z#Y\R>(^S[/EZ>/*4VL<H4R0^\BHFF^8^.@1Y*(/BZ_>\PC
MY-QA4L431PL?K-S",F(Z]Y0*'MK7CO8,+VBG:IYDQL\9AB^7_YB-#5;.,&'+
M247?&$,L\2./UQ(?T\=@3N2Y7!L-NQP2:-F4(>PJP^%#$[R #'P.NOX0T1F2
M?U$\Q!><4;<]P)$F.IA4]4['<;XE*<_2-B76CY]B3$3^ TL."RLV?TKI0.9I
MK:MKV+CC(&$YA"P.GYA=A:\U;T625B%N,,%!WQQ\F6G0BZS?^RL[GOM0;PV%
MM7[W$.<W86M^\I$SM'':3K-D\M>=E?1X46<I\9JD NM&;FJLH9T3_MA.)^_>
MQ^8MPRLKW5HEXL+EMH*ZY/)&M'4S=_G0'N8@3@2.$)9Z*"X1=N?38)+/>U<"
M5'FZ!%)L2W1OXB38_"TFHK+3XXW49B9J;)+\'-\@=P_J9 -7B@C(-X2KYFGT
M8<_4J2,!^3)6MIKTY#'+4A3M7^$X9]BC<M&MIIY=G :FMMF&# <*D=JO $+P
M+HH/=(3QH<ZOPCAFF!Y]07^9$-?E\5@QZX>K1EQ)C9WYGPN6417MP+QHM.D$
M'5/1'PD.E 3G'HR*PCMNB;5@;DJ-K9^:-@G-0&%]A)&;#-.S\+D2^?=K4@UX
M%C@<A.B,<YP2?,AZ!.H\O]/YEAMK"KNI/3_,OIQ>:%'6+E'*'R##6XHPA^.4
M2;0:4@*"I3T3M)@&_^L)>>:&TZST,!&-G<?,@T6EE!PUA\9TXN#4#^;TQ#JI
MWKU;5&:YA576<L6-9F:9G3OH8Y1@],@HA=U!B5G<L!%+)OF=XHJY,)K[2!JB
M+2!+Q ^'W1=#:]R)2)!B=3B9#.RR5R8[&!))_ZF9E5%#'AX!("=<-<2%(?;M
M+LF<F:(_TK#\.O4=[]F?-;YSN\FMK/9O:SQ-;0CR&#1VJUY(0-WBRB%*7+=-
M7 53P4"XZY*E:M9TR<0M4-DJ&B=>T, WT'8GC:4QY[BRX(;<Z K0FDCG4B_^
MR&^^F(]VGK?]Y=%Y22G*D9M(GUI6<U(&4[1XF+(T-F+1E-D8QOW/3-XN#9&-
MI_3=!OEIYLCC4[SI\/C>N<JJ]\TQJ7!>^Z(#ONG3*OGD=\(I[Z8\Y,/1O6F"
M&K*)O+D 5B?#B/-8]SVD.XQ.\AL=5M%],=*Q1G>: NREC\>$;+^;RCYUBGF)
M]\_66D7FKC'"P-5J3Z%ENJ_@B&[!@?Y6D<;1-E>B?2E3F%WL'1N71W6&Z:K=
MT%"HYX9_7^*@ZOYR> 1<2 'Q#7*/ MFJ6>/FQP?"@Q/@1 44@KWB,.RCSF)<
M?L(]IQ 2._;<38A] ?:HXI[5.Q('()]4G*'GD(<4A0258@KG__[*OZ L&&YO
MTD3O3CYNL#!@^,6KX0FQ_0+.\.:W>)D;4H+L\<Z.G@MV:M[',/&.BHBX(5;M
M&6!>AWS,Y[7J7($4QY2(6BR;J'D.U*(P3;FB=30 /]NX&5!.86-08=4$O;B*
M43,>E_7GLCA%VBGWUNVGJ4,MF4\U)YX&I\V/KD;F]G6G+=C%/8Q#=XI2'EJ7
M#K0+6M2)R[B7$XUIS #PM@T9YT]A3%^#>(QIMR%9\N<?U $,UYBX5\=/>=X>
M1VQ_EYYRAP=#8B]^"@B(.L[$>6DG6!D?4MB#6FL$[V(]+E[@II!8CJ!Z9$V#
M96[+?U+M?@M7Y3D@3T0I8C4;VLO**Q <R8&4D@YQ,).6H\&1:=(T,^_+*QNF
MY;*4K,9AW 5LE_Y\R[5)(MZ$+?.<.D,7BN/7ZB%GE />:&OYJD48:,3CHWL4
M>HJ?KKM),K>:W%3:T3"BQ(./OP\(EW10AM*61$)K69T&TF?58BM4AOR:@T'I
M2?TZL<8'@OBZ#W9+,3PE=NGRGMC.B%;]0QJL.6SW31FL6.?L2U ^8S9YVEP:
M.FGJCQZH)%V;*GKX<04:^(=FDII 4(2AL:\VU#U]W5;A/!RNNAT2E_+CUQ8J
M)RY7Q=3^\W)V%M':GYD30;IQMLB&<6"&!3Z9M] *3>1P)*&_<+B1AFOZBN4<
M2QAO?;Y4W0<1B!Q?DLOLO8'@L&B./A Y/'Z;Z,>6M-T(\J*F75+AST,BW$!4
M^4!<871LJG$4G(\,@A#'I0RX0;1>'=G8J(1-DY^#GKY\E-/$@T#+,@FM&E2H
MOO\!#?JTYZ?33<+%ZAZ_95!>'IV6'!#<I]'&^245)983S:%F9'-H[D(S.7P>
M&GK*RL1K44#^Y-U7'6/K3\69:Q[!HBM?&#(3XU@YTQC[*S'./THKG-W7YCDF
ME+39L*.X$35)@N 3-"S(K+%"40%X/I;CHLP/$)",Y->T)UY22'9)E'$6'T*F
M3W[;.TP=<8 -_>I[FF8)[#1)C-_YVDS'_;'@Z2)Q:CX49P7G?C<7*K[$0\QU
M]Y0PX;4Z3_<<GR:2X\[S'X2X$3"%#/%X_/$T_[8JM2E5V1ILI\F?IAMLQODI
M^,>61&#\=P\A*MCQ1&J^?LL*#%CD%=-[1&*,*GJ9U50T-X8-QN-"'!FF%?^#
MYR5+WOX&4(9M,1^CICKA4(YBI)_'XD&&LR*3E!F)%D.54I2XP 9G,?C/H8K=
M&ME^*PFQVY8U]<M!^"7@6,S.8[WV$2FEMA&?F(/_S"T@RTAJ)\Z=S'\6R>CK
M<Y90A;^!<?.07T.\+#_],D?<1XS _.6:ENWQ=OB[Q$K.Z3;@K(<\#V75&$4*
M @H?6_!$HCXGRV#8KO<U;;$N394%VH]B]6U7%,!G>EZ41MVY,YB//S)F?_D!
MT3[@C*4>:EPDX\HY5$3TZ00&ZQNK1KM8BLP+U=: 3\OL><.4%9/+70QA&B-V
M>0DTD[+4XB43*#G-*X T%;:8S<YP49,JDT/3;MI9O&NM]E-Z'CVBQ]A_;;P^
M1@(I6@.</:)@#/+I,TN%BN<D4Z$$^)21%.HP@ 6RWTV-R3I$-+*_<IU8.RL8
M4>7TY=6TD36TTF@_G5;08*F$5Z\(E7I:-H\H*>9#3DA0F*>.<"19A;; I9$,
MFL2C:NZH$O_\XVMQ, S\9SKK!'\Q^WAU2[$!?)UPC\T46[K)'0F.REKJM=0]
MJWM89@SQST4_L%26^GQ'6=3^* VA#^OQ6==W]?2&84\1!9,BTTJWI$/=*+_@
M:'2_+]>3[PO6QN#!^V'M[G@T?\T=!=5IYL!_A)5D3.JSZ>S+<T_MGGIR)K%5
M:=ZV=2$4-U"4$U"H3!29<>07SE7:<=D7B:<<'H>^S$4>DW;<  #(9SU&P?U6
M8I,S#QT!QBYU%(*C$(+9LK<*S.9/M-8P?KHXU"9\1W(^WNR?A;%?1R(AY%/*
M*99A^C?3OTOL6G:,?(CX>DTY? +19V586^8 8MQ#/!&@/I3IPWFK/OS$V_D*
MD!L*N!%=7)BZ'?RV>7*KN!/?E0..P.C^LDQ_)[MSLJZ^1LS'=BL+R8<1],A]
M^;ZW&_V/Z1/H7Y8%]^0+JKZ:\>3RL4G0>H<M$L^G).I7@+/3+J23UXEN>#<E
M\7M";L)MKKO6OZVZ N3)YS3_=?>S#.>>!*[LA0-[#FE\GL+M##T5'3CQOD[]
M5WP-+N/Q^*KLQ?*5V!#'HR[W/Y$=WRI9Q'=<_XWTN\%\G@60YKA?G/V9NPV?
MG.Z:N1K*U.;TUU 5/O@=O_P?/[Z^,ERO@(:$&55?G7_"2R13[J0B;YWLB9;B
MNX@P+OKE\4^$]+(B7KV[RS+BP^H0\?))D2R?\A<#XYYB\SDMGZU.%_>7BM@$
M<,"0Z<NG1?\YQ-5NIUQ)H%"_U<57 K%+U=R=;\/"'?X47S7_$ZWW*R#4_(;C
M93GQ--IE0&R5/5GL?:0+]/RN;!3LVR7HM*#FH&WZM$Z^BPK_E.]+SMN^K?!/
M"Q)+7Z@[(+A\!?SR:SC?$9E1X>_,5;((>@4L4SY<';Q<W?AVNT!W  UZ[2<S
MPR-N<WMU!3GU[_?8_[?I,=PY:?M3"\PJWG9D0+LYC=,OWK^1_GEY/78^LG6C
M._M"B,6+#OWW[:(\ GTM>^/&DJIBQD5T^1-=;_N..I-9CD,FR7;F8:Q7P%O;
M/!3)?X_]9P7NN?SB/B#0\^![_5+$Y5<BN-J#DUXQ]]^_'V1XRIK8W]J__4(.
ME.":).&QXNP-+"4DRC=1[%&*'W-$Q$P(Z?Y4!%:HWQ+)P,WE@B&!_]<E>5V]
MG?%_.63X!V5(V5NL_OL1+Y@M(K)7U^0?=1V&C6]E[Q,.%L2?]3&6;BQ/B^[M
MO7<"8LWW'M<37WIXR>[J2(R3[RF$^]@H'V[<7@%V2'7&DYUY10LJ?Y=\"TAN
M8DD%CB9LRX2O+X@TES+:H][.W:UO!%WC_<>2VOD$$SD"DP'8?0X#[5%-%-[^
M9X,S.O/7B^3]W-=8AHNA[J^+3/\E Y.$9;'/KD2WLOP[5@=-C>>TB22$5:&&
M>!U-$FUV;3F5TJ@II6-2KOP.Y:FH[4AWT<7F=$[1?BV(O98:"LI=09T<G7S)
M,G\%5M6T0]VQ:V4SLR>[3TCGLEU:A;D[JK_+ZTI&QX/FU<1A!O _-N-\;";%
M19'_M5#Z A J=)OZ> @?DBWL9\(_OSWB8RE<&:Q<"J4=23KY3%7]/=T=IVTB
ML\>"RE,M/AWQ*+HF_C<T(<_$P7'9F%G&,'PK 67-LC$@VFW#5#+Y<R ^HDS+
M8T3;!_=':S>?;U$,37!V7QK1^U8[<:)LY%'XWCEK1&>06KMUSM=*NQA$CUNV
M?KCR-/;OGOD_.$K*;XLQKKI@,%<NE;N6#R@I6)-\4/3>M;G!D=;N<!]M6=Z-
M2J2D"@E]+[28A<0:N1_*'%ZF]L&A4A$KXIWV?!+5N4WD_IJ981:P.U".25([
M)K494)Q8O'DWR9 H3DDKG&I7,SHXW&1LQ2UA(1DZWC#OCNPR7M+.04L_:*SO
M-^!8CIV& -.99,+5V.,F%"G@P)683FN5%;]F<)[NTV0Z[HXSS7T#P:0-<EWA
M%4TA5M0#2PQRLD9U1CLN9K/:8ELVA:[B/HT&.?ULY7ZH85K36&<^]7-.[H^"
M)9[QJ+708B)[P#4Z1XTF49/!'0]C./^I4:62"<)V)_[.,7,<9&>FX&K1Q&5Y
MDE(@-0<J#K7 #X:*"VSSXCN'.:(.66^;<V*'@3+,(J)*=JN!K 6,C@Z98]?V
M1'T8W[]I>F4SS<NX-,92I]2+?3(L[+72EMM=DAEI%6XV%=HH1J@%QS)10\S
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M]?\-D'1BSRET.P!'J$SE./WR[?(\^HXD8M2>Y_Y3\'*!?\[=-HY1L_LGY5P
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MG\)'X38V(8D5^4S<HZDQI5H3@Q61&H)J^*X2J1HX021,:I]= P$LA3!S< 0
M=TH%)(I$F0UX' SBH8U70%M0V_,4(D<T;O$.%C*M13!BR4^)T<MJ'/P $'Q(
M;O9<L9)&F;JT.?6<NB;)89X,,-Y=Y0<9ZO=4CI3W)&.\+QD"L51TDL=TV*I;
MAX(-OX,Y?@<7-G*,(WQAN"E'^ J8V[ @L?LH?@1/4XSE79_&2-U $_2=![E_
M ,0HM\8F (L]TDF);;%$E;:8*L<6K4&CQIS$$"7M#-!2H#(&ADKJX3$D*J3*
MP</*TR#X_2(-,C)/.BK_V4M 0$L3BX93T$;?7 ;GV52%5UB?6')&TH!M^=>:
M21@XUEOX3:A%"?'S+#$-Z<%8.( SIFRL8@) ]S'2J7Q-.^+;#KTS21[V\\BQ
MZM.:L1T6ABO,FO9%H^B!R2K9;Z^I;N^Y9A:A9%@5*G,=I5JEOQ75O97%S$TY
MN:>!$7*#2/1B0YP;I%=#=WVF9.VPXO XJ#(XXA3%UOSP=HCR_$06?T)A<9'A
MF1$^Q89A 1 DZP  KCP GL;Q\9P61$'S;7QN\!"Q%+1L42SGX^$1'+A(G^U0
M=L^.LTA2F13&T'#0;/L,'H2K?<IQ)?U:-J$5;0E?*$2XY:*/;B%H^,DF&&8+
M#WT"#PMF;0B% FZJ?&4"%^J(VA::8_=EG _07"/W41*#T-36X0-N/-)[+P8$
M"PL:/"SF+3G]CM! M4>C"(]%7NR27>4;:)D)SMG2O>SN0OTFL)1;JR=2B/R9
MQ3_[:7 =<Z7F+B__0? 5L' N>WEC^V=0),T3A7?%O'X#R?HZ*_71-P@L&5!7
MF\O:_'*H=Y<?&R!G+*8LM/V8%H#7U".S/M6V>]LJ.BG<WY@_UA&:U\W:W^5Y
M7&*I2O$*.#3.1@1!'BO,G]P"%IM4[OQW'0U9\X5? 3EUSY*D+L./3]?4=J<X
M]^;U9VHK >I>FDWEKX @;R_9T85==%4DAU= >\8S2\!5I=#F8UK/^Z9U69.(
M5T"1YH/7_<%Q%5AQ:6M%"/(B;:FZ?<YN\H?,C]_ ]GFEY\#\%5 BZ?P\MIR/
M,>U'ZO_0HV-BNO"OZ'HV5H3FQ :J*RX"]HU> 05&_$*VSW/_ME"Y>]D%BI19
M=Z[=FG2+#=@_,KZYD"-%%,+P[5<:"Q!3WO01=<J9+F<%%KXLFTZ;-[P"5&,9
MU\E7JM[H([\#O@)$_)*B3N:N\Y<3+/WZ5/]ZD!PLE+ SO@(P?O6D!&1RLP++
M'+K<7HAX>UX!7:J^8JYU6R"?JOL.&U$ELKBWL@=9TG%.:1T$>TX^6UJJ\N4,
M=#NQ/UP+O]%^:G+UYFVVS#? M77+PZ?UK_OCX5/"Y'?<F\\K-(>B;/U%]0%1
M7JJ3D.?=2P\[?@,;;M2,<R3S^U? 7D 37=[Y\UB[C_;44<*?H[=^>K*_>,\U
MGIXF^L9'T<O-YEK/!3.3[VHW[8M?>S[^<H [^X/N*^! R[/_EMDVW./;*V!S
MX150=73S+UWX^!I$!'CI:=YURO_S9]:D_RTX,5<01^_26W[J7HJNM,+*P(K=
M:ZS]>;*.S9UE];X_J-\U?!(NQ09@,H0OXX-^H:6-_WP%E,:+Z5?ZO&4WB@S2
MU/]&50_,Q9;84>W5SUO1.T!3O_1B5:?H5ELY(PB=UHQV&^9QY)Y@;R2IGZ]Z
ME9+)+<-Q\WV25JI2GR;N3PK!+;9[7Z =<'16K1DG[;LNJD)0+SSNOJQN7>7
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M]2ZG0;R9EI"X+-X9+ ZOHP'>RFRG!4@+UK;JC"^J\WV[/2:Z8#/>JV6^W1=
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MB=SQCVY'=\R,8T>U0R3/]XT'"^)WNWZ< ID'[)6KHJU;)!=AITWH3UQ>DLC
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MMWS?)>X)KU>T( 4+$MF"3:X=1I6+0N7 _!*5#-;-$TS907C+U/!4%'4\,HN
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MU9@]9MX0-N&]-9;53M&RXW/8'2;]PAJ>3+*?.MUDSBIT_NC%M%S[[W/V7;X
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M#^YKEM[:]DT.YI=S6X]8\JUPV56S"$Y3)$P\/&E=H.UP&R*H=R=\/0R_8C1
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MB,CK\4 .52ZTM3_^GIGWJ$Y!RD2(8<IP#$^29M8ND/1F3!J=S"6BT]JKB>2
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MA27,2,EL5&ZW:?Z&I[:BT:**8 IYL!MVE5=!3[IJ\:@CJ8V>,T.2G>MQ,4+
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MO!-3'SD;AF@A@IL=VH$,0L9&L+'M,_5%J]J>0,OC?==IXK9%VW2+U]*73NU
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M[K_(UOC# T $H"'P[]+_ %!+ P04    " #+/6%44IXW$A\2   "Q   $0
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M&&^>PA:?\L:1P+&@U5L9]M$G(G5*3%@J@M#[B-9'5/.*U'5N0]0%0R$F[9S
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M84:H#T0PX5R\P.F_\#TUCF EIRA\Q")Z.(TI5ITQV[,@>^^<XB R2#UB](F
M#ITO[F'<&(:IB1%#B0BYUNT'V132:!=N1J^*-L*FN9ST\(S0(C$1=[3O0?N(
MP2T;D51JHL[6M&VW[ 9;D3)*<%I?3B/. X#K8>PG,Q<1J+6^),0?P%1$7+<
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MG)7,!H-XM1%CD)"!87I@@2!:*C:>XB!0;*EUB! AD-" 85]8WTW= %P>U5;
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MJ=/3MR3_;Y(/R3AYCFDN]GN2A@G%O_@5?4[EH=NL(# %X";_<=IK,73ICX.
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M:?<19+CZ3%M_"C+R;_\?4$L#!!0    ( ,L]850<[==L.W,  &D;!P 5
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M.QS1K$SG299GK.HQ*]]<IADR\/YC.W99W7ZL#GKEYNLU5K)M%1I'19^(=;I
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M4,KZT/P&*@O'&U$2_!'"<#N;^'"O9V2GXX*6.YKD<C[_4_9_.LZGTLA,1K5
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MMAE>?_.4O'R;Y?N4PY;^Q"#+P4K^]>=/?Q+AKOR+"PA57/30</E']*?5W7^
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M2L9+AW%3.DBSL45@UY)LX0=2)?T\R)X5)M1M"%('O>!14?B<MH"N<#Z,2Y>
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MI4Y\E?'^_A2,5XCHH18LA/.(ZU?K[]Z'HNK!(_IR=74[4%*Q-7:-L;;%=EC
MLK9$TAW S>]$4C\\XQ0SMP)V#3P&J:U+8G"8&ETA3PM7V?/Q(]J7<-U4$\>1
MPC4+7V&OHIG$C4QC-P;)E;64SJ=_E12RB;Z8WAM4'N14=B:.^RE<BS3Q9*V%
M&5C XA]Q^/2<X\V2;+&")WR':1AE,SO-.X4-V7<%%KAH)*<V/T+9"RJZ054_
MQ=Q.>_(A?'&0N)5T02%=6DG'IX)<(!U<S*(Y=-5QB^:X]<5*+XI3];L@Q\6K
MD*%6*NS*%RL5RVEOI64_B'9$=L"\*S]R*0T2N6>IY3T+(CU[E G%'+=6)JH
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M@EZOVV"N=\MN SB R_:*%_)#^;OBWK.5\B'>E.&LE[M]E!QQ>2VJFE"G_ C
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MH,[F>UK4,8%#1I@EL!?)X<Q13FDM=UJU?1*-(K4KIZYQ<(!^3U)# 0QQN<H
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MB7M!#> ]FKC5U_X._H@Q5U=>/WO,0MB"\#PC!M-3US0X&F#L967#LIN.%KT
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M]#-:S9VE]U)^]I130:GFG:I9L']X@K#ZK-X*$2;V%2>MBJ'Q;7)/)9X!G_#
MMS3)YO^$21#QZ T3V$W? 3)"+MBM9U"\J#@6@:1L4:>VH;NJ?K=_Y$MI,S?<
M:Q3,0!B27,+=U)Z=ELG;/T).FV9#LT91S %+4O9T4U]6*L$-:E7)JUJ!:)!+
M9]5@4J,2,I22$+O.*\!^+0787XC&E\U(&PJPAE+B#=1-!?@R6Y'75<9*3XUF
MYIL-66L0%7+QK5WO--22D!AFNJDT(JBU-A<;K4%4R-6ZC?DTWT\(,4JL'IU7
MAWPQG<R_)HKF("SDE!O&C%IL,(4@Q1K1K50-2Z.402;N[8=!$,BY]G?RS9 !
M%VM MYR,U[&=AP5YIAZ'C$?MBJ!O#()"SIDD(\^$:CDBB0FK6V["FT'L6K[%
M#8)]K%2DMJR).5>ADO#<+5OE]X??TC>2)>RNYQF^@^SJX6GE(D++O&D7(#7D
M#6$S7;##*=&.;MDBSZF["+WX*DA^.[D@KVFNR+9FT ID@YRBOYD.:*%):.^6
M29'&QY!L%(7Q7?A*,CWAHN=!'L@;P(94RT%)2.Z6V? \S5[3#(1BN=PKVX%\
MO-K3V9.N!2<A?T<F0XGOU.*L<SM1GW;@A'._=L*YT>5@=- U2!QYU6_U+.A6
M3!+]ZI9UT7%F**Q"Q&Z9%2\Y&M@2=;"V+G;)I6HE/G?%<>KR?127\/+KY#R,
M1_ ".D38A$5Q68 0TCR_(QES44/RG;H,LP10+(9AX#<E:P+<8_A,+7W9SH"0
M,95L]+:2S7!.P17,$.I#6!85"9LX=(Y3;E\4[&-5^C/C43SQVY!!']RG&DKC
MRTS<@<:"W>);00F0[]/;4#7)UZQM,?;!Q4N,T:@4@:XI<(-L<&U= VP4;U,P
M?7#XNIR^QNF,$+8_XC%[VD.[M V(!?EH9D:<F'0-+$?>7<A9J^X)["4BFLR(
MP?R>1$5^__!=R[FR'0@(V3K7A'<#:*B.71(KS6,Z3S7TDL8PGGM2E%DB J.N
M:&+;#T@$V2I7A^P&4/O@H-7P.ZJRZ[E^!0@=.1*A,QO<#9GUP76LH42D2:"<
M]@_B1@YP<*LXK2CGJJC:<F%#,#J*PBO/QN.(8[M.)FDV9:]&LALNQ\?\":J<
MX<5L9;1Z2Z)Y)SS ?/\ 8:E8OU7;#(/5&0T-6E?8O+EX-N="/*&M(#LR_F&E
M"VCJ<,KE@&QILR),S+D*FB/KEQ\4N_<H97(:>N5EMLZ?">-J9(XL6*XR =(<
M]70A*\-X7NKJ:PK;:)I.*B'_)&%&;TM)GM/?//Y(Z6\TI]L&759B\M_E=$&G
MX,CK!+\CTQ?60K%+MU0N,^3307V=J8_7D8D,2T?<>"ER:2 ')C5G7P/.D4$,
MC^HV?!6Y=)!CW5U0;P32D:D)+9G8TL(G+;9I8O.TZJ?*Q8:\GW!PIJB)VI$1
M""WEIQ3KNDC/RXSRH+)!VO7$)7CHCU'<AG2):;&N!!Q%0B)?PJKGX/<D(V%,
MBS$P-T0:% )P:YNRQ-U5(D5>C)PJ53,Q]"+04BV"J@1<6N9B8<R/@8/]K_#D
M2WXV&I53ZAK+'ZNM@0W?6W&$[%FR0U5U)J]>!)6ZE=7.E)BQ,,0V'WJLM4L!
M]2*ZM9EPYD*YS6A%5^4QU.V+>+I=K"I8'JJI7$"M1>-Z<HN]"*?Q*(.P7!T,
M;K'UC;DJ+7++^+->.+N]QLZ29,-!PUMK>:ZDCW5KC9TDQ8HPNUMK>::4SUOK
M51.M7[E1UOEK=FLMSX;2_JUU5Z\CCSMR'7GLZ#KR6'H=V;&D&LX3YG#Q^)]4
M0Z,.1A#[D(S7X:WT<4=NI16LJ\'U(4RCQ:OIXXY<3:OX-P+9AR@(Q/MI[.AR
M!Z>'FJ@[?C^M%MS9-(5OYI^T6E=>G$U N\_B./T1)B/ZQ#F BXI&ESRF+^#R
MQHXKKZDB=2P4]H+I0[K?32ELR&AY8\7J'B]-L;^%4?*%3*B+:OAN8=NKU7\E
M\N[=T2@R%[B52R]NQ>O*A,[*-G5QK?]*YMV[Y7:OBQ*Y-+[-/N6ZF)!G=E7N
MB3;NV(_L!/D<V*J&&4N@M2MGI+N\!+1UMA3MXE<5<,185#:,91Y"P^!32:O@
M!-@[P+BN6PSJ/OSQ%9:/+ KC_!LI;B?WP&T&9UL31-+&')@'ACF=X.76>T.
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M[2<X&@R/3K'3:^YTUUE70LCE(G3;"I" *R5JTB<7%W;@#,I>I(FT7/F0((?
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MW<\*TJ[*6TM38KSN5D6.IE);R;K8NKYOO8M1<?!Y8*LK-HD&=RMVVN&G;J,
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M&I8]]D7KCX?GP5[W\Q+@SAQ#&;N-5/T0)PL_)Y=MJ-?AR>'1P>?G::>R=A7
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M$H=8J.OLG!45*0N2UAY6X'70.\C%9Y/ ]LVK<^RHVT'9+;H!..; >$>R:9B
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MX1[Z770SX@3KBP5R">T[,D0:T;Z$_C6*25ZD";&C7M$!" &Y&D#K]&O12U0
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M_^W_ 5!+ 0(4 Q0    ( ,L]852'6T%U]LT" .E4'@ /              "
M 0    !D,C,T-3DP9#$P:RYH=&U02P$"% ,4    " #+/6%44(QHOR<A   D
MC@  $@              @ $CS@( 9#(S-#4Y,&1E>#$P,3,N:'1M4$L! A0#
M%     @ RSUA5"P.]V/V-@  8?,  !$              ( !>N\" &0R,S0U
M.3!D97@Q,#@N:'1M4$L! A0#%     @ RSUA5$8.7'EH P  BA   !$
M         ( !GR8# &0R,S0U.3!D97@R,S$N:'1M4$L! A0#%     @ RSUA
M5"_ ?F ,!P  X!<  !$              ( !-BH# &0R,S0U.3!D97@S,3$N
M:'1M4$L! A0#%     @ RSUA5-WX#_LB!P  5Q@  !$              ( !
M<3$# &0R,S0U.3!D97@S,3(N:'1M4$L! A0#%     @ RSUA5-)LVJI/!
MD@X  !$              ( !PC@# &0R,S0U.3!D97@S,C$N:'1M4$L! A0#
M%     @ RSUA5%>^AP*W#@  ,#(  !               ( !0#T# &0R,S0U
M.3!D97@T,BYH=&U02P$"% ,4    " #+/6%4VA#L>3VF 0#/!0( $0
M        @ $E3 , 9S(S-#4Y,&<P,&0P,"YJ<&=02P$"% ,4    " #+/6%4
M4IXW$A\2   "Q   $0              @ &1\@0 :71C:2TR,#(Q,3(S,2YX
M<V102P$"% ,4    " #+/6%489A*PP$.  "VQ   %0              @ '?
M! 4 :71C:2TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ RSUA5*47#GC6
M0P  QW($ !4              ( !$Q,% &ET8VDM,C R,3$R,S%?9&5F+GAM
M;%!+ 0(4 Q0    ( ,L]850<[==L.W,  &D;!P 5              "  1Q7
M!0!I=&-I+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #+/6%4:015Y69;
M  "X9 8 %0              @ &*R@4 :71C:2TR,#(Q,3(S,5]P<F4N>&UL
64$L%!@     .  X @ ,  ",F!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
